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Abstract 
 
The widespread development of bacterial resistance to antibiotics is an ongoing process 
which represents a growing problem for modern medicine. Vancomycin is used as a drug 
of last resort against methicillin-resistant Staphylococcus aureus (MRSA), but the 
increasing prevalence of vancomycin-resistant bacteria has intensified the search for new 
antibiotics. The introductory chapter of this thesis presents an overview of publications 
reporting the synthesis of glycopeptide analogues and derivatives in the last decade, 
highlighting the successful approaches which have brought new pharmaceutical drugs to 
the market.  
The results and discussion section of this work focusses first on the synthesis of a triaryl 
biether structure, which is a common feature of the glycopeptide antibiotic family and 
represents the beginning of a versatile synthetic approach towards natural products like 
orienticin C and vancomycin. The second discussion chapter describes the development 
of an asymmetric organocatalytic aza-Darzens aziridination protocol using diazopeptides 
and amino acid imines as substrates. A structurally diverse range of peptide aziridines are 
reported in yields and diastereoselectivity of up to 99%.  
It is anticipated that the remote asymmetric induction methodology described in this 
thesis will be applicable not only to the synthesis of novel glycopeptide antibiotics and 
other peptide-based pharmaceutical compounds, but also to the more general asymmetric 
synthesis of natural and unnatural amino acids. 
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CHAPTER ONE 
 
Synthesis of new glycopeptide antibiotics 
 
 
 
 
 
 
 
 
 
 
 
Note: Section 1.1-1.6 published as “Recent advances in the synthesis of new glycopeptide 
antibiotics”, P. Ashford and S. P. Bew, Chem. Soc. Rev., 2012, 41, 957. Reproduced by permission of 
the Royal Society of Chemistry. 
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1.1  History of vancomycin 
The discovery of vancomycin in 1956 was the dawn of a new age for antibacterial 
research, and over the last 50 years has led to the formation of a large class of 
compounds, natural and synthetic, known as the glycopeptide antibiotics. Scientists at Eli 
Lilly isolated vancomycin from the fermentation broth of Streptomyces orientalis, grown 
from a soil sample originating in the jungles of Borneo.1 It displays potent activity against 
a range of Gram-positive bacteria, with an in vitro minimum inhibitory concentration 
(MIC) of 0.25–10.0 µg mL-1 against Staphylococcus aureus.2 Vancomycin was approved 
by the FDA in 1958, but was initially limited in clinical use due to its apparent side 
effects,3 with methicillin becoming the antibiotic of choice against S. aureus. However, 
the sharp rise in drug-resistant strains, in particular the deadly methicillin-resistant 
Staphylococcus aureus (MRSA), has brought vancomycin back into the limelight, 
prompting a new wave of research into the chemistry and biology of this natural product. 
 
Figure 1.1 • Molecular structure of vancomycin (1) 
By 1989, a handful of glycopeptide antibiotics had been isolated and characterised. 
Among them, ristocetin (4) and teicoplanin (5) displayed antibacterial activity comparable 
to that of vancomycin (Figure 1.2).4 Avoparcin (8) was widely used as a growth promoter 
in animal feed until a link was established between its use and the increased prevalence of 
vancomycin-resistant enterococci (VRE) in the food industry.5 The use of avoparcin was 
banned in all EU countries by 1997.  
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 Figure 1.2 • The vancomycin family of glycopeptide antibiotics 
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While vancomycin continues to be a crucial drug of last resort, the rise in geographically 
isolated human cases of VRE and the appearance of vancomycin-resistant Staphylococcus 
aureus (VRSA)6 has signalled urgent research into the development of potent 
glycopeptide-based antibiotics in both an academic setting and in pharmaceutical and 
medicinal laboratories within industry. In the last ten years there has been increasing 
global interest in the design and development of semi-synthetic variants of natural 
product glycopeptides which have been aimed at providing a solution to this problem, 
either by modification of the existing scaffold, by the introduction of hydrophobic 
moieties or by dimerisation.7 From recent reports, patterns of activity have emerged that 
may influence and direct future studies.  
1.2  Structure of the glycopeptide antibiotics 
Notable early attempts to elucidate the structure of vancomycin included rigorous NMR 
experiments carried out by D. H. Williams,8 and X-ray crystallography of a less complex 
degradation product by G. Sheldrick,9 but the precise structure was finally confirmed in 
1982 by Harris and Harris.10 Further NMR studies in 1993 showed that the glycopeptide 
exists mainly as a dimer in solution,11 and thanks to advances in X-ray crystallography 
this observation was confirmed by a full crystal structure of vancomycin in 1996, which 
also gave an accurate picture of the stereochemistry.12 The molecular structure of 
vancomycin consists of the C-O-D-O-E triaryl biether backbone forming two 16-
membered ring macrocycles with a heptapeptide framework (Figure 1.1). A 12-membered 
ring comprising the A-B biaryl system forms a third macrocycle. It is interesting to note 
the conserved triaryl biether moiety in this class of compounds (Figure 1.2). 
Chloro substitution of aromatic rings C and E and the strained nature of the macrocyclic 
systems causes vancomycin to adopt the low energy conformation (atropisomer) shown in 
Figure 1.1. There is no rotation of the C or D rings about the adjacent C–C and C–O 
bonds at ambient temperature; a study by Boger showed that D-O-E ring of vancomycin 
algycon is able to undergo thermal interconversion to the unnatural atropisomer at 110 °C 
in o-dichlorobenzene with a half-life of 94 h.13  
There is a second region of atropisomerism associated with the A-B biaryl system, giving 
a total of 8 possible atropisomers and 18 chiral carbon centres. Selecting the natural 
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product atropisomer is therefore an important consideration when constructing these large 
ring systems.  
A characteristic vancomycin feature is the disaccharide moiety mounted on the D ring, 
which consists of a β-D-glucose unit attached to a unique amino-sugar, vancosamine. Of 
the naturally-occuring glycopeptides, orienticin C (2), chloroeremomycin (6) and 
balhimycin (7) possess an additional carbohydrate unit on amino acid residue 6, β-
hydroxytyrosine, (L-vancosamine, L-4-epivancosamine and 4-oxovancosamine 
respectively). Teicoplanin (5) is one of the most complex members of the vancomycin 
family, with N-acetyl-β-D-glucosamine and D-mannose at residue 6 and 7 respectively, 
and a nine-carbon chain appended to the top of the molecule, as well as an additional 14-
membered macrocycle (F-O-G). The complestatin sub-group discussed later in this 
review contains a tryptophan moiety in place of the D-O-E macrocycle. 
1.3  Mode of action  
Bacterial cell walls contain a semi-rigid polymer called peptidoglycan, or murein, which 
acts as a structural support. The peptidoglycan monomers consist of peptide and 
disaccharide units that are joined in long chains by glycosidic bonds via 
transglycosidation. Cross-linking of the chains, or transpeptidation, affords the polymer a 
rigid framework. The glycopeptide antibiotics are able to pass through the peptidoglycan 
layer to the site of polymerisation, whereupon they form non-covalent bonds with the 
terminal carbohydrates, in a process that ultimately inhibits cross-linking by the 
transpeptidase enzyme. The weakened cell wall is no longer able to withstand the positive 
osmotic pressure within the cell, leading to cytolysis and bacteria death.  
Previous NMR and X-ray studies14 indicate that vancomycin binds to the L-Lys-D-Ala-D-
Ala terminus of the peptidoglycan precursor via five hydrogen bonds (Figure 1.3a). It is 
interesting to note that a number of glycopeptides, such as vancomycin and ristocetin, 
have the ability to dimerise in aqueous solution. Dimerisation is of particular importance 
because glycopeptides such as eremomycin, with a high dimerisation constant (ca. 106 M-
1) are potent antibiotics even though binding to cell wall analogs is only moderate (Kb ca. 
104 M-1).15  
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Figure 1.3 • Vancomycin binding to a) D-Ala-D-Ala terminus of susceptible bacteria and 
b) D-Ala-D-Lac terminus of resistant strains 
X-ray crystallographic investigations by Sheldrick et al. in 1996 revealed the dimerisation 
activity of vancomycin (Figure 1.4), but recent X-ray crystal structures by Nitanai et al. 
provide a more detailed picture of the ‘‘back-to-back’’, ‘‘face-to-face’’ and ‘‘side-to-
side’’ arrangements observed in vancomycin binding to analogues of the peptidoglycan 
terminus (Figure 1.4). Teicoplanin (5) is unable to dimerise in solution, but contains a 
structural feature that is absent in vancomycin: an N-acylglucosamine moiety containing a 
2-methyloctanyl chain (in the dominant component, teicoplanin A2-2). It has been shown 
that this lipophilic tail anchors the antibiotic to the phospholipid bilayer of the bacterial 
cell membrane.15 
 
Figure 1.4 • Stereoview of the vancomycin dimer by Sheldrick et al.12 (left) Stereoview 
by Nitanai et al. showing the vancomycin dimer-to-dimer structure in the L-Lys-D-Ala-
D-Ala complex.18 (right) 
Changes in the structure of the peptidoglycan termini lead to vancomycin resistance. The 
most common phenotypes of vancomycin-resistant enterococci (VRE), VanA and VanB, 
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were found to have a D-lactate terminus in place of D-alanine.16 This removes one of the 
hydrogen bonding interactions and leads to lone pair-lone pair repulsion (Figure 1.3b). A 
comprehensive review covering the mode of action of the glycopeptides antibiotics and 
the mechanisms of bacterial resistance has been compiled by Walsh and Kahne et al.17 
1.4 Semi-synthetic glycopeptide antibiotics 
1.4.1 Oritavancin, telavancin and dalbavancin18 
Early studies by Nagarajan et al. into the development of semi-synthetic glycopeptide 
antibiotics focused on utilizing vancomycin as a structural starting point, but the 
inadequate activity of vancomycin analogues19 led to the selection of alternatives like 
teicoplanin (5) and chloroeremomycin (6) as platforms for novel glycopeptide 
elaboration. Structurally similar to teicoplanin (5) is the semi-synthetic compound 
dalbavancin (9) which is appended with an additional amide group at the C-terminus. 
Dalbavancin has come close to clinical success, and is currently undergoing phase III 
clinical trials funded by Durata Therapeutics.i Although its activity is similar to that of 
teicoplanin, the semi-synthetic compound has a remarkably long half-life of ca. 7 days as 
a result of strong binding to serum proteins.20 By comparison, vancomycin has an 
elimination half-life of 3–9 h.21 A drug that remains in the blood plasma for longer 
requires less frequent dosing, and is therefore clinically and economically advantageous. 
 
Figure 1.5 • Molecular structure of oritavancin (10) 
                                                          
i Since publication of this review, Dalbavancin has been approved by the FDA for the treatment of bacterial 
skin infections (May 2014).  
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Oritavancin (10) (Figure 1.5) is derived from chloroeremomycin (6) (Figure 1.2). The key 
modification of natural product 6 was the installation of a 4’-chlorobiphenylmethylene 
group, which affords oritavancin an additional mode of action that is absent from 
vancomycin; recent investigations have shown that this biaryl group is involved in cell 
membrane depolarisation and an increase in membrane permeability.22 As a consequence 
of this dual-action mechanism, oritavancin has excellent in vitro activity against gram 
positive bacteria, with MICs in the range of 0.004–1 µg mL-1 against VRE,23 and is 
currently in phase III clinical trials funded by The Medicines Company for the treatment 
of acute bacterial skin and skin structure infections (ABSSSIs).  
A derivative of vancomycin, telavancin (3) (Figure 1.2) also follows the pattern of N-
alkylation of the vancosamine moiety with a hydrophobic chain, in this case a 
decylaminoethyl group. In addition, a methylaminophosphonate group was installed on 
the A-ring of the A-B biaryl region for its hydrophilic properties, which improved the 
absorption, distribution, metabolism and excretion (ADME) profile of the compound.24 
With excellent activity against both VRE and VRSA, telavancin was approved by the 
FDA in September 2009 for complicated skin and skin structure infections (cSSSI). The 
success of these three semi-synthetic glycopeptides as drug candidates and their potent 
antibacterial activities in comparison to vancomycin,25 has encouraged further research in 
the field of glycopeptide modification. The structure–activity relationships of telavancin, 
dalbavancin and oritavancin have provided valuable information about the modes of 
action that this class of compounds possess, with the results having a significant influence 
on future drug design. 
 
1.4.2  Modification of the amino acids within the polypeptide chain 
The challenge of where and how to successfully modify existing natural products can be 
approached in different ways. The glycopeptide antibiotics are large, complex molecules 
with plenty of potential for N- and O-alkylation as well as changes to the component 
amino acids of the heptapeptide chain. Even the chloro substituents of the triaryl biether 
backbone can be envisaged as sites of reactivity and as such are viable sites for chemical 
transformation. 
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Figure 1.6 • Amino acid residues 1-7 of vancomycin (parent amino acids of the 
biosynthetic pathway are labelled in parentheses) 
Modifications of amino acid residue 3 (Figure 1.6) were first reported by Boger et al. in 
2002. In the process of developing a total synthesis of vancomycin,26 the Boger group 
noted that an intermediate containing a nitrile group at residue 3 rather than the 
carboxamide of asparagine showed increased biological activity against vancomycin-
sensitive and resistant bacteria. Various vancomycin and vancomycin aglycon analogues 
containing this modification were synthesised and evaluated.27 Compound 11 was 
identified as having the best overall activity against a range of relevant bacteria, with 
promising activity against VRE (VanB) compared to vancomycin (Figure 1.7).  
 
Figure 1.7 • Vancomycin aglycon nitrile methyl ether derivative generated by Boger et 
al. 
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However, despite the promising antibacterial activity of compound 11,  the nitrile 
derivatives were generally less active than the corresponding carboxamide. Crucially, 
removal of the four methyl ether modifications of 11 as well as hydrolysis of the methyl 
ester resulted in significantly lower activity, with an increase in the MIC against S. aureus 
from 0.625 to 10 µg mL-1. The effect of methylation is therefore clearly more pronounced 
than that of amino acid modification. When subjected to D-Ala-D-Ala peptide binding 
tests, nitrile derivative 11 and its corresponding carboxamide showed binding constants 
that were comparable to vancomycin (Ka = 9.9 x 10
5, 2.0 x 105 and 2.3–3.9 x 105 
respectively). Boger suggested that this result may be due to the increased hydrophobicity 
of these compounds, mimicking the effect of the hydrophobic chain in teicoplanin.  
A subsequent study on the activity of vancomycin-derived methyl ether analogues 
demonstrated that O-methylation of the phenolic hydroxyl groups can have mixed results 
with regard to the biological activity.28 O-methylated derivatives of vancomycin, 
teicoplanin and ristocetin were prepared from the corresponding aglycons using the 
following general procedure: N-Boc protection of the amine terminus followed by O-
methylation by trimethylsilyldiazomethane and removal of the Boc group by 4N 
hydrochloric acid in dioxane. Activity against S. aureus by 12 decreased by half 
compared to vancomycin and its aglycon, but a significant improvement in activity was 
observed against the VRE VanB phenotype (Figure 1.8). Similarly, compound 13 
performed better against VRE (VanB) than the parent compound, ristocetin, but was less 
active against S. aureus. In all cases the improvements in antibacterial activity afforded 
by methyl ether derivatisation clearly demonstrated the potential of O-alkylation as a 
protocol for the development of more potent vancomycin analogues. 
 
Figure 1.8 • Methyl ether derivatives of a) vancomycin aglycon and b) ristocetin aglycon 
by Boger et al. 
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While many of the novel vancomycin derivatives discussed later in this review rely on the 
addition of groups by alkylation etc., a limited amount of work has been undertaken on 
modifying the peptide backbone of vancomycin itself. Modification of the peptide 
backbone presents a considerable synthetic challenge, as changes to the internal peptide 
structure may involve a full synthesis of the compound rather than simple manipulation of 
naturally sourced material. Using their experience of vancomycin total synthesis, the 
Boger group developed an analogue that was specifically designed to target vancomycin 
resistant organisms (Figure 1.9).16 Compound 17 contains a modification in amino acid 
residue 4 (boxed), which is equipped with a methylene group in place of an amide 
carbonyl. The effect of this small change is to remove the oxygen-oxygen repulsion 
responsible for the observed decrease in binding affinity of vancomycin for the D-Ala-D-
Lac terminus in the peptidoglycan of VRE type A and B. 
 
Figure 1.9 • Predicted interaction between vancomycin aglycon derivative 17 and the D-
Ala-D-Lac peptidoglycan terminus (Boger et al.). 
Analogue 17 was prepared by a similar route to the previously reported total synthesis of 
vancomycin, with changes to the synthesis of the B and D-ring regions (Scheme 1.1). 
Thus intermediate 16 was synthesised via a reductive amination reaction between (R)-
methyl 2-amino-2-(3-bromo-4-methoxyphenyl)acetate 14 and (R)-tert-butyl-(1-(3,5-
bis(benzyloxy)-4-methoxyphenyl)-2-oxoethyl)carbamate 15 in place of the standard 
peptide coupling procedure.  
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Scheme 1.1 • Construction of a modified polypeptide chain for incorporation into 
vancomycin derivative 17 (Boger et al.) 
Gratifyingly, the design of analogue 17 improved affinity by removing lone pair 
repulsion, but relies on the strength of the four remaining hydrogen bonds involved in the 
interaction. Boger recognised that while affinity for D-Ala-D-Lac could be improved 
further by engineering a reverse hydrogen bond into the molecule, this may be clinically 
disadvantageous as it would disrupt H-bonding to D-Ala-D-Ala. The result would 
therefore be reduced activity against vancomycin-sensitive bacteria as well as resistant 
strains such as VanA that initially use the D-Ala-D-Ala terminus.  
In binding tests, compound 17 proved to exhibit the desired dual-binding properties, with 
a 40-fold increase in affinity for D-Ala-D-Lac compared to vancomycin and conversely a 
35-fold decrease in affinity for D-Ala-D-Ala, giving it the potential to be equally effective 
against both vancomycin-sensitive and resistant bacteria. Crucially, this analogue has an 
MIC of 31 µg mL-1 against VRE (VanA), the most challenging of the resistant bacteria to 
combat by synthetic design. This compares favourably to the values for vancomycin 
(2000 µg mL-1) and the aglycon (640 µg mL-1) but remains higher than the MIC of <1 µg 
mL-1 generally required for clinical applications. 
 
Scheme 1.2 • Synthesis of protected hydrazine-containing amino acid 22 reported by 
Boger and Crane 
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The Boger group turned next to the N-methyl-L-leucine residue of vancomycin (residue 
1). The aim of this investigation was to introduce additional hydrogen bonding to the 
peptidoglycan terminus away from the binding pocket of the molecule. Taking this idea 
further, they predicted that nucleophilic substituents might form a covalent attachment to 
D-Ala-D-Ala or D-Ala-D-Lac. With this in mind, a series of hydrazine-containing 
derivatives of vancomycin were synthesised and tested for their antibacterial activity.29 
Preparation of the modified amino acid is shown in Scheme 1.2. Reduction of (R)-Boc-N-
methyl-3-cyanophenylalanine methyl ester 18 by RANEY® Ni, hydrogen and 28% 
aqueous ammonium hydroxide in methanol afforded the corresponding methylamine 19. 
Amination with oxaziridine 20 afforded N-Boc protected hydrazine 21 in a 58% yield. 
Finally, lithium hydroxide hydrolysis of the methyl ester (and a second N-Boc protection) 
afforded 22, the free acid substrate for peptide coupling. 
 
Figure 1.10 • Vancomycin benzylhydrazine derivative generated by Boger et al. 
Compound 23 (Figure 1.10) had the same activity against S. aureus as vancomycin (MIC 
= 1.23 µg mL-1), and activity against VRE remained poor. There was no evidence of a 
general trend in the activity of the hydrazine-containing derivatives or of an improvement 
in activity arising from exchange of the natural product N-terminal amino acid for those 
containing H-bond donors or reactive nucleophiles. Attempts to use the hydrazine group 
to form a covalent adduct between the vancomycin derivatives and the C-terminal ester of 
D-Ala-D-Lac were unsuccessful, even though this reaction could be carried out between 
the peptidoglycan chain and phenyl hydrazine. 
Several members of the glycopeptide antibiotic family are appended with chlorine 
substituents on the aryl ring of β-hydroxytyrosine amino acid residues 2 and 6 (Figure 
1.6), and the significance of these halogen atoms has been examined through structure–
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activity relationship (SAR) studies. The presence of chlorine atoms has been shown to 
strongly enhance the potency of the compounds, probably as a result of their stabilising 
role in dimerisation.12 In order to investigate the importance of the chlorine atoms further, 
Sussmuth et al. synthesised a series of balhimycin variants containing chlorine, bromine 
and fluorine substituents (Figure 1.11).30,31 
 
Figure 1.11 • Fluorobalhimycin 24 (top), bromobalhimycin 25 and chlorobromobalhimycins 26 
and 27 by Süssmuth et al. 
Fluorobalhimycin (24) was produced via an enzymatic procedure to incorporate 3-fluoro-
β-hydroxytyrosine into the glycopeptide in place of the chlorinated amino acid. In a 
subsequent report, calcium chloride and magnesium chloride (1:1 ratio) were substituted 
by the corresponding bromide salts in the culture media of the balhimycin-producing 
Amycolatopsis balhimycina, resulting in the synthesis of bromobalhimycin 25. Attempts 
to incorporate fluoride and iodide atoms by this method failed due to the toxicity of the 
salts. When equimolar amounts of bromide and chloride salts were added, a product with 
one bromine and one chlorine atom was observed in addition to the balhimycin and 
bromobalhimycin products. The hetero-halogen species was shown by mass spectrometry 
to be present as positional isomers 26 and 27 (1:1 ratio). Bromobalhimycin 25 showed 
similar in vitro antibacterial activity to balhimycin, with the exception of an 8-fold 
increase in MIC against S. aureus. Balhimycin 24 and bromobalhimycin 25 both 
performed up to 16 times better than dechlorobalhimycin against Gram-positive bacteria, 
confirming the important role that halogen substituents play within the glycopeptide 
family. 
Following earlier work on the synthesis of chloroorienticin B derivatives,32 Yasukata et 
al. turned to extending the heptapeptide chain as a possible method of improving 
antibiotic activity. Chloroorienticin B derivatives bearing a tripeptide chain at the C-
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terminus were prepared by solid-phase parallel synthesis, allowing fast access to a library 
of over 80 compounds.33 These compounds were tested for antibacterial activity against 
MRSA and VRE; a selection of the data is presented in Table 1.1. Compounds that 
incorporated tryptophan and tyrosine residues, such as 28 and 29, were found to exhibit 
activity against VRE as well as matching the activity of the parent compound against 
MRSA. As a general rule, the tryptophan residue in particular was crucial for activity 
against VRE. The introduction of glutamic acid totally removed anti-VRE properties of 
the compound. Yasukata et al. concluded that amino acid residues with basic and 
hydrophobic character provided the most potent derivatives.  
 
Table 1.1 • MICs (µg mL-1) of chloroorienticin B tripeptide derivatives by Yasukata et al. 
 
                           
A1-A2-A3 
Staph. aureus 
SR3637 (MRSA) 
E. faecalis 
SR7914a 
E. faecium 
SR7917a 
28: Leu-Trp-Tyr 0.5 16 8 
29: Tyr-Trp-His 0.5 16 8 
30: Trp-Lys-His <0.125 64 8 
31: Glu-Trp-Tyr 8 >128 >128 
Chloroorienticin B 0.5 >128 >128 
a Vancomycin-resistant enterococci (VanA) 
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1.4.3  Introduction of hydrophobic side chains to the peripheral glycopeptide 
structure 
Many of the early modifications of vancomycin and the glycopeptide family involved the 
addition of hydrophobic chains to the molecule, frequently at the vancosamine nitrogen 
atom.34 These derivatives mimicked the natural hydrophobic character of teicoplanin (5) 
(Figure 1.2), but alkylation of the polar hydroxyl, acid and amino groups can compromise 
the naturally high aqueous solubility of the parent compound. 
 
Scheme 1.3 • Double modification of chloroorienticin B by Yasukata et al. 
Yasukata et al.35 proposed a solution to this problem with a double modification of 
chloroorienticin B, inspired by earlier work on the double modification of teicoplanin by 
Preobrazhenskaya et al.36 In the first step, protection of the amino peptide terminal with a 
para-methoxybenzyloxycarbonyl (pMZ) group was followed by N-alkylation of the 
amino sugar with (E)-4-(4-chlorostyryl)benzaldehyde 33 (Scheme 1.3). Subsequent pMZ 
removal afforded 34. This compound has a higher antibacterial activity than 
chloroorienticin B or vancomycin but the hydrochloride salt has <1% solubility in water, 
compared to that of vancomycin, which is >99% soluble in water. The second step 
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employed a Mannich reaction previously reported by the Preobrazhenskaya group37 to 
introduce a hydrophilic aminoalkyl group into the A-B biaryl region of the molecule. 
Thus the reaction of 34 with 5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-6-methylamine 
35 under Mannich conditions afforded doubly-modified derivative 36. Compound 36 
exhibited MICs of 0.78 µg mL-1 against MRSA (compared to 1.56 µg mL-1 for 
vancomycin) and 3.13–6.25 µg mL-1 against VRE (VanA). Crucially, the aqueous 
solubility of the hydrochloride salt was increased to 10% by the second modification.  
 
Scheme 1.4 • Vancomycin glycorandomisation process by Thorson et al. 
Vancomycin derivatives that contain hydrophobic side chains are disadvantaged by their 
poor solubility. Yasukata et al. have demonstrated that secondary modifications on these 
glycopeptides can successfully increase solubility, hence making them more suitable for 
clinical use. One of the most versatile and currently widely employed methods of ligation 
is the Huisgen or Click reaction; a copper catalysed 1,3-dipolar cycloaddition reaction 
between an azide and an alkyne. The application of Click chemistry for glycopeptides 
modification was first reported in 2005 by Thorson et al., who used a chemoenzymatic 
approach to install 6-azido glucose onto the vancomycin aglycon for subsequent 
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glycorandomization (Scheme 1.4).38 Batta and Herczegh employed the Click reaction for 
the synthesis of ristocetin and teicoplanin aglycon derivatives bearing a hydrophobic side 
chain.39 The N-termini of the glycopeptide aglycons were converted to an azide 
functionality via a diazo transfer reaction of the amine with triflic azide and catalytic 
amounts of copper(II) sulfate in pyridine. The alkyne substrates were prepared by 
propargylation of the corresponding alcohols (Scheme 1.5).  
 
Scheme 1.5 • Click chemistry for the generation of novel teicoplanin aglycon derivatives 
by Batta and Herczegh et al. (2009) 
Reaction between the azide and alkyne with 10% CuI and triethylamine at room 
temperature afforded the 1,4-substituted 1,2,3-triazoles in 44–71% yield. The teicoplanin 
derivatives showed much higher activity than the parent compound, with 42 and 43 being 
potent against both VanA and VanB phenotypes of resistant enterococci (MICs of 0.5 µg 
mL-1 in both cases). Batta and Herczegh postulated that the amphiphilic nature of these 
derivatives (the presence of the carboxylate group and a lipophilic side chain) favours the 
formation of a multivalent aggregate in aqueous medium, contributing to increased 
antibacterial activity. Compound 44, a product of esterification at the C-terminus, showed 
decreased activity overall, and removal of the N-acetyl glucosamyl group at R1 
(compound 45) drastically reduced potency against vancomycin-resistant and susceptible 
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strains. The presence of this sugar is key to the biological activity of these compounds. 
The ristocetin derivatives lost all antibacterial activity, although the ristocetin azide 
intermediate matched the activity of vancomycin against MRSA (MIC = 2 µg mL-1). 
Further work by Herczegh et al. employed the Click reaction to add a saccharide moiety 
to the N-terminus of ristocetin aglycon (Figure 1.12).40 This modification was shown to 
improve both antibacterial and anti-influenza activity of the glycopeptide. 
 
Figure 1.12 • Ristocetin triazole saccharide derivatives generated by Herczegh et al. 
 
The anti-influenza virus properties of ristocetin algycon derivatives were reported by 
Sztaricskai and Naesens in 2009, with the synthesis of a series of compounds bearing 
hydrophobic chains via a cyclobutenedione linker (Table 1.2).41 Coupling of the ristocetin 
aglycon with dimethyl squarate and subsequent reaction with various primary amines 
afforded the corresponding asymmetric squaric diamides. The mild reaction conditions 
are a notable advantage of this ligation method. Furthermore, the lead compound in the 
series, 4-phenylbenzyl derivative 53, showed excellent anti-viral activity against influenza 
A and B strains, with an average EC50 of 0.4 µM, which compares favourably with 
antiinfluenza drugs currently on the market, including ribavirin (8.4 µM) and oseltamivir 
(2.8 µM).  
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Interestingly, the corresponding aglycovancomycin derivatives showed no antiviral 
activity, suggesting that the core aglycoristocetin structure is essential for antiviral 
activity. There are a number of differences between the two compounds; ristocetin 
contains additional aromatic rings F and G, connected via a diphenylether linkage, and 
features a methyl ester at the C-terminus instead of the free carboxylic acid, but lacks the 
chloro substituents of lvancomycin. It is unclear which of these properties contributes to 
the antiviral characteristics of aglycoristocetin derivatives. 
Table 1.2 • Squaric diamide derivatives of ristocetin aglycon by Naesens and Sztaricskai 
et al. 
 
 
a Influenza A/H3N2 
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Figure 1.13 • Adamantyl-containing eremomycin amides generated by Preobrazhenskaya 
et al. 
 
Following work on the modification of eremomycin by the incorporation of hydrophobic 
sugar substituents,42 Preobrazhenskaya et al. turned their attention to glycopeptides 
derivatives that were active against Bacillus anthracis. With this in mind they generated a 
series of eremomycin and vancomycin derivatives appended with an adamantyl amide 
moiety (Figure 1.13).43  
Anthrax has attracted much attention in the media as a biological weapon, and the 
mortality rate of patients who are infected by inhalation remains high. The appearance of 
drug-resistant strains of Bacillus anthracis indicates a particular need for the development 
of new compounds that are effective against these bacteria. The most potent compound in 
the series, adamantyl-2-amide eremomycin derivative 59 (Figure 1.13) showed wide-
ranging potency against vancomycin-susceptible, intermediate and resistant strains of S. 
aureus, E. faecalis and E. faecium (MIC = 0.25–8 µg mL-1).  
 
 
Figure 1.14 • Structure of anti-anthrax drug ciprofloxacin (63)  
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Compound 59 also proved to be very effective against Bacillus anthracis in in vivo 
testing, while it showed excellent in vitro activity against strains that are resistant to 
ciprofloxacin (63), the current drug of choice for treatment of anthrax poisoning (Figure 
1.14). 
 
Scheme 1.6 • Application of the Suzuki-Miyaura cross-coupling on vancomycin by 
Arimoto et al. 
Given the importance of the aryl halide derived glycopeptides and the multitude of 
transition metal-based protocols available to the chemist, it is interesting to note that it 
was not until 2010 that investigations probing their chemical transformation were 
undertaken. Focusing on amino acid residues 2 and 6, Arimoto et al. reported the 
application of a Suzuki-Miyaura coupling procedure using trans-2-(4-
biphenyl)vinylboronic acid as the key coupling agent.44  
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Vancomycin has poor solubility in most organic solvents but high solubility in water. In a 
procedure that did not require any protecting group strategies Arimoto et al. reported the 
first example of a Suzuki coupling conducted in aqueous solution on a complex natural 
product. The protocol utilises a water-soluble catalyst combination using ligand 64, 
originally developed for the Suzuki-Miyaura coupling reaction by Buchwald et al.45 The 
synthesis of derivatives 65–70 was readily performed in the presence of the 
corresponding boronic acid, 20 mol% of palladium(II) acetate, sodium acetate (10 equiv.) 
and water soluble phosphine ligand sodium 2-dicyclohexylphosphino-20,60-
dimethoxybiphenyl-30-sulfonate 64 (0.4 equiv.) (Scheme 1.6).  
 
Scheme 1.7 • Suzuki-Miyaura coupling of vancomycin with octenylboronic acid by 
Arimoto et al. 
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Although the aryl boronic acids used to generate derivatives 65–69 were found to have 
low reactivity towards vancomycin, those that did react did so with good selectivity. 2D 
1H-NMR studies showed that C–C bond formation occurred only at residue 2, where the 
chloro substituent is on the less-hindered side of the molecule. Alkenylboronic acids were 
found to be more reactive; the reaction between vancomycin and octenylboronic acid 
afforded mono-substituted product 70 in a 42% yield, and di-substituted product 71 in a 
30% yield (Scheme 1.7). 
Novel vancomycin derivatives 65–71 were tested for their biological activity against a 
range of vancomycin resistant and susceptible bacteria. Simple aryl substitution of 
vancomycin at residue 2 (compounds 65 and 66) gave a minor decrease in activity against 
vancomycin-susceptible bacteria and these derivatives remained inactive against VRE and 
VRSA. Styryl derivative 67 showed activity against VRSA (16 µg mL-1) but this property 
was lost as the size of the substituent increased; 68 and 69 were inactive against VRSA 
but did exhibit activity against VRE (VanB). The overall antibacterial activity of 
compound 69 was particularly promising, with better activity against MRSA than 
vancomycin, and excellent activity against the VanB phenotype of vancomycin resistant 
E. faecium (MIC 0.5 µg mL-1). Disubstituted products showed no activity against 
vancomycin-resistant bacteria, and importantly, also lost activity against vancomycin-
susceptible strains. Arimoto et al. concluded that this behaviour is due to unfavourable 
steric interactions between the large substituent on residue 6 and the D-Ala-D-Ala peptide 
terminus, citing the reduced binding affinity of 71 for the D-Ala-D-Ala dipeptide 
compared to mono-substituted product 70 (KD = 11.6 µM and 3.77 µM respectively). 
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1.5  Glycopeptide dimerisation studies 
Glycopeptide antibiotics are known to dimerise spontaneously in aqueous solution. 
Furthermore, dimerisation contributes to their potency. A 1999 study by Williams and 
Cooper used Surface Plasmon Resonance analysis to show that vancomycin, which 
dimerises weakly, has a low binding affinity for –Lys-D-Ala-D-Lac peptides found in 
VRE, whereas strongly dimerising antibiotics like chloroeremomycin had a higher 
binding affinity for the VRE mimic.46 In the search for improved biological activity, a 
number of investigations have aimed to harness or exploit this characteristic by 
synthesizing covalently-linked glycopeptide dimers. In the design of effective dimers 
there are a number of options to consider: the site of dimerisation, the length and nature of 
the bridge, and the reaction employed for ligation. 
Following a successful total synthesis of vancomycin, the Nicolaou group began to 
investigate the efficient synthesis of covalently-linked vancomycin dimers using target-
accelerated combinatorial synthesis (TACS).47 TACS allows the simultaneous evaluation 
of the effect of both the length of the linker and modifications in the binding pocket on 
the activity of the novel compounds produced. Initiating this study, the nitrogen atom of 
the vancosamine sugar was chosen as the linking site of dimerisation, and two ligation 
methods were tested; disulfide formation and olefin metathesis (Scheme 1.8). 
Saponification of thioacetate 72 in aqueous sodium hydroxide at 23 °C gave the 
corresponding disulfide 73, one of the most biologically active in a series consisting of 
tether lengths n = 3–9. Finding suitable conditions for an aqueous olefin metathesis 
proved more challenging, but the reaction proceeded smoothly in a mixed solvent system 
(H2O/DCM 95:5) with a phase transfer catalyst, trimethyldodecylammonium bromide, 
and Grubbs 1st generation catalyst, at room temperature. In each case the dimer was 
isolated as a 1:1 mix of cis and trans isomers in the olefin bridge in a 30–80% yield. The 
novel dimers were tested for activity against a range of vancomycin-susceptible and 
resistant strains of bacteria, and a number of general structure–activity trends were 
observed.  
 
 
CHAPTER  1    Synthesis of new glycopeptide antibiotics 
 
25 
 
 
 
Scheme 1.8 • Vancomycin dimers by disulfide formation n = 3 (top) and olefin 
metathesis n = 2 (bottom) by Nicolaou et al. 
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The antibacterial activity of both classes of dimer was found to be strongly dependant on 
the length of the tether employed, especially for the olefin-bridged dimers, where the 
optimum length was sixteen atoms between the vancosamine nitrogens (compound 75). 
Dimer 75 had MICs of 1–2 µg mL-1 against VRE (VanA) and vancomycin-intermediate 
S. Aureus, but antibacterial activity was lost on removal of the residue 1 D-leucine from 
the binding pocket. Of the disulfide dimers, compound 73 was particularly effective 
against VRE (VanA) with MICs of 0.06–0.5 µg mL-1 compared to the vancomycin MIC 
of 50–100 µg/mL. In this case, removal of amino acid residue 1 did not remove all 
antibacterial activity of the dimer, which retained MICs of 2 µg mL-1 against vancomycin 
susceptible enterococci and 2–16 µg mL-1 against VRE (VanA). 
With promising biological results using the traditional synthetic approach described 
above, the Nicolaou group turned to applying a combinatorial methodology that allows an 
array of building blocks to assemble and react in the presence of a biological target. The 
biologically optimal combination of building blocks is then generated as the most 
prevalent species. For this study, three vancomycin analogues with tethers of different 
lengths were mixed, and under olefin metathesis conditions the reaction was monitored by 
mass spectrometry. In the presence of the peptide terminus analogue (Ac2-L-Lys-D-Ala-
D-Ala), dimers with shorter tethers were formed preferentially, a result which matched 
the outcome of the antibacterial activity study. In conducting this study the Nicolaou 
group has therefore demonstrated that target induced rate acceleration is a powerful 
method for the rapid generation of biologically active dimers in the vancomycin family. 
The application of this approach to other biologically active systems would seem to hold 
promise for the development of more potent bioactive compounds. 
The precise mode of action of vancomycin dimers has been called into question by 
Ellman et al.,48 who compared the antibacterial activities of vancomycin and a series of 
tail-to-tail dimers with the corresponding desleucyl compounds, which were prepared by 
double Edman degradation (Scheme 1.9). Desleucyl vancomycin is unable to bind to L-
Lys-D-Ala- D-Ala, a fact that is attributed to the lack of the leucine amino acid in the 
binding pocket, and it is therefore inactive against vancomycin-susceptible or resistant 
bacteria. However, the desleucyl dimers performed well against VRE (VanA) strains, and 
showed only a 3.5-8-fold increase in MIC over the vancomycin dimers (Table 1.3). 
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Scheme 1.9 • Vancomycin tail-to-tail dimers, 76,77 and the corresponding desleucyl 
dimers 78,79 generated by Ellman et al. 
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Table 1.3 In vitro antibacterial activity and peptide model binding affinity (Ellman et al.) 
Compound MIC 
(µg/mL)a 
Kd (µM)
b 
Vancomycin 1200 1.3 
Desleucylvancomycin >1200 >60 
76 1.5 1.1 
77 1.5 2.1 
78 12 >60 
79 5.8 >60 
 
a Against E. Faecium (VanA). b Binding to dansyl-Lys(Ac)-D-Ala-D-Ala. 
 
Crucially, a binding affinity study showed that 79 did not bind to the peptide model 
dansyl-Lys(Ac)-D-Ala-D-Ala or to surface-immobilised L-Lys-D-Ala-D-Lac. This 
indicates that the in vitro behaviour of vancomycin dimers is due to an alternative 
mechanism.  
 
 
Figure 1.15 • Molecular structure of actinomycin D (80) 
Many of the previously reported dimers have been connected by long, flexible tethers, but 
a review of polyvalent interactions by Whitesides et al. highlighted the entropic 
disadvantages of such flexible linkers.49 Changing tack, Arimoto et al. investigated the 
effect that incorporating a rigid natural product scaffold from actinomycin 80 (Figure 
1.15) would have on the biological activity of vancomycin.50 Reductive alkylation of 
vancomycin with 2-benzyloxy-3-nitrobenzaldehyde 81 was followed by a one-pot 
catalytic hydrogenation that removed the benzyl protecting group and reduced the nitro 
group to an amine (Scheme 1.10).  
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Scheme 1.10 • Synthesis of actinomycin-inspired vancomycin dimers by Arimoto et al. 
The unstable product was subjected to dimerisation using quinine in methanol, and 
afforded dimer 83 in a good yield (68%). This procedure benefits from mild reaction 
conditions, good selectivity and high yields. Actinocin-based dimers 83–86 were prepared 
with variations in linker length and character (Figure 1.16), all of which showed good 
stability in vivo. 
 
Figure 1.16 • Structure of actinomycin-inspired dimers by Arimoto et al. (R = 
vancomycin) 
Dimers 83–86 were tested for biological activity against a range of vancomycin-
susceptible and resistant bacteria (Table 1.4). As predicted, the short, rigid linker gave the 
best activity; compound 83 showed particularly promising activity against VRE but 
somewhat lower potency against MRSA than vancomycin.  
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The low potency problem was overcome by changing the trifluoroacetate salt for the 
hydrochloride salt. This simple ‘‘anion switch’’ increased activity up to 32-fold. 
Furthermore, an in vivo study indicated that dimer 83 rivals the activity of the currently 
employed anti-pneumonia drug, linezolid, against S. pneumoniae. 
 
Table 1.4 Antibacterial activity of novel vancomycin dimers by Arimoto et al. 
 1 83 84 85 86 
S. aureus (MRSA) 1 16 (8) 32 16 (2) 32 
E. faecium  0.5 0.5 1 2 0.5 
E. faecium (VanA) >64 32 2 8 32 
E. faecium (VanB) >64 1 (0.25) 1 2 (0.5) 1 
S. aureus VRSA-2 >64 8 (4) - 32 (1) - 
S. pneumonia Type 1 0.5 0.125 (≤0.063) - 1 (0.25) - 
 
 
a MICs of the HCl salt shown in parentheses. 
 
Acknowledging that the synthesis of covalently-linked dimers can be time-consuming and 
problematic, the Xu group have focussed on developing a different strategy based on self-
assembly51 and coordination chemistry. In 2003 Xu et al. reported on the exploitation of 
the unique structural geometry and stability that metal complexes can afford in the 
formation of vancomycin dimers.52 Vancomycin reacted with the corresponding amine to 
give carboxamide derivatives 87a–d in high yields (>65%) (Figure 1.17).  
 
Figure 1.17 • Vancomycin carboxamide derivatives generated by Xu et al. 
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Figure 1.18 • Platinum-based vancomycin dimers by Xu et al. 
Subsequent co-ordination with cis-platin derivative [Pt(en)(H2O)2]
2+ in DMSO (20 h, rt, 
no light) afforded the dimeric complexes 88a–d (Figure 1.18). Platinum complex-based 
vancomycin dimers 88a–d exhibited higher biological activity against VRE than 
vancomycin itself, while retaining activity against vancomycin-susceptible enterococci 
(Table 1.5). Compounds 88a and 88c, with short chains, performed particularly well 
against a range of VRE, with MICs of 0.03–3.3 µg mL-1. Conversely, the more flexible 
dimers 88b and 88d lost activity against VRE (VanA) but remained relatively active 
against the VanB and VanC phenotypes, with MICs in the range of 0.05–4.8 µg mL-1. 
Crucially, platinum complex precursor 90 was completely inactive against gram positive 
bacteria, and vancomycin carboxamide derivatives 87a–d only showed activity against 
vancomycin-susceptible enterococci and VRE (VanC).  
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Table 1.5 • Antibacterial activity of Pt-based vancomycin dimers by Xu et al.  
 1: Vancomycin 88a 88b 88c 88d   
E. faecalis TCC29212 2 1 1 1 1   
E. faecalis (VanA) 576 0.8 14 3.3 38   
E.faecium (VanB) 102 0.28 2 1.2 4.8   
E. gallinarum (VanC) 8 0.03 0.05 1 1   
 
 
In this preliminary study, Xu et al. have shown that the rigid platinum complexes work 
well as linkers for the construction of multivalent inhibitors, but the cytotoxicity of such 
metal complexes is a factor that would need further investigation if the compounds were 
to find use in a clinical setting.  
 
Figure 1.19 • Mono- and divalent vancomycin-porphyrin conjugates generated by Xu et 
al. 
In a more recent study, Xu et al. demonstrated the potential for application of a divalent 
vancomycin-porphyrin conjugate within photodynamic antimicrobial chemotherapy 
(PACT).53 Porphyrin acts as a photosensitizer that generates a reactive oxygen species 
(ROS) on exposure to a suitable wavelength of light. The ROS causes cell death by 
attacking cell walls and membranes. The synthesis of a vancomycin-porphyrin conjugate 
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allowed PACT to accurately target areas of bacterial infection. Thus vancomycin was 
coupled to porphyrin using HBTU affording divalent conjugate 92 in a 54% yield (Figure 
1.19). The use of excess quantities of porphyrin afforded monovalent conjugate 91 in a 
53% yield. Both conjugates performed poorly against VRE (VanA and VanB) in the in 
vitro testing, with MICs in excess of 32 µg mL-1. However, divalent vancomycin-
porphyrin conjugate 92 proved to be a successful affinity ligand in PACT evaluation, 
efficiently directing the porphyrin moiety to the surface of vancomycin-resistant bacteria. 
The majority of studies investigating glycopeptide dimerisation use vancomycin as the 
parent compound because of its proven activity against Gram-positive bacteria, and 
because dimers of other members of the glycopeptide family are rarely seen in the 
literature.54 The exact structural requirements for good dimer activity remain elusive, 
though attempts to clarify patterns and trends have been made.  
 
Figure 1.20 Four sites of vancomycin ligation; vancosamine (V), N-terminus (N), C-
terminus (C) and resorcinol ring (R). 
Griffin et al. took a systematic approach to dimer design, identifying four sites of ligation; 
the C-terminus (C), N-terminus (N), vancosamine residue (V) and resorcinol ring (R) 
(Figure 1.20). Vancomycin synthons 93–96 were prepared using appropriate procedures; 
reductive alkylation was employed for preparation of the N and V synthons, amide bond 
formation for the C synthon and Mannich aminomethylation for the R synthon. The four 
vancomycin synthons 93–96 were connected in 10 unique combinations by linker 
synthons A-E to build an array of 40 dimers (Figure 1.21).55  
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Figure 1.21 • Synthons for an array of vancomycin dimers by Griffin et al. 
The V-V series was the most effective against vancomycin susceptible bacteria and the 
VRE E. faecalis VanB phenotype, whereas C-C, C-V and V-R combinations afforded 
broad spectrum activity, with MICs as low as 9.4 µg mL-1 against the VanA resistant 
strain. The shortest linker, A, which placed a total of 11 atoms between the vancomycin 
molecules, was preferred for activity against VRE (VanA and VanB), whereas activity 
against vancomycin-susceptible enterococci was generally unaffected by linker length. 
Ultimately, this comprehensive study did not reveal many easily comprehensible 
structure–activity relationships for the vancomycin dimers; potency remained highly 
dependent on the strain of bacteria. 
A key problem with the design of effective dimers is the ambiguity over the nature of the 
interactions between the dimers and the bacterial cells at a molecular level. The precise 
mode of action of the dimers has been called into question by several groups over the last 
decade, but there has been little investigation into the subject until earlier this year. The 
Arimoto group have recently reported the first biochemical study of the mechanism for 
vancomycin dimer activity.56 Previously reported actinocin-based dimers 83 and 84 
(Figure 1.16) were evaluated for their inhibitory action against bacterial macromolecules 
such as proteins, RNA, DNA, peptidoglycan and lipid biosynthesis. Vancomycin dimers 
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joined by the C-terminus of each monomer by the same actinocin linkers were also tested. 
The incorporation of radio-isotope-labelled precursors was used as a measure of activity 
for each process; protein synthesis (14C-leucine), DNA synthesis (14C-thymidine), RNA 
synthesis (3H-uracil) and fatty acid synthesis (14C-acetic acid) were unaffected by the 
presence of the vancomycin dimers, which exhibited selective inhibition of peptidoglycan 
synthesis (3H-N-acetyl-D-glucosamine). This represents the first experimental evidence 
that vancomycin and the dimers that are formed act as VRE cell wall synthesis 
suppressors. 
Table 1.6 Inhibition of lipid intermediate (LI) and peptidoglycan (PG) synthesis by 
vancomycin dimers (Arimoto et al.) 
 Susceptible Modela  Resistant Modela  
 LI PG LI PG 
Vancomycin 180 4.5 2300 85 
83 98 2.2 700 31 
84 74 11 300 61 
Van-M-02 32 4.2 76 36 
a IC50 (µg/ mL) 
 
Figure 1.22 • Structure of novel vancomycin derivative Van-M-02 generated by Arimoto 
et al. 
A sophisticated in vitro cell wall synthesis assay was then used to establish the effect of 
these compounds on the two stages in this process: lipid intermediate (LI) synthesis and 
peptidoglycan (PG) synthesis (Figure 1.23).  
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Figure 1.23 • In vitro inhibition assay of peptidoglycan (PG) synthesis in the bacterial 
membrane of S. aureus (Arimoto et al.). [Reproduced from Ref. 56.] 
Measurement of the radioactivity derived from 14C-labelled glycine was used to quantify 
the LI and the cross-linked peptidoglycan product. For vancomycin-resistant and 
susceptible models, the dimmers inhibit both steps in this process; LI and PG synthesis. 
This contrasts with vancomycin, which mainly inhibits peptidoglycan synthesis (Table 
1.6). Dimers 83 and 84 were able to inhibit both LI and PG synthesis in the resistant 
model, with greater inhibition of PG synthesis. A monomeric vancomycin derivative, 
with a modification at the vancosamine nitrogen, Van-M-02 (Figure 1.22), showed a 
different inhibition pattern to dimers also linked at the sugar moieties. 
The mode of action of dimers 83–84 and Van-M-02 can therefore be assumed to have 
significant differences. In the light of this recent study, the importance of the traditional 
‘‘binding pocket’’ of vancomycin to the activity of the dimers will inevitably re-emerge 
as a topic of debate. There is an urgent need for further biochemical studies that elucidate 
the details of dimer antibacterial activity and can subsequently inform the design of new 
and more effective vancomycin dimers. 
 
1.6  Synthesis of complestatin 
Complestatin (chloropeptin II) 98 (Figure 1.24) was first reported in the literature in 1980, 
as an inhibitor of the alternate pathway of human complement,57 although details of its 
original isolation from Streptomyces lavendulae and structural connectivity were not 
published until 1989.58 Both complestatin and the structurally related compound 
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chloropeptin I (97) were isolated from Streptomyces sp. WK3419 in 1997, and the full 
stereochemistry of these compounds were elucidated from NMR data.59 
 
Figure 1.24 Structure of the chloropeptins: chloropeptin I, complestatin (or chloropeptin 
II) and isocomplestatin 
The structure of the chloropeptins is reminiscent of the glycopeptides antibiotics, with 
two macrocycles formed by coupling of the amino acid groups in the linear peptide chain. 
While the left hand side of the molecule shares the characteristic biaryl ether linkage of 
the vancomycin family, the second macrocycle is formed by a tryptophan indole ring. 
Restricted axial rotation about the indole means that there are two possible atropisomers 
of each compound, and while the natural products 97 and 98 consist only of the (R)-
atropisomer, an (S)-atropisomer, isocomplestatin (99), has also been synthesised.60 
Compounds 97 and 98 differ only in the position of the junction between phenyl ring D 
and the indole ring E. Complestatin (98) can be easily converted to the less strained 
isomer, chloropeptin I (97), by an acid-catalysed rearrangement.61 Also of note is the α-
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keto amide moiety connecting aryl ring G to the polypeptide chain, a structural feature 
which is not present in the vancomycin family. 
Unlike the glycopeptide antibiotics, the chloropeptins show no activity against gram-
positive bacteria, but they have attracted considerable interest for their significant activity 
against HIV. Studies have shown that this class of compounds inhibits binding of the HIV 
gp-120 glycoprotein to the CD4 receptor of T-lymphocytes, thus preventing HIV 
infection of the cells.62 Isocomplestatin has also been shown to have activity against HIV 
integrase, the enzyme responsible for integration of viral DNA into the DNA of the 
infected cell.63 
 
Scheme 1.11 • Two macrocyclisation procedures for construction of the D-F ring of 
complestatin by Rich and Elder.  
While complestatin was isolated and characterised in the 1980s, synthetic studies have 
been slow to emerge. The challenges presented by this compound are centred around the 
atropisomerism of the D–F macrocycle and, as with vancomycin, finding an effective 
solution to the problematic biaryl ether formation/cyclisation step. Until 2000, only a 
handful of complestatin fragments had been synthesised.64 In the first of these, Gurjar et 
al. employed a Suzuki-Miyaura cross-coupling method to construct the aryl-indole C–C 
bond prior to cyclisation, but discovered that subsequent peptide coupling protocols could 
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not be used to complete this macrocycle.65 The problem was overcome by Rich and Elder 
two years later (Scheme 1.11).66 
The first stereoselective total synthesis of chloropeptin I was published in 2003 by 
Snapper and Hoveyda.67 The synthetic design involved a copper-mediated biaryl ether 
formation to close the B-O-D macrocycle followed by palladium-mediated cross-coupling 
to generate the D-F macrocycle (Scheme 1.12).  
 
Scheme 1.12 • D-F macrocyclisation step in the synthesis of Chloropeptin I reported by 
Snapper and Hoveyda 
For this key step, stannyl tryptophane 101 was incorporated via peptide coupling, 
affording intermediate 102. The subsequent cyclisation step was achieved with one 
equivalent of bis(tri-tertbutylphosphine) palladium(0), 10 equivalents of collidine and 
cesium fluoride (5 equiv.). The macrocyclisation product 103 was obtained in a 40% yield 
from 100. The addition of collidine (10 equiv.) to the standard conditions previously 
reported68 for this Stille-type C–C bond formation proved crucial to the efficiency of the 
reaction; in the absence of this additional base the reaction ceased after 30 minutes and 
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the solution turned black. Snapper and Hoveyda speculated that collidine has a role in the 
stabilization of the active palladium complex.  
 
Scheme 1.13 • Intramolecular Suzuki-Miyaura coupling and SNAr macrocyclisation steps 
by Zhu et al. 
After chloropeptin I, complestatin (chloropeptide II) became the next target for total 
synthesis. The Zhu group first chose to apply the well-used nucleophilic aromatic 
substitution reaction promoted by a nitro substituent on the aromatic ring to close the B-
O-D macrocycle (Scheme 1.13).69 The right hand side of the molecule was then 
constructed via an intramolecular Suzuki-Miyaura coupling reaction that completed 
assembly of the D-F macrocycle. It was during this study that Zhu et al. discovered that 
this approach resulted in the synthesis of the unnatural (S)-atropisomer, isocomplestatin. 
Reversing the order of cyclisation favoured the correct (R)-atropisomer, a conclusion also 
reached by the Boger group in their publication of the same year.70 Preparation of linear 
peptide 104 afforded the substrate for intramolecular Suzuki–Miyaura coupling with 1,10-
bis(diphenylphosphino)-ferrocene-palladium(II)dichloride, which afforded 105 in a 66% 
yield. NOE studies confirmed the (R) axial chirality of 105. The intramolecular SNAr 
reaction of 106 for the formation of the B-O-D biaryl ether linkage in 107 was achieved 
in a pleasing 62% yield under mild conditions. 
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Scheme 1.14 • Larock macrocyclisation by Boger et al. 
In a unique approach to the challenge of the D-F ring system of complestatin, Boger et al. 
investigated the use of an intramolecular Larock indole synthesis71 that would provide 
simultaneous construction of both the right-hand macrocycle and the five-membered 
indole ring (Scheme 1.14).70 Studies by Larock et al. indicated that the steric influence of 
a large terminal alkyne substituent, such as a triethylsilyl group, would induce the correct 
regioselectivity in the indole cyclisation process.72 The reaction was found to benefit from 
the incorporation of an electron-rich bidentate phosphine ligand, 1,10-bis(di-
tertbutylphosphino) ferrocene (DtBPF). Yields of up to 89% were obtained with aniline 
acetamide 108a, with 4:1 (R:S) atropodiastereoselectivity. However, incorporating the 
larger benzamide group, intermediate 108b, afforded >95% of the (R)-atropisomer in a 
70% yield. 
 
Scheme 1.15 • Intramolecular SNAr macrocyclisation for formation of the B-O-D biaryl 
ether linkage of complestatin (Boger et al.) 
These promising results were applied to a total synthesis of complestatin with great 
success. Taking a reverse approach to the order of macrocyclisation chosen by the Zhu 
group, the Boger group found that construction of the B-O-D ring system before indole 
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macrocyclisation produced better results. Thus intramolecular nucleophilic aromatic 
substitution of 110 with potassium carbonate at 60 °C for 12 h in the presence of 4 Å 
molecular sieves and 18-crown-6 afforded 111 in an excellent 95% yield (Scheme 1.15). 
The nitro substituent used as a promoter for this step was subsequently removed by a 
previously reported same two-step procedure.73 The alkyne required for Larock 
cyclisation, with its triethylsilyl substituent, was introduced as amino acid component 113 
(Scheme 1.16). Fmoc deprotection followed by peptide coupling afforded 114 in a 
quantitative yield ready for subsequent indole synthesis. Unlike analogue 108 on which 
the reaction conditions were developed, the substrate in the total synthesis contained a 
number of potentially problematic functional groups: notably the four unprotected 
phenols and ‘‘four labile aryl chlorides’’ (circled in Scheme 1.16).70 However, the 
intramolecular Larock cyclisation afforded 115 as a single (R)-atropisomer, in an 
unoptimised yield of 56%. The remaining triethylsilyl substituent was easily removed 
from the indole ring using dilute hydrochloric acid. 
 
Scheme 1.16 • Intramolecular Larock indole synthesis applied to the total synthesis of 
complestatin by Boger et al. 
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1.7 Latest developments in the synthesis of new glycopeptide antibiotic 
analoguesii 
Employing their expertise in the area of functionalisation of complex molecules,74 the 
Miller group investigated the site-selective bromination of the A-B ring of vancomycin 
(1) (Scheme 1.17), with the expectation that incorporating bromine into the binding 
pocket region of 1 would have an impact on its biological activity.75 To this end, peptide 
catalyst 116 was designed around the D-Ala-D-Ala dipeptide moiety known to have a 
good binding affinity for vancomycin (see Section 1.3). Catalyst 116 also features the 
N,N’-dimethylamido functionality which was anticipated to accelerate the rate of 
bromination in these reactions based on the observed efficiency and selectivity of the 
NBS-DMF reagent reported by Mitchell et al.76  
 
Scheme 1.17 • Site-selective monobromination of vancomycin reported by Miller and 
Pathak 
While the uncatalysed bromination of vancomycin with N-bromophthalimide 117 
afforded a 1:1 ratio of monobromination at the two available positions on ring A, the 
addition of catalyst 116 afforded compound 118 in a 41% yield on a preparative 100 mg 
scale. Dibromination of ring A was observed to be the major byproduct by HPLC analysis 
of the reaction mixture. Antibacterial studies carried out on these compounds showed that 
bromination of ring A failed to improve the biological activity of vancomycin against 
gram-positive bacteria. 
                                                          
ii Section 1.7 presents an overview of research reported in this area since publication of the following 
review:   P. Ashford and S. P. Bew, Chem. Soc. Rev., 2012, 41, 957. 
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A similar approach to the “chemical tailoring” of teicoplanin (5) afforded a series of 
brominated derivatives with potential as substrates for metal-catalysed cross-coupling 
reactions.77 With this in mind, the palladium(II) acetate catalysed Suzuki coupling of 
compound 119 with a series of aryl and alkyl boronic acids was carried out (Scheme 
1.18). The Suzuki reaction was initially unsuccessful, and [substrate+Pd] molecular ions 
were observed by LC-MS, indicating that the palladium species in the reaction was able 
to bind to teicoplanin, inhibiting catalysis. An unusually high catalyst loading of 50 mol% 
was therefore required for these reactions to take place. Thus compound 119 was coupled 
with 3-furanylboronic acid in the presence of water-soluble S-PHOS ligand 120 (1 equiv.) 
at 35 °C to afford product 121 in a 28% yield. Employing a higher temperature of 50 °C 
brought about a second Suzuki coupling reaction at the C-Cl bond on ring E to afford 
compound 122.   
 
Scheme 1.18 • Suzuki cross-coupling reaction of bromo-tericoplanin 119 reported by 
Miller and Pathak 
3-Furanyl substituted derivatives 121 and 122 showed slightly improved activity against 
MRSA compared to teicoplanin (MIC = 0.25 µg mL-1 compared to 0.5 µg mL-1 for 
teicoplanin A2-2) but were equally inactive against the VanE strain of vancomycin-
resistant enterococci.   
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Following their earlier work on the application of the Click reaction to the synthesis of 
novel teicoplanin derivatives (Section 1.4.3), Herczegh et al. set out to synthesise a series 
of fluorescent teicoplanin and ristocetin derivatives which could be used to elucidate their 
mode of action at the bacterial cell wall.78 Inspired by the early studies of Nagarajan et al. 
on the N-alkylation of glycopeptides described earlier in this review (Section 1.4.1), 
Herczegh et al. employed a three-component isoindole formation to tag the N-terminus of 
the peptide chain with a fluorescent moiety (Scheme 1.19).  
 
Scheme 1.20 • Synthesis of isoindole and benzoisoindole derivatives of teicoplanin 
aglycon reported by Herczegh et al. 
Thus teicoplanin pseudoaglycon 123 reacted with o-phthalaldehyde and an aryl or alkyl 
thiol at the N-terminus, affording a series of isoindole and benzoisoindole derivatives 
124-127 in moderate to good yields of 31–76%. The new compounds were tested against 
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a range of resistant and non-resistant bacteria, and almost all exhibited better MICs than 
the parent natural product, teicoplanin. Compound 125 in particular shows excellent 
broad activity against both VanA and VanB strains of resistant bacteria, with MICs of 
0.0313 µg mL-1 and 0.0625 µg mL-1 respectively, compared to values of >256 µg mL-1 
and 4 µg mL-1 for teicoplanin A2-2.   
Bacteria are known to be slow in developing resistance to cell membrane disrupting 
agents such as antimicrobial peptides.79 In order to counter bacterial resistance to 
vancomycin as well as increase its potency, Haldar et al. designed a series of derivatives 
bearing a permanent cationic quaternary ammonium moiety at the C-terminus (Figure 
1.25).80 These new glycopeptides were synthesised by coupling the carboxylic acid group 
of vancomycin with the desired amine using HBTU. This peptide coupling step was 
achieved in yields of 70-80% to afford compounds 128-134 bearing alkyl chains between 
2 and 18 carbons in length.  
 
Figure 1.25 • Alkyl quaternary ammonium trifluoroacetate derivatives of vancomycin 
reported by Haldar et al. 
Haldar et al. propose that the lipophilicity of the added alkyl chain disrupts the integrity 
of the bacterial cell membrane, while the permanent positive charge may strengthen the 
interaction between the antibiotic and the negatively charged bacterial membrane, 
“anchoring” the drug in place. By adding a secondary mode of action to the inherent 
antibacterial activity of vancomycin, Haldar et al. have synthesised a highly potent broad-
spectrum antibiotic (compound 133) which shows 25-fold improvement in activity 
against VRE compared to the second generation glycopeptide dalbavancin 9. 
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Furthermore, the repeated exposure of MRSA to compounds 131 and 133 resulted in no 
change in MIC after 52 days, compared to a 20-fold increase in MIC for vancomycin, 
indicating that they are slow to induce bacterial resistance in this strain. 
 
1.8  Conclusions 
It is clear that the race to complete a total synthesis of vancomycin in the late 1990s was 
not the end of the glycopeptide story; the 21st century demand for effective novel 
antibiotics is reflected in the plethora of articles published in this field. This review has 
brought together the many and varied approaches to vancomycin modification; in 
particular the alkylation of oxygen and nitrogen-containing groups has been shown to 
significantly increase antibacterial activity. Other modifications take their cues from 
nature, with the construction of covalent dimers mimicking the dimerisation of 
vancomycin in aqueous solution, and the addition of long tethers similar to the 
hydrophobic ‘‘anchor’’ of teicoplanin.  
The importance of a tandem approach to drug design and biochemical investigation is 
particularly highlighted by recent research into the mode of action of glycopeptide 
dimers, and stronger links forged between antibiotic design and the nature of the intended 
target will undoubtedly lead to further reports of biologically active molecules. Alongside 
these ongoing investigations, the total synthesis of the closely-related complestatin family 
has been completed by a number of research groups in the last decade. Following the 
success of vancomycin modification, it may well be that future publications will report 
the design and discovery of highly biologically active analogs and derivatives of 
complestatin, a natural product whose full potential has yet to be explored. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER TWO 
 
Remote asymmetric induction (>1,5-stereocontrol) 
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2.1 Introduction 
Remote stereocontrol, or remote asymmetric induction, occurs when the existing 
stereochemical centre or axis of the substrate molecule in a chemical reaction influences 
the formation of a new stereochemical feature in the product through more than five 
covalent bonds, equivalent to a through-space distance of  >0.7 nm.111  
 
Figure 2.1 Comparison of cross-membrane communication by the β-adrenergic G-
protein-coupled receptori (top) with state of the art remote asymmetric induction by a 
helical peptide foldamer, reported by Clayden et al., 2014 (bottom) 
Long-range communication of stereochemical information is common in biological 
systems. A particularly well understood example is the structure and mechanism of the β-
2 adrenergic G-protein-coupled receptor (GPCR) which takes part in cell signaling by 
spanning the width of the phospholipid bilayer (Figure 2.1).81 When a ligand such as (R)-
                                                          
iFigure 2.1 image top right adapted and reproduced by permission of MacMillan Publishers Ltd: Nature,81 
copyright 2008.  
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epinephrine (adrenaline) binds to the β-2 adrenergic receptor outside the cell, a 
conformational change takes place in the peptide structure which activates G-proteins 
within the cell, leading to changes in the levels of intracellular messengers such as Ca2+ 
ions. By the long-range communication of stereochemical information, the β-2 adrenergic 
receptor therefore effects a change in cell processes across an impressive distance of 5 - 7 
nm from the ligand binding site.  
Remote stereocontrol in synthetic chemistry has generally been limited to a distance of 5 
to 8 covalent bonds by the need for rigidity in the reaction transition states. However, 
research by Clayden and co-workers over the last five years has pushed the boundaries of 
remote asymmetric induction to through-space distances of up to 4 nm.82 This advance 
makes synthetic remote stereocontrol comparable to biological systems. The recent high-
impact publications by Clayden et al. have led to a renewed interest in the development of 
the long-range communication of stereochemical information associated with remote 
asymmetric induction for potential new applications in the design of artificial peptide-
based cell structures such as synthetic receptors.83     
2.2 Overview of remote stereocontrol 
The stereoselective synthesis of a new chiral centre in an organic compound can be 
achieved either by reagent control (i.e. using a chiral catalyst or additive) or by substrate 
control, in which existing chiral information is relayed through the covalent bonds of the 
compound to the site of reactivity. In organocatalysis, C2-symmetric chiral catalysts based 
on rigid frameworks such as BINOL and BINAP have become increasingly popular in the 
synthesis of aziridines, epoxides, and for asymmetric hydrogenation.84 They are efficient 
with regard to the amount of chiral material used, and the stereochemistry (R / S, or M / P 
in the case of helical compounds) of the catalyst can be selected to obtain the desired 
enantiomer of the reaction product. However, such catalysts can be expensive to purchase 
and time-consuming to make. As a typical example, (S)-VAPOL 141, employed as a 
catalyst in asymmetric aziridination,85 can be purchased at a cost of £104 per mg. The 
first reported synthesis of (S)-VAPOL by Wulff et al. was achieved in a 37% yield over 7 
steps (Scheme 2.1).86 An (S)-VAPOL-borate complex (10 mol%) catalysed the 
asymmetric aza-Darzens reaction of N-benzylidene-1,1-diphenylmethanamine with ethyl 
diazoacetate 144 to afford aziridine (R,R)-145 in an 83% yield and with 90% ee.  
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Scheme 2.1 • Synthesis of (R)- and (S)-VAPOL reported by Wulff et al. and the Brønsted 
acid complex formed between the (S)-VAPOL-borate active catalyst and N-benzylidene-
1,1-diphenylmethanamine (143) in the asymmetric synthesis of cis-aziridine (R,R)-145 
The transmission of stereochemical information through distances of three or more bonds 
has been a particularly useful synthetic tool since the development of chiral auxiliaries by 
Corey and Evans in the 1980s.87 Amongst these, the oxazolidinone (147, 148),88 
oxazoline (149)89 and camphorsultam (150)90 “chiral auxiliaries” have received the most 
attention (Figure 2.2). The chiral auxiliaries listed above share key structural features: 
they are conformationally constrained, cyclic systems bearing a sterically bulky chiral 
group, such as the benzyl substituent in example 146.  
 
Figure 2.2 • Oxazolidinone (Evans-type and SuperQuat91), oxazoline and camphorsultam 
chiral auxiliaries 
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The Evans oxazolidinone chiral auxiliary is commercially available and has been 
employed in a number of landmark total syntheses, including the synthesis of 
talaromycins A and B reported by Smith et al. in 1984, in which (S,R)-152 was obtained 
as a single diastereomer in a 76% yield (Scheme 2.2).92 The ability to easily remove the 
chiral auxiliary from the product makes this method particularly versatile and applicable 
to a wide range of substrates. 1,4-Stereocontrol of the type shown in Scheme 2.2 is 
frequently found in the literature, and a number of comprehensive reviews have been 
published on the subject.93 
 
Scheme 2.2 • Use of the Evans chiral auxiliary in the synthesis of talaromycins A and B 
reported by Smith et al. 
Acyclic substrates such as allylstannane 154 (Scheme 2.3) lack the rigid conformation of 
a 5- or 6-membered ring, and tend to rely on self-assembly of the reagents by chelation 
with a metal reagent via oxygen or nitrogen lone pairs, forming a highly ordered, 
conformationally constrained complex. In transition state 156, co-ordination of both the 
alcohol and aldehyde oxygen atoms to the metal centre (via their lone pairs) bring the 
existing chiral centre and the newly forming chiral centre into close proximity, bringing 
about a 1,5- steric induction. Hydrolysis of intermediate 157 releases diol 158, with a 1,7-
cis relationship.  Despite the restricted conformation of the transition state, Lewis acid-
mediated remote asymmetric induction reactions of acyclic substrates generally proceed 
with moderate yield and diastereomeric excess. As Scheme 2.3 shows, diol 158 (the 
major syn product of the reaction) was obtained in a low 36% yield, and with a syn/anti 
ratio of 90:10.    
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Scheme 2.3 • Structural features influencing stereoselectivity in the reaction between 
acetaldehyde 159 and acyclic allylstannane 154  
Metal-free acyclic systems lack the conformational constraint of a cyclic co-ordination 
complex in the transition state and are therefore extremely rare. Indeed a comprehensive 
review of “substrate-directable chemical reactions” by Evans et al. published in 1993 
contained no examples of organocatalytic substrate-controlled chiral induction reactions, 
and a search of the literature from 1993-2015 revealed no subsequent examples.94 A 
review of stereochemical communication “over nanometer distances” published by 
Clayden in 2009 found that such transformations were limited to transition metal-
catalysed, Lewis acid-mediated, and Grignard reactions.95 
This introductory chapter will present an overview of the major advances made in remote 
asymmetric induction (RAI) over the last 30 years, with a particular focus on examples 
where the stereocentre of the chiral substrate is more than 3 covalent bonds from the 
newly formed chiral centre in the product. Examples of 1,5- to 1,8-asymmetric induction 
and beyond, including those comparable to enzyme-catalysed reactions, are rare and 
particularly difficult to achieve with good diastereoselectivity. Exploring the structural 
features and mechanisms of these reactions will provide insight and inspiration for the 
design of future RAI transformations. Achieving absolute communication of 
stereochemical information on a nanometer scale within a biologically relevant 
architecture is a challenge that has not yet been met by synthetic chemistry. 
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2.3 Cyclic substrates in remote asymmetric induction 
Substrates with a 5- or 6-membered ring cyclic structure are generally conformationally 
restricted and inflexible. As a result, the angle of approach of a second molecule to the 
site of reactivity is limited, causing the preferential formation of a single diastereomer in 
the product. This is the classical approach to remote asymmetric induction led by the use 
of the chiral auxiliaries illustrated in Figure 2.2 (Section 2.2). Examining the mechanism 
of stereocontrol in these examples, and the success of various approaches to improving 
the diastereomeric ratio of the product, will inform substrate design and optimization of 
stereoselectivity in future remote asymmetric induction reactions.      
2.3.1 Steric control in cyclisation reactions 
The Nazarov cyclisation involves the Lewis acid activation of a divinyl ketone followed 
by the 4π electrocyclic ring closure of a pentadienyl cation.96 Very few diastereoselective 
examples of this cyclisation exist. However, in 1999 Pridgen et al. reported a remarkable 
1,5-asymmetric induction methodology in the Nazarov cyclisation for the synthesis of 
non-racemic indanes, which were found to be effective as endothelin receptor 
antagonists.97 Substrate 160, bearing the Evans chiral auxiliary, underwent Lewis acid-
mediated cyclisation to afford two products, diastereomers trans-161 and cis-162 (Table 
2.1).   
Table 2.1 • Diastereoselective Nazarov cyclisation reported by Pridgen et al. 
 
 Acid Yield (%) Isomer ratio 161:162 
Lewis acid SnCl4 85 88:12 
Lewis acid TiCl4 60 70:30 
Brønsted acid CH3SO3H 88 85:15 
When the cyclisation was carried out with Lewis acids tin(IV) tetrachloride and 
titanium(IV) chloride, indane 161 was obtained as the major diastereomer, with ratios 
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(161:162) of 88:12 and 70:30 respectively. This moderate diastereoselectivity was 
thought to result from the formation of reaction intermediate 163 (Figure 2.3), in which 
Lewis acid complexation restricts the conformation of the substrate with a temporary 6-
membered ring. However, one of the highest diastereomeric ratios (85:15, trans-161:cis-
162) was obtained using methanesulfonic acid rather than a Lewis acid, which 
surprisingly suggests that metal-carbonyl complexation is not crucial for a stereoselective 
cyclisation in this case. 
 
Figure 2.3 • Mechanistic comparison of the Lewis acid and Brønsted acid mediated 
Nazarov cyclisation reported by Pridgen et al. 
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In fact, computational calculations suggested that the lowest energy conformation of the 
starting material 166 without Lewis acid complexation has a trans-coplanar geometry of 
the imide carbonyls, as represented in Figure 2.3. In this conformation, steric demands 
alone bring the alkene into sufficiently close proximity to the aromatic ring for π-π 
interaction and the formation of a new covalent bond. Thus both the Lewis and Brønsted 
acid mediated reactions proceed with diastereoselectivity in favour of trans product 161. 
An Evans chiral auxiliary was also used by Hsung et al. for a 1,6-asymmetric induction in 
the stereoselective 6π electrocyclic ring closure of 2-halo-amidotrienes (Scheme 2.5).98 
Substrates 171a-c were synthesised by the electrophilic isomerization of allenamide 169 
with an X+ source of the halogen (pyridinium bromide, NCS or NIS) in the presence of 
two equivalents of DABCO and 4Å molecular sieves (Scheme 2.4). After 16 hours at 
room temperature, the 1,3,5-hexatrienes 171a-c were obtained, via deprotonation of the 
acyliminium ion intermediate 170 (X = Cl, Br, I).  
 
Scheme 2.4 • Synthesis of 2-halo-amidotrienes 171a-c reported by Hsung et al. 
The 6π-electron electrocyclisation of 171a-c proceeded with good yields of up to 95%, 
and diastereomeric ratios of up to 90:10 (where X = bromine or chlorine, major product 
172a and 172c) (Scheme 2.5). The choice of halogen did not appear to have a significant 
effect on the diastereomeric ratio, although the yield of the cyclisation was lower where X 
was chlorine or iodine, affording 172b+173b and 172c+173c in 61% and 73% overall 
yields respectively. The newly installed vinyl halide was shown to play an important role 
in relaying the chirality of the Evans auxiliary in the 1,6-asymmetric induction as well as 
being a site of possible functionalization in subsequent reactions.  
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Scheme 2.5 • Diastereoselective cyclisation of 1,3,5-hexatrienes 171a-c reported by 
Hsung et al. 
The mechanism of the thermally allowed disrotatory ring-closure provides an explanation 
for the selective formation of 172a-c over 173a-c (Figure 2.4). Clockwise rotation of the 
sp2 orbital of the carbon bearing the phenyl substituent (right) would bring this group into 
proximity of the benzyl group of the Evans auxiliary, whereas anticlockwise rotation 
(left) has no such unfavourable steric interactions.  
 
Figure 2.4 • Mechanistic explanation for the diastereoselective synthesis of 1,3,5-
hexatrienes 172a-c 
2.3.2 Remote stereocontrol by the π-allyltricarbonyliron lactone chiral auxiliary 
Ley et al. have investigated the effect of a π-allyltricarbonyliron lactone complex as a 
chiral auxiliary, for example in the addition of trimethylaluminium to ketone 174 
(Scheme 2.6).99 The synthesis of 174 was achieved in 4 steps from the commercially 
available starting material (E,E)-hexa-2,4-dienoic acid, (employing the toxic, highly 
flammable solid iron source diiron nonacarbonyl) with an overall yield of just 23%. In the 
reaction between ketone 174 and two equivalents of trimethylaluminium, tertiary alcohol 
175 was obtained in an excellent 92% yield, and with >95% diastereomeric excess. The 
high diastereoselectivity of this reaction is thought to be due to a combination of the 
stability of the lactone tether, and the steric bulk of the irontricarbonyl group, blocking 
one face of the ketone against nucleophilic attack (Figure 2.5). 
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Scheme 2.6 • A π-allyltricarbonyliron lactone complex as a chiral auxiliary, reported by 
Evans et al. 
 
Figure 2.5 • π-Allyltricarbonyl group blocking one face of the substrate from 
nucleophilic addition (left) and Mukaiyama aldol addition (right) 
Similarly, the C-F bond formation resulting from the reaction between silyl enol ether 176 
and Selectfluor® proceeded with >95 diastereomeric excess (Scheme 2.7).100 The same π-
allyltricarbonyliron lactone moiety also directed a 1,7-stereocontrol in the Mukaiyama 
aldol reaction of 178 with benzaldehyde, affording β-hydroxycarbonyl 179 in a 95% de 
and an overall yield of 65% after desilylation. 
 
Scheme 2.7 • Asymmetric fluorination (above) and Mukaiyama aldol reaction (below) 
reported by Evans et al. 
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Ley et al. have shown that the use of a π-allyltricarbonyliron lactone auxiliary is 
applicable to a range of reactions, with the benefit of releasing the free (E,E)-diene on 
decomplexation.101 As a chiral auxiliary, the π-allyltricarbonyliron lactone is therefore 
highly reliable and cheap, although synthesis of the lactone itself is low yielding and 
employs reagents which may be difficult to handle.  
2.3.3 Asymmetric keto boronate reduction  
Reactions which progress via a highly ordered cyclic transition state have excellent 
potential for remote chiral induction. In a particularly successful example, Molander et al. 
achieved a 1,7-induction in the reduction of keto boronates (180) under optimized 
conditions of borane-dimethylsulfide (2 equivalents) in dimethylsulfide at 0 C (Scheme 
2.8).102  The diol products 183-187 were obtained in high yields of 81-95% and with 
excellent enantioselectivity (85-98% ee).  
 
Scheme 2.8 • Asymmetric keto boronate reduction reported by Molander et al. 
Molander et al. proposed that the steric interactions between the approaching nucleophile 
and the isopropyl group of boronate 180 result in a preferred face of attack, in what is 
thought to be a 6-membered cyclic transition state (represented by 181 and 182). The 
basic solvent, dimethyl sulfide, is also likely to form a sterically bulky complex with the 
borane reducing agent, further limiting the possible trajectory of the nucleophilic attack. 
This method provides a straightforward way to synthesise chiral non-racemic secondary 
alcohols bearing sterically and electronically similar alkyl substituents. In terms of remote 
asymmetric induction, the synthesis of non-racemic diols 183-187 was achieved by a 
combination of a cyclic chiral substrate and a conformationally restricted cyclic transition 
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state – an approach which is also common to the transformations described in Section 
2.3.4.  
2.3.4    Chiral sulfoxides in remote asymmetric induction 
The sulfoxide group is generally represented in Lewis structures as being analogous to a 
carbonyl moiety. However, when the R substitutents are not equivalent, the sulfur atom is 
a stereogenic centre (Figure 2.6). The energy barrier to interconversion of the two 
enantiomers is around 40 kcal/mol, meaning that they are conformationally stable at room 
temperature and will only racemise under harsh conditions of high temperature or 
irradiation.103 
 
Figure 2.6 • Chirality of a disubstituted sulfinyl group, where R1 ≠ R2 
Optically active sulfoxides have been employed as chiral auxiliaries in a diverse range of 
diastereoselective transformations, particularly those involving 1,3- and 1,4-stereocontrol. 
Examples of dihydroxylation,104 reduction,105 halogenation106 and ring cleavage107 using 
substrates bearing chiral sulfoxides can be readily located in the literature. The popularity 
of the sulfur-based chiral auxiliaries can be explained by three key points: sulfur lone 
pairs are able to coordinate to Lewis acids, promoting highly ordered transition states, the 
large steric difference between the substituents (eg. lone pair, phenyl group, oxygen) 
results in good differentiation of the faces of the sulfoxide, and the chiral sulfoxides are 
straightforward to prepare in very high enantiomeric excess. The stereoselective 
Mukaiyama aldol reaction of (S)-2-(2-(p-tolylsulfinyl)phenyl)acetaldehyde 188 and O-
silylated ketenethioacetal 189 was reported by Ruano and Maestro et al. in 2006 (Scheme 
2.9).108  
 
Scheme 2.9 • 1,5-Asymmetric induction in the Mukaiyama aldol reaction and subsequent 
hydrolysis of thioester 190 to β-hydroxy carboxylic acid 192 
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Aldehyde 188 was prepared in 4 steps from 2-bromobenzaldehyde and (S)-(-)-methyl p-
toluenesulfinate with an overall yield of 55%.109 The chiral sulfoxide group of 188 
exerted a clear 1,5-stereocontrol in the Mukaiyama aldol reaction, which was found to be 
influenced by the choice of Lewis acid (Table 2.2). Ytterbium(III) triflate (1.2 equiv) gave 
the highest diastereoselectivity of the series, affording 190 and 191 in a ratio of 88:12, 
which increased to 96:4 when the reaction was carried out in acetonitrile at -40 °C instead 
of dichloromethane at -78 °C. Utilising the optimised conditions, this asymmetric 
Mukaiyama aldol reaction, followed by desulfinylation and further transformations, 
proved to be an effective route to 1,3-diols and beta-hydroxy acids with >98% ee. 
Table 2.2 • Asymmetric Mukaiyama aldol reaction reported by Ruano et al.      
Lewis acid Conversion (%) Ratio 190:191 
TiCl4 87 61:39 
AlCl3 34 66:34 
ZnI2 72 72:28 
Yb(OTf)3 60 88:12 
A mechanistic explanation for the diastereoselective synthesis of β-hydroxythioester 190 
is presented in Figure 2.7. Bidentate co-ordination of the sulfoxide and aldehyde oxygen 
atoms of substrate 188 to the metal centre of the Lewis acid creates cyclic complex 193. 
Steric interactions therefore limit attack of the aldehyde carbonyl to the exposed Si face. 
However, the degree of stereocontrol was only moderate, with a maximum 76% de in the 
synthesis of 190. This may be due to the inherent size and flexibility of the 8-membered 
ring in intermediate 193.   
 
Figure 2.7 • Reaction intermediates in the Mukaiyama aldol reaction 
Arai et al. then turned their attention to the Diels-Alder reaction, employing α,β-
unsaturated amide 195 as a chiral dienophile in the reaction with cyclopentadiene 196 
(Table 2.3).110 Where the Mukaiyama aldol addition had an 8-membered ring 
intermediate, the Diels-Alder reaction proceeded via the more conformationally restricted 
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7-membered ring complex 201 (Figure 2.8). This Lewis acid-promoted [4+2] 
cycloaddition proceeded smoothly at room temperature in overall yields of up to 99% and 
favoured the endo product in each case. The endo/exo ratio depended on the Lewis acid 
used: zinc chloride and the lanthanum triflates gave moderate endo selectivity, while 
aluminium trichloride gave a 95:5 ratio of endo/exo products and an excellent endo de of 
98%.  
Table 2.3 • Diels-Alder reaction of chiral sulfinyl dienophile 195 reported by Arai et al. 
 
Lewis Acid Time (h) Yield (%) Ratio endo/exo 
(197+198) / (199+200) 
endo de (%) 
ZnCl2 29 60 77/23 38 
AlCl3 13 99 95/5 98 
Yb(OTf)3 45 61 69/31 89 
 
Figure 2.8 • Reaction transition states in the Diels-Alder addition using 1 equivalent of 
Lewis acid (left) and two equivalents of Lewis acid (right), reported by Arai et al. 
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When the synthesis of 197 was attempted with two equivalents of Lewis acid (for 
example aluminium trichloride), the endo/exo selectivity dropped dramatically from 95:5 
to 59:41, with a similar decrease in diastereomeric excess of the endo product from 98% 
to 11%. With more than one equivalent of Lewis acid, the reaction proceeds via transition 
state 202, which lacks the conformational restraint of the 7-membered ring found in 201 
(Figure 2.8).  
Following its use in asymmetric reactions, the chiral sulfoxide group is usually cleaved by 
the reaction with activated Raney nickel,109 releasing the unstable sulfenic acid, which 
prevents recycling of the chiral material. Arai et al. demonstrated the recycling of the 
chiral sulfoxide following the Diels-Alder reaction by treatment of 197 with two 
equivalents of lithium methanolate to afford methyl ester 203 in a 99% yield (Scheme 
2.10).111 (S)-2-(p-Tolylsulfinyl)-1H-pyrrole 204 was recovered in a 99% yield, and with 
>99% optical purity, making it economically viable as a reusable chiral auxiliary.  
 
Scheme 2.10 • Recycling of the (S)-2-(p-Tolylsulfinyl)-1H-pyrrole chiral auxiliary 204 in 
the asymmetric Diels-Alder reaction, reported by Arai et al. 
2.4 Acyclic substrates in remote asymmetric induction 
In their 2001 review of acyclic remote stereocontrol,111 Mikami and Maryanoff identified 
common structural features which have been used to improve enantioselectivity in 
substrate-controlled chiral induction: i) sp2 centres, such C=C bonds and amide groups, 
which restrict rotation of the molecule and provide planarity, ii) biasing substituents, i.e. 
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sterically bulky nitrogen or oxygen protecting groups, which restrict the conformation of 
the molecule, and iii) alcohol or amino functional groups capable of coordinating metals 
via oxygen or nitrogen lone pairs. These characteristics are also desirable for the control 
of regio- and stereoselectivity in the field of supramolecular chemistry, and are found in 
architectures such as metal-organic frameworks (MOFs),112 calixarenes113 and 
dendrimers.114 In the following reports of remote asymmetric induction, the acyclic 
reaction substrates all bear at least one of the structural features described by Mikami and 
Maryanoff. In many cases the remarkable through-bond distance over which 
stereochemical information appears to be communicated can be explained by the 
formation of highly ordered, cyclic reaction transition states in which the through-bond 
and through-space distance between the existing and forming chiral centres is in fact 
shorter than it first appears.  
2.4.1 Remote asymmetric induction in the aldol addition reaction 
The aldol addition of an enolate to an aldehyde or ketone is one of the most powerful 
reactions in organic synthesis, and the “primary engine” of C-C bond formation in 
nature.115 The β-hydroxy carbonyl functionality resulting from the aldol addition is a 
precursor of the 1,3-diol relationship commonly found in natural products, particularly the 
polyketides.116 The low natural abundance of marine-derived polyketides has placed great 
emphasis on the ability of total synthesis to provide enantiopure samples of these 
compounds in sufficient quantity for structure elucidation, biological evaluation and 
possible clinical development.117 Stereoselective 1,5-anti aldol reactions are a particularly 
well investigated class of remote asymmetric induction, following boron-mediated aldol 
methodology developed by Evans and Paterson in the 1990s,118 which has since been 
employed in a number of natural product total syntheses.119 Following their previous 
work on 1,3-induction in the boron-mediated asymmetric aldol reaction,120 Evans and co-
workers investigated the reaction of an achiral aldehyde with a ketone enolate substrate 
bearing a chiral β-alkoxy substituent (Scheme 2.11).121  
 
Scheme 2.11 • 1,5-Stereocontrol in the boron-mediated aldol reaction, by Evans et al. 
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Ketone 206 first reacted with 1.05 equivalents of dibutylboron triflate in the presence of 
Hunig’s base at -78 C to form a boron enolate intermediate. The subsequent addition of 
dihydrocinnamaldehyde 207 (1.1 equivalents) afforded 1,5-anti diastereomer 208 as the 
major product, with an anti/syn ratio of 95:5 and a good overall yield of 89%. The high 
stereoselectivity of the boron-mediated aldol reaction is thought to be the result of the 
short boron-oxygen bond in the enolate, giving rise to a tight cyclic transition state 
(Figure 2.9).122 
 
Figure 2.9 • Cyclic transition states for the boron-mediated asymmetric aldol reaction: 
boat conformations (left) and chair conformations (right), by Goodman et al. 
By contrast, Evans et al. found that a Lewis-acid catalyzed enol silane addition protocol 
removed any 1,5-stereocontrol by ketone substrate 210 (Scheme 2.12), affording the anti 
and syn products 211 and 212 in a 1:1 ratio. Effectively “switching off” the 1,5- 
influence, this route would therefore allow a dominant 1,3-stereocontrol from a chiral 
aldehyde if desired.  
 
Scheme 2.12 • Lewis acid-catalysed enol silane aldol addition reported by Evans et al. 
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A comprehensive investigation into the full scope and limitations of these reactions was 
published by Evans et al. in 2003.123 In their total synthesis of the anti-cancer polyketide 
(+)-discodermolide 213 (Figure 2.10), Paterson et al. were able to extend the 
stereocontrol of the boron-mediated aldol reaction to a 1,6-induction.124 Model studies 
demonstrated that the boron enolate of (Z)-enone 215 reacted with isobutyraldehyde 216 
to afford 1,6-anti aldol product 217 as the major diastereomer, with an anti/syn ratio of 
81:19 (Scheme 2.13).    
 
Figure 2.10 • Molecular structure of (+)-discodermolide 213 (left) and (-)-ericanone 214 
(right) showing the aldol disconnection. 
 
Scheme 2.13 • 1,6-Stereocontrol in the boron-mediated aldol reaction, reported by 
Paterson et al. 
This test reaction was successfully exploited in the synthesis of (+)-discodermolide 213, 
in which the key aldol addition step proceeded with a total yield of 64% and an excellent 
diastereomeric ratio of >95:5 in favour of the desired natural product isomer. The same 
boron reagent, chlorodicyclohexylborane, was also used by Dias et al. in their 2013 total 
synthesis of the natural product (-)-ericanone (214, Figure 2.10), in which the key aldol 
addition step afforded the desired 1,5-anti diol relationship in the product with a 
diastereomeric ratio of 94:6 (anti/syn). 125 
The absence of 1,5-stereocontrol encountered by Evans et al. in the enol silane aldol 
addition reaction (Scheme 2.12) indicated that the boron-mediated aldol methodology was 
unsuitable for such substrates. Following investigations into this limitation, Yamamoto et 
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al. reported the use of “super silyl” protecting groups126 in the aldol reaction of β-siloxy 
methyl ketones with pivalaldehyde (Table 2.4).127  
Table 2.4 • Asymmetric aldol reaction reported by Yamamoto et al.      
 
R =  Enolisation reagent T (C) Solvent Yield (%) dr (syn/anti) 
Si(TMS)3 LiHMDS -60 DCM 50 60:40 
Si(TMS)3 LiHMDS -60 Toluene 70 60:40 
Si(TMS)3 LiHMDS -60 DMF 94 87:13 
Si(TES)3 LiHMDS -60 DMF 82 96:4 
Si(TES)3 TMSOTf/Et3N -78 Toluene 79 2:98 
The extraordinary steric bulk of the super silyl group was found to bring about high 
selectivity in this reaction, favouring a 1,5-syn product 220 when lithium 
hexamethyldisilazide was used as the enolisation reagent. The stereoselectivity of the 
reaction was found to be highly solvent dependent, with non-coordinating solvents such 
as dichloromethane and toluene leading to a moderate diastereomeric ratio of 60:40 
(220:221) compared with a ratio of 87:13 when the reaction was carried out in N,N’-
dimethylformamide. This can be explained by the formation of a cyclic transition state in 
which co-ordination of two molecules of N,N’-dimethylformamide to the lithium centre 
stabilizes the conformation of the 6-membered ring (Figure 2.11).  
Changing the protecting group from a TMS-type super silyl to the bulkier TES-type 
brought about the highest diastereomeric ratio of 96:4 (220:221). Yamamoto et al. found 
that the favoured diastereomer of the product could be switched from syn to anti by 
employing a silyl enol ether in place of the lithium enolate, with a resulting dr of 2:98 
(syn/anti 220:221) (Table 2.4, entry 5). Without the formation of a conformationally 
restricted cyclic transition state around a metal centre, the direction of approach of 
pivaldehyde to the silyl enol ether in transition states 226 and 227 is influenced by steric 
interactions only, leading to a preferential formation of the 1,5-anti product 221 (Figure 
2.12). 
CHAPTER 2 Remote asymmetric induction 
 
68 
 
 
Figure 2.11 • Transition states of the lithium mediated aldol reaction reported by 
Yamamoto et al. 
 
Figure 2.12 • Transition states in the Mukaiyama aldol synthesis: 1,5-anti 
diastereoselectivity, reported by Yamamoto et al. 
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In each case (syn or anti favoured) the reaction was found to tolerate a wide range of 
aldehydes (RCHO where R = cyclohexyl, isopropyl, 4-methoxyphenyl, 4-nitrophenyl) 
with excellent diastereomeric ratios of between 85:15 and 98:2. 
2.4.2 Allylstannanes in remote asymmetric induction  
The addition of allylstannanes to aldehydes, promoted by the addition of a tin(IV) halide 
reagent, has been found to afford homoallylic alcohols with high enantioselectivity.128 
Much of the investigation into remote asymmetric induction in this reaction has been 
carried out by E. J. Thomas and coworkers over the last 25 years.129 Thomas et al. found 
that the addition of 4-, 5-, and 6-substituted allylstannanes to benzaldehyde 228 favoured 
the syn product in each case (Scheme 2.14).130 The addition of 229 to benzaldehyde 
proceeded via a transmetallation between stannane 229 and tin(IV) chloride. After five 
minutes, the addition of benzaldehyde 228 afforded the 1,5-syn-(Z) isomer of allylic 
alcohol 156 as the major product. The excellent diastereomeric ratio of 98:2 (syn/anti) in 
the 1,5-asymmetric induction dropped slightly with extension of the substrate carbon 
chain. Thus, the reaction between stannane 231 and benzaldehyde 228 afforded 1,6-syn 
product 232 with a diastereomeric ratio of 92:8, which was matched by the corresponding 
1,7-induction (addition product 234).  
 
Scheme 2.14 • 1,5- to 1,7-stereocontrol in the addition of benzaldehyde 228 to 
allylstannanes 229, 231 and 233, reported by Thomas et al. 
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Figure 2.13 • Mechanism of the Lewis acid-mediated reaction between allylstannane 233 
and benzaldehyde 228 
The mechanism of the reaction between allylstannane 233 and benzaldehyde 228 reveals 
the source of the high degree of stereocontrol (Figure 2.13). Following the 
transmetallation step, the alcohol group is able to co-ordinate to the tin centre via an 
oxygen lone pair. As a result, 6-membered ring intermediate 236 is formed, in which the 
vinyl and methyl substituents have an anti-relationship across the ring to achieve the 
lowest energy conformation. The approach of benzaldehyde is further limited by co-
ordination of the carbonyl oxygen atom to the metal centre (237). Consequently, the 
addition reaction that follows actually occurs via a 1,5-asymmetric induction through the 
co-ordinated tin atom, despite the 1,7-relationship in the free diol (234).  
The remote stereocontrol shown by the tin(IV) halide mediated addition of substituted 
allylstannanes to simple aldehydes (Scheme 2.14) has led to the development of new 
strategies in the synthesis of various natural products. For example, the total synthesis of 
the antibacterial macrolide (±)-patulolide C 163 by Thomas et al. (Scheme 2.15) featured 
a 1,5- remote asymmetric induction in the reaction between tributylstannane 239 and 
acrolein 240 to afford alcohol 241 with a diastereomeric ratio of 96:4 in favour of the syn 
product, and a good overall yield of 77%.131 An Ireland-Claisen rearrangement was then 
used to relay the stereochemical information down the chain, resulting in the 1,6-syn 
relationship found in the natural product (242).  
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Scheme 2.15 • 1,5-Stereocontrol in the synthesis of (±)-patulolide C, reported by Thomas 
et al. 
While the organotin chemistry described above provided a reliable method for acyclic 
remote stereocontrol, the reactions require very low temperatures (-78 C) and anhydrous 
conditions. Organotin compounds are also notoriously toxic, and cause well-documented 
damage to the environment.132 Finally, the removal of tin residues such as tributyltin 
chloride from the final product of the reaction can be very challenging. In order to 
overcome these limitations, Thomas et al. turned to allylgermane substrates in place of 
the allylstannanes (Table 2.5).133 
Table 2.5 • 1,6-Stereocontrol in the addition of aldehydes to allylgermane 243 
 
Germane E/Z Aldehyde R Isolated Yield (%) Ratio 244:245 
(E)-243 Ph 63 89:11 
(Z)-243 Ph 80 94:6 
(Z)-243 (CH3)2CH 82 93:7 
(Z)-243 4-ClC6H4 81 92:8 
(Z)-243 3-ClC6H4 83 93:7 
(Z)-243 4-NO2C6H4 81 91:9 
(E)-243 was found to react with tin(IV) tetrabromide and then benzaldehyde 263 with 
promising 1,6-stereocontrol to afford diol 244 as the major product, with a diastereomeric 
ratio of 89:11 (244:245). This diastereomeric ratio, as well as the overall yield, was found 
to improve when the (Z)-isomer of 243 was used, increasing the dr to 94:6 in favour of 
the syn product 244. The reaction shown in Table 2.5 was also able to tolerate a range of 
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aldehyde substrates including those bearing aliphatic chains (entry 3) and substituted 
benzaldehydes (entries 4-6, Table 2.5). 
2.4.3    Remote asymmetric induction in the Grignard reaction 
Tamai et al. employed (R)-BINOL as the chiral auxiliary in the Grignard reaction of 
ketoester 246 (Table 2.6).134 By extending the carbon chain of the ketoacid starting 
material, they were able to achieve up to 1,12-asymmetric induction with significant 
enantiomeric excess. However, the ee decreased with increasing length of the carbon 
chain, with an optimum of n = 1 (1,8-stereocontrol), which afforded the (R)-isomer 247a 
as the major product with 97% ee and an overall yield of 82%.  
Table 2.6 • 1,8- to 1,10-stereocontrol in the Grignard reaction, reported by Tamai et al. 
 
Product n R 1,X-induction Yield (%) ee (%)  
(R)-247a 1 -C9H19 1,8 82 97 
(S)-247b 2 -CH3 1,9 90 82 
(S)-247c 3 -CH3 1,10 89 4 
The reaction was thought to proceed via a pseudo-macrocyclic chelate such as 248, where 
the oligoether substituent functions as a podand around the Mg2+ centre. The stability of 
this complex fixes the orientation of the ketone carbonyl group, allowing nucleophilic 
attack only from the outside of the macrocycle. A short chain ketoester, where n = 1, 
appears to hinder the formation of complex 248, and no enantioselectivity was observed 
in the product. As the chain extends beyond n = 3, the complex becomes too flexible to 
limit the direction of nucleophilic attack. The stability of the pseudo-macrocyclic 
intermediate therefore governs the stereoselectivity of this reaction. The in situ 
lactonisation means that the (R)-BINOL chiral framework is released during the reaction, 
and could therefore be recovered and re-used if desired.   
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Table 2.7 • 1,6-Stereocontrol in the nucleophilic addition to ketones, reported by 
Takahashi et al.   
 
 MeLi MeMgBr MeTi(OiPr)3 
Product Yield (%) dr (SS:RS) Yield (%) dr (SS:RS) Yield (%) dr (SS:RS) 
250a 53 55:45 63 54:46 27 11:89 
250b 63 51:49 53 68:32 34 49:51 
 
Following their earlier work on the 1,5-asymmetric induction in the diastereoselective 
reaction of carbonyl compounds with organotitanium reagents,135 Takahashi et al. 
reported a comparison of the 1,6 remote asymmetric induction achieved using three 
different organometallic reagents: the Grignard reagent methylmagnesium bromide, 
methyllithium, and methyltitanium triisopropoxide (Table 2.7).136 Valinol-derived (S)-4-
amino-1-phenylbutanones 249a and 249b reacted with methyltitanium triisopropoxide in 
tetrahydrofuran at room temperature to afford diastereomeric mixtures of products 250a 
and 250b. When the same reaction was carried out with methyllithium or 
methylmagnesium bromide as the organometallic reagent, little diastereoselectivity was 
observed.  
 
Scheme 2.16 • Cyclic reaction intermediate complex 251 in the methylation of ketone 
(S)-249a, reported by Takahashi et al.  
With methyltitanium triisopropoxide, moderate diastereoselectivity was achieved in the 
synthesis of 250a, favouring the R,S diastereomer in a ratio of 89:11 (R,S: S,S). However, 
there was no stereocontrol observed in the synthesis of 250b (where R = -CH3), 
suggesting that the free hydroxyl group is necessary for a cyclic chiral reaction 
intermediate. To explain the reagent- and substrate-dependent diastereoselectivity of the 
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reaction, Takahashi et al. proposed the formation of transition state 251 (Scheme 2.16), in 
which co-ordination of the carbonyl and hydroxyl oxygen atoms to the titanium centre 
brought the existing and forming chiral centres into close proximity - a conformation 
further stabilized by the possible co-ordination of the tertiary amine via the nitrogen lone 
pair. The steric bulk of the isopropoxy ligands compared to the methyl ligand would give 
rise to preferential addition of the methyl group to the same face as the existing chiral 
centre. Methylmagnesium bromide and methyl lithium are stronger nucleophiles than 
methyltitanium triisoproxide, as reflected in the yield of the reactions (63% and 53% 
yield respectively, compared to 27% with MeTi(OiPr)3). When these reagents are used, 
methylation occurs before the formation of a highly ordered metal complex can take 
place.  
2.4.4    Organolithium reagents in remote asymmetric induction 
Phosphorylated amino acids are found in a range of antibiotics, antivirals, and enzyme 
inhibitors as well as natural products.137 In their 2001 synthesis of β-amidophosphonates, 
Quirion et al. compared a number of synthetic routes, each involving a 1,5-asymmetric 
induction.138 In the first approach, β-amidobenzene 252 was deprotonated at the benzylic 
carbon by s-butyllithium, before the addition of diethyl chlorophosphite as an electrophile 
(Scheme 2.17). While compound 253 was obtained in a 55% yield, no diastereoselectivity 
was observed for this reaction due to the flexibility of the substrate molecule. 
 
Scheme 2.17 • Synthesis of β-amidophosphonates 253 reported by Quirion et al. 
However, in a more successful approach, diethylphosphite reacted with a series of α,β-
unsaturated chiral amide 254 via a Michael addition (Table 2.8). The diastereoselectivity 
of this reaction was found to be particularly dependant on the nitrogen protecting group, 
with an N-benzyl group affording the highest de of 92%, and the more hindered N-
isopropyl group resulted in a significant loss of selectivity, with a de of just 22%. A 
mechanistic rationale for this effect is presented in Figure 2.14. In A, where there is no N-
substituent, the molecule is largely flat due to the planarity of the alkene and amide 
bonds.   
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Table 2.8 • Asymmetric synthesis of β-amidophosphonates, reported by Quirion et al. 
 
Major Product R Yield (%) de (%) 
(R,R)-255 H 55 82 
(R,R)-256 Me 60 76 
(R,R)-257 iPr 45 22 
(R,R)-258 Bn 50 92 
Diethyl phosphite therefore preferentially approaches the upper face of the alkene to 
avoid interactions with the phenyl ring. Similarly in B, the lower face is blocked by the 
phenyl group, and further steric interactions with the N’-benzyl substituent also limit the 
trajectory of the nucleophile, leading to a slight increase in diastereomeric excess from 
82% to 92%. Finally, the N’-isopropyl substituent in C lies perpendicular to the plane of 
the amide, cause steric hindrance on both the upper and lower face of the alkene substrate 
which is reflected the lower de of 22%.   
  
Figure 2.14 • Mechanistic explanation for the diastereoselectivity in the Michael addition 
of diethylphosphite to α,β-unsaturated chiral amides, reported by Quirion et al. 
Examples of remote chiral induction beyond a distance of 8 covalent bonds are extremely 
rare – only a handful exist, and these tend to rely on supramolecular complexation of an 
acyclic substrate (bearing a chiral auxiliary) around a metal centre, such as the work by 
Magnus et al. described below. 
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In 1997, following earlier investigations into 1,9-stereocontrol for the same 
methodology,139 Magnus and Magnus reported a 1,13- and 1,14-asymmetric induction in 
the synthesis of linear chiral sulfones (Scheme 2.18).140 Substrate 259, bearing the (R)-α-
methylbenzylamine chiral auxiliary, was deprotonated by n-butyllithium at -70 C before 
the addition of benzaldehyde 228 at -100 C. There are four possible diastereomeric 
products of this reaction: two syn-isomers (R,R,R/S,S,R) and two anti-isomers 
(R,S,R/S,R,R). However, only two diastereomers were observed in the 1H-NMR of the 
impure reaction mixture: one syn, and one anti.  
 
Scheme 2.18 • 1,13 and 1,14-asymmetric induction in the synthesis of chiral sulfones, 
reported by Magnus and Magnus. 
Magnus and Magnus proposed that the unexpected long-range stereoselectivity of this 
reaction may be due to the formation of bicyclic chelate intermediate 262, in which the 
chiral centre of the starting material is only three atoms from the C-Li bond. The 
stereocontrol therefore operates over a much shorter distance than it would appear from 
the long-chain structure of starting material 259, being a 1,4- rather than a 1,14- remote 
asymmetric induction. The ratio of 260:261 deteriorated as the chain length increased 
from n = 2 to n = 4, as the corresponding change in ring size from 7 to 9 atoms increased 
the flexibility of the transition state.  
Taking a highly flexible substrate such as 259, with no C=C bonds, alcohol groups or 
cyclic features, and achieving an apparent 1,14-stereocontrol is undoubtedly a significant 
achievement. However, the examples of RAI described so far in this review lack truly 
impressive through-space distance in the chiral induction.  
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2.5   Atropisomeric and helical chiral substrates for RAI 
In order to achieve the long-range communication of stereochemical information over 
nanometer distances, it is necessary to employ a substrate which is structurally linear and 
has a global conformational constraint. Clayden and co-workers initially investigated the 
use of atropisomeric amide compounds for this purpose, and in 1997 they reported a rare 
case of remote chiral induction by a rotationally restricted amide (Scheme 2.19).141 
Naphthamide 263 was deprotonated by s-butyl lithium before the addition of 
benzaldehyde 228, to afford secondary alcohol diastereomers 264 and 265 in an overall 
yield of 51%. Unfortunately, no significant diastereoselectivity was observed in this 
reaction. However, when an N-benzylidenemethylamine 266 was employed as the 
electrophile, secondary amine 267 was obtained as a single diastereomer in a 74% yield. 
 
Scheme 2.19 • 1,5-Stereocontrol by atropisomerism, reported by Clayden et al. 
The conformation of amides can be controlled by nearby stereogenic centres, and can 
further influence the conformation of neighbouring amide groups.142 This approach 
mirrors the “chiral relay” methodology introduced by Davies et al. in the synthesis of 
enantiomerically pure α-amino acids (Scheme 2.20).143 Sterically bulky groups such as 
the N-benzyl substituents of cyclic amide 269 can increase the influence of the existing 
chiral centre on the remote site of reactivity. Thus diastereomer 270 was obtained by 1,4-
stereocontrol with 93% de and an overall yield of 72%.  
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Scheme 2.20 • Chiral relay auxiliary for the synthesis of optically active α-amino acids 
(R)-alanine 271 and (S)-valine 272, reported by Davies et al. 
Viewing substrate 263 as a promising building block, Clayden et al. constructed a highly 
rigid polyxanthene structure (273) bearing rotationally restricted amides whose 
atropisomeric stereochemistry was fixed by a (1S,2R)-ephedrine moiety (Scheme 2.21).144  
At the far end of the molecule, an aldehyde group provided a target for asymmetric 
nucleophilic attack by a suitable Grignard reagent.   
 
Scheme 2.21 • 1,23-Stereocontrol in a polyxanthene structure, reported by Clayden et al.  
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The conformationally constrained nature of compound 273 meant that the chiral centre 
was both spatially remote from the aldehyde carbonyl group as well as separated by the 
chain of covalent bonds (coloured purple, Scheme 2.21). The energy barrier to 
epimerization of this class of compounds, such as amide 275 (85 kJ mol-1) is sufficiently 
high to prevent changes in conformation through the structure, and each amide substituent 
is angled anti to its neighbours. Remarkably, Clayden et al. found that the distance of the 
stereocontrol was limited by difficulties in synthesis of suitable substrates rather than the 
reliability of the chiral relay, as they were unable to synthesise a tetraxanthene starting 
material.  
In a change of strategy, Clayden et al. instead built substrate 276: a peptide chain 
consisting of multiple aminoisobutyric acid (Aib) subunits, which adopts a helical 
conformation.145 The direction of the helix was established by either one or two (S)-α-
methyl valine residues at one end (276a and 276b respectively). Under hydrogenation 
conditions of Crabtree’s catalyst146 (10% w/w) and a hydrogen atmosphere, peptides 277a 
and 277b were obtained as the major diastereomers, featuring (S)-phenylalanine residues 
highlighted in red.  
 
Scheme 2.22 • Asymmetric hydrogenation for the synthesis of an (S)-phenylalanine 
residue within a right-handed helical peptide foldamer: 1,16-asymmetric induction, 
reported by Clayden et al. 
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Table 2.9 • Asymmetric hydrogenation in a peptide foldamer reported by Clayden et al. 
Product n solvent dr (S)-Phe-277 : (R)-Phe-277 
277a 1 EtOH 79:21 
277a 1 CH2Cl2 88:12 
277b 2 EtOH 89:11 
277b 2 CH2Cl2 >95:5 
The diastereoselectivity of the hydrogenation reaction was improved by using 
dichloromethane as the solvent rather than ethanol, with an increase in dr from 79:21 to 
88:12 in the synthesis of 277a. This can be explained by the ability of polar protic 
solvents such as ethanol and methanol to disrupt hydrogen bonding, which would 
compromise the conformational integrity of right-handed helical foldamer 276a. The 
highest dr (>95:5) was achieved with two units of (S)-α-methyl valine in the substrate (n 
= 2, compound 276b). 
 
Scheme 2.23 • Foldamer-mediated remote stereocontrol reported by Clayden et al. 
Aiming to improve on the 1,16-asymmetric induction achieved for the hydrogenation 
reaction (Scheme 2.22), Clayden et al. increased the length of the peptide chain, 
maintaining the ordered helix by the incorporation of cyclohexane (Ac6c) residues 
(compound 278, Scheme 2.23).145 The resulting peptide formed a helical foldamer at low 
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temperatures (down to -50 C) held in a stable conformation by multiple hydrogen bonds. 
The chiral centres of the (S)-α-methyl valine dimer again influenced a preference for a 
right-handed screw-sense of the helix. Thus chiral information could be relayed through 
up to 60 covalent bonds to the site of reactivity. In the Friedel-Crafts reaction between N-
alkenes 278a-c and 1,3,5-trimethoxybenzene 279 in the presence of 
trifluoromethanesulfonic acid in THF at -50 C, a mixture of two diastereomers were 
formed, where (S,S,R)-280 was the major product. In the 1,31-induction (n = 1), a 
diastereomeric ratio of 92:8 was achieved in favour of 280a, which dropped only slightly 
to 90:10 for the 1,46-induction (280b) and 88:12 for the 1,61-induction (280c). The yields 
of the reactions also remained high, with an overall range of 78-91%.  
The 1,61-asymmetric induction described in Scheme 2.23 represents the communication 
of stereochemical information over a distance of around 4 nm,146 which is far greater than 
any remote stereocontrol reaction previously reported. The mode of chiral induction 
showcased by this peptide foldamer is comparable to the stereoselectivity shown by 
enzymes, and may therefore find potential use in artificial cell structures for biological 
applications.  
2.6   Conclusions  
Remote asymmetric induction is a concept that has been used by organic chemists for half 
a century. Chiral auxiliaries have been widely employed in the synthesis of chiral non-
racemic small compounds and in large natural products total syntheses. They are efficient, 
commercially available, and in many cases recyclable. However, the future of remote 
asymmetric induction lies beyond the synthesis of isolated small molecules. Mastering the 
transfer of information via remotely-triggered conformational changes in large molecules, 
particularly peptides, opens up the possibility of designing and manipulating artificial 
trans-membrane receptors in human cells.   
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2.7 Project Aims 
In the first chapter of this thesis, an introductory review of previously published work on 
the synthesis and biological activity of glycopeptide antibiotic analogues showed that this 
is an important class of antibiotics to pursue, and that an efficient, low cost route to the 
triaryl biether backbone (C-O-D-O-E) would be highly desirable for future syntheses of 
compounds featuring this structural motif. To this end, the early aim of this project 
(presented in Chapter 3) was to investigate the feasibility of a double nucleophilic 
aromatic substitution between methyl gallate and 4-fluorobenzaldehyde, and to then 
employ previously reported transformations for the synthesis of the ring D α-amino acid 
moiety of orienticin C (Scheme 2.24). 
 
Scheme 2.24 • Plan for the construction of the C-O-D-O-E triaryl biether backbone of the 
glycopeptide antibiotic family 
In a parallel study, the aldehyde functional group of the C-O-D-O-E backbone would be 
subject to imine condensation and aza-Darzens aziridination, with the intention of ring-
opening a suitable aziridine to afford the functional group protected β-hydroxy α-amino 
acid (Scheme 2.25), which is a key component of the D-O-E macrocycle of orienticin C.  
 
Scheme 2.25 • Proposed aza-Darzens aziridination for the synthesis of the β-hydroxy α-
amino acid moiety of orienticin C 
In order to increase the efficiency of this approach in the synthesis of glycopeptide 
antibiotic analogues, the direct synthesis of peptide from amino acid-based precursors 
was also investigated. As the literature review of remote asymmetric induction in Chapter 
2 shows, existing chiral centres in reaction substrates can influence the stereochemical 
outcome of a reaction, even when the substrates are acyclic.  It was anticipated that amino 
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acid derived imines or diazoacetamides might exert a 1,3- or 1,5-induction in the 
Brønsted acid catalyzed aza-Darzens aziridination reaction (Scheme 2.26). 
 
Scheme 2.26 • Brønsted acid catalyzed aza-Darzens synthesis of a peptide aziridine 
precursor to the β-hydroxy α-amino acid moiety of orienticin C 
As well as being investigated for the synthesis of glycopeptide antibiotic analogues, the 
remote chiral induction strategy described in Chapter 4 may prove more generally useful 
in the synthesis of chiral non-racemic peptide aziridines as precursors for unnatural 
dipeptides and α-amino acids.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER THREE 
 
Construction of the orienticin C backbone 
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3.1 Introduction 
In order to explore the application of an organocatalytic asymmetric aza-Darzens reaction 
to the synthesis of vancomycin-type compounds, an aldehyde-functionalised core starting 
point for the C-O-D-O-E backbone was required (Figure 3.1). Ideally this would feature 
the central (R)-3,4,5-trihydroxyphenylglycine derivative (ring D) already in place. 
Protecting group Pt2 at the amino acid on ring D will be necessary to prevent an unwanted 
imine condensation at this position during subsequent aziridination steps, and protecting 
group Pt3 will be required for ease of purification.  Phenol derivatives are poor 
nucleophiles, but still under specific conditions are able to ring-open substituted 
aziridines.147 This potential side reaction will be prevented by incorporating a phenol 
protecting group on ring D (Pt1). 
 
Figure 3.1 • Summary of project aims for construction of the triaryl vancomycin 
backbone 
The initial starting material for the synthesis of the C-O-D-O-E backbone, methyl gallate 
281, is commercially available and can be easily obtained by esterification of gallic 
acid,148 an inexpensive natural product found in a range of plant sources including acacia 
bark and grape seeds.149 It was anticipated that the ester functionality of compound 281 
would influence the chemoselectivity of the SNAr reaction with 4-fluorobenzaldehyde 
282, leading to coupling only at the 3- and 5-hydroxy positions of 281 (Scheme 3.1). 
Protection of the dialdehyde functionality on 283 in the form of a cyclic or acyclic acetal 
is necessary during the reduction of the methyl ester to primary alcohol 284 and the 
subsequent oxidation that leads to the formation of the Wittig reaction precursor, 
aldehyde 285. 
CHAPTER 3 Construction of the orienticin C backbone 
86 
 
 
Scheme 3.1 • Retrosynthetic analysis for the construction of the triaryl biether core 287 of 
orienticin C (R = -CH3, -Bn; R’ = -Cbz, -Boc) 
With the styrene moiety of 286 in place, a Sharpless asymmetric aminohydroxylation 
reaction should afford an amino alcohol which could be oxidised to 287, completing the 
synthesis of the (R)-alpha-amino acid of ring D. Acid-catalysed hydrolysis of the two 
acetal protecting groups on rings C and E would restore the aldehyde functionality in 
preparation for imine condensation and subsequent asymmetric aza-Darzens aziridination.  
3.2 Diaryl ether coupling 
Since Fritz Ullmann reported the copper(0)-catalysed reaction between phenol and 
bromobenzene in 1905,150 a myriad of methods have been developed for diaryl ether 
synthesis. Traditionally, the Ullmann ether synthesis uses high temperatures (100–300 
ºC), long reaction times (48–72 hours) and stoichiometric metal reagents or high catalyst 
loading.151 Modern variations include the use of 2 mol% of copper(II) trans-bis-
(glycinato) catalyst 288 by Jain et al., which enables lower reaction temperatures, shorter 
reaction times and lower catalyst loading than previous protocols (Scheme 3.2).152 
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Scheme 3.2 • Copper(II)-catalysed diaryl ether coupling reported by Jain et al., 2012. 
The copper(II)-mediated Chan-Lam coupling of a hydroxyl group with 4-
methoxyphenylboronic acid 290 was employed by Evans et al. in their 1998 formal 
synthesis of L-thyroxine 292 from (S)-ethyl 2-acetamido-3-(4-hydroxy-3,5-
diiodophenyl)propanoate 289 (Scheme 3.3).153 A range of palladium(II)-catalysed 
protocols have also been reported, exploiting the recent interest in using platinum-group 
metals in coupling methodologies, such as that of Buchwald et al. which employed the 
bulky and sterically hindered phosphorus diaryl ligand, tBuXPhos 297 (Scheme 3.3).154 
 
Scheme 3.3 • Copper(II)-catalysed arylboronic acid coupling reported by Evans et al., 
1998; palladium(II)-catalysed coupling reported by Buchwald et al., 2006. 
Previous syntheses of vancomycin and its analogues have employed as key strategies 
either copper(I)-catalysed or transition metal-free coupling methods. In their 1997 
synthesis of monomacrocyclic vancomycin analogues, the Boger group performed a 
nucleophilic aromatic substitution to generate the C-O-D macrocycles 299 and 300 
(atropisomers which were separable by flash column chromatography) (Scheme 3.4).155 
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The presence of an electron withdrawing nitro group ortho to the fluoro substituent 
(compound 298, ring C) has previously been shown to activate the halogen towards 
nucleophilic attack.156  The macrocyclisation of 298 proceeded in a moderate 50% yield 
overall, althought there was no selectivity for the natural (M)-diastereomer 300 over the 
unnatural (P)-diastereomer 299 in this case. The nitro group of 300 was converted in three 
steps to the chloro substituent found in vancomycin (1, p. 1) later in the synthesis.   
 
Scheme 3.4 • Synthesis of vancomycin C-O-D ring analogues reported by Boger et al. 
 
Scheme 3.5 • Triazene-based 16 atom macrocyclisation reported by Nicolaou et al. 
Taking a novel approach to this problem for their 1998 total synthesis of vancomycin, the 
Nicolaou group developed a triazene-based macrocyclisation reaction which employed an 
excess of a copper(I) bromide dimethyl sulfide complex (Scheme 3.5).157 It was proposed 
that the reaction proceeded via intermediate 303, in which the attacking nucleophile was 
brought into the proximity of the aryl bromide by coordination of the metal counterion to 
the triazene functionality of ring D, which itself became an “electron sink” for the 
nucleophilic substitution. Following the synthesis of model C-O-D ring 302 in a 77% 
yield, this methodology also proved to be moderately efficient in the synthesis of 
vancomycin, closing the D-O-E macrocycle in a 60% yield.158 
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3.2.1 SNAr synthesis of triaryl biether and diaryl ether aldehydes 
An aldehyde-functionalised triaryl biether was required as the starting point for our 
synthesis of the C-O-D-O-E backbone of orienticin C. With this in mind, a double 
nucleophilic aromatic substitution reaction between methyl gallate 281 and 4-
fluorobenzaldehyde 282 (Scheme 3.6) was investigated, exploring a range of reaction 
conditions (Table 3.1 and 3.2).  
Scheme 3.6 • General scheme for the SNAr reaction between methyl gallate 281 and 4-
fluorobenzaldehyde 282 
At room temperature, no reaction was observed between methyl gallate 281 and 4-
fluorobenzaldehyde 282 in the presence of 2.5 equivalents of potassium carbonate (Table 
3.1). Increasing the temperature to 70 ºC afforded 304 in a poor 20% yield after 
prolonged heating for 48 hours.  
Table 3.1 Attempted synthesis of 304 and 305 (oil bath heating) 
 
Base 
 
Solvent 
4-Fluoro-
benzaldehyde  
(equiv) 
Temp. 
(ºC) 
Time 
(h) 
Yield  304 
mono 
(%) 
Yield 305 
di 
(%) 
Total 
Yield 
(%) 
K2CO3 DMF 1.1 25 24 0 0 0 
K2CO3 DMA 2 70 48 20 - 20 
K2CO3 DMF 2 160 4 <5 - 0 
In an attempt to reduce the reaction time, the flask was heated to reflux (~160 ºC) in 
DMF. After four hours, a white crystalline precipitate was observed, whose 
physicochemical properties matched those of 1-(4-(dimethylamino)phenyl)ethanone 306. 
Formation of 306 was undoubtedly due to the in situ decomposition of DMF into 
dimethylamine and carbon monoxide. Presumably the dimethylamine underwent a 
nucleophilic aromatic substitution with 4-fluorobenzaldehyde (Scheme 3.7). Indeed this 
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reaction has recently been exploited by Ulven et al. in a flow chemistry protocol using a 
range of aryl halides.159 DMF was therefore deemed an unsuitable solvent for this 
reaction at the temperature indicated. Instead, using DMA or DMSO as the reaction 
solvent for the synthesis of 304 and 305 prevented the formation of byproduct 306.  
 
Scheme 3.7 • Mechanism for the SNAr reaction between dimethylamine and 4-
fluorobenzaldehyde following the in situ decomposition of DMF 
Compared to the low yield, high temperature and long reaction time of using a 
conventional oil bath set-up, the application of microwave irradiation offered several 
significant advantages for this reaction. A comparable 21% yield of 304 was obtained in 
just 30 minutes by changing the heating method to microwave irradiation at the same 
temperature (160 ºC), in DMA (Table 3.2). Changing the base to cesium carbonate and 
the solvent to DMSO increased the yield of 304 to 32%, and triaryl biether 305 was 
observed for the first time in a 5% yield. By adding 3.2 equivalents of 4-
fluorobenzaldehyde, dialdehyde 305 could be obtained in a 56% yield, with a total 
reaction yield of compounds 304 and 305 of 77%.  
Table 3.2 Base and solvent study for the synthesis of 304 and 305 (microwave 
irradiation) 
Base Solvent 4-Fluoro-
benzaldehyde  
(equiv) 
Temp. 
(ºC) 
Time 
(h) 
Yield  304 
mono 
(%) 
Yield 305 
di 
(%) 
Total 
Yield 
(%) 
K2CO3 DMA 1 160 0.5 21 - 21 
K2CO3 DMSO 1 160 2 <5 - 0 
Cs2CO3 DMSO 1 160 2 32 5 37 
Cs2CO3 DMSO 1.2 160 1 42 <5 42 
Cs2CO3 DMSO 3.2 160 2 21 56 77 
Increasing the reaction time, temperature or number of equivalents beyond those reported 
in Table 3.2 did not increase the yield of either 304 or 305. Instead only decomposition of 
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the starting materials and products was observed, presumably by base-mediated 
hydrolysis of the methyl ester. The marked increase in yield of 304 on switching from 
potassium carbonate to cesium carbonate in DMSO (Table 3.2, entries 2 and 3) may be a 
result of the “cesium effect”, a term which refers to the large electronic polarizability and 
cationic radius (1.67 Å vs. 1.33 Å for K+) of Cs+ compared to other alkali metal ions.160 
Cesium carbonate therefore releases the “naked” carbonate anion more readily. In 
addition, cesium carbonate has a much higher solubility in DMSO, DMF, and DMA than 
potassium carbonate (Table 3.3).161 
Table 3.3 Solubility of alkali carbonates determined by Cella et al. (g/10 mL) 
Solvent Cs2CO3 K2CO3 Li2CO3 Na2CO3 
DMF 1.195 0.075 0.003 0.038 
DMSO 3.625 0.470 0.014 0.143 
DMA  0.490 0.047 0.004 0.021 
 
Scheme 3.8 • Synthesis of dialdehyde 305 on a 10 g scale by oil bath heating 
Though the microwave reactor provided a relatively fast and efficient route to 305, the 
key aldehyde starting material of the orienticin C backbone, the scale was limited to a 
‘batch synthesis’ using 500 mg of methyl gallate. Fortunately, the improved reaction 
conditions could be applied to a 10 g scale oil bath protocol with a minimal reduction in 
yield (Scheme 3.8). In this case, the impure reaction product could be brought to 98% 
purity (estimated by 1H-NMR) without column chromatography by washing the orange 
solid with cold diethyl ether.  
3.2.2 Mechanistic rationale and spectroscopic analysis of diaryl ether 304 and triayl 
diether 305 
The nucleophilic aromatic substitution described above (Scheme 3.7) shows 
chemoselectivity for the 3- and 5-hydroxy positions of methyl gallate 281. The most 
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acidic proton is at the 4-hydroxy position, with a calculated pKa of 8 compared to a pKa 
of 12 for the 3- and 5-hydroxy positions.162 Deprotonation at the 4-hydroxy position of 
281 results in anion 307 which is stabilised by conjugation with the ester group para to 
the phenoxide (Figure 3.2). By contrast, the anion formed by deprotonation at the 3-
hydroxy position (309) is not stabilised by the ester, making intermediate 309 the more 
reactive nucleophile. 
 
Figure 3.2 • Resonance stabilisation of the reaction intermediates formed by 
deprotonation of methyl gallate 281 
This analysis indicates that two equivalents of base are required for the first SNAr. 
Deprotonation is followed by an addition-elimination mechanism (Scheme 3.9) in which 
the electron-withdrawing aldehyde para to the halide provides stabilisation of anion 312.  
 
Scheme 3.9 • Postulated mechanism of the SNAr reaction between deprotonated methyl 
gallate 281 and 4-fluorobenzaldehyde 282 
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The carbon-fluorine bond has been referred to as “the strongest single bond in organic 
chemistry”.163 The short C-F bond length (1.4 Å compared to 1.9 Å for C-Br)164 and high 
bond dissociation energy (averaging around 500 kJ mol-1 compared to 290 kJ mol-1 for C-
Br)165 are due to the large difference in electronegativity between carbon and fluorine (2.5 
vs. 4.0).166 Consequently the C-F bond is highly polar, and the electron-poor carbon 
makes an excellent electrophile in the rate-determining addition step of the SNAr reaction. 
Re-aromatisation of the benzene ring in 312 is sufficiently exothermic to permit the 
energetically disfavourable breaking of the strong C-F bond.  
 
Figure 3.3 • X-ray crystal structure of dialdehyde 305: front view (left) and side view 
(right) 
 
Figure 3.4 • Intra- and intermolecular hydrogen bonding in the X-ray crystal structure of 
dialdehyde 305 
Pale brown crystals of dialdehyde 305 were obtained by crystallisation from diethyl ether 
and subjected to X-ray crystallographic analysis. This confirmed the symmetry of the 
C 
D 
E 
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double nucleophilic aromatic substitution product (Figure 3.3). In the monoclinic crystal, 
compound 305 has a non-planar conformation where aryl rings C and E are tilted at an 
angle of approximately 70 ° to the central D-ring, compared to 80 ° in the crystal structure 
of vancomycin 1.167 There is evidence of intermolecular hydrogen bonding between the 
hydroxyl group on ring D and the aldehyde carbonyl of ring E, with a bond length of 2.65 
Å and an angle of 118 ° (O—H---O, Figure 3.4). A possible intramolecular hydrogen 
bond was also identified between the hydroxyl on ring D and the oxygen of the 
neighbouring diaryl ether, with a bond length of 2.41 Å compared to 0.84 Å for the O-H 
covalent bond. 
 
Figure 3.5 • Partial 1H-NMR spectra of 305 (300 MHz, CDCl3) and 304 (400 MHz, 
CD3OD) 
The 1H-NMR spectrum supported our hypothesis that aldehyde 304 is substituted only at 
the 3-hydroxy position (Figure 3.5). The non-equivalent aromatic protons of the D ring 
appear as doublets at 7.30 and 7.12 ppm. The coupling constant 4J = 2 Hz is consistent 
with meta proton-proton coupling across an aromatic ring.168 By contrast, the 
magnetically equivalent D-ring protons in dialdehyde 305 appear as one peak: a singlet at 
7.62 ppm. In each case the aldehyde protons appear at 9.95 ppm (di-305, CDCl3) and 9.77 
ppm (mono-304, CD3OD) and the methyl ester signals appear in the appropriate region at 
305 
304 
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3.85 ppm (305) and 3.73 ppm (304). The FT-IR spectrum confirmed the presence of the 
aldehyde and ester functional groups, with carbonyl stretch bands at 1692 and 1669 cm-1 
for dialdehyde 305 and an overlapping band at 1686 cm-1 for mono-aldehyde 304. The 
C=O signals appear at a lower frequency than the expected range for carbonyl stretch 
bands due to the conjugation in these molecules.169 
3.2.3 Diaryl ether coupling under continuous flow conditions  
Continuous processes in the synthesis of fine chemicals and pharmaceuticals have grown 
increasingly sophisticated over the last three decades, and versatile modular flow systems 
are now commercially available and within the reach of both academic and industrial 
laboratories. Chemical reactions conducted in flow micro-reactors benefit from rapid heat 
transfer, increased safety and the ability to handle unstable reaction species.170 On an 
industrial scale, continuous flow processes have attractive economic and environmental 
benefits due to their high energy efficiency and reduced consumption of resources 
compared with batch processes.171 Flow system software offers precise control over 
reaction conditions and continuous measurement of temperature and pressure inside the 
reactor. Flow systems are therefore also highly compatible with continuous in-line and 
on-line reaction monitoring by analytical techniques such as ReactIR infrared 
spectroscopy and flow NMR spectroscopy.172,173 The differences in mass and heat 
transfer, surface area, catalyst exposure and reaction concentration between flow systems 
and corresponding batch processes can have profound effects on the efficiency and 
selectivity of a chemical reaction.174 This so-called “flash chemistry” concept coined by 
Jun-ichi Yoshida175 was applied to the synthesis of diaryl ethers by Wiles and Watts in 
2011 (Scheme 3.10).176  
 
Scheme 3.10 • Continuous flow synthesis of 1-chloro-4-nitro-2-(4-nitrophenoxy)benzene 
316 reported by Wiles et al. 
Using an organic base, DBU, to ensure the reaction was homogenous, 1,2-dichloro-4-
nitrobenzene 314 was coupled with 4-hydroxynitrobenzene 315 in acetonitrile at 195 °C 
to afford diaryl ether 316. Employing this flow protocol reduced the reaction time from 
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ten minutes to two minutes compared to the microwave-assisted reaction reported by 
Moseley et al. in 2010, with an accompanying increase in yield from 70% to >99%.177 
Subsequent investigation into the use of a biphasic aqueous potassium carbonate / 
acetonitrile mixture within the micro-reactor indicated that inorganic bases could be used 
in place of DBU, which significantly reduced the costs of the reaction.i 
Preliminary investigations into the continuous flow synthesis of dialdehyde 305 were 
carried out using a Uniqsis FlowSyn reactor. Employing the most favourable base/solvent 
conditions (outlined in Section 3.2.1, Table 3.2) of cesium carbonate in DMSO, a system 
was devised in which separate solutions of methyl gallate 281 and 4-fluorobenzaldehyde 
282 in DMSO were simultaneously pumped at a flow rate of 1 mL/min via a static mixer 
through a preheated glass column packed with cesium carbonate (Figure 3.6).  
 
Figure 3.6 • Continuous flow synthesis of triaryl biether 305 and diaryl ether 304; 1) 
using a heated column only and 2) with an additional 20 mL heated coil 
                                                          
i Potassium carbonate ~£20 per kg compared to DBU ~£400 per kg based on current prices from 
Sigma-Aldrich Co. 
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The concentrations of the organic starting materials were such that 2.5 equivalents of 4-
fluorobenzaldehyde 282 were present to one equivalent of methyl gallate 281. It was 
anticipated that the presence of the inorganic base cesium carbonate in a large excess 
relative to the amount of methyl gallate flowing through the column would increase the 
efficiency of the diaryl ether coupling. The amount of base inside the column decreased 
slightly over the course of the reaction, partly due to the slight solubility of cesium 
carbonate in DMSO (Section 3.2.1, Table 3.3) but mainly due to reaction with methyl 
gallate to form the soluble cesium salt 311 (Scheme 3.9, Section 3.2.2). However, the 
high temperature and high polarity of the solvent ensured that no precipitation of the 
intermediates or byproducts occurred inside the PTFE tubing of the reactor. 
In an attempt to improve the yield of dialdehyde 305, a 20 mL PTFE coil reactor heated 
to 150 °C was added to the FlowSyn set-up between the glass column and the collection 
flask (Figure 3.6). This increased the reaction time by 10 minutes and changed the ratio of 
the mono- and di-substitution products 304 and 305 to ~1:1 by 1H-NMR spectroscopy of 
the impure reaction mixture (Figure 3.7).  
 
Figure 3.7 • Partial 1H-NMR spectra of the impure reaction mixture of flow synthesis 
reaction 2 (Figure 3.6) (CDCl3, 500 MHz)  
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Measuring the integration of the methyl ester –OCH3 protons shows a total conversion of 
81% from the starting material methyl gallate 281 to products 304 and 305. However, the 
isolated yields of 304 and 305 (29% and 33% respectively) add up to an overall reaction 
yield of 62%, indicating some loss of material due to base hydrolysis of the methyl ester 
moiety. The yield of the diaryl ether coupling step using a flow reactor is comparable to 
(but no better than) the yield of the corresponding microwave-assisted reaction discussed 
in Section 3.2.1, but these initial studies demonstrate the potential of continuous flow 
systems for the fast automated synthesis of the triaryl biether core of orienticin C. 
In the microwave irradiation, flow synthesis and conventional oil bath procedures 
discussed above, the yield of the desired dialdehyde 305 remained frustratingly low. It is 
likely that employing an ortho nitro electron-withdrawing group on the electrophile (as 
demonstrated by both Evans and Boger, Section 3.2) would increase the yield of the 
reaction. There is also the possibility of switching to a transition metal-catalysed reaction 
such as that developed by Nicolaou et al. (Scheme 3.4, Section 3.2). However, the 
commercial availability and low cost of methyl gallate (and its precursor gallic acid) 
make our nucleophilic aromatic substitution route more appealing in terms of minimising 
the time and number of synthetic steps required. The byproduct of the SNAr discussed 
above, diaryl ether 304, is extremely useful as the starting material for the single-ring 
glycopeptide analogues which could be employed as test systems for new 
macrocyclisation chemistry in this field.178 Alternatively, diaryl ether 304 could be 
resubmitted to the SNAr reaction conditions for triaryl biether formation.  
3.3 Towards the synthesis of the ring D α-amino acid  
Aldehydes 304 and 305 described in Section 3.2 contain phenolic hydroxyl groups which 
required functional group protection at this stage to prevent possible ring-opening of the 
aziridines later in the synthesis. The phenol functional group can be routinely protected 
by a methyl, benzyl or allyl ether.179 The synthesis of a cyclic para-methoxybenzylidene 
acetal of methyl gallate, compound 281, was reported simultaneously by the groups of S. 
Tsuboi180 and T. H. Chan181 in 2005. 
Following a similar procedure to Chan et al., the transacetalisation reaction of methyl 
gallate 281 with para-methoxylbenzaldehyde dimethyl acetal 317182 was carried out in 
toluene under reflux conditions, with a catalytic amount (0.5 mol%) of para-
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toluenesulfonic acid (Scheme 3.11).  The round-bottom flask was fitted with a Soxhlet 
apparatus containing flame-dried 4Å molecular sieves to remove methanol from the 
reaction, and cyclic acetal 318 was obtained in a 41% yield. Methyl gallate 281 was 
recovered in a 47% yield after purification by flash column chromatography. 
 
Scheme 3.11 • Protection of methyl gallate 281 as PMB acetal 318, and subsequent SNAr 
diaryl ether coupling with 4-fluorobenzaldehyde 
Coupling of acetal 318 with 4-fluorobenzaldehyde 282 under the conditions described in 
Section 3.2.1 was initially unsuccessful (Scheme 3.11); microwave irradiation at 80-120 
°C for several hours produced no change by thin layer chromatography. After further 
heating at 160 °C for one hour the starting material was consumed and the reaction was 
quenched with distilled water. However, the 1H-NMR spectrum of the impure reaction 
mixture contained a mixture of 4-fluorobenzaldehyde 282, methyl gallate 281 and para-
methoxybenzaldehyde, indicating that hydrolysis of the acetal occurred during the 
workup. The same result was obtained using a copper(II) oxide coupling protocol reported 
by Kodama et al.183 
 
Scheme 3.12 • Protection of compound 304 as para-methoxybenzylidene acetal 319 
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Compound 319 was finally obtained in a poor 20% yield by oil bath heating at 75 °C over 
a period of three days, employing potassium carbonate as the base and acetonitrile as the 
solvent (Scheme 3.11).Compound 319 could also be obtained by transacetalisation of 
diaryl ether 304 with para-methoxylbenzaldehyde dimethyl acetal 317 (Scheme 3.12). 
However the overall yield of this two-step synthesis from methyl gallate 281 was only 
11%, and with an 8% overall yield for the reactions described in Scheme 3.10, neither 
route is suitable for this synthesis.  
Protecting the catechol functional group as the O-benzyl ether was more successful 
(Scheme 3.13). The reaction of diaryl ether 304 with benzyl bromide and potassium 
carbonate in DMF at 120 °C for 7 hours afforded compound 320 in a 73% yield.184 The 
mono-protected product was not observed in a quantity large enough to isolate. 
 
 
Scheme 3.13 • O-Benzyl protection of the 1,2-diol functionality of diaryl ether 304 
Cleavage of a benzyl ether is generally carried out via hydrogenation in the presence of a 
catalytic amount of palladium on carbon.185 In the case of diaryl ether 320 it is unlikely 
that any chemoselectivity would be shown, and both benzyl groups would be removed 
simultaneously under these conditions. To achieve a chemoselective deprotection, two 
protecting groups of differing reactivity were required. The 4-hydroxyl group (para to the 
methyl ester) of compound 304 is present in the aglycon of orienticin C (Chapter 1, 
Figure 1.2) and may remain protected until the end of the synthesis. In their 1999 
synthesis of vancomycin, Boger et al. chose to install a methyl ether at the 4-hydroxyl 
position; a highly robust group which was removed only by a global demethylation in the 
final stages of the synthesis using aluminium tribromide and ethanethiol.13 Following a 
procedure by Nishiyama et al.,186 the reaction of compound 304 with one equivalent of 
lithium carbonate and one equivalent of iodomethane in DMF chemoselectively protected 
the 4-hydroxy group, affording compound 321 in a 71% yield (Scheme 3.14).  
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Scheme 3.14 • Phenolic hydroxyl protection of 304 as i) methyl ether 321 and ii) TBDPS 
ether 322  
The chemoselectivity of this reaction is likely to be due to the influence of the electron 
withdrawing methyl ester on the acidity of the hydroxyl groups of compound 304.  
Deprotonation by lithium carbonate at the more acidic 4-hydroxy position on 304 results 
in anion 324 which is stabilised by conjugation with the ester group para to the phenoxide 
(Scheme 3.15). By contrast, deprotonation at the 3-hydroxy position of 323 is not 
stabilised by the ester, resulting in a higher pKa. As only one equivalent of base was been 
added, anion 324 will be the major deprotonated species and will further react with 
iodomethane via an SN2 mechanism to generate compound 321. 
 
Scheme 3.15 • Mechanism of the SN2 nucleophilic substitution of iodomethane with 
diaryl ether 304 
To confirm that the methyl ether was located para to the methyl ester, a second reaction 
was carried out, in which methyl 3,5-dihydroxy-4-methoxybenzoate 32638 was coupled 
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with one equivalent of 4-fluorobenzaldehyde 282 under the SNAr reaction conditions 
described in Section 3.2.1 (Scheme 3.16). The 1H- and 13C-NMR spectra of the resulting 
product matched those of compound 321 obtained by the alternative route illustrated by 
Scheme 3.14. 
 
Scheme 3.16 • SNAr reaction of 4-fluorobenzaldehyde 282 with methyl 3,5-dihydroxy-4-
methoxybenzoate 326 
A tert-butyldiphenylsilyl (TBDPS) group was chosen for protection of the remaining 
phenolic hydroxyl of compound 321.  More robust than the trimethyl silyl (TMS) ether 
group, aryl TBDPS ethers are stable towards weak acid, such as 1 M hydrochloric acid at 
room temperature, and can be selectively deprotected using TBAF187 or DBU.188 
Following a procedure by Coelho et al., compound 321 was added to a mixture of tert-
butyldiphenylsilyl chloride (1.1 equiv.) and imidazole (2.2 equiv.) in DMF at room 
temperature (Scheme 3.14).189 After 18 hours, TBDPS ether 322 was obtained in a 
moderate 57% yield after flash column chromatography. The yield of 322 is comparable 
to those reported by Coehlo et al., however it has since been found that the addition of 3 
equivalents of iodine dramatically accelerates the reaction between aryl alcohols and 
TBDPS-Cl by the formation of a polyhalide I2Cl
- anion, so there is potential to reduce the 
reaction time of the protection described in Scheme 3.14.190 
The methyl ether and benzyl ether protections described in Section 3.3.1 above were also 
applied to triaryl biether 305 in excellent yields of 92% and 87% respectively (Schemes 
3.17 and 3.18).  
Scheme 3.17 • Reaction of triaryl diether 305 with iodomethane to form methyl ether 327 
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Scheme 3.18 • Reaction of phenoxide 305 with benzyl bromide to form benzyl ether 328 
The benzyl ether was ultimately chosen as a convenient group to both synthesise and 
cleave later in the synthesis, as benzyl ethers can be efficiently removed by hydrogenation 
with palladium on carbon but are stable towards standard reduction and oxidation 
reactions as well as the mildly acidic conditions of the aza-Darzens aziridination 
reaction.37 
As it was decided to focus initially on conversion of the methyl ester of compound 328 to 
an α-amino acid (analogous to the core ring D of orienticin C), it was necessary to protect 
the aldehyde functionality of 328, which would be incompatible with subsequent 
reduction and oxidation steps. The acetal moiety is a widely used protecting group of the 
aldehyde carbonyl, and can be synthesised by the acid-catalysed reaction of an aldehyde 
with an alcohol, as discussed previously in this section. 
Dimethyl acetals can be readily synthesised by the reaction of aldehydes with trimethyl 
orthoformate in methanol with a catalytic amount of p-toluenesulfonic acid.191 However, 
they are prone to hydrolysis during aqueous reaction work-ups, and can be challenging to 
purify using flash column chromatography due to the slightly acidic nature of silica gel.192 
Cyclic acetals tend to be more stable towards hydrolysis than acyclic acetals, for entropic 
reasons (two compounds are obtained by hydrolysis of a cyclic acetal compared with 
three compounds for an acyclic acetal), and steric hindrance in the case of substituted 
cyclic acetals, which increases resistance to nucleophilic attack.193  
 
Scheme 3.19 • Protection of dialdehyde 328 as pinacol acetal 329 
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Following a similar procedure originally reported by Ovaa et al.,194 compound 328 
reacted with 2.3 equivalents of pinacol in refluxing toluene in the presence of 0.5 mol% 
p-toluenesulfonic acid to afford the bis-acetal 329 in an 86% yield (Scheme 3.19). A 
Dean-Stark apparatus was used to collect the water produced in the reaction. The 
formation of a cyclic acetal is accelerated by the kinetically favourable intramolecular 
ring-closing step (intermediate 333, Scheme 3.20). In the case of pinacol, the gem-
dimethyl groups may aid the cyclisation step due to the Thorpe-Ingold effect, by which 
the size of the methyl substituents compresses the angle of the neighbouring substituents, 
bringing the nucleophilic alcohol group into closer proximity to the electrophilic carbon 
reaction site.195     
 
Scheme 3.20 • Mechanism of acetal condensation between dialdehyde 328 and pinacol 
With the acetal protecting groups in place, methyl ester 329 was reduced to primary 
alcohol 336 using 2.5 equivalents of lithium aluminium hydride in an excellent 97% yield 
following a similar procedure reported by Percec et al.196 Oxidation of the alcohol 336 
proceeded smoothly using 20 equivalents of activated manganese(II) dioxide to afford 
aldehyde 337 in a moderate yield of 69% after 18 hours at room temperature. The 
reduction of a methyl ester to an aldehyde has previously been achieved in one step using 
diisobutylaluminium hydride (DIBAL-H), which would be an advantage in this 
synthesis.197 However, significant over-reduction of the ester to alcohol 336 was observed 
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by thin layer chromatography during the reaction between 329 and one equivalent of 
DIBAL-H at -78 C. This route was therefore disregarded in favour of the less efficient 
but more reliable two-step process shown in Scheme 3.21.  
The Wittig reaction of aldehyde 337 to form styrene 338 was carried out using standard 
conditions, in which 3 equivalents of sodium hydride reacted with an equimolar amount 
of methyltriphenylphosphonium bromide (initially at a reaction temperature of -25 C) to 
form a phosphorus ylide which then reacted with aldehyde 337 to afford styrene 338 in a 
51% yield. 
 
Scheme 3.21 • Functional group interconversions from ester 329 to aldehyde 337 and 
subsequent Wittig olefination 
The initially disappointing yield and slow rate of this reaction was thought to be a result 
of the low temperature employed. Indeed, maintaining the reaction temperature at 0 C 
afforded compound 338 in a much improved 76% yield. Cyclic acetals such as those on 
338 can be challenging to remove, often requiring strongly acidic conditions (10% 
aqueous hydrochloric acid / THF198 or 50% aqueous trifluoroacetic acid199). In order to be 
sure that the pinacol acetals of 338 could be hydrolysed when required, a test deprotection 
was carried out (Scheme 3.22). The deprotection of a pinacol acetal in the presence of a 
1,2-disubstituted alkene with similar success has been reported on multiple occasions in 
the literature, with no reports of alkene polymerisation.200 
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Scheme 3.22 • Test hydrolysis of pinacol acetal 338 using 1 M aqueous hydrochloric acid 
in THF 
Following a procedure adapted from Eichen et al.,201 acetal 338 was dissolved in a 1:1 
homogeneous mixture of tetrahydrofuran and 1 M aqueous hydrochloric acid. The 
reaction was monitored regularly by thin layer chromatography. After stirring at room 
temperature for 2 hours no change was observed. The reaction temperature was increased 
to 50 C, and after 3 hours the starting material was completely consumed. 1H-NMR 
analysis of the impure reaction mixture indicated that the pinacol deprotection was 
complete. A small amount of the corresponding mono-aldehyde was observed by 1H-
NMR (400 MHz) but was not isolated in this case. Dialdehyde 339 was obtained in an 
excellent 90% yield after purification by flash column chromatography on silica gel.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER FOUR 
 
Synthesis of peptide aziridines via the aza-Darzens reaction 
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4.1 Racemic aza-Darzens aziridination of biaryl and triaryl ether aldehydes 
Initial attempts to synthesise N-aryl aziridines from the triaryl and biaryl ether aldehydes 
described in chapter 2 were based on racemic organocatalytic methodology previously 
established within the Bew group (Scheme 4.1).
202
 The reaction between imine 345 and 
tert-butyl diazoacetate (TBDA) 346 was catalysed by 10 mol% of pyridinium triflate 347 
to afford racemic cis-aziridine 348 in a 71% yield. This reaction was also reported as a 
one-pot procedure from benzaldehyde, with the addition of 4Å molecular sieves to 
facilitate the initial imine condensation. 
 
Scheme 4.1 • Pyridinium triflate-catalysed aza-Darzens synthesis of racemic cis-aziridine 
348 reported by Bew et al., 2009 
Applying this methodology to the triaryl biether system, a three-component one-pot 
reaction between aldehyde 328, 2-tert-butoxyaniline 349 and tert-butyl diazoacetate 346 
was catalysed by pyridinium triflate 347 (10 mol%) at -60 °C, affording bis-aziridine cis-
350 in a 59% yield. Byproduct racemic, cis-351 was isolated in a 23% yield (Scheme 
4.2).  
 
Scheme 4.2 • One-pot imine condensation / racemic aza-Darzens aziridination reaction of 
aldehyde 328 catalysed by pyridinium triflate 347  
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The one-pot protocol shown in Scheme 4.2 is a reaction in two parts; first the imine 
condensation between aldehyde 328 and 2-tert-butoxyaniline 349, which took place at 
room temperature. Only 1.95 equivalents of 349 were added, to ensure complete 
consumption of the amine, which would otherwise be protonated by the pyridinium 
triflate catalyst and slow down the reaction. For the second part, the aza-Darzens reaction 
of the activated imine with a diazo compound, catalyst pyridinium triflate (347) was 
added at room temperature, and the sealed vial was cooled to -60 °C before the addition 
of tert-butyl diazoacetate 346. 
C2,3-disubstituted aziridines can be identified as their cis or trans diastereomer by their 
1
H-NMR doublet coupling constant.
203
 The Karplus equation provides a relationship 
between the three-bond coupling constant (
3
J) and the H-C-C-H dihedral angle (Figure 
4.1).
204
 In the cis-aziridine, the protons are eclipsed, where the dihedral angle ϕ = 0 °, 
therefore coupling constamt 
3
J = ~7-11 Hz. In the trans-aziridine, the dihedral angle ϕ = 
120 °, giving a coupling constant of 
3
J  = ~2-4 Hz.   
 
Figure 4.1 • The Karplus relationship applied to cis and trans C2,3-disubstituted aziridines 
Compounds 350 and 351 isolated from the reaction in Scheme 4.2 have aziridine C-H 
doublets with coupling constants of 6.7 Hz, which is consistent with a cis configuration. 
An overall diastereoselectivity of >99:1 (cis:trans) was observed by 
1
H-NMR analysis of 
the impure reaction mixture (Figure 4.2). When the same reaction was conducted at room 
temperature rather than -60 °C, the overall cis/trans ratio dropped to 90:10, although the 
ratio of mono:bis aziridines (351:350) remained approximately the same.    
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Figure 4.2 • Partial 1H-NMR spectra of the impure reaction mixtures in the formation of 
aziridines 350 and 351 
The reaction conditions outlined in Scheme 4.2 were applied to biaryl ether aldehyde 320 
with similar success (Scheme 4.3). It was found that the one-pot imine condensation / 
racemic aza-Darzens aziridination reaction between 320, 2-tert-butoxyaniline 349 and 
TBDA 346 could be carried out at 0 °C rather than -60 °C, affording racemic cis-aziridine 
352 in a moderate 57% yield. The trans aziridine diastereomer was not observed in this 
case. 
 
Scheme 4.3 • One-pot imine condensation / racemic aza-Darzens reaction of aldehyde 
320 with 2-tert-butoxyaniline 349 and tert-butyl diazoacetate 346 
Attempting to carry out a selective mono-aziridination of aldehyde 339 using one 
equivalent of tert-butyl diazoacetate 346 proved more problematic (Scheme 4.4). Cis-
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aziridine 353 was isolated in a poor 19% yield after purification by flash column 
chromatography, which is unlikely to reflect the true outcome of the reaction, as 
compound 353 was very difficult to separate from 2-tert-butoxyaniline 349 which was 
present in the impure reaction mixture. 2-tert-Butoxyaniline 349 was likely to have been 
produced by hydrolysis of the unreacted imine intermediate upon removal of the 4Å 
molecular sieves by filtration, or during the flash column chromatography itself. 
 
Scheme 4.4 • One-pot imine condensation / racemic aza-Darzens reaction of aldehyde 
339 with 2-tert-butoxyaniline 349 and tert-butyl diazoacetate 346 
The cis-selectivity of the racemic pyridinium triflate-catalysed aza-Darzens reactions 
described above are consistent with previous findings by the Bew group.
202
 Wulff et al. 
have put forth a number of mechanistic explanations for this selectivity in relation to their 
VANOL/VAPOL-boroxinate catalyst.
244
 With regard to the pyridinium triflate-catalysed 
reactions described above, a possible mechanism is proposed in Scheme 4.5. Aldehyde 
354 first reacts with 2-tert-butoxyaniline 349 in a condensation reaction to form imine 
359 in situ. On the addition of pyridinium triflate 347, imine 359 is in equilibrium with 
protonated species 360, which now is activated towards attack at the electrophilic sp
2
-
hybridised carbon. Due to the difference in pKa of the imine (pKa around 7-8)
205
 and 
pyridinium triflate 347 (pKa = 5.2),
206
 the equilibrium lies towards the protonated imine 
species 358. Diazoacetate 346 is nucleophilic at the –CHN2 carbon due to resonance of 
the diazocarbonyl group,
207
 and can attack either the top or bottom face of the imine on 
360. 
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Scheme 4.5 • Proposed mechanism of the one-pot pyridinium triflate-catalysed aza-
Darzens aziridination reaction 
The orientation of the diazoacetate relative to the imine as it approaches defines the 
stereochemistry of the chiral centre in intermediate 361 produced by C-C bond formation. 
The approach of diazoacetate 346 to imine 360 is drawn such that the diazo group is in 
close proximity to the imine bond, which is consistent with tentative evidence that the 
reaction may alternatively proceed via a concerted cycloaddition mechanism.
208
 In 
intermediate 361 the bulky tert-butyl group occupies the least sterically hindered position 
relative to the phenyl group of the imine. The ring-closing step requires a rotation of the 
bond indicated in 361 so that the nitrogen lone pair overlaps with the empty σ* orbital of 
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the electrophilic carbon in a “backside attack” mechanism. The –N2
+
 group leaves 
irreversibly as nitrogen gas, observed as bubbles produced during the reaction.   
Overall, the results of the racemic aza-Darzens aziridination reactions described in this 
section were encouraging; the triaryl biether aldehydes 328 and 339 and biaryl ether 320 
all reacted successfully in a one-pot procedure. These reactions all produced the cis-
aziridine and little or no trans-aziridine. The yields of the aziridination reaction were poor 
to moderate, however, mainly due to problems with purification. 2-tert-Butoxyaniline 349 
and its decomposition products proved difficult to remove from the cis-aziridine by 
column chromatography. The 2-tert-butoxyphenyl group has been found to enhance the 
enantioselectivity of the non-racemic version of the organocatalytic aza-Darzens reaction 
catalysed by BINOL-derived triflamides.
209
 However, there have so far been no reports of 
methods to cleave the 2-tert-butoxyphenyl group from an amine, making it an undesirable 
protecting group for this multi-step synthesis. Following these initial investigations it was 
clear that a higher yielding, more flexible, and crucially non-racemic aza-Darzens 
aziridination route was required. 
4.2 Remote asymmetric induction in the organocatalytic synthesis of peptide 
aziridines  
The initial approach to the synthesis of orienticin C described in this work involved the 
construction of (S)-phenylalanine derivative ring E as a protected α-amino acid which 
would be subsequently deprotected by hydrolysis of the ester ready for peptide coupling 
with the asparagine residue of the peptide chain (Route 1, Figure 4.3).  
 
Figure 4.3 • Retrosynthetic analysis outlining the construction of the E-ring of orienticin 
C via a peptide aziridine  
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However, an approach involving the synthesis of a peptide aziridine (Route 2) would 
remove the need for a deprotection and peptide coupling step, making this route more 
efficient. The synthesis of N-aryl C2,3-disubstituted α-amino acid derived aziridines by 
aza-Darzens reaction of an imine with a diazopeptide has not yet been reported in the 
literature. Diazo substrates have so far been restricted to diazoacetates and simple phenyl 
diazoacetamides. It was anticipated that the reaction illustrated by Scheme 4.7 would be 
catalysed by achiral Brønsted acid pyridinium triflate 347 as in Section 4.1.  
 
Scheme 4.7 • General scheme for the pyridinium triflate-catalysed aza-Darzens reaction 
of an imine with a diazopeptide to afford a peptide-derived cis-aziridine 
However, the influence of an α-amino acid chiral centre in the diazoacetamide starting 
material may result in a diastereoselective reaction, due to a 1,5-asymmetric induction 
(Scheme 4.7). In order to investigate this hypothesis, a series of chiral non-racemic 
diazopeptides were required. Their synthesis and characterisation are described in Section 
4.2.1. 
4.2.1 Synthesis of diazopeptides using N,N’-ditosylhydrazine  
α-Diazocarbonyl compounds have found a wide range of applications since the work of 
Theodor Curtius on their synthesis in the late 19
th
 century (Scheme 4.8).
210
 Diazopeptides 
exhibit biological activity in a number of areas, and notably they have been shown to 
display antibacterial
211
 and anti-cancer properties.
212
 Ethyl diazoacetate 144 was first 
synthesised by Curtius in 1883 by diazotisation of glycine methyl ester 366 in aqueous 
acid.
210
 N-(Diazoacetamido)glycine ethyl ester 369 was subsequently synthesised from N-
glycylglycine ethyl ester 368 employing the same conditions.
213
 Despite the early 
synthesis of 369, only a small number of diazopeptides have been reported, of which the 
majority are benzyl, benzoyl and methyl ester variants of N-(diazoacetamido)- glycine 
and phenylalanine.
214
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Scheme 4.8 • Synthesis of ethyl diazoacetate 144 and N-(diazoacetamido)glycine ethyl 
ester 369 reported by Curtius et al. 
In 2007, Fukuyama et al. reported the synthesis of diazoacetates from the corresponding 
alcohol in two steps using N,N’-ditosylhydrazine as the diazoacetylating reagent (Scheme 
4.9).
215
 This method represented a significant improvement on the conventional 
diazotisation route, affording a diverse range of phenyl, alkyl, allyl and benzyl 
diazoacetates in yields of 52-90%. N,N’-Ditosylhydrazine reacts with organic bases such 
as DBU and TMG according to the mechanism in Scheme 4.9 put forth by Ragnarsson et 
al. to afford nitrogen gas and two equivalents of a tosylate salt.
216
  
 
Scheme 4.9 • Synthesis of diazoacetates reported by Fukuyama et al.  
 
Scheme 4.10 • Mechanism of reaction between N,N’-ditosylhydrazine 376 and a base (B), 
where B = DBU, TMG postulated by Ragnarsson and Grehn. 
CHAPTER 4 Aza-Darzens synthesis of peptide aziridines 
116 
 
However, in the presence of an alkyl bromide, the deprotonated species 377 acts as a 
nucleophile, and a diazo compound is formed as the major product. In order to synthesise 
N-(diazoacetamido)-L-phenylalanine methyl ester 386 by the method reported by 
Fukuyama et al., the corresponding bromoacetamide 381 was first made according to a 
procedure by Calorini et al (Scheme 4.11).
217
  
 
Scheme 4.11 • Synthesis of α-amino acid bromoacetamides 381-385 
L-Phenylalanine methyl ester hydrochloride 380 reacted with one equivalent of 
triethylamine at room temperature to release the free amine in situ before the flask was 
cooled to -10 °C for the addition of one equivalent of bromoacetyl bromide and a further 
one equivalent of triethylamine to react with the HBr produced in the reaction. 
Gratifyingly, N-(bromoacetamido)-L-phenylalanine methyl ester 381 was obtained in an 
excellent 94% yield and could be used in the next step without further purification. These 
reaction conditions were applied to a further five α-amino acids, affording compounds 
382-385 in yields of 76-91%. α-Amino acid bromoacetamides 381, 382 and 385 are 
known compounds, and their physicochemical properties (
1
H-NMR, FT-IR, and MS) 
were consistent with those reported previously.
218,
 
219, 220 
The conversion of bromoacetamide 381 to N-(diazoacetamido)-L-phenylalanine methyl 
ester 386 proceeded smoothly at 0 °C in a 60% yield (Scheme 4.12). The product was 
isolated as a bright yellow solid, and the physicochemical data was consistent with that 
published for rac-386 reported previously by Lowe et al. Diazopeptides 387-390 were 
also synthesised by this method in moderate yields of 57-79%. 
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Scheme 4.12 • Synthesis of α-amino acid diazoacetamides 386-390 
The striking yellow colour is common to compounds containing the diazo functional 
group, which also has a characteristic peak of strong intensity known as the “diazoband” 
at around 2106 cm
-1
 in the FT-IR spectrum (Figure 4.3). This has been attributed to the 
effect of the –C=N=N cumulative double bond, as the stretching frequency of 
diazomethane in the gas phase is 3712 cm
-1
. Figure 4.3 also shows the ester and amide 
carbonyl stretch of diazopeptide 390 at 1738.6 and 1621.2 cm
-1
 respectively. 
 
Figure 4.3 • FT-IR (thin film) spectrum of compound 390 
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In the case of N-(diazoacetamido)-(S)-phenylalanine methyl ester 386, which was 
reported previously by Lowe et al., the specific rotation is comparable to the literature 
value: [α]D
21
 +175.0 (c 1.0, CHCl3) cf. [α]D
20
 +186.0 (c 1.0, CHCl3).
221
  
Unfortunately, the Fukuyama diazoacetate synthesis described above could not be applied 
successfully to the synthesis of diazopeptide with side-chains bearing more reactive 
functional groups such as N-(diazoacetamido)-(S)-methionine methyl ester 393 (Scheme 
4.13). A 
1
H-NMR of the impure bromoacetamide 392 was obtained which appeared to 
show a successful reaction between (S)-methionine methyl ester hydrochloride 391 and 
bromoacetyl bromide to afford 392 as the major product.
i
 However, this compound 
proved to be very unstable and could not be fully characterised. Consequently, an impure 
sample of 392 was submitted to the Fukuyama reaction conditions (N,N’-ditosylhydrazine 
/ DBU) immeditately after workup. The impure 
1
H-NMR of diazopeptide 393 contained 
no peaks that could be identified as corresponding either to the starting material 392 or 
the product 393. In order to obtain a diazopeptide with a methionine side-chain such as 
393, an alternative method of synthesis was investigated, which is described in section 
4.2.2. 
 
Scheme 4.13 • Attempted synthesis of N-(diazoacetamido)-(S)-methionine methyl ester 
393  
4.2.2 Synthesis of α-amino acid diazopeptides using succinimidyl diazoacetate 
Succinimidyl diazoacetate 396 was first synthesised in 1993 by Badet et al. as a 
convenient and versatile reagent for diazoacylation.
222
 The Steiglich esterification of N-
hydrosuccinimide 394 with glyoxylic acid tosylhydrazine 395 using DCC in 1,4-dioxane 
afforded succinimidyl diazoacetate 396 in a reported yield of 65%. Compound 396 
reacted with a range of aliphatic and aromatic amine nucleophiles, displacing N-
hydroxysuccinimide to afford the corresponding N-diazopeptides in yields of 30-98%. A 
                                                          
i
 Attempted synthesis of 393 (Scheme 4.13) carried out by Miss Haseena Seylani, BSc Chemistry final year 
dissertation (University of East Anglia) 
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number of novel N-diazopeptides were reported, including N-diazoacetamido-(S)-
phenylalanine benzoyl ester 397.  
 
Scheme 4.14 • Synthesis of succinimidyl diazoacetate 396 and N-(diazoacetamido)-(S)-
phenylalanine benzoyl ester 397 by Badet et al. 
The yield of succinimidyl diazoacetate 396 reported by Badet proved challenging to 
reproduce on a large (5-10 g) scale, partly due to the difficulty of removing unreacted 
DCC and the byproduct DCU from the product by column chromatography on silica gel. 
A 47% yield of 396 was the highest achieved. The reaction of compound 396 with (S)-
methionine methyl ester hydrochloride 391 was carried out in THF at room temperature 
with three equivalents of Hünig’s base (ethyl diisopropylamine or DIPEA), to afford 393 
in 50% yield (Scheme 4.15).  
 
Scheme 4.15 • Synthesis of amino acid diazoacetamides 393, 386, 387 and 398-402 using 
succinimidyl diazoacetate 396 
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This method was used to synthesise novel N-(diazoacetamido)-α-amino acids 238-240 in 
moderate to good yields of 65-75%. The β-amino acid diazoacetamide 237 was obtained 
in a 61% yield from the commercially available free amine tert-butyl (3S)-3-amino-3-
phenylpropanoate. 
The poor yield of N-(diazoacetamido)-(R,S)-phenylalanine benzyl ester 402 can be 
explained by problems with purification. Overall the reaction was consistently reliable, 
with α-amino acid diazopeptides 386 and 387 obtained in similar yields to those observed 
using the N,N’-ditosylhydrazine method described in Section 3.2.2. The disadvantages of 
the succinimidyl diazoacetate (396) route are the long reaction times (<24 hours) and the 
low yield of the 396 itself, which invariably required more than one purification by 
column chromatography following the DCC-mediated esterification (Scheme 4.14). 
4.2.3 Asymmetric organocatalytic aza-Darzens aziridination of non-chiral N-aryl 
imines with α-amino acid diazopeptides 
N-Benzylidene-4-methoxyaniline 405 was chosen as the achiral imine substrate for our 
initial investigations into the asymmetric synthesis of peptide aziridines (Scheme 4.17). 
Compound 405 has previously been found by the Bew group to react successfully with 
ethyl diazoacetate 144 to afford a cis-aziridine.
223
 Mayer et al. have established that the p-
methoxyphenyl nitrogen protecting group can be removed with relative ease using 
cerium(IV) ammonium nitrate (CAN) (Scheme 4.16). 
224
 
 
Scheme 4.16 • CAN-mediated cleavage of the N-p-methoxyphenyl group from aziridine 
242 reported by Mayer et al. 
Employing similar conditions to the aza-Darzens reactions described in Section 3.1, imine 
405 was cooled to 0 C in an ice bath before the addition of 10 mol% pydridinium triflate 
347 and 1.2 equivalents of N-(diazoacetamido)-(S)-phenylalanine methyl ester 386 
(Scheme 4.17). The sealed reaction vial was allowed to warm slowly to room temperature 
over 16 hours.   
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Scheme 4.17 • Pyridinium triflate-catalysed aza-Darzens synthesis of cis-aziridine 406aii  
The 
1
H-NMR of the impure reaction mixture shows poor conversion of imine 405 to 
aziridine 406a (Figure 4.4). There is also a singlet peak at 10 ppm consistent with the –
CHO proton of benzaldehyde, indicating partial hydrolysis of the imine during the 
reaction. Overall the reaction mixture contains benaldehyde, imine 405 and aziridine 406a 
in a ratio of approximately 1.5:2.5:1, which is consistent with the 23% isolated yield of 
406a. 
 
Figure 4.4 • Partial 1H-NMR of cis-aziridine 406a (blue) overlaid with the impure 
reaction mixture (red) 
                                                          
ii
 Absolute stereochemistry of 406a inferred from x-ray crystal structure, Figure 4.5 
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The 
1
H-NMR of compound 406a has aziridine C-H doublet peaks at 3.57 ppm and 3.05 
ppm with coupling constants of 7.0 Hz, which is characteristic of a cis-aziridine. N-
(Diazoacetamido)-(S)-phenylalanine methyl ester 386 is absent from the 
1
H-NMR of the 
impure reaction, which would prevent further conversion of imine 405 to product 406a. It 
is likely that compound 386 decomposed during the course of the reaction; diazo 
compounds are known to be both light and acid sensitive.
149
 In the synthesis of 406a it 
may be that the rate of decomposition of 386 is faster than the rate of aziridination. 
A small sample of aziridine 406a crystallised in the eluent of the column chromatography 
during purification (petroleum ether / diethyl ether 1:1). X-ray crystallographic analysis 
revealed that compound 406a crystallised in the centrosymmetric spacegroup triclinic P-
1, indicating a racemic mixture of the cis-enantiomers (R,R,S) and (S,S,R) (Figure 4.5).   
 
Figure 4.5 • X-ray crystal structure of racemic cis-aziridine 406a 
The diazopeptide substrate 386 was synthesised with the S configuration (as supported by 
the specific rotation), but the ee was not confirmed by chiral HPLC, so either a small 
amount of the R configuration was present in the sample, or some racemisation of 386 
occurred during the reaction. The two or three crystals formed during column 
chromatography may not be representative of the whole sample, as opposite enantiomers 
can have a greater affinity for each other than the same enantiomer, resulting in a small 
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amount of the “true racemate” crystals.225 Taking this into account, from the crystal 
structure of 406a we can still infer that for the 1,5-induction there is a mismatch in the 
stereochemical outcome of the aziridination reaction: an S configuration in the 
diazopeptide substrate leads to an R,R configuration in the aziridine ring. 
A second reaction was attempted under the same conditions using N-(diazoacetamido)-
(S)-methionine methyl ester 393 (Scheme 4.18). Again only a single cis-aziridine product 
was obtained, according to the 
1
H-NMR of the isolated product, 407a or 407b, which 
showed an aziridine C-H doublet coupling constant of 7.0 Hz. However, the yield was 
poor at 27% and the 
1
H-NMR of the impure reaction mixture did not conclusively 
confirm the diastereoselectivity of this reaction. No crystals of the aziridine product were 
obtained in this case. The cis-selectivity of the aziridination reactions in Scheme 4.17 and 
4.18 is surprising in the context of similar research reported in the literature. It has been 
generally accepted that acid catalysed aza-Darzens reactions with a diazoacetate substrate 
afford a cis-aziridine as the major product, while diazoacetamides generally afford a trans 
aziridine.
226
 
 
Scheme 4.18 • Pyridinium triflate-catalysed synthesis of cis-aziridine 407  
In 2008 Maruoka et al. reported the use of BINOL-based dicarboxylic acid catalyst (R)-
410 for the trans-selective asymmetric aziridination of phenyl diazoacetamide 409 and N-
Boc imine 408 (Scheme 4.19).
227
 Aziridine (R,S)-411 was isolated in a 61% yield, with an 
excellent 97% ee determined by chiral HPLC and a trans:cis ratio of >20:1. Similarly, 
Zhong et al. used BINOL-phosphoric acid catalyst (R)-414 for the synthesis of p-
methoxyphenyl aziridine (R,S)-415 with a trans:cis ratio of >50:1. 
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Scheme 4.19 • BINOL-derived Bronsted acid-catalysed aza-Darzens aziridinations 
reported by Maruoka et al. (top) and Zhong et al. (bottom) 
In order to make a comparison to the work by Maruoka and Zhong, N-Boc imine 408
iii
 
was reacted with N-(diazoacetamido)-(S)-phenylalanine methyl ester 386 by the addition 
of 10 mol% of pyridinium triflate 347 (Scheme 4.20). Contrary to the outcome of the 
reactions using p-anisidine imine 405, trans-aziridine 416 (a or b) was obtained in an 
isolated yield of 72% as the only product observed by 
1
H-NMR of the impure reaction 
mixture (Scheme 4.20).  
 
Scheme 4.20 • Pyridinium triflate-catalysed trans-selective aza-Darzens aziridination 
between N-Boc imine 408 and diazopeptide 386 
                                                          
iii
 Kindly provided by postgraduate research student Mr Victor Zdorichenko, University of East Anglia. 
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Figure 4.6 • Possible explanation for the trans selectivity of the reaction between N-Boc 
imine 408 and N-(diazoacetamido)-(S)-phenylalanine 386 
Thus replacing the p-methoxyphenyl group on the imine with a Boc group resulted in a 
switch from cis selectivity to trans selectivity, showing that the nitrogen protecting group 
significantly influences the reaction. An explanation for the formation of a trans aziridine 
is presented in Figure 4.6. For the trans isomer (right), the approach of the 
diazoacetamide is influenced by hydrogen bonding between the amide –NH- and the 
carbonyl of the Boc group on the imine, affording intermediate 418 which is free from 
steric repulsion. Conversely reaction transition state 417 for the cis isomer (left) is made 
unfavourable by steric repulsion between the amide and the phenyl group. A single set of 
peaks corresponding to a trans aziridine was observed in the crude 1H-NMR of 416, 
indicating that there is excellent 1,5-stereocontrol in this reaction, although the absolute 
stereochemistry of 416 (either a or b) cannot be assigned without further investigation.   
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4.2.4 One-pot asymmetric organocatalytic aza-Darzens reaction of peptide imines 
with diazopeptides 
Peptide aziridines have attracted particular interest over the last 15 years as protease 
enzyme inhibitors.
228
 The natural product miraziridine A, for example, is a cysteine 
protease inhibitor isolated from a marine sponge found in the Japanese archipelago 
(Figure 4.7).
229
 
 
Figure 4.7 • Molecular structure of miraziridine A 
Recent work by the Yudin group has highlighted the use of aziridines in peptide ligation 
and macrocyclisation.
230
 The chemical synthesis of peptide aziridines reported in the 
literature largely relies on peptide coupling reagents to bring together simple carboxylate 
aziridines and amino acids or peptide chains.
231
 For example, T. Schirmeister et al.  
reported the synthesis of cis-aziridine 424 as a potential inhibitor of the secreted aspartic 
protease 2 (SAP2) of Candida albicans (Scheme 4.21).
232
  
 
Scheme 4.21 • Synthesis of peptide aziridine cis-424 reported by Schirmeister et al. 
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Racemic aziridine 421 was synthesised from trans-420 as a mixture of two enantiomers 
(R,R) and (S,S). Hydrolysis of the ethyl ester of 421 afforded carboxylic acid 422 ready 
for DPPA coupling with dipeptide 423. The resulting mixture of two diastereomers of cis-
424 could then be separated by a combination of column chromatography and preparative 
HPLC. 
Following the initial work on the synthesis of α-amino acid derived cis-aziridines by an 
aza-Darzens route presented in section 3.3.4, it was decided that to be practical and useful 
this route needed improved flexibility and higher yields. To this end, the N-aryl group 
would be replaced by an α-amino acid, and functional groups introduced on the aldehyde 
substrate (Scheme 4.22). This approach was designed to install three directions of 
functionality, with the aziridine ring as the “connector” scaffold. 
 
Scheme 4.22 • Summary of the one-pot asymmetric aza-Darzens synthesis of peptide 
aziridines 
The route illustrated in Scheme 4.22 offers considerable advantages over the conventional 
stepwise approach outlined in Scheme 4.21; there are significantly fewer steps required, 
and crucially the chirality of the α-amino acid substrates were anticipated to influence the 
stereochemistry of the aziridine formation by both 1,3- and possibly 1,5-asymmetric 
induction.  
 
Scheme 4.23 • Synthesis of α-amino acid imine 425 reported by Spring et al. 
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The imine condensation reaction between benzaldehyde 228 and (S)-phenylalanine 
methyl ester hydrochloride 380 was reported previously by Spring et al. (Scheme 4.23).
233
 
This reaction was successfully reproduced, and imine 425 was obtained in a 90% yield. 
The optical rotation of 425, [α]D
25
 -198.5 (c 0.92, CHCl3), was close to the literature value 
of [α]D
25
 -206.7 (c 0.92, CHCl3). However, despite being stored at low temperature, the 
rotation was found to have dropped to [α]D
25
 -11.2 (c 1.0, CHCl3) after 24 hours, possibly 
due to isomerism of the imine. It was important to avoid racemisation of 425 prior to the 
aziridination step, so the synthesis of 425 was carried out in situ from benzaldehyde 228 
and (S)-phenylalanine methyl ester 426 (Scheme 4.24). After one hour, 10 mol% of 
pyridinium triflate 347 and 1.2 equivalents of N-(diazoacetamido)-(S)-phenylalanine 
methyl ester 386 were added to the vial at 0 C. 
 
Scheme 4.24 • Synthesis of peptide aziridine cis-427iv via a one-pot pyridinium triflate-
catalysed aza-Darzens reaction  
Gratifyingly, the 
1
H-NMR of the impure reaction mixture after 16 hours showed complete 
consumption of benzaldehyde 228 and imine intermediate 425, with the exclusive 
formation of a single cis-aziridine product 427 (where the aziridine doublet coupling 
constant J = 7.2 Hz) which was isolated in an excellent 91% yield. The same reaction 
conditions were applied to the synthesis of a further three peptide aziridines 428-430 
which bear α-amino acid side-chains including N-Cbz-(S)-tryptophan, (S)-methionine, 
(S)-leucine and O-allyl-(S)-tyrosine (Figure 4.8). In each case, a single cis aziridine 
diastereomer was observed in the 
1
H-NMR of the crude reaction mixture, where the 
absolute stereochemistry has not yet been determined.  
                                                          
iv
 Absolute stereochemistry established in Section 4.2.7 
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Figure 4.8 • Peptide aziridines 428-430 synthesised by a pyridinium triflate-catalysed 
aza-Darzens methodology 
Aziridine 429, featuring allyl ester and allyl amide functional groups, was designed as a 
potential precursor for transition metal-catalysed ring-closing metathesis to form a 
peptide macrocycle. 
To achieve the “three directional” functionality described in Scheme 4.22, benzaldehyde 
228 was replaced by commercial available aldehydes 4-trifluoromethylbenzaldehyde 431 
and fluorene-2-carboxaldehyde 434 (Scheme 4.25). The incorporation of trifluoromethyl 
groups into peptides as a labelling technique in 
19
F-NMR is a key tool in structural 
biology.
234
 Fluorene derivatives have been employed as fluorescent probes in two photon 
fluorescence microscopy.
235
  
 
Scheme 4.25 • Synthesis of CF3-bearing peptide aziridine cis-433a/b via a pyridinium 
triflate-catalysed aza-Darzens methodology 
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Scheme 4.26 • Synthesis of fluorene-based peptide aziridine cis-436a/b via a pyridinium 
triflate-catalysed aza-Darzens methodology 
CF3-bearing cis-aziridine 433 was obtained in a disappointing 49% yield, indicating that 
this methodology may be less able to tolerate strongly electron withdrawing groups on the 
aldehyde substrate. The one-pot imine condensation / aziridination of fluorene-2-
carboxaldehyde 434, by contrast, afforded cis-aziridine 436 in a 79% yield after 
purification.  
Ferrocenecarboxaldehyde 438 (Scheme 4.26) was identified as a potentially useful 
substrate for the aza-Darzens reaction due to the redox activity of ferrocene in 
biochemical processes.
236
 For example, ferrocene-peptide conjugates have been used in 
the electrochemical probing of HIV enzymes.
237
 Aldehyde 276 has been previously 
reported to react successfully with amines to form stable Schiff base ligands for transition 
metal complexes.
238
 Indeed 
1
H-NMR analysis of intermediate 277 contained a singlet 
peak at 8.16 ppm consistent with the imine –CH=N- proton. However, on the addition of 
catalyst 347 and N-(diazoacetamido)-(S)-leucine methyl ester 387 there was no further 
reaction observed. This may be due to stabilisation of the partial positive charge of the α-
carbon attached to the Cp ring by the iron(II) centre – a recognised property of substituted 
ferrocene compounds.
239
 In order to obtain a ferrocene-based peptide aziridine, therefore, 
a spacer was required between the Cp and the aziridine ring. 
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Scheme 4.26 • Attempted aza-Darzens synthesis of ferrocenyl aziridine 440a/b from 
ferrocenecarboxaldehyde 438 
Imrie et al. synthesised 4-(ferrocenyl)benzaldehyde 443 by a Suzuki coupling reaction 
between iodoferrocene 441 and 4-formylphenylboronic acid 442 (Scheme 4.27).
240
 
However, the yield of this reaction was just 13%, and iodoferrocene 441 is not 
commercially available; it had to be synthesised in 2 steps from ferrocene in an overall 
31% yield.  
 
Scheme 4.27 • Synthesis of 4-(ferrocenyl)benzaldehyde 443 reported by Imrie et al. 
In order to obtain 4-(ferrocenyl)benzaldehyde 443 in a reasonable quantity, an alternative 
synthesis was designed in which methyl-4-aminobenzoate first reacted with sodium nitrite 
in a solution of aqueous hydrochloric acid to afford diazonium salt 444 in situ (Scheme 
4.28). The addition of ferrocene 445 afforded methyl 4-(ferrocenyl)benzoate 446 as a 
deep red solid in a 37% yield. Subsequent DIBAL-H reduction of the ester group of 446 
to alcohol 447 proceeded in an excellent 90% yield, and a manganese(IV) oxide oxidation 
of 447 afforded the desired aldehyde 443 in an 86% yield.  
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Unlike ferrocenecarboxaldehyde 438, 4-(ferrocenyl)benzaldehyde 443 formed an imine 
with (S)-phenylalanine methyl ester 426 and then reacted successfully with N-
(diazoacetamido)-(S)-leucine methyl ester 387 in the presence of 10 mol% of pyridinium 
triflate 347 to afford cis-aziridine 440 in a 73% yield.  
 
Scheme 4.28 • Four step synthesis of ferrocene-based peptide aziridine 440 from 
ferrocene 445 and diazoester 444 
 
4.2.5 Asymmetric synthesis of N-α-methylbenzyl peptide aziridine 455 
The α-methylbenzyl group is a highly useful nitrogen protecting group; it has found 
numerous applications in remote chiral induction,
 241
 for example in the synthesis of 
isoquinoline alkaloids by Czarnocki et al..
242
 After use as a chiral auxiliary the group can 
be subsequently cleaved under Pd/C hydrogenation conditions.
243
 The asymmetric 
synthesis of aziridines bearing an (R)- or (S)-N-α-methylbenzyl group has been reported 
by the groups of Wulff and Lee (Scheme 4.29). Lee et al. investigated the Lewis acid-
catalysed aza-Darzens reaction of ethyl diazoacetate 144 with a series of (S)-N-α-
methylbenzyl imines using a combination of 20 mol% cobalt chloride and 40 mol% silver 
tetrafluoroborate.
244
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Scheme 4.29 • Synthesis of aziridines bearing the N-α-methylbenzyl protecting group 
reported by Lee et al., 2005, and Wulff et al., 2012. 
Cis diastereomers 449 and 450 were obtained in yields of up to 65%, however the 
diastereomeric ratio was generally poor (≤ 27:73 in favour of 450). Wulff et al. employed 
a double stereodifferentiation approach, using the chiral (R)-VANOL boroxinate catalyst 
for the reaction between (R)-N-α-methylbenzyl imine 451 and phenyl diazoacetamide 
409.
245
 They reported a trans/cis ratio of 96:4 by this method, and ratio of the two trans 
diastereomers 452 and 453 of 95:5 (diastereomeric ratios obtained from the 
1
H-NMR 
spectrum of the impure reaction mixture).   
The pyridinium triflate-catalysed aza-Darzens reaction described in section 4.3.5 was 
applied to the synthesis of N-α-methylbenzyl aziridine 451 as a comparison to the work 
by Wulff et al. In the one-pot protocol (Scheme 4.30), benzaldehyde 228 reacted with 
(R)-α-methylbenzyl amine 454 to form imine intermediate 451 by a condensation 
reaction. Following the addition of 10 mol% of achiral catalyst 347 and 1.2 equivalents of 
N-(diazoacetamido)-(S)-leucine methyl ester 387, 
1
H-NMR analysis of the impure 
reaction mixture after 16 hours (Figure 4.9) showed the formation of a single major cis-
aziridine product 455, which was isolated in a 90% yield. 
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Scheme 4.30 • One-pot pyridinium triflate-catalysed synthesis of N-α-methylbenzyl 
aziridine 455 (a or b) 
 
Figure 4.9 • Partial 1H-NMR of the impure reaction mixture (Scheme 4.30) 
Figure 4.9 shows the presence of two further doublets in the aziridine ring C-H region, 
with similar coupling constants to that of 455 (J = 7.1 Hz). It is presumed that the doublet 
at 2.44 ppm (far right) represents a diastereomer of 455, giving a dr of 95:5. The starting 
material for this reaction, (R)-α-methylbenzyl amine 454, was purchased at reagent grade, 
with an ee of 96% by GLC (see Experimental section for details). This may account for 
the presence of a third diastereomer 456 indicated by the doublet at 2.46 ppm, and the 
peak integration of 0.04 (4% of the reaction products) supports this theory.    
Employing the remote chiral induction protocol in this way removes the need for 
expensive catalysts and introduces more functionality into the molecule in a single step 
than the reactions shown in Scheme 4.29. Isolated as a single isomer, 455 is potentially a 
direct precursor to a range of natural and unnatural, nitrogen-protected, non-racemic 
dipeptides accessible via nucleophilic ring opening of the cis-aziridine moiety.  
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4.2.6 Investigating the effect of temperature and chiral distance on stereoselectivity 
The peptide aziridines described in Section 4.2.5 contain two α-amino acid chiral centres 
– the first directly connected to the nitrogen of the aziridine ring, and the second 
separated from the aziridine ring by a single amide bond. In order to establish the degree 
of influence of each chiral centre on the stereochemistry of the aziridine ring being 
formed, a comparison was made between aziridines 457 and 459, which feature the 
achiral α-aminoisobutyric acid (Aib) amino acid (Scheme 4.31).  
 
Scheme 4.31 • Pyridinium triflate-catalysed aza-Darzens synthesis of aziridines 457 and 
459 
The synthesis of cis-457 (where the aziridine doublet coupling constant J = 7.2 Hz) was 
carried out at 0 C using the protocol described previously (Section 4.3.5). The solvent 
was changed from chloroform to chloroform-d3 to make monitoring the reaction by 
1
H-
NMR more convenient. The reaction was complete after 10 hours, and a single aziridine 
product 457 was observed in the 
1
H-NMR of the impure reaction mixture, which was 
isolated in an 80% yield.  
In the synthesis of cis-459, the formation of a major aziridine product was observed, with 
a set of doublets at 2.78 ppm (J = 6.9 Hz) and 3.27 ppm (J = 6.9 Hz) corresponding to the 
aziridine C-H protons. However, a second minor set of doublets was observed with an 
identical coupling constant of 6.9 Hz. It is presumed that these peaks correspond to the 
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second diastereomer of 459. A temperature study showed that the ratio of the two 
diastereomers was influenced by the reaction temperature (Figure 4.10).  
 
Figure 4.10 • Partial 1H-NMR of the impure reaction mixture in the synthesis of cis-
aziridine 459 carried out at 25 C, 0 C, and -30 C 
When the reaction was carried out at room temperature (25 C), the ratio of major:minor 
diastereomers (measured by integration of the C-H doublets in the 
1
H-NMR) was 47.6:1, 
increasing to 60.1:1 when a 0 C chiller bath was used. The optimum temperature for the 
synthesis of 459 was -30 C, achieving a diastereomeric ratio of 94.4:1. Below this 
temperature, precipitation of N-(diazoacetamido)-(S)-phenylalanine methyl ester 386 was 
observed and the reaction failed.  
The findings from the synthesis of 457 and 459 are consistent with the expectation in 
remote chiral induction reactions that the closer the chiral centre of the starting material to 
the chiral centre formed during the reaction, the stronger the influence, and the higher the 
stereoselectivity. 
 
Figure 4.11 • Comparison of the distance between the two key chiral centres of aziridines 
457, 459 and 460 
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Thus in aziridine 457, the (S)-phenylalanine chiral centre is two bonds from the first 
aziridine chiral centre formed during the aza-Darzens reaction (Figure 4.11), and a single 
diastereomer product is observed. In the synthesis of compound 459, a 1,5-chiral 
induction takes place through four bonds, and selectivity is slightly lower, with a 
maximum dr of 94:1. It was hoped that inserting an Aib unit between the phenylalanine 
chiral centre and the aziridine ring would still result in a degree of stereoselectivity. This 
would be a 1,8 chiral induction (compound 460, Figure 4.11). To this end, diazodipeptide 
464 was synthesised from Boc-Aib-(S)-phenylalanine methyl ester 461 in three steps with 
an overall yield of 36% (Scheme 4.32).  
 
Scheme 4.32 • Synthesis of diazoacetamide dipeptide 464  
Compound 464 was found to be poorly soluble in chloroform at low temperature, so for 
the one-pot aziridination step (Scheme 4.33) the reaction was cooled to -30 C for the 
addition of 464 using a dry ice bath, which was allowed to warm slowly to room 
temperature overnight. Two cis-aziridine diastereomers were identified in the 
1
H-NMR of 
the impure reaction mixture and were subsequently separated by column chromatography 
(Figure 4.12). The dr based on 
1
H-NMR integration of the aziridine C-H doublets and the 
isolated yields were in close agreement at 2:1.   
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Scheme 4.33 • One-pot pyridinium triflate-catalysed aza-Darzens synthesis of cis-
aziridine 460a and 460b  
 
Figure 4.12 • Partial 1H-NMR of i) the impure reaction mixture and ii) an overlay of 
separated, pure cis diastereomers  460a and 460b 
It is clear that despite the conformationally restricted nature of the Aib unit, the 1,8 chiral 
induction was much less successful in terms of stereoselectivity than the 1,5- and 1,3- 
chiral induction reactions. Further work to increase the 2:1 ratio obtained in Scheme 4.33 
may include changing the Aib unit for a cyclohexyl group or a dehydro amino acid, as 
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sections of fixed planarity and restricted rotation are known to relay chiral information 
over longer distances.
246
  
4.2.7 Assigning the absolute stereochemistry of cis-aziridine 427a 
The peptide aziridines described in Section 4.3.5 were isolated and characterised as single 
cis diastereoisomers. However, it was not possible to assign the absolute stereochemistry 
of the aziridine ring in these compounds without further investigation. An alternative 
method of synthesis was required in which these unknown chiral centres would be 
derived from known enantiomerically pure starting materials. To simplify this process, 
the cis-aziridine would first be submitted to palladium(0)-catalysed hydrogenation, 
affording a pseudopeptide with just three chiral centres; a more convenient target for 
synthesis from commercially available amino acid starting materials (Scheme 4.34). Thus 
palladium on carbon (10 mol%) was added to a solution of aziridine 427a in ethanol and 
the reaction pressurised to 50 psi with hydrogen in a Biotage Endeavour system to afford 
compound 466 in a 96% yield.  
 
Scheme 4.34 • Hydrogenation of the aziridine ring of 427 catalysed by palladium on 
carbon 
A retrosynthetic summary of the alternative route to (S,R,S)-466 is presented in Scheme 
4.35. Peptide coupling of O-acetyl-(S)-phenyllactic acid 467 with (S)-phenylalanine 
methyl ester 426 affords compound 468, which can be deprotected under basic conditions 
to afford alcohol 469. The corresponding triflate 470 will then be displaced by (S)-
phenylalanine methyl ester 426 via an SN2 mechanism to afford compound 466.  
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Scheme 4.35 • Retrosynthetic analysis of the synthesis of pseudopeptide (S,R,S)-466 
O-Acetyl-(S)-phenyllactic acid 467 was prepared from (S)-phenylalanine 471 according 
to a procedure by Plenkiewicz et al.;
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 a reaction in which the (S) stereochemistry is 
retained in the product (Scheme 4.36). Subsequent coupling of 467 with (S)-
phenylalanine methyl ester hydrochloride was achieved using TBTU, affording 
compound 468 in a 38% yield.  
 
Scheme 4.36 • Synthesis of (S)-methyl 2-((S)-2-acetoxy-3-phenylpropanamido)-3-
phenylpropanoate 468 from (S)-phenylalanine 471 
 
Scheme 4.37 • Synthesis of 468 and 473 as a mixture of two diastereomers: (S,S) and 
(R,S) 
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These reactions were repeated using rac-phenylalanine as the initial starting material to 
obtain diastereomers 468 and 473 (Scheme 4.37) from O-acetyl-(R,S)-phenyllactic acid 
472. Compounds 468 and 473 could not be separated by column chromatography and 
were used in the next step of the synthesis as a 1:1 mixture of the two diastereomers.  
The TBTU-mediated coupling steps in Scheme 4.36 and 4.37 were repeated with the 
hydrochloride salts of (S)-methionine methyl ester, (S)-leucine methyl ester and α-
aminoisobutyric acid methyl ester to afford compounds 474-477 (Figure 4.13), with the 
intention of assigning the stereochemistry of a further range of peptide aziridines. In the 
synthesis of 476, a minor diastereomer 477 was also formed, in a ratio of 8:1 (476:477). 
This indicates that the O-Acetyl-(S)-phenyllactic acid 467 was not enantiomerically pure, 
and diastereomers 476 and 477 proved impossible to separate by flash column 
chromatography.  
 
Figure 4.13 • Compounds 474-477 synthesised by TBTU-mediated coupling illustrated 
by Scheme 4.37 
Hydrolysis of the acetyl protecting group of compound 468 was achieved under basic 
conditions using 0.25 equivalents of potassium carbonate in aqueous methanol, following 
a procedure by Yang et al.
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 Complete consumption of the starting material was 
observed by thin layer chromatography after one hour, however the moderate 57% yield 
of the reaction indicates that some material may be lost by hydrolysis of the methyl ester.  
 
Scheme 4.38 • Base hydrolysis of acetate 468 to afford alcohol 469 
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The acetate hydrolysis reaction was carried out on compounds 474-476, affording peptide 
alcohols 478-480 as a single (S,S) diastereomer (Figure 4.14). Racemic mixtures of (R,S) 
and (S,S) acetate diastereomers were hydrolysed by the method shown in Scheme 4.36 to 
afford the corresponding alcohols, which could be separated easily by column 
chromatography on silica gel (Scheme 4.37).  
 
Figure 4.14 • Alcohols 478-480 synthesised by base hydrolysis of acetates 474-476  
 
Scheme 4.39 • Hydrolysis of racemic acetates to afford separable (R,S) and (S,S) 
diastereomers 469, 479 and 480-483 
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Scheme 4.40 • Synthesis of methyl iminodiacetic derivative 486 reported by Langlois et 
al. 
In their 2008 publication on the synthesis of iminodiacetic acid derivatives as potential 
inhibitors of HIV-1 aspartyl protease, Langlois et al. reported the reaction between triflate 
485 and (S)-phenylalanine methyl ester 426 to afford compound 486 in a 42% yield 
(Scheme 4.40).
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 This route was applied to the synthesis of peptides 305 and 328 
(Scheme 4.41). It was found that triflates 488 and 490 were highly unstable and had to be 
used immediately in the second step without purification. Despite careful handling, and 
the low reaction temperature of -78 C, compounds 489 and 466 were obtained in low 
yields of 19% and 24% respectively. Fortunately, for the purposes of assigning absolute 
stereochemistry only pure samples of 489 and 466 were required for characterisation, and 
the yield was of less importance.  
 
Scheme 4.41 • Synthesis of pseudopeptide diastereomers 489 and 466 from phenyllactic 
acid derivatives 487 and 469 
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Figure 4.15 • Partial 1H-NMR of the crude reaction mixture of hydrogenation of aziridine 427a (top), pure diastereomer 466 (middle) and 
pure diastereomer 489 (bottom)
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The impure reaction mixture of the aza-Darzens reaction for the synthesis of aziridine 
427a was submitted for hydrogenation by palladium on carbon in a vial pressurised with 
hydrogen (50 psi). Purification of 427a by column chromatography was avoided to 
prevent enrichment of the diastereomeric ratio. The 
1
H-NMR spectrum of the impure 
hydrogenation reaction mixture was compared with the spectra of pure diastereomers 466 
and 489 (Figure 4.15), and there is a clear match to (S,R,S) diastereomer 466. The (S,S,S) 
diastereomer 489 is not visible in the 
1
H-NMR of the impure reaction mixture, indicating 
that the diastereoselectivity of the aziridination reaction is >99%. Cis-aziridine 427a 
therefore has (R,R) stereochemistry at the chiral centres of the three-membered ring. A 
proposed mechanistic rationale for the formation of 427a as the only product is presented 
in Figure 4.16. 
 
Figure 4.16 • Mechanistic rationale for the selective synthesis of cis-(S,R,R,S) 
diastereomer 427a over cis-(S,S,S,S) 427b 
In Figure 4.16a (above), the N-diazopeptide is shown approaching the bottom face of the 
imine, in a suitable orientation for the addition of the diazo group to the protonated imine 
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(as discussed in Section 4.1). In this proposed orientation of the two substrates (ii), the 
phenyl rings of the amino acid side chains are directed away from each other, minimising 
unfavourable steric interactions. Conversely, the approach of the diazopeptide to the top 
face of the imine in representations (iii) and (iv) brings the benzyl side chains into close 
proximity, leading to unfavourable steric interactions which prevent the formation of 
diastereomer 427b. 
4.3   Conclusions 
The peptide aziridines described in this chapter were prepared by a previously unreported 
Bronsted acid-catalysed remote asymmetric induction methodology, achieving a 2:1 
diastereomeric ratio in the 1,8-asymmetric induction which increased to  94:1 in the 1,5-
induction, and >99:1 in the 1,3-induction, where only a single stereoisomer of the product 
was observed. The absolute stereochemistry of cis-aziridine 427 was established by 
hydrogenation of the three-membered ring to afford pseudopeptide 466. It was revealed 
that the natural (S)-stereochemistry of the phenylalanine imine and diazoacetamide 
starting materials influenced the formation of the (R,R) stereochemistry in the aziridine 
product. This methodology therefore provides access not only to the synthesis of simple 
(R,S)-dipeptides, but also to the incorporation of unnatural, functionalised (R)-amino acid 
residues into an existing peptide chain, with potential applications in synthesis of the 
artificial cell structures discussed in Chapter 2. 
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4.4   Future work 
Taking the conclusions from the work described in chapters 3 and 4, the next step would 
be to apply the aza-Darzens remote asymmetric induction methodology to the synthesis of 
a glycopeptide antibiotic analogue. A proposed strategy is presented in Scheme 4.42, in 
which the (S)-α-methylbenzylamine group is employed as both a chiral auxiliary for 1,3-
stereocontrol in the aza-Darzens reaction, and an easily cleaved nitrogen protecting group.   
 
Scheme 4.42 • Application of aza-Darzens remote asymmetric induction methodology to 
the synthesis of an orienticin C analogue 
In order the further investigate the mechanism of the asymmetric aza-Darzens 
aziridination, it would be useful to establish the effect of different stereochemical 
configurations in the reaction substrates on the diastereoselectivity of the reaction. In the 
examples presented in Chapter 4, the (S)-amino acids were used exclusively to prepare 
both the imine and diazopeptide starting materials. This led to a mis-matched 
stereochemistry in the product, with cis-(R,R) configuration of the aziridine ring. 
Changing the configuration of the stereocentre in one or both of the substrates may 
produce the opposite diastereomer, or have a detrimental effect on the diastereoselectivity 
of the reaction, which may provide useful information about the competing or synergetic 
effect of combiningg 1,3- and 1,5- remote asymmetric induction in this context. 
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General Information 
Air and water-sensitive reactions were carried out under a nitrogen atmosphere and 
anhydrous conditions with magnetic stirring unless otherwise stated. Analytical thin-layer 
chromatography (TLC) was performed on Merck silica gel 60 F254 plates (0.2 mm), with 
visualization by UV light and/or potassium permanganate stain followed by heating. 
Flash column chromatography was performed using Davisil silica gel 60 (40-63 µm). 
1
H- 
and 
13
C-NMR spectra were recorded on a Bruker Avance spectrometer 500 (500 MHz), 
an Oxford Gemini 400 spectrometer (400 MHz) or an Oxford Gemini 300 spectrometer 
(300 MHz). Chemical shifts are reported in δ (ppm) and referenced to residual solvent 
signals (
1
H-NMR: CDCl3 at 7.26 ppm, CD3CN at 1.94 ppm; 
13
C-NMR: CDCl3 at 77.16 
ppm, CD3CN at 1.32, 118.26 ppm). Signal multiplicities are described as follows: s = 
singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet, br = 
broad. FT-IR spectra were recorded on a Perkin Elmer Spectrum 100 spectrometer as thin 
films on sodium chloride plates and are reported in wavenumbers (cm
-1
). Optical rotations 
were measured using a Perkin Elmer 241 polarimeter with a 1 mL cell (path length 1 dm) 
and are reported as follows: [α]D
T/°C
 concentration (c = g / 100 mL, solvent). MALDI-
TOF mass spectra were recorded on a Shimadzu Axima-CFR spectrometer. High 
resolution mass spectrometry (HRMS) was carried out by the EPSRC National Mass 
Spectrometry Facility (Swansea, UK). Melting points of crystalline solids were recorded 
using a Stuart Scientific SMP1 apparatus (solvent of crystallization in brackets) and are 
uncorrected. Percentage yield refers to the isolated yield of analytically pure material 
unless otherwise stated. Dichloromethane was distilled from calcium hydride before use. 
Chloroform and d-chloroform were filtered through basic alumina and stored over 4Å 
molecular sieves. Tetrahydrofuran was distilled from sodium/benzophenone prior to use. 
All other solvents and reagents were purchased from commercial sources (Sigma-Aldrich, 
Alfa Aesar, Fluorochem and Fisher Scientific) and used as received.  
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Methyl 3,5-bis(4-formylphenoxy)-4-hydroxybenzoate (305)  
Synthesis A: Microwave irradiation 
 
To a 15 mL microwave vial under a nitrogen atmosphere was added methyl 3,4,5-
trihydroxybenzoate 281 (500 mg, 2.72 mmol, 1 equiv.), cesium carbonate (2.41 g, 7.40 
mmol, 2.7 equiv.) and a magnetic stirrer bar. Dimethyl sulfoxide (7 mL) was added, and 
the resulting mixture stirred vigorously for 10 minutes at room temperature before the 
addition of 4-fluorobenzaldehyde (0.93 mL, 8.69 mmol, 3.2 equiv.) via a 2.5 mL syringe. 
The vial was sealed with a PTFE-lined aluminium crimp cap and the dark red suspension 
heated at 160 °C in a Biotage microwave reactor for three hours, after which the reaction 
mixture was allowed to cool to room temperature and poured into a 250 mL separating 
funnel containing 1 M aqueous hydrochloric acid (50 mL). The aqueous mixture was 
extracted with ethyl acetate (2 x 50 mL) and the combined organic extracts were washed 
with distilled water (3 x 50 mL) and then brine (50 mL). The solution was dried over 
magnesium sulfate, filtered, and the solvent removed in vacuo to afford a dark brown 
residue. Purification via flash column chromatography on silica gel (eluent: 
dichloromethane / ethyl acetate 9:1; Rf = 0.30) afforded a pale yellow solid (600 mg, 1.53 
mmol, 56% yield) whose physicochemical characteristics were consistent with those of 
the title compound (305).  
M.p. 161–162 °C; 1H-NMR (300 MHz, CDCl3) δ = 9.93 (s, 2H, -CHO), 7.88 (d, J = 8.7 
Hz, 4H, Ar-H), 7.62 (s, 2H, Ar-H), 7.13 (d, 4H, J = 8.8 Hz, Ar-H), 6.44 (s, 1H, -OH), 
3.84 (s, 3H, -CO2CH3); 
13
C-NMR (125 MHz, CDCl3) δ = 190.8 (-CHO), 165.5 (-
CO2CH3), 161.8, 144.8, 143.1, 132.3(1), 132.2(7), 122.9, 119.1, 117.6, 52.6 (-CO2CH3); 
FT-IR (ATR): υ (cm-1) = 3079 (O-H), 2846 (C-H), 1692 (ester C=O), 1669 (aldehyde 
C=O), 1578, 1502, 1423, 1341, 1194; MS (MALDI-TOF): m/z 414.82 [M+Na]
+
; HRMS 
(APCI) exact mass calculated for C22H17O7 requires m/z 393.0969, found m/z 393.0965 
[M+H]
+
.   
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A byproduct was isolated during the column chromatography (Rf = 0.60; dichloromethane 
/ methanol 2%); this was identified as methyl 3-(4-formylphenoxy)-4,5-
dihydroxybenzoate 304 (165 mg, 0.57 mmol, 21% yield). 
M.p. 191–193 °C (chloroform); 1H-NMR (300 MHz, CD3OD) δ = 9.87 (s, 1H, -CHO), 
7.88 (d, J = 8.8 Hz, 2H, Ar-H), 7.40 (d, J = 2.0 Hz, 1H, Ar-H), 7.22 (d, J = 2.0 Hz, 1H, 
Ar-H), 7.05 (d, J = 8.8 Hz, 2H, Ar-H), 3.83 (s, 3H, -CO2CH3); 
13
C-NMR (125 MHz, 
CD3OD) δ = 192.8 (-CHO), 168.0 (-CO2CH3), 164.7, 148.2, 144.3, 143.2, 133.0, 132.7, 
122.2, 117.7, 116.0, 114.6, 52.5 (-CO2CH3); FT-IR (thin film): υ (cm
-1
) = 3217 (O-H), 
1686 (C=O), 1593, 1504, 1439, 1319, 1224, 1156; MS (MALDI-TOF) m/z 311.12 
[M+Na]
+
; HRMS (NESI) exact mass calculated for C15H11O6 requires m/z 287.0561, 
found m/z 287.0566 [M-H]
-
.   
Methyl 3,5-bis(4-formylphenoxy)-4-hydroxybenzoate (305)  
Synthesis B: Conventional heating 
 
To a 500 mL two-necked round-bottom flask was added methyl 3,4,5-trihydroxybenzoate 
281 (9.93 g, 53.9 mmol, 1 equiv.) and a magnetic stirrer bar. The white solid was 
dissolved in dimethyl sulfoxide (160 mL) under a nitrogen atmosphere. Cesium carbonate 
(52.7 g, 162 mmol, 3 equiv.) was added in one portion and the resulting mixture stirred at 
room temperature for 15 minutes before the addition of 4-fluorobenzaldehyde (14.4 ml, 
135 mmol, 2.5 equiv.) via a 25 mL syringe. The flask was fitted with a reflux condenser 
and the reaction mixture heated at 120 °C for 48 hours using an aluminium heating block 
mounted on a hotplate magnetic stirrer. When no further conversion from 281 to 305 was 
observed by thin layer chromatography (eluent: dichloromethane / ethyl acetate 9:1), the 
reaction mixture was cooled to 0 °C, quenched with 1 M aqueous hydrochloric acid (200 
mL) and poured into a 2 L separating funnel. The aqueous mixture was extracted with 
ethyl acetate (2 x 200 mL) and the combined organic extracts were washed with distilled 
water (3 x 300 mL) and then brine (250 mL). The solution was dried over magnesium 
sulfate, filtered, and the solvent removed in vacuo to afford a dark brown solid. 
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Trituration with diethyl ether afforded a cream solid (8.89 g, 22.7 mmol, 42% yield) 
whose physicochemical properties were consistent with those of the title compound (305) 
described previously. 
Methyl 3,5-bis(4-formylphenoxy)-4-hydroxybenzoate (305)  
Synthesis C: Flow reactor 
 
 
  
 
A Uniqsis Flow Syn reactor was fitted with a 6.6 x 100 mm glass column packed with 
cesium carbonate (5 g). The column was pre-heated to 150 °C. A solution of methyl 
3,4,5-trihydroxybenzoate 281 (200 mg, 1.09 mmol, 1 equiv.) in dimethyl sulfoxide (2 
mL), solution A, and a solution of 4-fluorobenzaldehyde 282 (0.4 mL, 2.78 mmol, 2.5 
equiv.) in dimethyl sulfoxide (2 mL), solution B, were pumped simultaneously through 
the glass column, each with a flow rate of 1 mL / min. The dark red solution was 
collected in a 250 mL separating funnel containing 1 M hydrochloric acid (50 mL) at 
room temperature.  The aqueous mixture was extracted with ethyl acetate (3 x 30 mL) and 
the combined organic layers were washed with distilled water (3 x 50 mL) and then brine 
(50 mL). The organic solution was dried over magnesium sulfate, filtered, and the solvent 
removed in vacuo. Purification via flash column chromatography on silica gel (eluent: 
dichloromethane / ethyl acetate 9:1) afforded 305 as a pale yellow solid (141 mg, 0.36 
mmol, 33% yield) and 304 as a light brown solid (91 mg, 0.32 mmol, 29% yield). The 
physicochemical properties of these compounds matched the data obtained from the 
microwave-promoted synthesis outlined above.  
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Methyl 3-(4-formylphenoxy)-4,5-dihydroxybenzoate (304) 
 
To a 15 mL microwave vial was added methyl 3,4,5-trihydroxybenzoate 281 (1 g, 5.43 
mmol, 1 equiv.), cesium carbonate (3.89 g, 11.9 mmol, 2.2 equiv.) and a magnetic stirrer 
bar. The vial was purged with nitrogen, sealed with a PTFE-lined aluminium crimp cap 
and dimethyl sulfoxide (10 mL) was added via a 20 mL syringe. The resulting reaction 
mixture was stirred vigorously for 10 minutes at room temperature before the addition of 
4-fluorobenzaldehyde (0.7 mL, 6.53 mmol, 1.2 equiv.) via a 2 mL syringe. The dark red 
suspension was heated to 120 °C in a Biotage microwave reactor for 90 minutes. The 
reaction mixture was allowed to cool to room temperature and poured into a 250 mL 
separating funnel containing 1 M aqueous hydrochloric acid (50 mL). The aqueous 
mixture was extracted with ethyl acetate (2 x 50 mL) and the combined organic extracts 
were washed with distilled water (2 x 100 mL) and then brine (100 mL). The resulting 
solution was dried over magnesium sulfate, filtered, and the solvent removed in vacuo to 
afford a dark brown residue. Purification via flash column chromatography on silica gel 
(eluent: dichloromethane / ethyl acetate 9:1) afforded a yellow solid (603 mg, 2.09 mmol, 
39% yield) whose physicochemical properties matched those of the title compound (304). 
Byproduct 305 was isolated in a 7% yield (149 mg, 0.38 mmol); the physicochemical 
properties were as outlined previously. 
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Methyl 3,4-bis(benzyloxy)-5-(4-formylphenoxy)benzoate (320) 
 
To a 250 mL round-bottom flask containing methyl 3-(4-formylphenoxy)-4,5-
dihydroxybenzoate 304  (333 mg, 1.16 mmol, 1 equiv.) under a nitrogen atmosphere was 
added N,N-dimethylformamide (35 mL) and a magnetic stirrer bar. Potassium carbonate 
(481 mg, 3.48 mmol, 3 equiv.) was added to the stirred orange solution in one portion, 
following by the addition of benzyl bromide (0.41 mL, 3.48 mmol, 3 equiv.) via a 1 mL 
syringe. The resulting suspension was heated to 120 °C for 7 hours. After cooling to room 
temperature, distilled water (30 mL) was added, followed by 1 M aqueous hydrochloric 
acid (40 mL). The mixture was extracted with ethyl acetate (2 x 50 mL) and the combined 
organic layers were washed with distilled water (2 x 100 mL) and then brine (100 mL) 
before being dried over magnesium sulfate, filtered, and the solvent removed in vacuo. 
Purification via flash column chromatography on silica gel (eluent: petroleum ether / 
diethyl ether 7:3; Rf = 0.20) afforded a cream solid whose physicochemical properties 
were consistent with those of the title compound 320 (398 mg, 0.85 mmol, 73% yield).  
M.p. 88–90 °C (hexane / dichloromethane); 1H-NMR (400 MHz, CDCl3) δ 9.91 (s, 1H, -
CHO), 7.81 (d, J = 8.6 Hz, 2H, Ar-H), 7.62 (s, 1H, Ar-H), 7.49 – 7.33 (m, 6H, Ar-H), 
7.24 – 7.14 (m, 5H, Ar-H), 6.96 (d, J = 8.6 Hz, 2H, Ar-H), 5.20 (s, 2H, -CH2Ph), 5.07 (s, 
2H, -CH2Ph), 3.89 (s, 3H, -CO2CH3); 
13
C-NMR (126 MHz, CDCl3) δ 190.9 (-CHO), 
166.1 (-CO2CH3), 163.0, 153.3, 147.9, 144.8, 136.7, 136.2, 132.1, 131.5, 128.8, 128.5, 
128.4, 128.3, 127.8, 126.0, 116.8, 116.8, 112.2, 75.4 (-CH2Ph), 71.5 (-CH2Ph), 52.5 (-
CO2CH3); FT-IR (thin film): υ (cm
-1
) = 3064 (O-H), 3033, 2952, 2736 (C-H), 1724 
(C=O), 1697, 1584, 1503, 1427, 1341, 1220, 1157, 1076; MS (MALDI-TOF) m/z 491.05 
[M+Na]
+
, 507.00 [M+K]
+
; HRMS (HNESP) exact mass calculated for C29H25O6 requires 
m/z 469.1646, found m/z 469.1642 [M+H]
+
. 
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Methyl 3-(4-formylphenoxy)-5-hydroxy-4-methoxybenzoate (321) 
 
To a 15 mL microwave vial containing methyl 3-(4-formylphenoxy)-4,5-
dihydroxybenzoate 304 (603 mg, 2.09 mmol, 1 equiv.) and a magnetic stirrer bar under a 
nitrogen atmosphere was added N,N-dimethylformamide (10 mL). To the stirred orange 
solution was added lithium carbonate (155 mg, 2.09 mmol, 1 equiv.) in one portion, 
followed by the addition of iodomethane (0.13 mL, 2.09 mmol, 1 equiv.) dropwise via a 1 
mL syringe. The vial was sealed with a PTFE-lined aluminium crimp cap and heated to 
55 °C for 18 hours using a sand bath. After cooling to room temperature the mixture was 
poured into a 250 mL separating funnel containing distilled water (20 mL), to which 1 M 
aqueous hydrochloric acid (50 mL) was added. The mixture was extracted with ethyl 
acetate (3 x 50 mL) and the combined organic layers were washed with distilled water (3 
x 100 mL) and subsequently brine (100 mL). The organic solution was dried over 
magnesium sulfate, filtered, and the solvent removed in vacuo. Purification via flash 
column chromatography on silica gel (eluent: dichloromethane / diethyl ether 5%; Rf = 
0.31) afforded an orange oil whose physicochemical properties were consistent with those 
of the title compound 321 (449 mg, 1.49 mmol, 71% yield).    
1
H-NMR (500 MHz, CDCl3) δ 9.94 (s, 1H, -CHO), 7.87 (d, J = 8.8 Hz, 2H, Ar-H), 7.54 
(d, J = 2.0 Hz, 1H, Ar-H), 7.32 (d, J = 2.0 Hz, 1H, Ar-H), 7.05 (d, J = 8.8 Hz, 2H, Ar-H), 
5.94 (s, 1H, -OH), 3.95 (s, 3H, -OCH3), 3.87 (s, 3H, -OCH3); 
13
C-NMR (126 MHz, 
CDCl3) δ 190.8 (-CHO), 166.0 (-CO2CH3), 162.4, 149.8, 145.9, 142.8, 132.2, 131.9, 
126.3, 117.0, 115.7, 113.7, 61.6 (Ar-OCH3), 52.5 (-CO2CH3); FT-IR (thin film): υ (cm
-1
) 
= 3384 (O-H), 2955, 2843 (C-H), 1709 (C=O), 1582, 1503, 1436, 1354, 1227, 1156; MS 
(MALDI-TOF) m/z 325.03 [M+Na]
+
; HRMS (NESI) exact mass calculated for C16H15O6 
[M+H]
+
 requires m/z 303.0863, found m/z 303.0866. 
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Methyl 3-((tert-butyldiphenylsilyl)oxy)-5-(4-formylphenoxy)-4-methoxybenzoate 
(322) 
 
To a 5 mL round-bottom flask containing methyl 3-(4-formylphenoxy)-5-hydroxy-4-
methoxybenzoate 321 (100 mg, 0.33 mmol, 1 equiv.) and a magnetic stirrer bar under a 
nitrogen atmosphere was added N,N-dimethylformamide (2 mL). To the stirred orange 
solution was added imidazole (50 mg, 0.73 mmol, 2.2 equiv.) in one portion, followed by 
the addition of tert-butyldiphenylchlorosilane (95 μL, 0.36 mmol, 1.1 equiv.) via a 250 
μL syringe. The pale yellow solution was stirred at room temperature for 18 hours before 
being poured into a 50 mL separating funnel containing 5% aqueous sodium bicarbonate 
solution (10 mL) and the organics extracted with hexane (3 x 10 mL). The combined 
organic layers were washed with brine (30 mL), dried over magnesium sulfate, filtered, 
and the solvent removed in vacuo. Purification via flash column chromatography on silica 
gel (eluent: petroleum ether / diethyl ether 1:1; Rf = 0.56) afforded a colourless oil whose 
physicochemical properties were consistent with those of the title compound 322 (102 
mg, 0.19 mmol, 57% yield).  
1
H-NMR (500 MHz, CDCl3) δ 9.91 (s, 1H, -CHO), 7.80 (d, J = 8.6 Hz, 2H, Ar-H), 7.73 
(d, J = 7.8 Hz, 4H, Ar-H), 7.46 (t, J = 7.4 Hz, 2H, Ar-H), 7.39 (t, J = 7.4 Hz, 4H, Ar-H), 
7.36 – 7.31 (m, 2H, Ar-H), 6.83 (d, J = 8.6 Hz, 2H, Ar-H), 3.75 (s, 3H, -CO2CH3), 3.65 
(s, 3H, -OCH3), 1.14 (s, 9H, -C(CH3)3); 
13
C-NMR (126 MHz, CDCl3) δ 190.8 (-CHO), 
165.8 (-CO2CH3), 162.9, 149.9, 147.7, 147.3, 135.6, 132.4, 132.0, 131.3, 130.2, 127.9, 
125.5, 119.6, 117.3, 116.4, 60.9 (Ar-OCH3), 52.3 (-CO2CH3), 26.7 (-C(CH3)3), 19.8 (-
C(CH3)3); FT-IR (thin film): υ (cm
-1
) = 3074 (C-H), 2956 (C-H), 2859 (C-H), 1726 
(C=O), 1700 (C=O), 1603, 1582, 1506, 1430, 1345, 1227, 1155, 1109, 1071, 999; MS 
(MALDI-TOF) m/z 579.28 [M+K]
+
; HRMS (NESI) exact mass calculated for C32H33O6Si 
requires m/z 541.2041, found m/z 541.2038 [M+H]
+
. 
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Methyl 7-hydroxy-2-(4-methoxyphenyl)benzo[d][1,3]dioxole-5-carboxylate (318)
181
 
 
A flame-dried 250 mL two-necked round-bottom flask fitted with a Soxhlet apparatus 
containing 4Å molecular sieves was charged with a solution of p-anisaldehyde dimethyl 
acetal 317 (2.18 g, 12.0 mmol, 1.25 equiv.) in anhydrous toluene (100 mL) and a 
magnetic stirrer bar. Methyl gallate 281 (1.77 g, 9.60 mmol, 1 equiv.) and para-
toluenesulfonic acid (8 mg, 0.046 mmol, 0.5 mol%) were added, and the solution heated 
at reflux for 3 hours. After cooling to room temperature the majority of the solvent was 
removed in vacuo. The residue was redissolved in dichloromethane (50 mL) and washed 
with saturated aqueous sodium carbonate solution (50 mL). The addition of hexane (50 
mL) resulted in the precipitation of a pale yellow solid, which was filtered and 
recrystallised from dichloromethane / hexane (1:1) to afford a cream solid whose 
physicochemical properties matched those previously reported for this compound (1.20 g, 
3.97 mmol, 41% yield).  
M.p. 130–132 °C (dichloromethane / hexane); 1H-NMR (500 MHz, CDCl3) δ 7.50 (d, J = 
8.8 Hz, 2H, Ar-H), 7.34 (d, J = 1.5 Hz, 1H, Ar-H), 7.18 (d, J = 1.5 Hz, 1H, Ar-H), 7.00 
(s, 1H, -CH-), 6.96 (d, J = 8.8 Hz, 2H, Ar-H), 5.06 (s, 1H, -OH), 3.88 (s, 3H, -OCH3), 
3.84 (s, 3H, -OCH3); FT-IR (thin film): υ (cm
-1
) = 3347 (O-H), 2920 (C-H), 2850 (C-H), 
1696 (C=O), 1637, 1617, 1516, 1449, 1375, 1257, 1081; MS (MALDI-TOF) m/z 325.08 
[M+Na]
+
. 
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Methyl 7-(4-formylphenoxy)-2-(4-methoxyphenyl)benzo[d][1,3]dioxole-5-
carboxylate (319) 
A 15 mL microwave vial containing 4Å molecular sieves was flame-dried and allowed to 
cool to room temperature under a flow of nitrogen. Methyl 3-(4-formylphenoxy)-4,5-
dihydroxybenzoate 304 (100 mg, 0.347 mmol, 1 equiv.), anhydrous toluene (7 mL), para-
anisaldehyde dimethyl acetal
182
 317 (66 mg, 0.364 mmol, 1.05 equiv.), and para-
toluenesulfonic acid (0.7 mg, 0.0035 mmol, 1 mol%) were added. The vial was sealed 
with a PTFE-lined aluminium crimp cap and the stirred suspension was heated at 110 °C 
for 6 hours. After cooling to room temperature, sodium carbonate (0.4 mg, 0.0038 mmol, 
1.09 mol%) was added and the mixture stirred at room temperature for one hour before 
being filtered to remove the molecular sieves. The solvent was removed in vacuo, and 
purification via flash column chromatography on silica gel (eluent: dichloromethane 
100%; Rf = 0.30) afforded a pale yellow solid whose physicochemical properties were 
consistent with those of the title compound 319 (20 mg, 0.049 mmol, 28% yield). 
M.p. 76–78 °C;  1H-NMR (400 MHz, CDCl3) δ 9.93 (s, 1H, -CHO), 7.85 (d, J = 8.7 Hz, 
2H, Ar-H), 7.48 (d, J = 1.5 Hz, 1H, Ar-H), 7.46 – 7.40 (m, 3H, Ar-H), 7.09 (d, J = 8.7 Hz, 
2H, Ar-H), 7.05 (s, 1H, Ar-H), 6.93 (d, J = 8.7 Hz, 2H, Ar-H), 3.88 (s, 3H, -CO2CH3), 
3.83 (s, 3H, -OCH3); 
13
C-NMR (126 MHz, CDCl3) δ 190.8 (-CHO), 165.9 (-CO2CH3), 
162.0, 161.6, 150.1, 142.8, 136.5, 132.1, 131.8, 128.1, 127.0, 125.0, 118.4, 117.0, 114.2, 
112.8, 106.9, 55.5 (-OCH3), 52.5 (-CO2CH3); FT-IR (thin film): υ (cm
-1
) = 3076 (C-H), 
3011 (C-H), 2949 (C-H), 2843 (C-H), 2733 (C-H), 1717 (ester C=O), 1696 (aldehyde 
C=O), 1614, 1600, 1518, 1500, 1442, 1367, 1301, 1253, 1222, 1178, 1157, 1020, 1006; 
MS (MALDI-TOF) m/z 405.25 [M-H]
-
; HRMS (HNESP) exact mass calculated for 
C23H19O7 requires m/z 407.1125, found m/z 407.1128 [M+H]
+
. 
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Methyl 4-(benzyloxy)-3,5-bis(4-formylphenoxy)benzoate (328) 
 
A 250 mL round-bottom flask was charged with a solution of methyl 3,5-bis(4-
formylphenoxy)-4-hydroxybenzoate 305 (3.01 g, 7.65 mmol, 1 equiv.) in N,N-
dimethylformamide (50 mL) under a nitrogen atmosphere. Potassium carbonate (712 mg, 
11.5 mmol, 1.5 equiv.) was added in one portion, followed by the addition of benzyl 
bromide (0.91 mL, 7.65 mmol, 1 equiv.) via a 2 mL syringe. The mixture was stirred at 
room temperature for 18 hours before being transferred to a 250 mL separating funnel 
containing 1 M aqueous hydrochloric acid (100 mL). The organics were extracted with 
ethyl acetate (3 x 75 mL). The combined organic layers were washed with water (3 x 100 
mL) and subsequently brine (100 mL). The organic layer was dried over magnesium 
sulfate, filtered, and the solvent removed in vacuo. Purification via flash column 
chromatography on silica gel (eluent: petroleum ether / ethyl acetate 30%; Rf 0.38) 
afforded a pale yellow solid whose physicochemical characteristics were consistent with 
those of the title compound (328) (3.21 g, 6.64 mmol, 87% yield). 
M.p. 80–82 °C; 1H-NMR (400 MHz, CDCl3) δ 9.94 (s, 2H, -CHO), 7.86 (d, J = 8.8 Hz, 
4H, Ar-H), 7.66 (s, 2H, Ar-H), 7.23 – 7.13 (m, 3H, Ar-H), 7.06 – 6.99 (m, 6H, Ar-H), 
5.05 (s, 2H, -CH2Ph), 3.87 (s, 3H, -OCH3); 
13
C NMR (100 MHz, CDCl3) δ 190.8 (-CHO), 
165.3 (-CO2CH3), 162.3, 148.7, 147.2, 135.9, 132.2, 132.0, 128.6, 128.5, 128.3, 126.6, 
120.5, 117.1, 75.7 (-CH2Ph), 52.7 (-CO2CH3); FT-IR (thin film): υ (cm
-1
) = 3069 (C-H), 
2956 (C-H), 2835 (C-H), 2745 (C-H), 1724 (d) (ester and aldehyde C=O), 1602, 1503, 
1422, 1337, 1229, 1157; MS (MALDI-TOF) m/z 505.0 [M+Na]
+
, 520.96 [M+K]
+
; HRMS 
(NESP) exact mass calculated for C29H22O7Na requires m/z 505.1258, found m/z 
505.1250 [M+Na]
+
. 
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Methyl 3,5-bis(4-formylphenoxy)-4-methoxybenzoate (327) 
To a 15 mL microwave vial was added methyl 3,5-bis(4-formylphenoxy)-4-
hydroxybenzoate 305 (500 mg, 1.27 mmol, 1 equiv.), potassium carbonate (352 mg, 2.55 
mmol, 2 equiv.) and a magnetic stirrer bar. N,N’-Dimethylformamide (6 mL) was added 
and the vial sealed with a PTFE-lined aluminium crimp cap. The suspension was stirred at 
room temperature for 15 minutes. Iodomethane (111 µL, 1.78 mmol, 1.4 equiv.) was 
added via a 250 µL syringe, and the mixture heated at 80 ºC for 24 hours. After cooling to 
room temperature, the suspension was poured into a 250 mL separating funnel containing 
ethyl acetate (50 mL) and 1 M aqueous hydrochloric acid (50 mL). The aqueous layer 
was re-extracted with ethyl acetate (50 mL) and the combined organic layers were washed 
with distilled water (2 x 100 mL) and subsequently brine (100 mL) before being dried 
over magnesium sulfate and filtered. The solvent was removed in vacuo to afford a 
yellow oil whose physicochemical characteristics were consistent with those of the title 
compound (327) (478 mg, 1.18 mmol, 92%). 327 was used without further purification.  
1
H-NMR (500 MHz, CDCl3) δ 9.94 (s, 2H, -CHO), 7.88 (d, J = 8.7 Hz, 4H, Ar-H), 7.68 
(s, 2H, Ar-H), 7.07 (d, J = 8.7 Hz, 4H, Ar-H), 3.88 (s, 3H, -OCH3), 3.78 (s, 3H, -OCH3); 
13
C-NMR (126 MHz, CDCl3) δ 190.7 (-CHO), 165.3 (-CO2CH3), 162.5, 148.7, 148.1, 
132.2, 131.9, 126.2, 120.8, 117.0, 61.5 (-OCH3), 52.7 (-CO2CH3); FT-IR (thin film): υ 
(cm
-1
) = 2955 (C-H), 2836 (C-H), 2738 (C-H), 1727 (ester C=O), 1697 (aldehyde C=O), 
1602, 1579, 1503, 1421, 1335, 1223, 1156; MS (MALDI-TOF) m/z 429.2 [M+Na]
+
, 
445.21 [M+K]
+
; HRMS (NESP) exact mass calculated for C23H19O7 requires m/z 
407.1125, found m/z 407.1125 [M+H]
+
. 
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Methyl 4-(benzyloxy)-3,5-bis(4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-
yl)phenoxy)benzoate (329) 
 
A 100 mL two-neck round-bottom flask was charged with a solution of methyl 4-
(benzyloxy)-3,5-bis(4-formylphenoxy)benzoate 328 (1.0 g, 2.55 mmol, 1 equiv.) in dry 
toluene (40 mL). The flask was fitted with a Dean-Stark apparatus and reflux condenser 
under a nitrogen atmosphere. Pinacol (692 mg, 5.86 mmol, 2.3 equiv.) and para-
toluenesulfonic acid (20 mg, 0.11 mmol, 5 mol%) were added, and the solution heated at 
reflux for 6 hours. After cooling to room temperature, triethylamine (0.1 mL, 0.72 mmol, 
0.3 equiv.) was added via a 1 mL syringe and the solution was stirred for a further 30 
minutes before the solvent was removed in vacuo. Purification via flash column 
chromatography on silica gel (eluent: petroleum ether / diethyl ether 1:1; Rf = 0.58) 
afforded a white solid whose physicochemical properties were consistent with those of 
the title compound (329) (1.50 g, 2.19 mmol, 86% yield).  
M.p. 132–134 ºC; 1H-NMR (500 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 4H, Ar-H), 7.41 (s, 
2H, Ar-H), 7.24 – 7.16 (m, 5H, Ar-H), 6.96 (d, J = 8.7 Hz, 4H, Ar-H), 5.98 (s, 2H, -CH- 
pin.), 5.12 (s, 2H, -CH2Ph), 3.80 (s, 3H, -CO2CH3), 1.33 (s, 12H, -C(CH3)2-), 1.30 (s, 
12H, -C(CH3)2-); 
13
C-NMR (126 MHz, CDCl3) δ 165.8 (-CO2CH3), 157.4, 150.3, 146.0, 
136.6, 134.9, 128.6, 128.3, 128.2, 128.2, 125.8, 117.8, 117.4, 99.7 (-CH- pin.), 82.8 (-
C(CH3)2-), 75.3 (-CH2Ph), 52.3 (-CO2CH3), 24.6 (-C(CH3)2-), 22.3 (-C(CH3)2-); FT-IR 
(thin film): υ (cm-1) = 2980 (C-H), 2932 (C-H), 2877 (C-H), 1727 (C=O), 1614, 1583, 
1504, 1453, 1425, 1391, 1380, 1373, 1332, 1222, 1157, 1075, 1040, 1006; MS (MALDI-
TOF) m/z 681.7; HRMS (HNESP) exact mass calculated for C41H50O9N requires m/z 
700.3480, found m/z 700.3496 [M+NH4]
+
. 
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 (4-(Benzyloxy)-3,5-bis(4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenoxy)phenyl) 
methanol (336) 
 
To a flame-dried 250 mL round-bottom flask was added lithium aluminium hydride (118 
mg, 3.11 mmol, 2.5 equiv.) and dry tetrahydrofuran (40 mL) under a nitrogen atmosphere. 
The mixture was cooled to -15 °C using an acetone / dry ice bath before a solution of 
methyl 4-(benzyloxy)-3,5-bis(4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenoxy)benzoate 
329 (2.62 g, 4.56 mmol, 1 equiv.) in tetrahydrofuran (15 mL) was added dropwise via a 
20 mL syringe. The mixture was allowed to warm to 0 °C and stirred for 2 hours. On 
complete disappearance of the starting material by thin layer chromatography (petroleum 
ether / diethyl ether 1:1), ethyl acetate (50 mL) and 1 M aqueous sodium hydroxide (50 
mL) were added simultaneously in small portions while maintaining the temperature at 0 
°C. The reaction mixture was transferred to a 500 mL separating funnel and the aqueous 
phase extracted with ethyl acetate (2 x 75 mL). The combined organic phases were 
washed with brine (150 mL), dried over magnesium sulfate, filtered, and the solvent 
removed in vacuo to afford a colourless oil whose physicochemical properties were 
consistent with those of the title compound (336) (2.42 g, 4.42 mmol, 97% yield); no 
further purification was required. 
Rf = 0.21 (eluent: petroleum ether / diethyl ether 1:1); 
1
H-NMR (500 MHz, CDCl3) δ 7.46 
(d, J = 8.6 Hz, 4H, Ar-H), 7.22 – 7.15 (m, 5H, Ar-H), 6.97 (d, J = 8.6 Hz, 4H, Ar-H), 6.73 
(s, 2H, Ar-H), 5.97 (s, 2H, -CH- pin.), 5.01 (s, 2H, -CH2Ph), 4.48 (s, 2H, -CH2OH), 1.33 
(s, 12H, -C(CH3)2-), 1.29 (s, 12H, -C(CH3)2-); 
13
C-NMR (126 MHz, CDCl3) δ 157.7, 
150.8, 141.1, 137.2, 137.0, 134.5, 128.6, 128.3, 128.1, 128.1, 117.9, 114.4, 99.8 (-CH- 
pin.), 82.8 (-C(CH3)2-), 75.4 (-CH2Ph), 64.5 (-CH2OH), 24.6 (-C(CH3)2-), 22.3 (-C(CH3)2-
); FT-IR (thin film): υ (cm-1) = 3458 (O-H), 2984 (C-H), 2932 (C-H), 2877 (C-H), 1610, 
1586, 1507, 1435, 1370, 1322, 1219, 1154, 1075, 1034, 989; MS (MALDI-TOF) m/z 
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693.12 [M+K]
+
; HRMS (HNESP) exact mass calculated for C40H50O8N requires m/z 
672.3530, found m/z 672.3531 [M+NH4]
+
. 
4-(Benzyloxy)-3,5-bis(4-(dimethoxymethyl)phenoxy)benzaldehyde (337) 
 
A 250 mL round-bottom flask was charged with a solution of 4-(benzyloxy)-3,5-bis(4-
(dimethoxymethyl)phenoxy)benzyl alcohol 336 (447 mg, 0.68 mmol, 1 equiv.) in 
anhydrous dichloromethane (50 mL) under a nitrogen atmosphere. Activated manganese 
dioxide (1.19 g, 13.7 mmol, 20 equiv.) was added in small portions and the mixture 
stirred at room temperature for 18 hours. On complete disappearance of starting material 
336 by thin layer chromatography (eluent: petroleum ether / ethyl acetate 20%), the 
mixture was filtered through celite and the solvent removed in vacuo. Purification via 
flash column chromatography on silica gel (eluent: petroleum ether / ethyl acetate 20%; 
Rf = 0.38) afforded a white solid whose physicochemical characteristics were consistent 
with those of the title compound 337 (307 mg, 0.47 mmol, 69% yield). 
M.p. 118–120 ºC; 1H-NMR (500 MHz, CDCl3) δ 9.70 (s, 1H, -CHO), 7.49 (d, J = 8.6 Hz, 
4H, Ar-H), 7.25 – 7.22 (m, 5H, Ar-H), 7.20 (s, 2H, Ar-H), 6.98 (d, J = 8.6 Hz, 4H, Ar-H), 
5.98 (s, 2H, -CH- pin.), 5.19 (s, 2H, -CH2Ph), 1.34 (s, 12H, -C(CH3)2-), 1.29 (s, 12H, -
C(CH3)2-); 
13
C-NMR (126 MHz, CDCl3) δ 189.7 (-CHO), 156.7, 151.1, 146.6, 136.3, 
135.2, 131.8, 128.4, 128.2, 128.1(1), 128.0(5), 117.9, 116.3, 99.3 (-CH- pin.), 82.6 (-
C(CH3)2-), 75.2 (-CH2Ph), 24.3 (-C(CH3)2-), 22.1 (-C(CH3)2-); FT-IR (thin film): υ (cm
-1
) 
= 2977 (C-H), 2936 (C-H), 2864 (C-H), 1696 (C=O), 1614, 1579, 1507, 1435, 1377, 
1325, 1222, 1150, 1119, 1075, 1044; MS (MALDI-TOF) m/z 691.44 [M+K]
+
; HRMS 
(HNESP) exact mass calculated for C40H48O8N requires m/z 670.3374, found m/z 
670.3390 [M+NH4]
+
. 
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4,4'-((2-(Benzyloxy)-5-vinyl-1,3-phenylene)bis(oxy))bis((dimethoxymethyl)benzene) 
(338) 
 
A 250 mL round-bottom flask under a nitrogen atmosphere was charged with methyl 
triphenylphosphonium bromide (1.09 g, 3.06 mmol, 4 equiv.) and tetrahydrofuran (40 
mL). The suspension was stirred while being cooled to 0 °C in an ice bath before the 
addition of sodium hydride (60 % in mineral oil, 122 mg, 3.06 mmol, 4 equiv.). After 1 
hour, a solution of 4-(benzyloxy)-3,5-bis(4-(dimethoxymethyl)phenoxy)benzaldehyde 
337 (500 mg, 0.77 mmol, 1 equiv.) in tetrahydrofuran (10 mL) was added dropwise to the 
flask via a 20 mL syringe, and the resulting mixture stirred at 0 °C for a further 3 hours or 
until complete disappearance of the starting material by thin layer chromatography 
(eluent: petroleum ether / ethyl acetate 20%).  Diethyl ether (75 mL) was added, and the 
mixture transferred to a 500 mL separating funnel containing cold distilled water (100 
mL). The aqueous phase was extracted with diethyl ether (2 x 100 mL) and the combined 
organic layers washed with brine (150 mL) before being dried over magnesium sulfate, 
filtered, and the solvent removed in vacuo. Purification via flash column chromatography 
on silica gel (eluent: petroleum ether / ethyl acetate 20%; Rf = 0.53) afforded a white solid 
whose physicochemical properties were consistent with those of the title compound 338 
(379 mg, 0.58 mmol, 76% yield). 
M.p. 116–118 °C; 1H-NMR (500 MHz, CDCl3) δ 7.46 (d, J = 8.6 Hz, 4H, Ar-H), 7.23 – 
7.11 (m, 5H, Ar-H), 6.97 (d, J = 8.6 Hz, 4H, Ar-H), 6.81 (s, 2H, Ar-H), 6.47 (dd, J = 
17.5, 11.0 Hz, 1H, -CH=CH2), 5.97 (s, 2H, -CH- pin.), 5.51 (dd, J = 17.5, 0.4 Hz, 1H, -
CH=CH2), 5.16 (d, J = 11.0 Hz, 1H, -CH=CH2), 5.00 (s, 2H, -CH2Ph), 1.33 (s, 12H, -
CH(CH3)2-), 1.29 (s, 12H, -CH(CH3)2-); 
13
C-NMR (126 MHz, CDCl3) δ 157.9, 150.5, 
141.8, 137.0, 135.4, 134.4, 133.9, 128.6, 128.3, 128.1, 128.0, 117.6, 114.5, 114.3, 99.8 (-
CH- pin.), 82.8 (-C(CH3)2-), 75.4 (-CH2Ph), 24.6 (-CH(CH3)2-), 22.3 (-CH(CH3)2-); FT-
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IR (thin film): υ (cm-1) = 2983 (C-H), 2928 (C-H), 2855 (C-H), 1610, 1569, 1503, 1428, 
1410, 1390, 1321, 1228, 1155, 1076, 1031, 990; MS (MALDI-TOF) m/z 689.69 [M+K]
+
; 
HRMS (HNESP) exact mass calculated for C41H50O7N requires m/z 668.3582, found m/z 
668.3581 [M+NH4]
+
. 
4,4'-(2-(Benzyloxy)-5-vinyl-1,3-phenylene)bis(oxy)dibenzaldehyde (339) 
 
A 5 mL microwave vial was charged with a colourless solution of 4,4'-((2-(benzyloxy)-5-
vinyl-1,3-phenylene)bis(oxy))bis((dimethoxymethyl)benzene) 338 (50 mg, 0.08 mmol, 1 
equiv.) in tetrahydrofuran (1 mL). 1 M aqueous hydrochloric acid (1 mL) was added, and 
the solution was heated at 50 ºC with stirring for 3 hours. On complete disappearance of 
the starting material by thin layer chromatography (eluent: petroleum ether / ethyl acetate 
20%), the organic solvent was removed in vacuo and the residue extracted with 
dichloromethane (3 x 5 mL). The combined organic layers were washed with brine (20 
mL) before being dried over magnesium sulfate, filtered, and the solvent removed in 
vacuo. Purification via flash column chromatography on silica gel (eluent: petroleum 
ether / diethyl ether 50%; Rf = 0.31) afforded a white solid whose physicochemical 
characteristics were consistent with those of the title compound (31 mg, 0.069 mmol, 
90% yield). 
M.p. 101–103 °C; 1H-NMR (400 MHz, CDC3) δ 9.92 (s, 2H, -CHO), 7.84 (d, J = 8.6 Hz, 
4H, Ar-H), 7.22 – 7.10 (m, 3H, Ar-H), 7.06 (s, 2H, Ar-H), 7.03 (d, J = 8.6 Hz, 4H, Ar-H), 
7.00 – 6.96 (m, 2H, Ar-H), 6.59 (dd, J = 17.5, 11.0 Hz, 1H, -CH=CH2), 5.65 (d, J = 17.5 
Hz, 1H, -CH=CH2), 5.29 (d, J = 11.0 Hz, 1H, -CH=CH2), 4.92 (s, 2H, -CH2Ph); 
13
C-
NMR (100 MHz, CDCl3) δ 190.9 (-CHO), 162.9, 148.9, 142.8, 136.3, 134.9, 134.9, 
132.2, 131.6, 128.4(1), 128.3(7), 117.2, 116.9, 115.6, 75.7 (-CH2Ph); FT-IR (thin film): υ 
(cm
-1
) = 3070, 3033, 2834, 2741, 1696 (C=O), 1600, 1585, 1569, 1501, 1454, 1430, 1408, 
1321, 1225, 1154, 1104, 1057, 1026; MS (MALDI-TOF) m/z 473.32 [M+Na]
+
; HRMS 
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(HNESP) exact mass calculated for C29H26O5N requires m/z 468.1805, found m/z 
468.1802 [M+NH4]
+
. 
tert-Butyl 3-(4-(2,3-bis(benzyloxy)-5-(methoxycarbonyl)phenoxy)phenyl)-1-(2-(tert-
butoxy)phenyl)aziridine-2-carboxylate (rac,cis-352) 
 
To a flame-dried 5 mL microwave vial containing crushed 4Å molecular sieves under a 
nitrogen atmosphere was added a solution of methyl 3,4-bis(benzyloxy)-5-(4-
formylphenoxy)benzoate 320 (100 mg, 0.21 mmol, 1 equiv.) and 2-tert-butoxy aniline
209
 
349 (33 mg, 0.20 mmol, 0.95 equiv.) in anhydrous dichloromethane (2 mL). The mixture 
was stirred slowly at room temperature for 18 hours. After the addition of pyridinium 
triflate 347 (5 mg, 0.02 mmol, 10 mol%), the vial was sealed with a PTFE-lined 
aluminium crimp cap and cooled to 0 °C. Tert-butyl diazoacetate 346 (30 µL, 0.21 mmol, 
1 equiv.) was added dropwise via a 100 µL syringe. The solution was stirred at 0 °C for 
18 hours before being filtered through a short plug of silica and eluted with diethyl ether 
(3 x 5 mL). The organic solvent was removed in vacuo to afford a dark yellow residue. 
Purification via flash column chromatography on silica gel (eluent: petroleum ether / 
diethyl ether / dichloromethane 8:1:1; Rf = 0.20), afforded a white solid whose 
physicochemical properties were consistent with those of the title compound 352 (89 mg, 
0.12 mmol, 57% yield).  
M.p. 39–41 °C; 1H-NMR (500 MHz, CDCl3) δ 7.52 – 7.43 (m, 5H, Ar-H), 7.42 – 7.31 
(m, 5H, Ar-H), 7.28 – 7.21 (m, 4H, Ar-H), 7.05 – 6.99 (m, 1H, Ar-H), 6.98 – 6.92 (m, 
3H, Ar-H), 6.90 (d, J = 8.7 Hz, 2H, Ar-H), 5.17 (s, 2H, -CH2Ph), 5.13 (s, 2H, -CH2Ph), 
3.84 (s, 3H, -OCH3), 3.46 (d, J = 6.7 Hz, 1H, aziridine C-H), 3.04 (d, J = 6.7 Hz, 1H, 
aziridine C-H), 1.38 (s, 9H, -C(CH3)3), 1.23 (s, 9H, -C(CH3)3); 
13
C-NMR (126 MHz, 
CDCl3) δ 167.3 (-CO2
t
Bu), 166.3 (-CO2CH3), 156.8, 153.1, 150.3, 148.1, 146.7, 144.2, 
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137.2, 136.5, 130.4, 129.6, 128.7, 128.6, 128.4, 128.3, 128.2, 127.8, 125.6, 123.3, 123.3, 
123.1, 121.1, 117.5, 114.9, 110.8, 81.5 (-C(CH3)3), 80.5 (-C(CH3)3), 75.3 (-CH2Ph), 71.4 
(-CH2Ph), 52.3 (aziridine C-H), 47.5 (-OCH3), 47.1 (aziridine C-H), 28.8 (-C(CH3)3), 
28.0 (-C(CH3)3); FT-IR (thin film): υ (cm
-1
) 3070, 3035, 2976, 2880, 1716 (C=O), 1585, 
1490, 1424, 1367, 1338, 1210, 1164, 1077; HRMS (NESI) exact mass calculated for 
C45H48O8N requires m/z 730.3374, found m/z 730.3376 [M+H]
+
. 
Di-tert-butyl 3,3'-(((2-(benzyloxy)-5-(methoxycarbonyl)-1,3-
phenylene)bis(oxy))bis(4,1-phenylene))bis(1-(2-(tert-butoxy)phenyl)aziridine-2-
carboxylate) (cis-350) 
 
A 5 mL microwave vial containing 4Å molecular sieves was flame-dried and cooled 
under a flow of nitrogen. A solution of methyl 4-(benzyloxy)-3,5-bis(4-
formylphenoxy)benzoate 328 (100 mg, 0.21 mmol, 1 equiv.) and 2-tert-butoxyaniline 349 
(67 mg, 0.40 mmol, 1.95 equiv.) in dry chloroform (1.5 mL) was added, along with a 
magnetic stirrer bar. The vial was sealed with a PTFE-lined aluminium crimp cap and the 
reaction mixture was stirred slowly at room temperature for 18 hours. Pyridinium triflate 
347 (5 mg, 0.021 mmol, 10 mol%) was added, and the vial was resealed before being 
cooled to -30 °C in a chiller bath. Tert-butyl diazoacetate 346 (32 µL, 0.23 mmol, 2.2 
equiv.) was added via a 100 µL syringe and the mixture was stirred at -30 °C for 16 
hours. After warming to room temperature, the solution was filtered through a short plug 
of silica, eluting with diethyl ether (3 x 5 mL). The solvent was removed in vacuo, and 
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purification via flash column chromatography on silica gel (eluent: petroleum ether / 
diethyl ether / dichloromethane 7:2:1; Rf = 0.26) afforded a white solid whose 
physicochemical properties were consistent with those of the title compound 350 (224 
mg, 0.22 mmol, 59% yield).   
cis-350: M.p. 78–80 ºC; 1H-NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.6 Hz, 4H, Ar-H), 
7.34 (s, 2H, Ar-H), 7.33 – 7.24 (m, 4H, Ar-H), 7.05 – 6.92 (m, 13H, Ar-H), 5.17 (s, 2H, -
CH2Ph), 3.78 (s, 3H, -CO2CH3), 3.47 (d, J = 6.7 Hz, 2H, aziridine C-H), 3.05 (d, J = 6.7 
Hz, 2H, aziridine C-H), 1.38 (s, 18H, -C(CH3)3), 1.24 (s, 18H, -C(CH3)3); 13C-NMR (126 
MHz, CDCl3) δ 167.2 (-CO2
t
Bu), 165.8 (-CO2CH3), 156.3, 150.8, 148.1, 146.6, 145.5, 
136.8, 130.7, 129.7, 128.6, 128.4, 128.3, 125.7, 123.3, 123.3, 123.1, 121.1, 117.8, 116.5, 
81.5 (-C(CH3)3), 80.5 (-C(CH3)3), 75.4 (-CH2Ph), 52.3 (-CO2CH3), 47.5 (aziridine C-H), 
47.1 (aziridine C-H), 28.8 (-C(CH3)3), 28.0 (-C(CH3)3); FT-IR (thin film): υ (cm
-1
) = 2979 
(C-H), 1721 (C=O), 1582, 1494, 1423, 1368, 1334, 1260, 1216, 1161, 1043, 978, 846; 
MS (MALDI-TOF) m/z 1005.3 [M]
+
; HRMS (NESP) exact mass calculated for 
C61H72N3O11 requires m/z 1022.5161, found m/z 1022.5169 [M+NH4]
+
. 
A byproduct was isolated during the flash column chromatography (Rf = 0.23); this was 
identified as rac, cis-tert-butyl 3-(4-(2-(benzyloxy)-3-(4-formylphenoxy)-5-
(methoxycarbonyl)phenoxy)phenyl)-1-(2-(tert-butoxy)phenyl)aziridine-2-carboxylate 351 
(64 mg, 0.087 mmol, 23% yield; Rf = 0.23). 
rac,cis-351: 
1
H-NMR (500 MHz, CDCl3) δ 9.93 (s, 1H, -CHO), 7.84 (d, J = 8.8 Hz, 2H, 
Ar-H), 7.56 – 7.53 (m, 3H, Ar-H), 7.46 (d, J = 2.0 Hz, 1H, Ar-H), 7.24 – 7.13 (m, 5H, Ar-
H), 7.04 – 6.92 (m, 8H, Ar-H), 5.11 (s, 2H, -CH2Ph), 3.83 (s, 3H, -CO2CH3), 3.48 (d, J = 
6.7 Hz, 1H, aziridine C-H), 3.06 (d, J = 6.7 Hz, 1H, aziridine C-H), 1.38 (s, 9H, -
C(CH3)3), 1.24 (s, 9H, -C(CH3)3); 
13
C-NMR (126 MHz, CDCl3) δ 190.9 (-CHO), 167.1 (-
CO2
t
Bu), 165.5 (-CO2CH3), 162.7, 156.0, 151.1, 148.3, 148.1, 146.5, 146.3, 136.3, 132.1, 
131.6, 131.1, 129.8, 128.4(0), 128.3(8), 126.1, 123.2(4), 123.1(7), 121.0, 118.8, 118.1, 
117.8, 116.9, 81.5 (-C(CH3)3), 80.5 (-C(CH3)3), 75.5 (-CH2Ph), 52.5 (-CO2CH3), 47.5 
(aziridine C-H), 47.0 (aziridine C-H), 28.8 (-C(CH3)3), 28.0 (-C(CH3)3); FT-IR (thin 
film): υ (cm-1) = 3063 (C-H), 2978 (C-H), 1724 (ester C=O), 1699 (aldehyde C=O), 1580, 
1504, 1491, 1452, 1422, 1392, 1368, 1333, 1306, 1223, 1157, 1040, 1005; MS (MALDI-
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TOF) m/z 782.1 [M+K]
+
; HRMS (HNESP) exact mass calculated for C45H46NO9 requires 
m/z 744.3167, found m/z 744.3165 [M+H]
+
. 
tert-Butyl 3-(4-(2-(benzyloxy)-3-(4-formylphenoxy)-5-vinylphenoxy)phenyl)-1-(2-tert-
butoxyphenyl)aziridine-2-carboxylate (rac, cis-353) 
 
A 5 mL microwave vial containing crushed 4Å molecular sieves was flame-dried and 
cooled under nitrogen. The vial was charged with 4,4'-((2-(benzyloxy)-5-vinyl-1,3-
phenylene)bis(oxy))dibenzaldehyde 339 (100 mg, 0.22 mmol, 1 equiv.) and a solution of 
2-tert-butoxyaniline 349 (36 mg, 0.22 mmol, 0.98 equiv.) in chloroform (1 mL). The 
mixture was stirred at room temperature for 16 hours. Pyridinium triflate 347 (5 mg, 0.02 
mmol, 10 mol%) was added, and the vial sealed with a PTFE-lined aluminium crimp cap. 
Tert-butyl diazoacetate 346 (31 µL, 0.22 mmol, 1 equiv.) was added dropwise via 
syringe. The mixture was stirred at room temperature for a further 16 hours and filtered 
through a short plug of silica gel, eluting with diethyl ether (3 x 5 mL). The solvent was 
removed in vacuo to afford a brown oil. Purification via flash column chromatography on 
silica gel (eluent: petroleum ether / diethyl ether / dichloromethane (8:1:1); Rf 0.20) 
afforded a pale red liquid whose physicochemical properties were consistent with those of 
the title compound 353 (18 mg, 0.025 mmol, 19%). 
1
H-NMR (500 MHz, CDCl3) δ 9.91 (s, 1H -CHO), 7.83 (d, J = 8.7 Hz, 2H, Ar-H), 7.53 
(d, J = 8.7 Hz, 2H, Ar-H), 7.10 – 7.24 (m, 5H, Ar-H), 6.90 – 7.05 (m, 9H, Ar-H), 6.83 (d, 
J = 2.0 Hz, 1H, Ar-H), 6.50 (dd, J = 10.9, 17.5 Hz, 1H, -CH=CH2), 5.55 (d, J = 17.5 Hz, 
1H, -CH=CH2), 5.21 (d, J = 10.9 Hz, 1H, -CH=CH2), 5.00 (s, 2H, -CH2Ph), 3.48 (d, J = 
6.7 Hz, 1H, aziridine -CH-), 3.05 (d, J = 6.7 Hz, 1H, aziridine -CH-), 1.38 (s, 9H, -
C(CH3)3), 1.23 (s, 9H, -C(CH3)3); 
13
C-NMR (100 MHz, CDCl3) δ 190.9 (-CHO), 167.1 (-
CO2
t
Bu), 163.1, 156.4, 151.3, 148.5, 148.0, 146.5, 141.9, 136.7, 135.2, 134.3, 132.1, 
131.3, 130.6, 129.6, 128.4, 128.3, 128.2, 123.2(4), 123.2(2), 123.1, 121.0, 117.7, 116.6, 
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115.2, 114.9, 114.8, 81.4 (-C(CH3)3), 80.5 (-C(CH3)3), 75.6 (-CH2Ph), 47.5 (aziridine -
CH2-), 47.1 (aziridine -CH2-), 28.8 (-C(CH3)3), 28.0 (-C(CH3)3); FT-IR (thin film): υ (cm
-
1
) = 3065, 3033, 2976, 2930, 2733, 2250, 1744 (ester C=O), 1696 (aldehyde C=O), 1596, 
1584, 1568, 1490, 1452, 1428, 1407, 1392, 1367, 1319, 1225, 1155, 1111, 1028; [α]D
21
 
+6.1 (c 1.0, CHCl3); HRMS (HNESP) exact mass calculated for C45H46NO7 requires m/z 
712.3269, found m/z 712.3265 [M+H]
+
. 
General procedure for the synthesis of amino acid bromoacetamides: 
(S)-Methyl 2-(2-bromoacetamido)-3-phenylpropanoate (381)
218
 
A 250 mL round-bottom flask containing a magnetic stirrer bar was flame-dried and 
allowed to cool to room temperature under a nitrogen atmosphere. To the flask was added 
(S)-phenylalanine methyl ester hydrochloride 380 (2 g, 9.27 mmol, 1 equiv.) and dry 
dichloromethane (70 mL). Triethylamine (1.3 mL, 9.27 mmol, 1 equiv.) was added 
dropwise via a 2.5 mL syringe and the suspension stirred at room temperature for 20 
minutes. The reaction was cooled to -10 °C using an acetone / dry ice bath, and 
bromoacetyl bromide (0.8 mL, 9.27 mmol, 1 equiv.) was added dropwise via a 2 mL 
syringe followed by a further 1 equivalent of triethylamine (1.3 mL, 9.27 mmol, 1 equiv.). 
The solution continued to be stirred at -10 °C for 15 minutes before the cooling bath was 
removed and the reaction mixture was allowed to warm to room temperature. The 
solution was stirred for a further 30 minutes before the addition of distilled water (50 
mL). The mixture was then poured into a 250 mL separating funnel and the aqueous layer 
extracted with dichloromethane (2 x 50 mL). The combined organic layers were washed 
with 1 M aqueous hydrochloric acid (100 mL), then half-saturated aqueous sodium 
bicarbonate solution (100 mL) and finally brine (100 mL), before being dried over 
magnesium sulfate and filtered. Removal of the solvent in vacuo afforded a pale brown 
solid (used without further purification) whose physicochemical properties matched those 
previously reported for the title compound (2.62 g, 8.71 mmol, 94% yield). 
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1
H-NMR (500 MHz, CDCl3) δ = 7.33-7.24 (m, 3H, Ar-H), 7.14-7.10 (m, 2H, Ar-H), 6.83 
(br d, J = 6.0 Hz, 1H, N-H), 4.85 (dt, J = 7.9, 5.8 Hz, 1H, -NHCH-), 3.86 (d, J = 13.7 Hz, 
1H, AB -CH2Br), 3.83 (d, J = 13.7 Hz, 1H, AB -CH2Br), 3.74 (s, 3H, -OCH3), 3.18 (dd, J 
= 13.9, 5.8 Hz, 1H, -CH2Ph), 3.13 (dd, J = 13.9, 5.8 Hz, 1H, -CH2Ph); 
13
C-NMR (125 
MHz, CDCl3) δ = 171.4 (-CONH-), 165.2 (-CO2CH3), 135.5, 129.4, 128.9, 127.5, 53.9 (-
NHCH-), 52.6 (-OCH3), 37.9 (-CH2Ph), 28.8 (-CH2Br); FT-IR (thin film, cm
-1
) υ = 3295 
(N-H), 3033, 2959, 2854, 1746 (ester C=O), 1664 (amide C=O), 1533, 1440, 1365, 1216. 
(S)-Methyl 2-(2-bromoacetamido)-4-methylpentanoate (382)
250
 
 
Compound 382 was prepared according to the general procedure described above to 
afford a white solid (1.33 g, 5.01 mmol, 91% yield) which was used without further 
purification. The physicochemical properties matched those previously reported for the 
title compound. 
1
H-NMR (500 MHz, CDCl3) δ = 6.79 (d, J = 6.8 Hz, 1H, N-H), 4.62 (dt, J = 8.5, 5.1 Hz, 
1H, -NHCH-), 3.91 (d, J = 13.7 Hz, 1H, AB -CH2Br), 3.87 (d, J = 13.7 Hz, 1H, AB -
CH2Br), 3.75 (s, 3H, -OCH3), 1.74-1.55 (m, 3H, -CH2CH(CH3)2), 0.95 (d, J = 6.3 Hz, 6H, 
-C(CH3)2); 
13
C-NMR (125 MHz, CDCl3) δ = 172.9 (-CONH-), 165.4 (-CO2CH3), 52.6 (-
OCH3), 51.5 (-NHCH-), 41.5 (-CHCH2-), 28.9 (-CH2Br), 25.0 (-CH(CH3)2), 22.9 (-
CH(CH3)2), 22.1 (-CH(CH3)2); FT-IR (thin film, cm
-1
) υ = 3295 (N-H), 3074, 2959, 2873, 
1746 (ester C=O), 1660 (amide C=O), 1544, 1440, 1208, 1156; [α]D
21
 +5.6 (c 1.0, 
CHCl3). 
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(S)-Allyl 2-(2-bromoacetamido)-3-phenylpropanoate (384) 
 
Compound 384 was prepared according to the general procedure described above to 
afford a pale brown oil (1.26 g, 3.86 mmol, 76% yield) that was used without further 
purification.  
1
H-NMR (500 MHz, CDCl3) δ 7.33 – 7.27 (m, 3H, Ar-H), 7.17 – 7.10 (m, 2H, Ar-H), 
6.84 (br d, J = 7.6 Hz, 1H, N-H), 5.88 (ddt, J = 17.2, 10.4, 5.9 Hz, 1H, -CH=CH2), 5.32 
(dd, J = 17.2, 1.4 Hz, 1H, -CH=CH2), 5.27 (dd, J = 10.4, 1.4 Hz, 1H, -CH=CH2), 4.87 (dt, 
J = 7.9, 5.9 Hz, 1H, -NHCH-), 4.63 (dt, J = 5.9, 1.4 Hz, 2H, -OCH2-), 3.87 (d, J = 13.7 
Hz, 1H, AB -CH2Br), 3.83 (d, J = 13.7 Hz, 1H, AB -CH2Br), 3.19 (dd, J = 13.9, 5.9 Hz, 
1H, -CH2Ph), 3.14 (dd, J = 13.9, 5.9 Hz, 1H, -CH2Ph); 
13
C-NMR (126 MHz, CDCl3) δ 
170.7 (amide C=O), 165.3 (ester C=O), 135.4, 131.4 (-CH=CH2), 129.5, 128.8, 127.5, 
119.4 (-CH=CH2), 66.4 (-OCH2-), 53.9 (-NHCH-), 37.9 (-CH2Ph), 28.8 (-CH2Br); FT-IR 
(thin film): υ (cm-1) = 3307 (N-H), 3032 (C-H), 2935 (C-H), 2863 (C-H), 1743 (ester 
C=O), 1662 (amide C=O), 1536, 1498, 1455, 1379, 1197, 1138, 1049; [α]D
21
 +22.3 (c 1.0, 
CHCl3); MS (MALDI-TOF) m/z 364.08, 366.07 [M+K]
+
; HRMS (HNESP) exact mass 
calculated for C14H17BrNO3 requires m/z 326.0386, 328.0366, found m/z 326.0390, 
328.0367 [M+H]
+
.  
(S)-Methyl 2-(2-bromoacetamido)-2-phenylacetate (385)
220
 
 
Compound 385 was prepared according to the general procedure described above to 
afford an orange solid (1.18 g, 4.12 mmol, 83% yield) which was used without further 
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purification. The physicochemical properties matched those previously reported for the 
title compound. 
M.p. 74–76 °C; 1H-NMR (500 MHz, CDCl3) δ 7.45 (br d, J = 6.1 Hz, 1H, N-H), 7.41 – 
7.31 (m, 5H, Ar-H), 5.54 (d, J = 7.1 Hz, 1H, -CH-), 3.91 (d, J = 13.7 Hz, 1H, AB -
CH2Br), 3.86 (d, J = 13.7 Hz, 1H, AB -CH2Br), 3.75 (s, 3H, -OCH3); FT-IR (thin film): υ 
(cm
-1
) = 3298 (N-H), 3041 (C-H), 2955 (C-H), 1746 (ester C=O), 1660 (amide C=O), 
1529, 1339, 1216; [α]D
19
 +84.4 (c 1.0, CHCl3). 
 
Methyl 2-(2-bromoacetamido)-2-methylpropanoate (383) 
 
Compound 383 was prepared according to the general procedure described above to 
afford a white solid (1.27 g, 5.33 mmol, 78% yield) that was used without further 
purification.  
M.p. 83–85 °C; 1H-NMR (500 MHz, CDCl3) δ 7.06 (s, 1H, -NH-), 3.83 (s, 2H, -CH2Br), 
3.77 (s, 3H, -OCH3), 1.59 (s, 6H, -C(CH3)2);
 13C-NMR (126 MHz, CDCl3) δ 174.7 (ester 
–C=O), 164.9 (amide –C=O), 57.3 (-C(CH3)2), 53.0 (-OCH3), 29.2 (-CH2Br), 24.4 (-
C(CH3)2); FT-IR (thin film): υ (cm
-1
) = 3273 (N-H), 3074 (C-H), 2922 (C-H), 2859 (C-
H), 1734 (ester C=O), 1650 (amide C=O), 1548, 1493, 1472, 1282, 1197, 1155, 1049; 
MS (MALDI-TOF) m/z 261.92, 263.90 [M+Na]
+
; HRMS (HNESP) exact mass calculated 
for C7H13BrNO3 requires m/z 238.0073, 240.0053, found m/z 238.0076, 240.0051 
[M+H]
+
. 
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General procedure for the synthesis of amino acid diazoacetamides (Method A: N,N’-
Ditosylhydrazine): 
(S)-Methyl 2-(2-diazoacetamido)-3-phenylpropanoate (386)
217
 
 
A 250 mL round-bottom flask containing (S)-methyl 2-(2-bromoacetamido)-3-
phenylpropanoate 381 (1.23 g, 4.10 mmol, 1 equiv.) and a stirrer bar under a nitrogen 
atmosphere was cooled to 0 °C. Dry tetrahydrofuran (40 mL) was added via a 50 mL 
syringe, followed by the sequential addition of N,N’-ditosylhydrazine (2.79 g, 8.20 mmol, 
2 equiv.) in one portion, and 1,8-diazabicycloundec[7]ene (3.1 mL, 20.5 mmol, 5 equiv.) 
via a 5 mL syringe. The resulting deep yellow solution was stirred at 0 °C for 30 minutes. 
The reaction was quenched by the addition of saturated sodium bicarbonate solution (20 
mL) and poured into a 250 mL separating funnel containing distilled water (50 mL) and 
diethyl ether (50 mL). The mixture was extracted with diethyl ether (3 x 50 mL), and the 
combined organic layers were washed with brine (100 mL), dried over magnesium 
sulfate, filtered, and the solvent removed in vacuo. The yellow residue was redissolved in 
chloroform (50 mL) and the mixture filtered to remove the unreacted white solid N,N’-
ditosylhydrazine. The yellow filtrate was concentrated in vacuo. Purification via flash 
column chromatography on silica gel (eluent: diethyl ether / petroleum ether 3:1, Rf = 
0.28) afforded a yellow solid whose physicochemical properties were consistent with 
those of the title compound (598 mg, 0.24 mmol, 60% yield).  
M.p. 126–128 °C (dichloromethane / diethyl ether / petroleum ether); 1H-NMR (300 
MHz, CD3CN) δ = 7.39 – 7.15 (m, 5H, Ar-H), 6.33 (br s, 1H, -NH-), 5.03 (s, 1H, -CHN2), 
4.68 (dt, J = 8.2, 5.6 Hz, 1H, -NHCH-), 3.65 (s, 3H, -OCH3), 3.11 (dd, J = 13.9, 5.6 Hz, 
1H, -CH2Ph), 2.94 (dd, J = 13.9, 8.2 Hz, 1H, -CH2Ph); 
13
C-NMR (100 MHz, CD3CN) δ = 
173.1 (-C=O ester), 166.3 (-C=O amide), 137.8, 130.2, 129.4, 127.8, 55.0 (-NHCH-), 
52.7 (-OCH3), 47.5 (-CHN2), 38.4 (-CH2Ph); FT-IR (thin film, cm
-1
) υ = 3106 (N-H), 
3027, 2115 (diazo C=N2), 1748 (ester C=O), 1605 (amide C=O), 1527, 1385, 1208; [α]D
21
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+175.0 (c 1.0, CHCl3); MS (MALDI-TOF): m/z = 270.0 [M+Na]
+
; HRMS (ESI) exact 
mass calculated for C12H13N3NaO3 m/z 270.0849 m/z, found m/z 270.0850 [M+Na]
+
. 
(S)-Methyl 2-(2-diazoacetamido)-4-methylpentanoate (387) 
 
Compound 387 was prepared according to method A. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether / petroleum ether 3:1; Rf = 0.25) 
afforded a yellow oil whose physicochemical properties were consistent with those of the 
title compound (1.28 mg, 6.03 mmol, 65% yield). 
1
H-NMR (300 MHz, CD3CN) δ = 6.41 (br s, 1H, -NH-), 5.06 (s, 1H, -CHN2), 4.68 (m, 
1H, -NHCH-), 3.65 (s, 3H, -OCH3), 1.69 – 1.49 (m, 3H, -CH2CH(CH3)2), 0.92 (d, J = 6.9 
Hz, 3H, -CH(CH3)2), 0.89 (d, J = 6.9 Hz, 3H, -CH(CH3)2); 
13
C-NMR (100 MHz, CD3CN) 
δ = 174.3 (-C=O ester), 166.5 (-C=O amide), 52.7 (-NHCH-), 52.0 (-OCH3), 47.5 (-
CHN2), 41.4 (-CH2-), 25.5 (-CH(CH3)2), 23.1 (-CH(CH3)2), 21.8 (-CH(CH3)2); FT-IR 
(ATR, cm
-1
) υ = 3105 (N-H), 2959 (C-H), 2877 (C-H), 2100 (diazo C=N2), 1741 (C=O 
ester), 1616 (C=O amide), 1536, 1380, 1204, 1148 cm
–1; [α]D
19
 –6.3 (c 1.0, CHCl3); MS 
(MALDI-TOF): m/z = 252.0 [M+K]
+
; HRMS (ESI) exact mass calculated for C9H16N3O3 
requires m/z 214.1186, found m/z 214.1187 [M+H]
+
.  
(S)-Methyl 2-(2-diazoacetamido)-2-phenylacetate (389) 
 
Compound 389 was prepared according to method A. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether / petroleum ether 3:1; Rf = 0.31) 
afforded a yellow solid whose physicochemical properties were consistent with those of 
the title compound (1.00 g, 4.29 mmol, 68% yield). 
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M.p. 87–89 °C; 1H-NMR (400 MHz, CDCl3) δ 7.42 – 7.28 (m, 5H, Ar-H), 6.26 (br s, 1H, 
-NH-), 5.63 (d, J = 7.2 Hz, 1H, -CHN2), 4.83 (s, 1H, -NHCH-), 3.73 (s, 3H, -OCH3); 
13
C-
NMR (100 MHz, CDCl3) δ 171.6 (-C=O ester), 164.8 (-C=O amide), 136.6, 129.0, 128.6, 
127.2, 56.7 (-NHCH-), 52.9 (-OCH3), 47.6 (-CHN2); FT-IR (thin film): υ (cm
-1
) = 3307 
(N-H), 3100 (C-H), 2965 (C-H), 2857 (C-H), 2111 (-HC=N2), 1746 (ester C=O), 1625 
(amide C=O), 1535, 1386, 1265, 1211, 1174, 1103; [α]D
20
 +12.6 (c 1.0, CHCl3); MS 
(MALDI-TOF) m/z 271.9 [M+K]
+
; HRMS (HNESP) exact mass calculated for 
C11H12N3O3 requires m/z 234.0873, found m/z 234.0876 [M+H]
+
. 
Methyl 2-(2-diazoacetamido)-2-methylpropanoate (390) 
 
Compound 390 was prepared according to method A. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether 100%; Rf = 0.55) afforded a yellow oil 
whose physicochemical properties were consistent with those of the title compound (829 
mg, 4.48 mmol, 57% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.65 (s, 1H, -NH-), 4.73 (s, 1H, -CHN2), 3.76 (s, 3H, -
OCH3), 1.58 (s, 6H, -C(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 175.4 (C=O ester), 164.9 
(C=O amide), 57.2 (-C(CH3)2), 53.0 (-OCH3), 47.8 (-CHN2), 25.3 (-C(CH3)2); FT-IR 
(thin film): υ (cm-1) = 3319 (N-H), 3096, 2991, 2951, 2106 (diazo C=N2), 1739 (ester 
C=O), 1621 (amide C=O), 1539, 1383, 1289, 1246, 1152; MS (MALDI-TOF) m/z 224.0 
[M+K]
+
; HRMS (HNESP) exact mass calculated for C7H12N3O3 requires m/z 186.0873, 
found m/z 186.0873 [M+H]
+
. 
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(S)-Allyl 2-(2-diazoacetamido)-3-phenylpropanoate (388) 
 
Compound 388 was prepared according to method A. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether / petroleum ether 2:1; Rf = 0.37) 
afforded a yellow solid whose physicochemical properties were consistent with those of 
the title compound (836 mg, 3.06 mmol, 79% yield). 
M.p. 66–68 °C; 1H-NMR (500 MHz, CDCl3) δ 7.32 – 7.22 (m, 3H, Ar-H), 7.15 – 7.08 
(m, 2H, Ar-H), 5.88 (ddt, J = 17.2, 10.4, 5.9 Hz, 1H, -CH=CH2), 5.46 (d, J = 7.5 Hz, 1H, 
-NH-), 5.32 (d, J = 17.2 Hz, 1H, -CH=CH2), 5.27 (d, J = 10.4 Hz, 1H, -CH=CH2), 4.98 
(br s, 1H, -NHCH-), 4.73 (s, 1H, -CHN2), 4.62 (d, J = 5.9 Hz, 2H, -OCH2-), 3.18 (dd, J = 
13.9, 5.7 Hz, 1H, -CH2Ph), 3.13 (dd, J = 13.9, 5.7 Hz, 1H, -CH2Ph); 
13
C-NMR (126 MHz, 
CDCl3) δ 171.9 (C=O ester), 165.5 (C=O amide), 135.9, 131.4, 129.4, 128.6, 127.2, 119.2 
(-CH=CH2), 66.2 (-OCH2-), 53.6 (-NHCH-), 47.4 (-CHN2), 38.3 (-CH2Ph); FT-IR (thin 
film): υ (cm-1) = 3306 (N-H), 3092, 2953, 2108 (diazo C=N2), 1742 (ester C=O), 1625 
(amide C=O), 1534, 1458, 1385, 1196; [α]D
18
 -47.4 (c 1.0, CHCl3); MS (MALDI-TOF) 
m/z 312.05 [M+K]
+
; HRMS (HNESP) exact mass calculated for C14H16N3O3 requires m/z 
274.1186, found m/z 274.1188 [M+H]
+
. 
General procedure for the synthesis of amino acid diazoacetamides (Method B): 
(S)-Methyl 2-(2-diazoacetamido)-4-(methylthio)butanoate (393) 
 
To a flame-dried 25 mL round-bottom flask containing (S)-methionine methyl ester 
hydrochloride 391 (218 mg, 1.09 mmol, 2 equiv.) and a magnetic stirrer bar was added 
dry tetrahydrofuran (5 mL) via syringe under a nitrogen atmosphere. The resulting 
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suspension was cooled to 0 °C using an ice bath and N,N-diisopropylethylamine (0.95 
mL, 5.46 mmol, 3 equiv.) was added dropwise via a 2 mL syringe. The solution was 
stirred for 10 minutes while maintaining the temperature at 0 °C. A solution of 
succinimidyl diazoacetate
222
 396 (100 mg, 0.55 mmol, 1 equiv.) in tetrahydrofuran (10 
mL) was added dropwise to the flask, and the solution was allowed to warm to room 
temperature. After stirring at room temperature for 24 hours, the solvent was removed in 
vacuo and the yellow residue extracted with dichloromethane (2 x 20 mL). The combined 
organic layers were washed with distilled water (3 x 30 mL), dried over magnesium 
sulfate, filtered, and the solvent removed in vacuo. Purification via flash column 
chromatography on silica gel  (eluent: diethyl ether / petroleum ether; Rf = 0.24) afforded 
a yellow solid (63 mg, 0.27 mmol, 50% yield) whose physicochemical properties were 
consistent with those of the title compound.  
M.p. = 40–42 °C; 1H-NMR (500 MHz, CD3CN) δ = 6.39 (br s, 1H, -NH-), 5.06 (s, 1H, -
CHN2), 4.54 (dt, J = 8.9, 4.9 Hz, 1H, -NHCH-), 3.68 (s, 3H, -OCH3), 2.57 – 2.45 (m, 2H, 
-CH2S-), 2.06 (s, 3H, -SCH3), 2.05 – 2.00 (m, 1H, -CH2CH2S-), 1.92 – 1.85 (m, 1H, -
CH2CH2S-); 
13
C-NMR (125 MHz, CD3CN) δ = 173.5 (C=O ester), 166.6 (C=O amide), 
52.8 (-NHCH-), 52.6 (-OCH3), 47.6 (-CHN2), 32.2 (-CH2CH2S-), 30.6 (-CH2S-), 15.3 (-
SCH3); FT-IR (thin film, cm
-1
) υ = 3095 (N-H), 2925, 2111 (diazo C=N2), 1746 (ester 
C=O), 1620 (amide C=O), 1544, 1386, 1215; [α]D
20
 +5.31 (c 1.0, CHCl3); MS (MALDI-
TOF) m/z 269.9 [M+K]
+
; HRMS (HNESP) exact mass calculated for C8H14N3O3S 
requires m/z 232.0750, found m/z 232.0754 [M+H]
+
. 
(S)-tert-Butyl 3-(2-diazoacetamido)-3-phenylpropanoate (398) 
 
Compound 398 was prepared according to method B. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether / petroleum ether 3:1; Rf = 0.31) 
afforded a yellow oil whose physicochemical properties were consistent with those of the 
title compound (33 mg, 0.114 mmol, 61% yield). 
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1
H-NMR (300 MHz, CD3CN) δ 7.49 – 7.20 (m, 5H, Ar-H), 6.66 (d, J = 6.7 Hz, 1H, -NH-
), 5.28 (m, 1H, -NHCH-), 5.02 (s, 1H, -CHN2), 2.71 (dd, J = 14.5, 7.0 Hz, 1H, -
CH2CO2
t
Bu), 2.64 (dd, J = 14.5, 7.0 Hz, 1H, -CH2CO2
t
Bu), 1.34 (s, 9H, -C(CH3)3); 
13
C-
NMR (100 MHz, CD3CN) δ 170.6 (ester -C=O), 165.7 (amide –C=O), 142.9, 129.4, 
128.3, 127.5, 81.4 (-C(CH3)3), 51.6 (-NHCH-), 47.5 (-CHN2), 42.9 (-CH2CO2
t
Bu), 28.1 (-
C(CH3)3); FT-IR (ATR): υ (cm
-1
) = 3277 (N-H), 3095 (C-H), 2983 (C-H), 2938 (C-H), 
2099 (diazo C=N2), 1727 (ester C=O), 1619 (amide C=O), 1561, 1375, 1251, 1146, 701; 
[α]D
19 
-54.7 (c 1.5, CHCl3); MS (MALDI-TOF) m/z 327.9 [M+K]
+
; HRMS (HNESP) 
exact mass calculated for C15H20N3O3 requires m/z 290.1499, found m/z 290.1503 
[M+H]
+
. 
(S)-Methyl 1-(2-diazoacetyl)pyrrolidine-2-carboxylate (401) 
 
Compound 401 was prepared according to method B. Purification via flash column 
chromatography on silica (diethyl ether 100%; Rf = 0.19) afforded a yellow oil whose 
physicochemical properties were consistent with those of the title compound (70 mg, 0.35 
mmol, 65% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.88 (s, 1H, -CHN2), 4.53 (br s, 1H, -NCH-), 3.72 (s, 3H, -
OCH3), 3.43 (br s, 1H, -NCH2-), 3.28 (br s, 1H, -NCH2-), 2.25–1.90 (m, 4H, -CH2-); 
13
C-
NMR (101 MHz, CD3CN) δ 174.0 (-C=O ester), 165.1 (-C=O amide), 59.8 (-NHCH-), 
52.6 (-OCH3), 47.2 (-NCH2- + -CHN2), 30.0 (-CH2-), 25.2 (-CH2-); FT-IR (thin film): υ 
(cm
-1
) = 3075 (C-H), 2861 (C-H), 2927 (C-H), 2855 (C-H), 2107 (diazo C=N2), 1736 
(ester C=O), 1607 (amide C=O), 1413, 1163, 730; [α]D
22 
-11.4 (c 0.8, CHCl3); MS 
(MALDI-TOF) m/z 220.9 [M+K]
+
; HRMS (HNESP) exact mass calculated for 
C8H12N3O3 requires m/z 198.0873, found m/z 198.0873 [M+H]
+
. 
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(S)-Methyl 2-(2-diazoacetamido)-3-(4-iodophenyl)propanoate (400) 
 
Compound 400 was prepared according to method B. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether / petroleum ether 3:1; Rf = 0.37) 
afforded a yellow solid whose physicochemical properties were consistent with those of 
the title compound (89 mg, 0.24 mmol, 67% yield). 
M.p. 73–75 °C; 1H-NMR (500 MHz, CDCl3) δ 7.61 (d, J = 8.2 Hz, 2H, Ar-H), 6.84 (d, J 
= 8.2 Hz, 2H, Ar-H), 5.50 (d, J = 6.0 Hz, 1H, -NH-), 4.93 (m, 1H, -NHCH-), 4.75 (s, 1H, 
-CHN2), 3.74 (s, 3H, -OCH3), 3.13 (dd, J = 13.9, 6.0 Hz, 1H, -CH2Ph), 3.05 (dd, J = 13.9, 
6.0 Hz, 1H, -CH2Ph); 
13
C-NMR (126 MHz, CDCl3) δ 172.3 (-C=O ester), 165.4 (-C=O 
amide), 137.7, 135.6, 131.4, 92.7 (C-I), 53.3 (-NHCH-), 52.6 (-OCH3), 47.5 (-CHN2), 
37.7 (-CH2Ar); FT-IR (thin film): υ (cm
-1
) = 3361 (N-H), 3091 (C-H), 3011 (C-H), 2922 
(C-H), 2854 (C-H), 2106 (diazo C=N2), 1743 (ester C=O), 1620 (amide C=O), 1540, 
1493, 1447, 1383, 1206, 1054; [α]D
20
 +151.8 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 
412.02 [M+K]
+
; HRMS (HNESP) exact mass calculated for C12H13IN3O2 requires m/z 
373.9996, found m/z 373.9997 [M+H]
+
. 
rac-Benzyl 2-(2-diazoacetamido)-3-phenylpropanoate (402) 
 
Compound 402 was prepared according to method B. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether / petroleum ether 3:1; Rf = 0.47) 
afforded a yellow solid whose physicochemical properties were consistent with those of 
the title compound (2.01 g, 6.22 mmol, 37% yield). 
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M.p. 78–80 °C; 1H-NMR (500 MHz, CDCl3) δ 7.41 – 7.34 (m, 3H, Ar-H), 7.34 – 7.29 
(m, 2H, Ar-H), 7.24 – 7.20 (m, 3H, Ar-H), 7.02 – 6.98 (m, 2H, Ar-H), 5.46 (d, J = 7.2 Hz, 
1H, -NH-), 5.18 (d, J = 12.1 Hz, 1H, -OCH2Ph), 5.13 (d, J = 12.1 Hz, 1H, -OCH2Ph), 
4.99 (br s, 1H, -NHCH-), 4.72 (s, 1H, -CHN2), 3.15 (dd, J = 13.9, 5.9 Hz, -CH2Ph), 3.12 
(dd, J = 13.9, 5.9 Hz, 1H, -CH2Ph); 
13
C-NMR (126 MHz, CDCl3) δ 171.8 (-CO2Bn), 
165.3 (-CONH-), 135.8, 135.1, 129.5, 128.8, 128.7, 128.7, 127.2, 67.5 (-CO2CH2Ph), 
53.6 (-NHCH-), 47.5 (-CHN2), 38.3 (-CH2Ph); FT-IR (thin film): υ (cm
-1
) = 3289 (N-H), 
3094, 3070, 3035, 2946, 2108 (diazo C=N2), 1741 (ester C=O), 1621 (amide C=O), 1538, 
1456, 1387, 1195, 1109, 1078, 1027, 992; MS (MALDI-TOF) m/z 361.80 [M+K]
+
; 
HRMS (HNESP) exact mass calculated for C18H18N3O3 requires m/z 324.1343, found m/z 
324.1344 [M+H]
+
. 
(S)-Benzyl 3-(2-(2-diazoacetamido)-3-methoxy-3-oxopropyl)-1H-indole-1-
carboxylate (399) 
 
Compound 399 was prepared according to method A. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether / dichloromethane / petroleum ether 
7:1:2; Rf = 0.38) afforded a pale yellow solid whose physicochemical properties were 
consistent with those of the title compound (876 mg, 2.08 mmol, 75% yield). 
M.p. 120–122 °C; 1H-NMR (500 MHz, CDCl3) δ 8.07 (br s, 1H, -CHind), 7.45 – 7.39 (m, 
3H, Ar-H), 7.38 – 7.28 (m, 4H, Ar-H), 7.25 (t, J = 7.3 Hz, 1H, Ar-H), 7.21 – 7.16 (m, 1H, 
Ar-H), 5.52 (d, J = 7.6 Hz, 1H, -NH-), 5.37 (s, 2H, -CH2Ph), 4.93 (m, 1H, -NHCH-), 4.62 
(s, 1H, -CHN2), 3.60 (s, 3H, -OCH3), 3.28 (dd, J = 14.7, 5.6 Hz, 1H, -CH2-indole), 3.22 
(dd, J = 14.7, 5.6 Hz, 1H, -CH2-indole); 
13
C-NMR (125 MHz, CDCl3) δ 172.3 (-C=O 
ester), 165.2 (-C=O amide), 150.8 (-C=O carbamate), 135.2, 130.7, 128.9, 125.1, 123.9, 
123.2, 119.1, 116.0, 115.5, 68.9 (-CH2Ph), 52.9 (-NHCH-), 52.7 (-OCH3), 47.7 (-CHN2), 
27.9 (-CH2-indole); FT-IR (thin film, cm
-1
) υ = 3335 (N-H), 3092, 2920, 2106, 1739 
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(ester C=O), 1617 (amide C=O), 1539, 1457, 1394, 1250; [α]D
25 
+23.9 (c 1.0, acetone); 
MS (MALDI-TOF): m/z = 443.12 [M+Na]
+
; HRMS (NSI) exact mass calculated for 
C22H21O5N4 requires m/z 421.1506, found m/z 421.1505 [M+H]
+
. 
trans-Tert-butyl 2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)carbamoyl)-3-
phenylaziridine-1-carboxylate (416a/b) 
 
A 5 mL microwave vial containing crushed 4Å molecular sieves was flame-dried and 
cooled under a nitrogen atmosphere. The vial was charged with a solution of tert-butyl 
benzylidenecarbamate 408 (100 mg, 0.49 mmol, 1 equiv.) in chloroform-d3 (1 ml) via 
syringe and a magnetic stirrer bar before being cooled to 0 °C using an ice bath. 
Pyridinium triflate (11 mg, 0.05 mmol, 10 mol%) was added, and the vial was sealed with 
a PTFE-lined aluminium crimp cap. A solution of (S)-methyl 2-(2-diazoacetamido)-3-
phenylpropanoate 386 (145 mg, 0.59 mmol, 1.2 equiv.) in chloroform-d3 (1 mL) was 
added dropwise via syringe, and the reaction was allowed to warm slowly to room 
temperature over 16 hours. On complete disappearance of imine 408 by 
1
H-NMR, the 
mixture was filtered through a short plug of silica, eluting with diethyl ether, and the 
solvent removed in vacuo. Purification via flash column chromatography on silica gel 
(eluent: petroleum ether / diethyl ether 1:1; Rf = 0.34) afforded a white solid whose 
physicochemical properties were consistent with those of a single diastereomer of the title 
compound (149 mg, 0.35 mmol, 72% yield).  
M.p. 125–127 °C; 1H-NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (m, 8H, Ar-H), 7.11 (m, 2H, 
Ar-H), 6.56 (d, J = 8.0 Hz, 1H, -NH-), 4.93 (dt, J = 8.0, 5.8 Hz, 1H, -NHCH-), 3.73 (m, 
4H, -CO2CH3 + aziridine C-H), 3.19 (d, J = 2.2 Hz, 1H, aziridine C-H), 3.18 (m, 1H, -
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CH2Ph), 3.14 (dd, 1H, J = 13.9, 5.8 Hz, -CH2Ph), 1.33 (s, 9H, -C(CH3)3); 
13
C-NMR (126 
MHz, CDCl3) δ 171.6 (-C=O ester), 166.2 (-C=O amide), 158.3 (-C=O carbamate), 
135.6, 134.3, 129.4, 128.8, 128.6(8), 128.6(6), 127.4, 127.2, 82.2 (-C(CH3)3), 53.4 (-
NHCH-), 52.5 (-OCH3), 45.8 (aziridine C-H), 44.2 (aziridine C-H), 38.0 (-CH2Ph), 27.9 
(-C(CH3)3); FT-IR (thin film): υ (cm
-1
) = 3323 (N-H), 2977 (C-H), 1726 (ester C=O), 
1680 (amide C=O), 1535, 1455, 1367, 1321, 1215, 1152, 1086; [α]D
23
 +17.5 (c 1.0, 
CHCl3); MS (MALDI-TOF) m/z 463.27 [M+K]
+
; HRMS (HNESP) exact mass calculated 
for C24H28N2O5Na requires m/z 447.1890, found m/z 447.1887 [M+Na]
+
. 
cis-(2S)-Methyl 2-(1-(4-methoxyphenyl)-3-phenylaziridine-2-carboxamido)-3-
phenylpropanoate (406a) 
 
Compound 406a was prepared according to the procedure for compound 416 above. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 1:1; Rf = 0.13) afforded a white solid whose physicochemical properties 
were consistent with those of the title compound (47 mg, 0.11 mmol, 23% yield). 
M.p. 140–142 °C (petroleum ether / diethyl ether); 1H-NMR (500 MHz, CDCl3) δ 7.42 – 
7.36 (m, 2H, Ar-H), 7.32 – 7.21 (m, 6H, Ar-H), 7.14 – 7.06 (m, 2H, Ar-H), 6.92 (d, J = 
9.0 Hz, 2H, Ar-H), 6.88 – 6.81 (m, 3H, Ar-H + N-H), 4.60 (dt, J = 8.3, 6.0 Hz, 1H, -
NHCH-), 3.80 (s, 3H, Ar-OCH3), 3.57 (d, J = 7.0 Hz, 1H, aziridine -CH-), 3.47 (s, 3H, -
CO2CH3), 3.10 (dd, J = 13.7, 6.0 Hz, 1H, -CH2Ph), 3.05 (d, J = 7.0 Hz, 1H, aziridine -
CH-), 3.00 (dd, J = 13.7, 6.0 Hz, 1H, -CH2Ph); 
13
C-NMR (126 MHz, CDCl3) δ 171.0 (-
C=O ester), 166.7 (-C=O amide), 156.2 (-COCH3), 145.2, 136.0, 134.5, 129.5, 128.6, 
128.4, 127.9, 127.7, 127.2, 120.9, 114.7, 55.8 (-NHCH-), 52.7 (Ar-OCH3), 52.2 (-CH- 
aziridine), 48.0 (-CO2CH3), 47.1 (-CH- aziridine), 38.3 (-CH2Ph); FT-IR (thin film): υ 
(cm
-1
) = 3393 (N-H), 3033, 2961, 1745 (ester C=O), 1673 (amide C=O), 1506, 1242, 
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1033; [α]D
21
 -21.7 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 453.08 [M+Na]
+
; HRMS 
(HNESP) exact mass calculated for C26H27N2O4 requires m/z 431.1965, found m/z 
431.1973 [M+H]
+
. 
cis-(2S)-Methyl 2-(1-(4-methoxyphenyl)-3-phenylaziridine-2-carboxamido)-4-
(methylthio)butanoate (407a/b) 
 
Compound 407a/b was prepared according to the procedure for compound 416 above. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 1:1; Rf = 0.10) afforded a colourless oil whose physicochemical 
properties were consistent with those of the title compound (18 mg, 0.04 mmol, 27% 
yield). 
1
H-NMR (400 MHz, CDCl3) δ 7.46 (d, J = 7.1 Hz, 2H, Ar-H), 7.36 – 7.24 (m, 3H, Ar-H), 
7.05 – 6.96 (m, 3H, Ar-H + -NH-), 6.85 (d, J = 8.9 Hz, 2H, Ar-H), 4.35 (dt, J = 6.1, 5.6 
Hz, 1H, -NHCH-), 3.79 (s, 3H, -OCH3), 3.59 (d, J = 7.0 Hz, 1H, aziridine -CH-), 3.54 (s, 
3H, -CO2CH3), 3.13 (d, J = 7.0 Hz, 1H, aziridine -CH-), 2.38 (t, J = 7.8 Hz, 2H, -SCH2-), 
2.12 – 2.00 (m, 1H, -SCH2CH2-), 2.06 (s, 3H, -SCH3), 1.98 – 1.84 (m, 1H, -SCH2CH2-); 
13
C-NMR (126 MHz, CDCl3) δ 171.3 (-CO2CH3), 167.2 (-CONH-), 156.3 (C-OCH3), 
145.1, 134.5, 128.5, 127.9, 127.8, 121.0, 114.8, 55.8 (Ar-OCH3), 52.4 (-NHCH-), 51.1 
(aziridine -CH-), 48.1 (-CO2CH3), 46.8 (aziridine -CH-), 32.0 (-SCH2CH2-), 29.9 (-SCH2-
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), 15.6 (-SCH3); FT-IR (thin film): υ (cm
-1
) = 3312 (N-H), 2962 (C-H), 2923 (C-H), 1740 
(ester C=O), 1653 (amide C=O), 1508, 1245, 1036; [α]D
21
 -23.8 (c 1.0, CHCl3); MS 
(MALDI-TOF) m/z 452.8 [M+K]
+
; HRMS (ASAP, solid) exact mass calculated for 
C22H27N2O4S requires m/z 415.1686, found m/z 415.1687 [M+H]
+
. 
General procedure for the one-pot synthesis of peptide aziridines: 
(S)-Methyl 2-((2R,3R)-1-((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-3-
phenylaziridine-2-carboxamido)-3-phenylpropanoate (427) 
 
A 5 mL microwave vial containing crushed 4Å molecular sieves was flame-dried and 
cooled under a nitrogen atmosphere, followed by the addition of a magnetic stirrer bar. 
Benzaldehyde 228 (56 mg, 0.528 mmol, 1.1 equiv.) and (S)-phenylalanine methyl ester 
426 (91 mg, 0.508 mmol, 1 equiv.) were weighed into a sample vial, dissolved in 
chloroform (1 mL) and transferred to the microwave vial via a 2 mL syringe. The solution 
was stirred at room temperature for 1 hour before being cooled to 0 °C using an ice-water 
bath. Pyridinium triflate 347 (12 mg, 0.0524 mmol, 10 mol%) was added and the vial was 
sealed with a PTFE-lined aluminium crimp cap. (S)-Methyl 2-(2-diazoacetamido)-3-
phenylpropanoate 386 (150 mg, 0.607 mmol, 1.2 equiv.) was dissolved in chloroform (1 
mL) and added dropwise to the reaction vial via a 2 mL syringe. Effervescence indicated 
the evolution of nitrogen gas during the reaction. The reaction was allowed to warm 
slowly to room temperature. After 16 hours the mixture was filtered through a short plug 
of silica, eluting with diethyl ether, and the solvent removed in vacuo. Purification via 
flash column chromatography on silica gel (eluent: diethyl ether / petroleum ether 3:1; Rf 
= 0.17) afforded a colourless oil whose physicochemical properties were consistent with 
those of the title compound (224 mg, 0.460 mmol, 91% yield).  
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1
H-NMR (500 MHz, CDCl3) δ = 7.32-7.10 (m, 15H, Ar-H), 4.57 (dt, J = 8.2, 6.2 Hz, 1H, 
-NHCH-), 3.64 (s, 3H, -OCH3), 3.47 (s, 3H, -OCH3), 3.29 (dd, J = 13.8, 6.2 Hz, 1H, -
CH2Ph), 3.12 – 3.05 (m, 2H, -CH2Ph), 3.02 (dd, J = 13.8, 6.2 Hz, 1H, -CH2Ph), 2.90 (t, J 
= 6.6 Hz, 1H, -NCH(Bn)CO2CH3), 2.78 (d, J = 7.2 Hz, 1H, aziridine -CH-), 2.60 (d, J = 
7.2 Hz, 1H, aziridine -CH-); 
13
C-NMR (125 MHz, CDCl3) δ = 171.7 (-C=O ester), 171.3 
(-C=O ester), 166.4 (-C=O amide), 136.7, 136.1, 134.4, 129.5, 129.4, 128.6, 128.5, 128.0, 
127.6, 127.5, 127.1, 126.9, 72.5 (-NCH-), 52.7 (-NHCH-), 52.2 (-OCH3), 52.1 (-OCH3), 
47.4 (-CH- aziridine), 46.8 (-CH- aziridine), 39.2 (-CH2Ph), 38.3 (-CH2Ph); FT-IR (thin 
film, cm
-1
) υ = 3391 (N-H), 3035, 2955, 2935, 2867, 1745 (ester C=O), 1681 (amide 
C=O), 1521, 1497, 1217, 1181, 1125, 1053, 828; [α]D
20
 –48.3 (c 1.0, CHCl3); MS 
(MALDI-TOF): m/z = 509.4 [M+Na]
+
; HRMS (NSI) exact mass calculated for 
C29H31O5N2 requires m/z 487.2227, found m/z 487.2221 [M+H]
+
. 
cis-Benzyl 3-((2S)-3-methoxy-2-(2-((S)-1-methoxy-4-(methylthio)-1-oxobutan-2-
ylcarbamoyl)-3-phenylaziridin-1-yl)-3-oxopropyl)-1H-indole-1-carboxylate (428a/b) 
 
Compound 428a/b was prepared according to the procedure for compound 427. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 1:1; Rf = 0.13) afforded a colourless oil whose physicochemical 
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properties were consistent with those of a single diastereomer of the title compound (188 
mg, 0.292 mmol, 83% yield). 
1
H-NMR (500 MHz, CD3CN) δ = 8.06 (d, J = 8.0 Hz, 1H, -NH-), 7.55 (d, J = 7.7 Hz, 1H, 
Ar-H), 7.52 – 7.37 (m, 6H, Ar-H), 7.35 – 7.29 (m, 2H, Ar-H), 7.25 (t, J = 7.5, 1H, Ar-H), 
7.16 – 7.04 (m, 5H, Ar-H), 5.34 (d, J = 12.2 Hz, 1H, -CH2Ph), 5.26 (d, J = 12.2 Hz, 1H, -
CH2Ph), 4.34 (dt, J = 8.3, 5.0 Hz, 1H, -CONHCH-), 3.70 (s, 3H, -CO2CH3), 3.59 (s, 3H, -
CO2CH3), 3.32 (dd, J = 14.4, 4.9 Hz, 1H, -CH2-indole), 3.25 – 3.14 (m, 1H, -CH2-indole, 
-NCH-), 2.68 (d, J = 7.2 Hz, 1H, -CH- aziridine), 2.61 (d, J = 7.2 Hz, 1H, -CH- 
aziridine), 2.04 – 1.99 (m, 2H, -CH2SCH3), 2.07-1.98 (m, 1H, -CH2CH2SCH3), 2.03 (s, 
3H, -SCH3), 1.87 (ddt, J = 14.0, 8.2, 6.2 Hz, 1H, -CH2SCH3); 
13
C-NMR (126 MHz, 
CD3CN) δ = 173.4 (-C=O ester), 172.7 (-C=O ester), 167.3 (-C=O amide), 151.2 (-C=O 
carbamate), 136.6, 136.4, 136.3, 131.0, 129.7, 129.5, 129.3, 128.8, 128.2, 128.1, 125.7, 
125.6, 123.7, 120.2, 117.1, 115.9, 70.0 (-NCH-), 69.3 (-CH2PH), 52.8(6) (-NHCH-), 
52.8(5) (-OCH3), 51.5 (-OCH3), 48.0 (-CH- aziridine), 47.7 (-CH- aziridine), 32.6 (-
NHCHCH2-), 30.1 (-CH2S-), 29.0 (-CH2-indole), 15.3 (-SCH3); FT-IR (thin film, cm
-1
) υ 
= 3385 (N-H), 2951, 2920, 2848, 1737 (ester C=O), 1677 (amide C=O), 1519, 1455, 
1396, 1248, 1215, 1083; [α]D
23
 –41.4 (c 1.0, CHCl3); MS (MALDI-TOF): m/z = 666.5 
[M+Na]
+
; HRMS (NSI) exact mass calculated for C35H38O7N3S requires m/z 644.2425, 
found m/z 644.2440 [M+H]
+
. 
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cis-Benzyl 3-((2S)-3-methoxy-2-(1-((S)-1-methoxy-4-methyl-1-oxopentan-2-yl)-3-(4-
(trifluoromethyl)phenyl)aziridine-2-carboxamido)-3-oxopropyl)-1H-indole-1-
carboxylate (433a/b) 
 
Compound 433a/b was prepared according to the procedure for compound 427. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether / dichloromethane 3:2:1; Rf = 0.16) afforded a colourless oil whose 
physicochemical properties were consistent with those of a single diastereomer of the title 
compound (122 mg, 0.18 mmol, 51% yield). 
1
H-NMR (500 MHz, CDCl3) δ 8.16 (br s, 1H, -NH-), 7.52 (d, J = 7.8 Hz, 2H, Ar-H), 7.50 
– 7.46 (m, 2H, Ar-H), 7.43 – 7.36 (m, 5H, Ar-H), 7.34 – 7.29 (m, 4H, Ar-H), 7.28 – 7.23 
(m, 1H, Ar-H), 5.47 (d, J = 12.1, 1H, -CH2Ph), 5.43 (d, J = 12.1, 1H, -CH2Ph), 4.59 (dt, J 
= 8.0, 5.9 Hz, 1H, -CONHCH-), 3.57 (s, 3H, -CO2CH3), 3.38 (s, 3H, -CO2CH3), 3.19 (dd, 
J = 14.8, 5.8 Hz, 1H, -CH2-indole), 3.13 (dd, J = 14.8, 5.8 Hz, 1H, -CH2-indole), 3.03 (d, 
J = 7.1 Hz, 1H, -CH- aziridine), 2.67 (t, J = 6.4 Hz, 1H, -NCH-), 2.61 (d, J = 7.1 Hz, 1H, 
-CH- aziridine), 1.85 – 1.78 (m, 1H, -CH(CH3)2), 1.75 – 1.62 (m, 2H, -CH2CH(CH3)2), 
0.89 (d, J = 6.2 Hz, 3H, -CH(CH3)2), 0.88 (d, J = 6.2 Hz, 3H, -CH(CH3)2); 
19
F-NMR (471 
MHz, CDCl3) δ -62.6; 
13
C-NMR (125 MHz, CDCl3) δ 172.6 (-C=O ester), 171.4 (-C=O 
ester), 166.3 (-C=O amide), 150.9 (-C=O carbamate), 138.7, 135.2, 130.6, 129.8 (q, J = 
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32 Hz), 128.9, 128.8, 128.5, 128.0, 125.6, 125.2 (q, J = 3.7 Hz), 125.0, 124.2 (q, J = 270 
Hz, –CF3), 124.1, 123.2, 119.1, 116.0, 115.4, 68.8 (-NHCH-), 68.5 (-CH2Ph), 52.1 (-
NHCH-), 51.7 (-OCH3), 46.7 (-OCH3), 46.2 (-CH- aziridine), 42.0 (-CH- aziridine), 30.4 
(-CH2CH(CH3)2), 27.8 (-CH2-indole), 24.8 (-CH(CH3)2), 22.8 (-CH(CH3)2), 22.7 (-
CH(CH3)2); FT-IR (thin film, cm
-1
) υ = 3385 (N-H), 2956, 2872, 1747 (ester C=O), 1685 
(amide C=O), 1622, 1520, 1457, 1399, 1358, 1325, 1249, 1164, 1131, 1095, 1065, 1018; 
[α]D
20
 –48.3 (c 1.0, CHCl3); MS (MALDI-TOF): m/z = 732.55 [M+K]
+
; HRMS (NSI) 
exact mass calculated for C37H38F3O7N3 requires m/z 694.2735, found m/z 694.2730 
[M+H]
+
. 
cis-Benzyl 3-((2S)-2-(2-(9H-fluoren-2-yl)-3-((S)-1-methoxy-4-(methylthio)-1-
oxobutan-2-ylcarbamoyl)aziridin-1-yl)-3-methoxy-3-oxopropyl)-1H-indole-1-
carboxylate (436a/b) 
 
Compound 436a/b was prepared according to the procedure for compound 427. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether / dichloromethane 3:2:1; Rf = 0.16) afforded a colourless oil whose 
physicochemical properties were consistent with those of a single diastereomer of the title 
compound (204 mg, 0.279 mmol, 79% yield). 
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1
H-NMR (500 MHz, CD3CN) δ 8.02 (br s, 1H, -NH-), 7.78 (d, J = 7.6 Hz, 1H, Ar-H), 
7.60 – 7.55 (m, 4H, Ar-H), 7.39 – 7.25 (m, 8H, Ar-H), 7.22 – 7.20 (m, 2H, Ar-H), 7.17 (s, 
1H, Ar-H), 6.98 (dd, J = 7.8, 1.7 Hz, 1H, Ar-H), 5.00 (d, J = 12.2 Hz, 1H, -CH2Ph), 4.78 
(br d, J = 12.2 Hz, 1H, -CH2Ph), 4.38 (dt, J = 8.4, 4.9 Hz, 1H, -NHCH-), 3.80 (d, J = 21.0 
Hz, 1H, AB -CH2- fluorene), 3.75 (s, 3H -OCH3), 3.74 (d, J = 21.0 Hz, 1H, AB -CH2- 
fluorene), 3.57 (s, 3H, -OCH3), 3.40 – 3.32 (m, 1H, -CH2-indole), 3.27 – 3.18 (m, 2H, -
CH2-indole + -NCH-), 2.62 (d, J = 7.2 Hz, 1H, -CH- aziridine), 2.56 (d, J = 7.2 Hz, 1H, -
CH- aziridine), 2.52 – 2.42 (m, 2H, -CH2S-), 2.07-2.00 (m, 1H, -CH2CH2SCH3), 2.03 (s, 
3H, -SCH3), 1.92 – 1.86 (m, 1H, -CH2CH2SCH3); 
13
C-NMR (126 MHz, CDCl3) δ 172.3 (-
C=O ester), 172.0 (-C=O ester), 166.5 (-C=O amide), 150.1 (-C=O carbamate), 143.6, 
143.2, 141.5, 141.1, 135.7, 135.1, 133.2, 129.7, 128.6, 128.5, 128.0, 126.9, 126.8, 126.1, 
125.2, 125.0, 124.0, 123.1, 119.9, 119.3, 118.7, 115.7, 115.6, 70.0 (-NCH-), 68.3 (-
CH2Ph), 52.5 (-NHCH-), 52.3 (-OCH3), 50.9 (-OCH3), 48.2 (-CH- aziridine), 47.3 (-CH- 
aziridine), 36.8 (-CH2- fluorene), 32.2 (-NHCHCH2-), 29.7 (-CH2S-), 29.1 (-CH2-indole), 
15.5 (-SCH3); FT-IR (ATR, cm
-1
) υ = 3385 (N-H), 2925, 1737 (ester C=O), 1675 (amide 
C=O), 1519, 1455, 1398, 1253, 1212, 1088; [α]D
23
 –106.2 (c 1.0, CHCl3); MS (MALDI-
TOF): m/z = 770.4 [M+K]
+
; HRMS (NSI) exact mass calculated for C42H41O7N3SO2H 
requires m/z 764.2636, found m/z 764.2654 [M+O2+H]
+
.* 
*Oxidation of methionine and/or tryptophan residues during MS analysis are commonly 
observed. 
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cis-Ferrocenyl-(S)-methyl 2-(1-((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-3-
phenylaziridine-2-carboxamido)-4-methylpentanoate (447a/b) 
 
Compound 447a/b was prepared according to the procedure for compound 427. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 1:1; Rf = 0.19) afforded a brown oil whose physicochemical properties 
were consistent with those of a single diastereomer of the title compound (160 mg, 0.252 
mmol, 73% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.33 (d, J = 8.3 Hz, 2H, Ar-H), 7.18 – 7.13 (m, 8H, Ar-H, 
-NH-), 4.59 (t, J = 1.5 Hz, 2H, Cp-H), 4.43 (dt, J = 8.7, 5.0 Hz, 1H, -NHCH-), 4.29 (t, J = 
1.9 Hz, 2H, Cp-H), 4.03 (s, 5H, Cp-H), 3.71 (s, 3H, -CO2CH3), 3.53 (s, 3H, -CO2CH3), 
3.33 (dd, J = 13.8, 6.1 Hz, 1H, -CH2Ph), 3.13 (dd, J = 13.8, 7.2 Hz, 1H, -CH2Ph), 2.91 
(dd, J = 7.2, 6.1 Hz, 1H, -NCH-), 2.76 (d, J = 7.2 Hz, 1H, -CH- aziridine), 2.60 (d, J = 7.2 
Hz, 1H, -CH- aziridine), 1.65 – 1.51 (m, 3H, -CH2CH(CH3)2), 0.92 (d, J = 4.6 Hz, 3H, -
CH(CH3)2), 0.91 (d, J = 4.6 Hz, 3H, -CH(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 172.5 (-
C=O ester), 171.8 (-C=O ester), 166.3 (-C=O amide), 138.4, 136.6, 131.9, 129.3, 128.4, 
127.6, 126.9, 125.7, 85.2 (Cp), 72.6 (-NCH-), 69.6 (Cp), 68.8(9) (Cp), 68.8(7) (Cp), 66.6 
(Cp), 66.3 (Cp), 52.1 (-OCH3), 52.0 (-OCH3), 50.0 (-NHCH-), 47.5 (-CH- aziridine), 46.9 
(-CH- aziridine), 41.8 (-CH2CH(CH3)2), 39.1 (-CH2Ph), 24.6 (-CH(CH3)2), 22.8 (-
CH(CH3)2), 22.1 (-CH(CH3)2); FT-IR (thin film, cm
-1
) υ = 3385 (N-H), 2951, 1742 (ester 
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C=O), 1677 (amide C=O), 1522, 1437, 1204, 1104, 1026, 819; [α]D
23
 –93.1 (c 1.0, 
CHCl3); MS (MALDI-TOF): m/z = 659.6 [M+Na]
+
; HRMS (NSI): exact mass calculated 
for C36H41O5N2Fe requires m/z 635.2406, found m/z 635.2406 [M+H]
+
. 
cis-(S)-Methyl 2-(1-((S)-3-(4-(allyloxy)phenyl)-1-methoxy-1-oxopropan-2-yl)-3-
phenylaziridine-2-carboxamido)-4-methylpentanoate (429a/b) 
 
Compound 429a/b was prepared according to the procedure for compound 427. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 1:1; Rf = 0.20) afforded a colourless oil whose physicochemical 
properties were consistent with those of a single diastereomer of the title compound (320 
mg, 0.63 mmol, 73% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.25 – 7.18 (m, 5H, Ar-H), 7.15 (d, J = 8.9 Hz, 1H, -NH-), 
7.03 (d, J = 8.7 Hz, 2H, Ar-H), 6.68 (d, J = 8.7 Hz, 2H, Ar-H), 6.01 (ddt, J = 17.3, 10.5, 
5.3 Hz, 1H, -CH=CH2), 5.37 (dd, J = 17.3, 1.6 Hz, 1H, -CH=CH2), 5.26 (dd, J = 10.5, 1.4 
Hz, 1H, -CH=CH2), 4.47 – 4.37 (m, 3H, -NHCH- + -OCH2-), 3.71 (s, 3H, -OCH3), 3.53 
(s, 3H, -OCH3), 3.24 (dd, J = 13.9, 6.0 Hz, 1H, -CH2Ph), 3.05 (dd, J = 13.9, 7.3 Hz, 1H, -
CH2Ph), 2.85 (dd, J = 7.2, 6.0 Hz, 1H, -NCH-), 2.77 (d, J = 7.2 Hz, 1H, -CH- aziridine), 
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2.57 (d, J = 7.2 Hz, 1H, -CH- aziridine), 1.62 – 1.50 (m, 3H, -CH2CH(CH3)2), 0.91 (d, J = 
6.4 Hz, 3H, -CH(CH3)2), 0.90 (d, J = 6.4 Hz, 3H, -CH(CH3)2); 
13
C-NMR (126 MHz, 
CDCl3) δ 172.6 (-C=O ester), 172.0 (-C=O ester), 166.4 (-C=O amide), 157.6 (C-OAllyl), 
134.6, 133.4, 130.4, 128.9, 128.0, 127.7, 127.6, 117.7, 114.8, 72.8 (-NCH-), 68.9 (-OCH2-
), 52.2 (-OCH3), 52.1 (-OCH3), 50.1 (-NHCH-), 47.6 (-CH- aziridine), 47.0 (-CH- 
aziridine), 41.9 (-CH2CH(CH3)2), 38.4 (-CH2Ph), 24.8 (-CH(CH3)2), 22.9 (-CH(CH3)2), 
22.2 (-CH(CH3)2); FT-IR (thin film): υ (cm
-1
) = 3388, 2955, 1742, 1679, 1512, 1436, 
1244, 1204, 1027; [α]D
24
 –25.4 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 531.5 [M+Na]
+
; 
HRMS (HNESP) exact mass calculated for C29H37N2O6 requires m/z 509.2646, found m/z 
509.2637 [M+H]
+
. 
cis-(2S)-Allyl 2-(1-((S)-1-(allylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylaziridine-
2-carboxamido)-3-phenylpropanoate (430a/b) 
 
Compound 430a/b was prepared according to the procedure for compound 427. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 3:1; Rf = 0.12) afforded a colourless oil whose physicochemical 
properties were consistent with those of a single diastereomer of the title compound (78 
mg, 0.16 mmol, 53% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.38 – 7.24 (m, 6H, Ar-H), 7.20 – 7.12 (m, 3H, Ar-H + -
NH-), 6.69 – 6.64 (m, 2H, Ar-H), 6.16 (d, J = 7.5 Hz, 1H, -NH-), 5.87 – 5.70 (m, 2H, -
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CH=CH2), 5.25 – 5.17 (m, 3H, -CH=CH2), 5.13 (dd, J = 10.3, 1.4 Hz, 1H, -CH=CH2), 
4.59 (dt, J = 7.5, 6.1 Hz, 1H, -NHCH-), 4.44 (dd, J = 5.9, 1.2 Hz, 2H, -OCH2-), 3.98 – 
3.90 (m, 1H, -NCH2-), 3.84 – 3.77 (m, 1H, -NCH2-), 3.09 (d, J = 6.9 Hz, 1H, -CH- 
aziridine), 2.91 (dd, J = 13.8, 5.1 Hz, 1H, -CH2Ph), 2.72 (dd, J = 13.8, 6.2 Hz, 1H, -
CH2Ph), 2.61 (d, J = 6.9 Hz, 1H, -CH- aziridine), 2.55 (t, J = 6.5 Hz, 1H, -NCH-), 1.86 – 
1.66 (m, 3H, -CH2CH(CH3)2), 0.90 (d, J = 3.4 Hz, 3H, -CH(CH3)2), 0.89 (d, J = 3.5 Hz, 
3H, -CH(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 172.3 (-C=O ester), 170.6 (-C=O ester), 
166.3 (-C=O amide), 135.5, 134.9, 134.3, 131.4, 129.4, 128.6, 128.2, 127.5, 127.2, 119.2 
(-CH=CH2), 116.5 (-CH=CH2), 71.0 (-NCH-), 66.1 (-OCH2-), 53.1 (-NHCH-), 47.3 (-CH- 
aziridine), 46.9 (-CH- aziridine), 43.2 (-NCH2-), 41.8 (-CH2CH(CH3)2), 38.2 (-CH2Ph), 
24.7 (-CH(CH3)2), 23.1 (-CH(CH3)2), 23.0 (-CH(CH3)2); FT-IR (ATR, cm
-1
) υ = 3310 (N-
H), 3066, 3032, 2956, 2936, 2860, 1744 (ester C=O), 1662 (amide C=O), 1531, 1452, 
1422, 1384, 1367, 1342, 1322, 1260, 1191, 1092, 1027, 930; [α]D
23
 +31.1 (c 1.0, CHCl3); 
MS (MALDI-TOF): m/z = 526.3 [M+Na]
+
; HRMS (NSI) exact mass calculated for 
C30H38O4N3 requires m/z 504.2857, found m/z 504.2852 [M+H]
+
. 
Methyl 4-(ferrocenyl)benzoate (446)
254
 
 
To a 250 mL round-bottom flask was added methyl-4-aminobenzoate (5 g, 33.1 mmol, 1 
equiv.) and distilled water (16 mL). Concentrated hydrochloric acid (8 mL) was added, 
and the reaction mixture was cooled to 0 °C using an ice bath. A solution of sodium 
nitrite (2.28 g, 33.1 mmol, 1 equiv.) in distilled water (13 mL) was added dropwise via 
pipette. A colour change from pale brown to yellow indicated the formation of diazonium 
salt 444. The solution was stirred for a further 30 minutes and the temperature maintained 
at 0 °C until use. To a 250 mL round-bottom flask containing a solution of ferrocene 445 
(6.16 g, 33.1 mmol, 1 equiv.) in diethyl ether (50 mL) was added 
cetyltrimethylammonium bromide (330 mg, 0.906 mmol, 2.7 mol%).  The mixture was 
cooled to 0 °C and the aqueous solution of diazonium salt 444 was added dropwise via 
pipette. The biphasic mixture was stirred vigorously for a further two hours before being 
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diluted with diethyl ether (50 mL). Saturated aqueous sodium bicarbonate solution (50 
mL) was added, and the aqueous layer extracted with diethyl ether (2 x 100 mL). The 
combined organic layers were washed with distilled water (200 mL) and brine (150 mL), 
dried over magnesium sulfate, filtered, and the solvent removed in vacuo. Purification via 
flash column chromatography on silica gel (eluent: petroleum ether / diethyl ether 5%) 
afforded dark red crystals (3.92 g, 12.2 mmol, 37% yield); the physicochemical properties 
matched those previously reported. 
M.p. 119–121 °C (petroleum ether / diethyl ether); 1H-NMR (500 MHz, CDCl3) δ 7.94 (d, 
J = 7.6 Hz, 2H, Ar-H), 7.48 (d, J = 7.6 Hz, 2H, Ar-H), 4.77 (br s, 2H, Cp-H), 4.45 (br s, 
2H, Cp-H), 4.09 (s, 5H, Cp-H), 3.92 (s, 3H, -OCH3); FT-IR (thin film, cm
-1
) υ = 2951 (C-
H), 1715 (C=O), 1609, 1430, 1281, 1183, 1105. 
4-(Ferrocenyl)benzyl alcohol (447)
240
 
 
A flame-dried 250 mL round-bottom flask was cooled under nitrogen and charged with 
methyl 4-(ferrocenyl)benzoate 446 (290 mg, 0.91 mmol, 1 equiv.) and anhydrous toluene 
(10 mL). The resulting solution was cooled to -78 °C using a dry ice/acetone bath. 
Diisobutylaluminium hydride (1.5 mL, 1.82 mmol, 2 equiv., 1.2 M in toluene) was added 
dropwise via a 2.5 mL syringe. The reaction was allowed to warm up slowly to room 
temperature over 18 hours. Ethyl acetate (20 mL) and distilled water (20 mL) were added 
to the reaction mixture, which was stirred vigorously for a further 30 minutes. The 
aqueous layer was extracted with ethyl acetate (30 mL) and the combined organic layers 
washed with distilled water (50 mL) and subsequently brine (50 mL). The orange solution 
was dried over magnesium sulfate, filtered, and the solvent removed in vacuo to afford an 
orange solid whose physicochemical properties matched those previously reported (238 
mg, 0.82 mmol, 90% yield).  
Rf = 0.10 (9:1 petroleum ether / ethyl acetate); m.p. 104–106 °C (hexane); 
1
H-NMR (500 
MHz, CDCl3) δ = 7.48 (d, J = 8.3 Hz, 2H, Ar-H), 7.29 (d, J = 8.3 Hz, 2H, Ar-H), 4.67 (d, 
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J = 5.6 Hz, 2H, CH2OH), 4.64 (t, J = 1.9 Hz, 2H, Cp-H), 4.32 (t, J = 1.9 Hz, 2H, Cp-H), 
4.04 (s, 5H, Cp-H), 1.60 (t, J = 5.6 Hz, 1H, -OH); MS (MALDI-TOF): m/z = 292.1 [M]
+
. 
4-(Ferrocenyl)benzaldehyde (443)
254 
 
To a 100 mL round-bottom flask containing 4-(ferrocenyl)benzyl alcohol 447 (237 mg, 
0.81 mmol, 1 equiv.) dissolved in anhydrous dichloromethane (30 mL) under an 
atmosphere of nitrogen was added activated manganese dioxide (1.76 g, 20.3 mmol, 25 
equiv.). The heterogeneous mixture was stirred at room temperature for 18 hours. The 
black solid manganese dioxide was removed by filtration and the solvent removed in 
vacuo to afford a red solid that was used without further purification (202 mg, 0.70 mmol, 
86% yield); the physicochemical properties matched those previously reported for the title 
compound 443. 
M.p. 121–123 °C (hexane / ethyl acetate); 1H-NMR (500 MHz, CDCl3) δ = 9.97 (s, 1H, -
CHO), 7.79 (d, J = 8.3 Hz, 2H, Ar-H), 7.60 (d, J = 8.3 Hz, 2H, Ar-H), 4.74 (t, J = 1.9 Hz, 
2H, Cp-H), 4.44 (t, J = 1.9 Hz, 2H, Cp-H), 4.05 (s, 5H, Cp-H); MS (MALDI-TOF): m/z = 
290.05 [M]
+
. 
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cis-(2S)-Methyl 4-methyl-2-(3-phenyl-1-((R)-1-phenylethyl)aziridine-2-
carboxamido)pentanoate (455a/b) 
 
Compound 455a/b was prepared according to the procedure for compound 427. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 3:1; Rf = 0.50) afforded a colourless oil whose physicochemical 
properties were consistent with those of a single diastereomer of the title compound (154 
mg, 0.39 mmol, 91% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.0 Hz, 2H, Ar-H), 7.28 (t, J = 7.5 Hz, 2H, Ar-
H), 7.23 – 7.20 (m, 2H, Ar-H), 7.12 – 7.03 (m, 4H, Ar-H), 6.77 (br d, J = 8.6 Hz, 1H, -
NH-), 4.32 – 4.26 (m, 1H, -NHCH-), 3.40 (s, 3H, -OCH3), 3.01 (d, J = 7.1 Hz, 1H, -CH- 
aziridine), 2.85 (q, J = 6.5 Hz, 1H, -NCH-), 2.55 (d, J = 7.1 Hz, 1H, -CH- aziridine), 1.55 
– 1.39 (m, 6H, -CH3 + -CH2CH-), 0.85 (d, J = 3.5 Hz, 3H, -CH(CH3)2), 0.84 (d, J = 3.5 
Hz, 3H, -C(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 172.4 (-C=O ester), 167.5 (-C=O 
amide), 143.2, 134.9, 128.7, 128.1, 127.8, 127.7, 127.3, 127.0, 69.1 (-NCH-), 52.1 (-
NHCH-), 50.2 (-OCH3), 47.7 (-CH- aziridine), 46.7 (-CH- aziridine), 42.0 (-CH2-), 25.0 
(-CH(CH3)2), 22.9 (-CH(CH3)2), 22.8 (-CH(CH3)2), 22.4 (-CH3); FT-IR (thin film): υ (cm
-
1
) = 3392 (N-H), 3036 (C-H), 2960 (C-H), 2872 (C-H), 1744 (ester C=O), 1680 (amide 
C=O), 1516, 1452, 1372, 1328, 1260, 1204, 1156, 1100, 1028; [α]D
18
 –167.0 (c 0.5, 
CHCl3); MS (MALDI-TOF) m/z 433.4 [M+K]
+
; HRMS (HNESP) exact mass calculated 
for C24H31N2O3 requires m/z 395.2329, found m/z 395.2320 [M+H]
+
. 
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cis-Methyl 2-(2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)carbamoyl)-3-
phenylaziridin-1-yl)-2-methylpropanoate (459a/b) 
 
A 5 mL microwave vial containing crushed 4Å molecular sieves was flame-dried and 
cooled under a nitrogen atmosphere, followed by the addition of a magnetic stirrer bar. 
Benzaldehyde 228 (15 mg, 0.14 mmol, 1.1 equiv.) and methyl 2-amino-2-
methylpropanoate (15 mg, 0.13 mmol, 1 equiv.) were weighed into a sample vial and 
dissolved in chloroform-d3 (1 mL) before being transferred to the microwave vial via a 2 
mL syringe. The solution was stirred at room temperature under nitrogen for 1 hour 
before pyridinium triflate (3 mg, 0.013 mmol, 10 mol%) was added and the vial was 
sealed with a PTFE-lined aluminium crimp cap. The reaction was cooled to -30 °C using 
a chiller bath before the addition of a solution of (S)-methyl 2-(2-diazoacetamido)-3-
phenylpropanoate 386 (38 mg, 0.15 mmol, 1.2 equiv.) in chloroform-d3 (1 mL) was added 
dropwise to the reaction vial via a 2 mL syringe. The progress of the reaction was 
monitored by 
1
H-NMR until complete disappearance of the imine intermediate (~24 h). 
After being allowed to warm to room temperature, the mixture was filtered through a 
short plug of silica eluting with diethyl ether and the solvent was removed in vacuo. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 3:1; Rf = 0.19) afforded a colourless oil whose physicochemical 
properties were consistent with those of a single diastereomer of the title compound (51 
mg, 0.12 mmol, 93% yield). 
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1
H-NMR (500 MHz, CDCl3) δ 7.34 – 7.16 (m, 8H, Ar-H), 7.12 – 7.06 (m, 2H, Ar-H), 
6.94 (d, J = 7.9 Hz, 1H, -NH-), 4.51 (dt, J = 8.0, 5.9 Hz, 1H, -NHCH-), 3.68 (s, 3H, -
OCH3), 3.44 (s, 3H, -OCH3), 3.35 (d, J = 6.9 Hz, 1H, -CH- aziridine), 3.07 (dd, J = 13.8, 
6.1 Hz, 1H, -CH2Ph), 2.99 (dd, J = 13.8, 5.7 Hz, 1H, -CH2Ph), 2.86 (d, J = 6.9 Hz, 1H, -
CH- aziridine), 1.36 (s, 3H, -CH3), 1.34 (s, 3H, -CH3); 
13
C-NMR (126 MHz, CDCl3) δ 
173.8 (-C=O ester), 171.1 (-C=O ester), 167.3 (-C=O amide), 136.0, 134.9, 129.4, 128.6, 
128.1, 127.8, 127.4, 127.1, 61.4 (-NC-), 52.5 (-NHCH-), 52.2 (-OCH3), 52.1 (-OCH3), 
42.1 (-CH- aziridine), 41.6 (-CH- aziridine), 38.1 (-CH2Ph), 23.7 (-CH3), 22.9 (-CH3); 
FT-IR (thin film): υ (cm-1) = 3384 (N-H), 3062, 3033, 2990, 2953, 1738 (ester C=O), 
1676 (amide C=O), 1512, 1450, 1366, 1279, 1195, 1147, 1078, 1031; [α]D
23
 –31.7 (c 1.0, 
CHCl3); MS (MALDI-TOF) m/z 462.9 [M+K]
+
; HRMS (HNESP) exact mass calculated 
for C24H29N2O5 requires m/z 425.2071, found m/z 425.2069 [M+H]
+
. 
 
cis-Methyl 2-(1-((R)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-3-phenylaziridine-2-
carboxamido)-2-methylpropanoate (457a/b) 
 
Compound 457a/b was prepared according to the procedure for compound 459 above. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether / 
petroleum ether 3:1; Rf = 0.14) afforded a colourless oil whose physicochemical 
properties were consistent with those of a single diastereomer of the title compound (76 
mg, 0.18 mmol, 80% yield). 
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1
H-NMR (500 MHz, CDCl3) δ 7.38 – 7.23 (m, 10H, Ar-H), 3.83 (s, 3H, -OCH3), 3.68 (s, 
3H, -OCH3), 3.42 (dd, J = 13.9, 6.1 Hz, 1H, -CH2Ph), 3.22 (dd, J = 13.9, 7.1 Hz, 1H, -
CH2Ph), 3.04 (dd, J = 7.0, 6.3 Hz, 1H, -NCH-), 2.93 (d, J = 7.2 Hz, 1H, -CH- aziridine), 
2.63 (d, J = 7.2 Hz, 1H, -CH- aziridine), 1.32 (s, 3H, -CH3), 1.28 (s, 3H, -CH3); 
13
C-NMR 
(126 MHz, CDCl3) δ 174.8 (-C=O ester), 171.9 (-C=O ester), 166.0 (-C=O amide), 136.8, 
134.7, 129.4, 128.5, 127.9, 127.8, 127.6, 127.0, 72.1 (-NCH-), 55.8 (-C(CH3)2), 52.5 (-
OCH3), 52.3 (-OCH3), 46.9 (-CH- aziridine), 46.6 (-CH- aziridine), 39.2 (-CH2Ph), 24.7 (-
CH3), 24.0 (-CH3); FT-IR (thin film): υ (cm
-1
) = 3585 (N-H), 3375 (N-H), 3032, 2991, 
2953, 2857, 1741 (ester C=O), 1676 (amide C=O), 1521, 1456, 1439, 1384, 1363, 1291, 
1264, 1212, 1195, 1154, 1119, 1027; [α]D
23
 –39.2 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 
462.9 [M+K]
+
; HRMS (HNESP) exact mass calculated for C24H29N2O5 requires m/z 
425.2071, found m/z 425.2070 [M+H]
+
. 
(S)-Methyl 2-(2-(tert-butoxycarbonylamino)-2-methylpropanamido)-3-
phenylpropanoate (461)
251
 
 
A 250 mL round-bottom flask was charged with 2-((tert-butoxycarbonyl)amino)-2-
methylpropanoic acid (1 g, 4.92 mmol, 1 equiv.) and the solid dissolved in a mixture of 
dichloromethane and N,N-dimethylformamide (5:1, 30 mL) under a nitrogen atmosphere. 
(S)-Phenylalanine methyl ester hydrochloride (1.27 g, 5.90 mmol, 1.2 equiv.) was added 
in one portion, followed by the addition of N,N-diisopropylethylamine (3.9 mL, 22.1 
mmol, 4.5 equiv.) via a 10 mL syringe. The solution was stirred at room temperature for 
18 hours before the addition of distilled water (40 mL). The reaction mixture was 
extracted with dichloromethane (2 x 40 mL) and the combined organic layers washed 
with brine (50 mL), dried over magnesium sulfate, filtered, and the solvent removed in 
vacuo. Purification via flash column chromatography on silica gel (eluent: 
dichloromethane / ethyl acetate 9:1; Rf = 0.33) afforded a white solid whose 
physicochemical properties matched those previously reported (1.29 g, 3.54 mmol, 72% 
yield). 
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M.p. 139–140 °C; 1H-NMR (500 MHz, CDCl3) δ 7.30 – 7.20 (m, 3H, Ar-H), 7.14 – 7.09 
(m, 2H, Ar-H), 6.85 (br s, 1H, -NH-), 4.87 (br s, 1H, -NH-), 4.85 (dt, J = 7.6, 5.9 Hz, 1H, 
-NHCH-), 3.69 (s, 3H, -OCH3), 3.17 – 3.07 (m, 2H, -CH2Ph), 1.45 (s, 3H, -C(CH3)2), 
1.42 (s, 12H, -C(CH3)2 + -C(CH3)3); FT-IR (thin film, cm-1) υ = 3319 (N-H), 2979 (C-H), 
2932 (C-H), 1750 (C=O ester), 1688 (C=O carbamate), 1656 (C=O amide), 1519, 1285, 
1167, 1085. 
(S)-Methyl 2-(2-amino-2-methylpropanamido)-3-phenylpropanoate (462)
252
 
 
A 250 mL round-bottom flask was charged with a solution of (S)-methyl 2-(2-(tert-
butoxycarbonylamino)-2-methylpropanamido)-3-phenylpropanoate 461 (1.29 g, 3.54 
mmol, 1 equiv.) in dichloromethane (30 mL) under a nitrogen atmosphere. Trifluoroacetic 
acid (2.5 mL, 28.3 mmol, 8 equiv.) was added dropwise via a 5 mL syringe and the 
solution stirred at room temperature for 8 hours or until complete disappearance of the 
starting material was observed by thin layer chromatography (eluent: dichloromethane / 
ethyl acetate 9:1). The reaction was cooled to 0 °C using an ice bath, and triethylamine 
(3.9 mL, 28.3 mmol, 8 equiv.) added via a 5 mL syringe. After stirring at room 
temperature for 10 minutes, the solution was diluted with distilled water (40 mL) and the 
organics extracted with dichloromethane (2 x 30 mL). The combined organic layers were 
washed with distilled water (2 x 50 mL) and brine (50 mL), and filtered. The solvent was 
removed in vacuo to afford a yellow oil which was used without further purification (725 
mg, 2.74 mmol, 77% yield); the physicochemical properties were consistent with those 
previously reported for the title compound. 
1
H-NMR (500 MHz, CDCl3) δ 7.98 (br d, J = 7.6 Hz, 1H, -NH-), 7.31 – 7.21 (m, 3H, Ar-
H), 7.15 – 7.11 (m, 2H, Ar-H), 4.83 – 4.78 (m, 1H, -NHCH-), 3.72 (s, 3H, -OCH3), 3.17 
(dd, J = 13.9, 5.8 Hz, 1H, -CH2-), 3.06 (dd, J = 13.9, 6.9 Hz, 1H, -CH2-), 1.47 (s, 2H, -
NH2), 1.32 (s, 3H, -C(CH3)2), 1.25 (s, 3H, -C(CH3)2); FT-IR (thin film, cm
-1
) υ = 3358 
(N-H), 3028 (C-H), 2960 (C-H), 2931 (C-H), 2867 (C-H), 1738 (ester C=O), 1667 (amide 
C=O), 1493, 1451, 1358, 1180, 1079; [α]D
21
 +50.1 (c 1.0, CHCl3). 
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(S)-Methyl 2-(2-(2-bromoacetamido)-2-methylpropanamido)-3-phenylpropanoate 
(463) 
 
Compound 463 was prepared according to the general procedure described above. 
Purification via flash column chromatography on silica gel (eluent: diethyl ether 100%; Rf 
= 0.23) afforded a white solid (514 mg, 1.34 mmol, 68% yield) whose physicochemical 
properties were consistent with those of the title compound. 
M.p. 128–130 °C (diethyl ether); 1H-NMR (500 MHz, CDCl3) δ 7.34 – 7.22 (m, 3H, Ar-
H), 7.17 – 7.07 (m, 3H, Ar-H + -NH-), 6.50 (br d, J = 7.5 Hz, 1H, -NH-), 4.85 (dt, J = 
7.6, 5.8 Hz, 1H, -NHCH-), 3.79 (s, 2H, -CH2Br), 3.75 (s, 3H, -OCH3), 3.19 (dd, J = 13.9, 
5.7 Hz, 1H, -CH2Ph), 3.11 (dd, J = 13.9, 6.0 Hz, 1H, -CH2Ph), 1.55 (s, 3H, -C(CH3)2), 
1.53 (s, 3H, -C(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 173.5 (C=O amide), 171.9 (C=O 
amide), 165.2 (C=O ester), 135.8, 129.4, 128.7, 127.4, 57.7 (-C(CH3)2), 53.5 (-NHCH-), 
52.6 (-OCH3), 37.8 (-CH2Ph), 29.4 (-CH2Br), 24.7 (-C(CH3)2), 24.6 (-C(CH3)2); FT-IR 
(thin film): υ (cm-1) = 3303 (N-H), 2931 (C-H), 2863 (C-H), 1734 (C=O), 1658 (C=O), 
1544, 1493, 1455, 1219, 1117, 1058; [α]D
19
 +42.2 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 
407.2, 409.2 [M+Na]
+
; HRMS (HNESP) exact mass calculated for C16H22BrN2O4 
requires m/z 385.0757, 387.0737 found m/z 385.0762, 387.0740 [M+H]
+
. 
(S)-Methyl 2-(2-(2-diazoacetamido)-2-methylpropanamido)-3-phenylpropanoate 
(464) 
 
Compound 464 was prepared according to method A. Purification via flash column 
chromatography on silica gel (eluent: diethyl ether 100%; Rf = 0.17) afforded a pale 
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yellow solid whose physicochemical properties were consistent with those of the title 
compound (548 mg, 1.62 mmol, 68% yield). 
M.p. 136–138 °C; 1H-NMR (500 MHz, CDCl3) δ 7.33 – 7.21 (m, 3H, Ar-H), 7.14 – 7.10 
(m, 2H, Ar-H), 6.79 (d, J = 7.5 Hz, 1H, -NH-), 5.61 (s, 1H, -NH-), 4.84 (dt, J = 7.6, 5.9 
Hz, 1H, -NHCH-), 4.69 (s, 1H, -CHN2), 3.74 (s, 3H, -OCH3), 3.17 (dd, J = 13.9, 5.6 Hz, 
1H, -CH2Ph), 3.11 (dd, J = 13.9, 6.2 Hz, 1H, -CH2Ph), 1.53 (s, 3H, -C(CH3)2), 1.51 (s, 
3H, -C(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 174.2 (C=O ester), 172.1 (C=O amide), 
165.3 (C=O amide), 135.9, 129.5, 128.6, 127.3, 57.9 (-C(CH3)2), 53.5 (-NHCH-), 52.5 (-
OCH3), 48.1 (-CHN2), 37.9 (-CH2Ph), 25.9 (-C(CH3)2), 25.4 (-C(CH3)2); FT-IR (thin 
film): υ (cm-1) = 3389 (N-H), 3252 (N-H), 3059, 2973, 2929, 2112 (diazo C=N2), 1734 
(ester C=O), 1648 (amide C=O), 1631 (amide C=O), 1542, 1470, 1435, 1380, 1356, 
1343, 1246, 1216, 1198, 1164, 1016, 972; [α]D
20
 +51.7 (c 1.0, CHCl3); MS (MALDI-
TOF) m/z 370.8 [M+K]
+
; HRMS (HNESP) exact mass calculated for C16H21N4O4 requires 
m/z 333.1557, found m/z 333.1557 [M+H]
+
. 
 
cis-Methyl 2-(2-((1-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-1-
oxopropan-2-yl)carbamoyl)-3-phenylaziridin-1-yl)-2-methylpropanoate (460a and 
460b) 
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Compound 460a and 460b were prepared according to the procedure for compound 459 
above. Purification via flash column chromatography on silica gel (eluent: diethyl ether 
100%) afforded two separable diastereomers, (S,S,S)-460a and (R,R,S)-460b as colourless 
oils whose physicochemical properties were consistent with those of the title compound.  
 Rf = 0.60 (diethyl ether 100%); 261 mg, 0.51 mmol, 60% yield; 
1
H-NMR (500 MHz, 
CDCl3) δ 7.39 – 7.36 (m, 2H, Ar-H), 7.31 – 7.18 (m, 6H, Ar-H), 7.12 – 7.08 (m, 2H, Ar-
H), 6.84 (d, J = 7.9 Hz, 1H, -NH-), 4.71 – 4.63 (m, 1H, -NHCH-), 3.68 (s, 3H, -OCH3), 
3.67 (s, 3H, -OCH3), 3.37 (d, J = 6.9 Hz, 1H, -CH- aziridine), 3.06 (dd, J = 13.9, 5.8 Hz, 
1H, -CH2Ph), 2.98 (dd, J = 13.8, 6.8 Hz, 1H, -CH2Ph), 2.77 (d, J = 6.9 Hz, 1H, -CH- 
aziridine), 1.43 (s, 3H, -CH3), 1.30 (s, 3H, -CH3), 1.05 (s, 3H, -CH3), 0.92 (s, 3H, -CH3); 
13
C-NMR (126 MHz, CDCl3) δ 174.3 (-C=O ester), 173.8 (-C=O ester), 172.0 (-C=O 
amide), 167.7 (-C=O amide), 136.3, 135.2, 129.5, 128.5, 128.3, 128.0, 127.8, 127.0, 61.3 
(-NC-), 56.7 (-NHC-), 53.4 (-NHCH-), 52.4 (-OCH3), 52.2 (-OCH3), 41.4 (-CH- 
aziridine), 41.3 (-CH- aziridine), 37.9 (-CH2Ph), 25.9 (-CH3), 24.5 (-CH3), 23.3 (-CH3), 
21.4 (-CH3); FT-IR (thin film): υ (cm
-1
) = 3341 (N-H), 3066, 3033, 2985, 2952, 1743 
(ester C=O), 1670 (amide C=O), 1512, 1457, 1388, 1366, 1278, 1212, 1150, 1029; [α]D
21
 
+61.1 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 547.76 [M+K]
+
; HRMS (HNESP) exact 
mass calculated for C28H36N3O6 requires m/z 510.2599, found m/z 510.2589 [M+H]
+
. 
 
Rf = 0.36 (diethyl ether 100%); 126 mg, 0.25 mmol, 29% yield; 
1
H-NMR (500 MHz, 
CDCl3) δ 7.39 – 7.34 (m, 2H, Ar-H), 7.30 – 7.18 (m, 6H, Ar-H), 7.13 – 7.05 (m, 3H, Ar-
H + -NH-), 4.68 (dt, J = 7.2, 6.2 Hz, 1H, -NHCH-), 3.68 (s, 3H, -OCH3), 3.68 (s, 3H, -
OCH3), 3.36 (d, J = 6.9 Hz, 1H, -CH- aziridine), 3.10 (dd, J = 13.8, 5.7 Hz, 1H, -CH2Ph), 
2.96 (dd, J = 13.8, 6.8 Hz, 1H, -CH2Ph), 2.75 (d, J = 6.9 Hz, 1H, -CH- aziridine), 1.42 (s, 
3H, -CH3), 1.31 (s, 3H, -CH3), 1.06 (s, 3H, -CH3), 0.97 (s, 3H, -CH3); 
13
C-NMR (126 
MHz, CDCl3) δ 174.3 (-C=O ester), 174.0 (-C=O ester), 172.0 (-C=O amide), 167.8 (-
C=O amide), 136.5, 135.2, 129.5, 128.5, 128.3, 127.9, 127.8, 127.0, 61.3 (-NC-), 56.9 (-
NHC-), 53.7 (-NHCH-), 52.4 (-OCH3), 52.3 (-OCH3), 41.4 (-CH- aziridine), 41.3 (-CH- 
aziridine), 37.9 (-CH2Ph), 25.9 (-CH3), 24.4 (-CH3), 23.4 (-CH3), 21.6 (-CH3); FT-IR 
(thin film): υ (cm-1) = 3341 (N-H), 3033, 2989, 2952, 2864, 1739 (ester C=O), 1666 
(amide C=O), 1512, 1450, 1388, 1366, 1278, 1208, 1150, 1029; [α]D
21
 -5.1 (c 1.0, 
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CHCl3); MS (MALDI-TOF) m/z 547.81 [M+K]
+
; HRMS (HNESP) exact mass calculated 
for C28H36N3O6 requires m/z 510.2599, found m/z 510.2588 [M+H]
+
. 
(S)-Methyl 2-((S)-2-acetoxy-3-phenylpropanamido)-3-phenylpropanoate (468) 
 
A 150 mL round-bottom flask containing (S)-2-acetoxy-3-phenylpropanoic acid 467 (500 
mg, 2.40 mmol, 1 equiv.) under a nitrogen atmosphere was charged with dichloromethane 
(25 mL), N,N-dimethylformamide (5 mL) and a magnetic stirrer bar. (S)-Phenylalanine 
methyl ester hydrochloride (621 mg, 2.88 mmol, 1.2 equiv.) and N,N,N′,N′-tetramethyl-O-
(benzotriazol-1-yl)uronium tetrafluoroborate (1.08 g, 3.36 mmol, 1.4 equiv.) were added 
in one portion, followed by the addition of N,N-diisopropylethylamine (0.4 mL, 10.8 
mmol, 4.5 equiv.) dropwise via a 1 mL syringe. The solution was stirred at room 
temperature for 18 hours before the addition of distilled water (30 mL). The mixture was 
extracted with dichloromethane (3 x 30 mL), washed with water (60 mL) and brine (60 
mL). The organic phase was dried over magnesium sulfate, filtered and the solvent 
removed in vacuo. Purification via flash column chromatography on silica gel (eluent: 
dichloromethane / ethyl acetate 10%; Rf = 0.60) afforded a pale yellow oil whose 
physicochemical properties were consistent with those of the title compound (340 mg, 
0.92 mmol, 38% yield).   
1
H-NMR (500 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H, Ar-H), 7.25 – 7.20 (m, 4H, Ar-H), 
7.20 – 7.17 (m, 2H, Ar-H), 6.87 – 6.82 (m, 2H, Ar-H), 6.38 (d, J = 8.2 Hz, 1H, -NH-), 
5.37 (dd, J = 6.6, 4.8 Hz, 1H, AcOCH-), 4.85 (dt, J = 8.1, 5.5 Hz, 1H, -NHCH-), 3.68 (s, 
3H, -CO2CH3), 3.19 (dd, J = 14.3, 4.7 Hz, 1H, -CH2Ph), 3.12 (dd, J = 14.3, 6.7 Hz, 1H, -
CH2Ph), 3.07 (dd, J = 13.8, 5.2 Hz, 1H, -CH2Ph), 2.93 (dd, J = 13.8, 5.8 Hz, 1H, -
CH2Ph), 2.03 (s, 3H, CH3CO2-); 
13
C-NMR (126 MHz, CDCl3) δ 171.5 (-C=O ester), 
169.4 (-C=O ester), 168.5 (-C=O amide), 135.9, 135.5, 129.9, 129.4, 128.64, 128.56, 
127.3, 127.2, 74.2 (AcOCH-), 52.6, 52.5, 38.1 (-CH2Ph), 37.6 (-CH2Ph), 21.0 (CH3CO2-); 
FT-IR (thin film, cm
-1) υ = 3323 (N-H), 3030 (C-H), 2955 (C-H), 1746 (ester C=O), 1684 
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(amide C=O), 1531, 1457, 1371, 1226; [α]D
22
 +52.1 (c 1.0, CHCl3); MS (MALDI-TOF): 
m/z = 392.2 [M + Na]
+
; HRMS (HNESP): exact mass calculated for C21H24O5N requires 
m/z 370.1649, found m/z 370.1653 [M+H]
+
. 
(S)-Methyl 2-((S)-2-acetoxy-3-phenylpropanamido)-3-phenylpropanoate (468) and 
(S)-methyl 2-((R)-2-acetoxy-3-phenylpropanamido)-3-phenylpropanoate (473) 
  
 
Compounds 468 and 473 were prepared according to the procedure for compound 468 
above. Purification via flash column chromatography on silica gel (eluent: 
dichloromethane / ethyl acetate (10 %) Rf = 0.61) afforded an inseparable mixture of two 
diastereomers 468 and 473 as a white solid whose physicochemical properties were 
consistent with those of the title compounds (318 mg, 0.86 mmol, 75% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.33 – 7.15 (m, 16H, Ar-H), 7.00 – 6.96 (m, 2H, Ar-H), 
6.87 – 6.82 (m, 2H, Ar-H), 6.39 (d, J = 7.9 Hz, 1H, -NH-), 6.34 (d, J = 7.6 Hz, 1H, -NH-), 
5.40 – 5.35 (m, 2H, AcOCH-), 4.90 – 4.83 (m, 2H, -NHCH-), 3.72 (s, 3H, -CO2CH3), 
3.68 (s, 3H, -CO2CH3), 3.24 – 2.99 (m, 7H, -CH2Ph), 2.93 (dd, J = 13.8, 5.9 Hz, 1H, -
CH2Ph), 2.02 (s, 3H, CH3CO2-), 1.96 (s, 3H, CH3CO2-); 
13
C-NMR (126 MHz, CDCl3) δ 
171.5 (-C=O), 171.5 (-C=O), 169.4 (-C=O), 169.4 (-C=O), 168.9 (-C=O), 168.5 (-C=O), 
136.0, 135.9, 135.5(1), 135.4(7), 129.9, 129.6, 129.4, 128.7, 128.6, 128.5(3), 128.5(2), 
127.4, 127.3, 127.2, 127.1, 74.3 (AcOCH-), 74.2 (AcOCH-), 52.7, 52.6, 52.5(2), 52.4(5), 
38.0 (-CH2Ph), 37.9 (-CH2Ph), 37.8 (-CH2Ph), 37.6 (-CH2Ph), 20.9 (CH3CO2-), 20.8 
(CH3CO2-); FT-IR (thin film): υ (cm
-1
) = 3327 (N-H), 3066 (C-H), 3032 (C-H), 2949 (C-
H), 2850 (C-H), 1748 (ester C=O), 1679 (amide C=O), 1528, 1497, 1452, 1439, 1370, 
1219, 1119, 1061; MS (MALDI-TOF) m/z 392.2 [M+Na]
+
. 
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(S)-Methyl 2-((S)-2-acetoxy-3-phenylpropanamido)-4-methylpentanoate (476) 
 
Compound 476 was prepared according to the procedure for compound 468. Purification 
via flash column chromatography on silica gel (eluent: dichloromethane / ethyl acetate 
(5%) Rf = 0.31) afforded a colourless oil whose physicochemical properties were 
consistent with a mixture of 476 and 477 in a diastereomeric ratio (S,S/R,S) of 8:1 by 
1
H-
NMR (491 mg, 1.46 mmol, 61% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.29 – 7.20 (m, 3H, Ar-H), 7.20 – 7.14 (m, 2H, Ar-H), 
6.31 (d, J = 8.5 Hz, 1H, -NH-), 5.40 (dd, J = 6.3, 4.8 Hz, 1H, AcOCH-), 4.62 – 4.56 (m, 
1H, -NHCH-), 3.70 (s, 3H, -CO2CH3), 3.20 (dd, J = 14.3, 4.8 Hz, 1H, -CH2Ph), 3.15 (dd, 
J = 14.3, 6.3 Hz, 1H, -CH2Ph), 2.12 (s, 3H, CH3CO2-), 1.57 – 1.49 (m, 1H, -
CH2CH(CH3)2), 1.45 – 1.32 (m, 2H, -CH2CH(CH3)2 + -CH(CH3)2), 0.87 (d, J = 6.5 Hz, 
3H, -CH(CH3)2), 0.85 (d, J = 6.5 Hz, 3H, -CH(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 
173.2 (-C=O), 169.4 (-C=O), 168.6 (-C=O), 135.8, 129.8, 128.5, 127.1, 74.3 (AcOCH-), 
52.5, 50.4, 41.7, 37.6, 24.6 (-CH(CH3)2), 22.8 (-CH(CH3)2), 22.0 (-CH(CH3)2), 21.1 
(CH3CO2-); FT-IR (thin film): υ (cm
-1
) = 3319 (N-H), 2959 (C-H), 1750 (ester C=O), 
1668 (amide C=O), 1535, 1371, 1226, 1066; [α]D
24– 3.2 (c 0.5, CHCl3); MS (MALDI-
TOF) m/z 374.39 [M+K]
+
; HRMS (HNESP) exact mass calculated for C18H26NO5 
requires m/z 336.1807, found m/z 336.1805 [M+H]
+
. 
(S)-Methyl 2-((S)-2-acetoxy-3-phenylpropanamido)-4-methylpentanoate (476) and 
(S)-methyl 2-((R)-2-acetoxy-3-phenylpropanamido)-4-methylpentanoate (477) 
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Compounds 476 and 477 were prepared according to the procedure for compound 468. 
Purification via flash column chromatography on silica gel (eluent: dichloromethane / 
ethyl acetate 5%; Rf = 0.31) afforded an inseparable mixture of two diastereomers 476 
and 477 as a colourless oil whose physicochemical properties were consistent with those 
of the title compound (540 mg, 1.61 mmol, 67% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.24 – 7.08 (m, 10H, Ar-H), 6.27 – 6.20 (m, 2H, -NH-), 
5.37 – 5.29 (m, 2H, AcOCH-), 4.56 – 4.50 (m, 2H, -NHCH-), 3.65 (s, 3H, -CO2CH3), 
3.64 (s, 3H, -CO2CH3), 3.17 (dd, J = 14.2, 5.0 Hz, 1H, -CH2Ph), 3.14 – 3.06 (m, 2H, -
CH2Ph), 3.02 (dd, J = 14.2, 7.7 Hz, 1H, -CH2Ph), 2.06 (s, 3H, CH3CO2-), 2.00 (s, 3H, 
CH3CO2-), 1.59 – 1.25 (m, 6H, -CH2CH(CH3)2), 0.83 (d, J = 4.4 Hz, 3H, -CH(CH3)2), 
0.82 (d, J = 4.4 Hz, 3H, -CH(CH3)2), 0.81 (d, J = 6.5 Hz, 3H, -CH(CH3)2), 0.79 (d, J = 6.5 
Hz, 3H, -CH(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 173.2 (-C=O), 173.0 (-C=O), 169.6 
(-C=O), 169.4 (-C=O), 169.0 (-C=O), 168.6 (-C=O), 136.0, 135.8, 129.8, 129.6, 128.5(2), 
128.4(6), 127.1, 127.0, 74.4 (AcOCH-), 74.3 (AcOCH-), 52.5, 50.6, 50.4, 41.7(3), 
41.6(7), 37.8, 37.6, 24.9 (-CH(CH3)2), 24.6 (-CH(CH3)2), 22.8 (-CH(CH3)2), 22.1 (-
CH(CH3)2), 22.0 (-CH(CH3)2), 21.1 (CH3CO2-), 20.9 (CH3CO2-); MS (MALDI-TOF) m/z 
358.6 [M+Na]
+
. 
(S)-Methyl 2-(2-acetoxy-3-phenylpropanamido)-2-methylpropanoate (474) 
 
Compound 474 was prepared according to the procedure for compound 468. Purification 
via flash column chromatography on silica gel (eluent: dichloromethane / ethyl acetate 
10%; Rf = 0.56) afforded a colourless oil whose physicochemical properties were 
consistent with those of the title compound (374 mg, 1.22 mmol, 51% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.30 – 7.21 (m, 3H, Ar-H), 7.20 – 7.16 (m, 2H, Ar-H), 
6.62 (s, 1H, -NH-), 5.32 (dd, J = 6.7, 5.0 Hz, 1H, AcOCH-), 3.73 (s, 3H, -CO2CH3), 3.20 
(dd, J = 14.3, 5.0 Hz, 1H, -CH2Ph), 3.13 (dd, J = 14.3, 6.7 Hz, 1H, -CH2Ph), 2.10 (s, 3H, -
CH3CO2-), 1.52 (s, 3H, -C(CH3)2), 1.48 (s, 3H, -C(CH3)2); 
13
C-NMR (126 MHz, CDCl3) 
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δ 175.1 (-C=O), 169.5 (-C=O), 168.2 (-C=O), 136.0, 129.8, 128.5, 127.0, 74.4 (AcOCH-), 
56.8, 52.9, 37.6, 24.5 (-C(CH3)2), 24.3 (-C(CH3)2), 21.1 (CH3CO2-); FT-IR (thin film): υ 
(cm
-1
) = 3335 (N-H), 3034 (C-H), 2991 (C-H), 2955 (C-H), 1746 (ester C=O), 1676 
(amide C=O), 1531, 1453, 1371, 1230, 1152, 1070; [α]D
20– 10.7 (c 1.0, CHCl3); MS 
(MALDI-TOF) m/z 346.1 [M+K]
+
; HRMS (HNESP) exact mass calculated for 
C16H21NO5 requires m/z 308.1492, found m/z 308.1496 [M+H]
+
. 
(S)-Methyl 2-((S)-2-acetoxy-3-phenylpropanamido)-4-(methylthio)butanoate (475) 
 
Compound 475 was prepared according to the procedure for compound 468. Purification 
via flash column chromatography on silica gel (eluent: dichloromethane / ethyl acetate 
10%; Rf = 0.44) afforded a colourless oil whose physicochemical properties were 
consistent with those of the title compound (302 mg, 0.85 mmol, 36% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.31 – 7.22 (m, 3H, Ar-H), 7.19 – 7.15 (m, 2H, Ar-H), 
6.65 (d, J = 7.7 Hz, 1H, -NH-), 5.41 (t, J = 5.4 Hz, 1H, AcOCH-), 4.68 – 4.63 (m, 1H, -
NHCH-), 3.73 (s, 3H, -CO2CH3), 3.19 (d, J = 5.9 Hz, 2H, -CH2Ph), 2.31 – 2.16 (m, 2H, -
CH2S-), 2.14 (s, 3H, CH3CO2-), 2.07 – 2.00 (m, 1H, -CH2CH2S-), 2.03 (s, 3H, -SCH3), 
1.93 – 1.84 (m, 1H, -CH2CH2S-); 
13
C-NMR (126 MHz, CDCl3) δ 172.1 (-C=O), 169.4 (-
C=O), 168.8 (-C=O), 135.7, 129.8, 128.5, 127.2, 74.3 (AcOCH-), 52.8, 51.3, 37.6 (-
CH2Ph), 31.4 (-CH2CH2S-), 29.6 (-CH2S-), 21.1 (CH3CO2-), 15.4 (-SCH3); FT-IR (thin 
film): υ (cm-1) = 3324 (N-H), 3030 (C-H), 2955 (C-H), 2921 (C-H), 2856 (C-H), 1746 
(ester C=O), 1674 (amide C=O), 1531, 1439, 1374, 1227, 1063; [α]D
20
 + 20.5 (c 1.0, 
CHCl3); MS (MALDI-TOF) m/z 376.3 [M+Na]
+
, 392.3 [M+K]
+
; HRMS (HNESP) exact 
mass calculated for C17H24NO5S requires m/z 354.1370, found m/z 354.1372 [M+H]
+
. 
 
    Experimental Section  
207 
 
(S)-Methyl 2-((S)-2-acetoxy-3-phenylpropanamido)-4-(methylthio)butanoate (475) 
and (S)-methyl 2-((R)-2-acetoxy-3-phenylpropanamido)-4-(methylthio)butanoate 
(491) 
 
Compounds 475 and 491 were prepared according to the procedure for compound 468. 
Purification via flash column chromatography on silica gel (eluent: dichloromethane / 
ethyl acetate 10%; Rf = 0.44) afforded a colourless oil whose physicochemical properties 
were consistent with those of the title compound (441 mg, 1.25 mmol, 52% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.26 (s, 6H, Ar-H), 7.21 – 7.16 (m, 4H, Ar-H), 6.65 (d, J = 
7.3 Hz, 2H, -NH-), 5.41 (t, J = 5.4 Hz, 1H, AcOCH-), 5.39 – 5.36 (m, 1H, AcOCH-), 4.69 
– 4.63 (m, 2H, -NHCH-), 3.74 (s, 3H, -CO2CH3), 3.73 (s, 3H, -CO2CH3), 3.24 (dd, J  = 
14.2, 4.9 Hz, 1H, -CH2Ph), 3.19 (d, J = 5.8 Hz, 2H, -CH2Ph), 3.09 (dd, J = 14.1, 7.7 Hz, 
1H, -CH2Ph), 2.39 (m, 1H, -CH2S-), 2.30 – 2.16 (m, 2H, -CH2S-), 2.14 (s, 3H, CH3CO2-), 
2.13 – 2.09 (m, 1H, -CH2S-), 2.09 (s, 3H, CH3CO2-), 2.06 (s, 3H, -SCH3), 2.05 – 2.00 (m, 
4H, -SCH3 + -CH2CH2S-), 1.96 (m, 2H, -CH2CH2S-), 1.88 (m, 1H, -CH2CH2S-); 
13
C-
NMR (126 MHz, CDCl3) δ 172.1 (-C=O), 172.0 (-C=O), 169.7 (-C=O), 169.4 (-C=O), 
169.1 (-C=O), 168.8 (-C=O), 136.0, 135.7, 129.9, 129.6, 128.6, 128.6, 127.2, 127.1, 74.5 
(AcOCH-), 74.3 (AcOCH-), 52.8, 51.5, 51.3, 37.8 (-CH2Ph), 37.6 (-CH2Ph), 31.4(4) (-
CH2CH2S-), 31.3(5) (-CH2CH2S-), 30.0 (-CH2S-), 29.6 (-CH2S-), 21.1 (CH3CO2-), 21.0 
(CH3CO2-), 15.6 (-SCH3), 15.4 (-SCH3); FT-IR (thin film): υ (cm
-1
) = 3326 (N-H), 2950 
(C-H), 2923 (C-H), 2852 (C-H), 1745 (ester C=O), 1677 (amide C=O), 1528, 1437, 1376, 
1227, 1061; MS (MALDI-TOF) m/z 376.33 [M+Na]
+
, 392.34 [M+K]
+
. 
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(S)-Methyl 2-((S)-2-hydroxy-3-phenylpropanamido)-3-phenylpropanoate (469) 
 
A 150 mL round-bottom flask containing (S)-methyl 2-((S)-2-acetoxy-3-
phenylpropanamido)-3-phenylpropanoate 468 (320 mg, 0.87 mmol, 1 equiv.) was charged 
with a mixture of methanol and distilled water (30 mL, 9:1), and a magnetic stirrer bar. 
Potassium carbonate (30 mg, 0.22 mmol, 0.25 equiv.) was added in one portion. The 
colourless solution was stirred at room temperature for 1 hour, and then concentrated by 
rotary evaporation. The aqueous residue was extracted with dichloromethane (3 x 25 mL) 
and the combined organic layers were washed with 1 M aqueous hydrochloric acid (50 
mL) and subsequently brine (50 mL). The organic phase was dried over magnesium 
sulfate, filtered and the solvent removed in vacuo. Purification via flash column 
chromatography on silica gel (eluent: dichloromethane / ethyl acetate 10%; Rf = 0.22) 
afforded a white solid whose physicochemical properties were consistent with those of 
the title compound (162 mg, 0.49 mmol, 57% yield). 
M.p. 104–106 °C; 1H-NMR (500 MHz, CDCl3) δ 7.36 – 7.30 (m, 2H, Ar-H), 7.29 – 7.20 
(m, 6H, Ar-H), 6.96 (d, J = 7.9 Hz, 2H, Ar-H), 6.91 (d, J = 8.4 Hz, 1H, -NH-), 4.89 (dt, J 
= 8.2, 6.0 Hz, 1H, -NHCH-), 4.30 (m, 1H, -CHOH), 3.71 (s, 3H, -OCH3), 3.15 (dd, J = 
14.0, 4.0 Hz, 1H, -CH2Ph), 3.05 (d, J = 6.0 Hz, 2H, -CH2CHOH), 2.82 (dd, J = 13.9, 8.1 
Hz, 1H, -CH2Ph), 2.42 (d, J = 5.0 Hz, 1H, -OH); 
13
C-NMR (126 MHz, CDCl3) δ 172.2 (-
C=O), 171.9 (-C=O), 136.7, 135.8, 129.8, 129.4, 128.9, 128.7, 127.2(8), 127.2(6), 72.9 (-
CHOH), 52.8 (-NHCH-), 52.5 (-OCH3), 40.8 (-CH2Ph), 38.2 (-CH2Ph); FT-IR (thin film, 
cm
-1) υ = 3398 (N-H), 2967, 2854, 1739 (ester C=O), 1653 (amide C=O), 1539, 1441, 
1093, 1030; [α]D
19
 +5.0 (c 1.0, CHCl3); MS (MALDI-TOF): m/z = 350.2 [M+Na]
+
; 
HRMS (HNESP) exact mass calculated for C19H22NO4 requires m/z 328.1543, found m/z 
328.1537 [M+H]
+
. 
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(S)-Methyl 2-((S)-2-hydroxy-3-phenylpropanamido)-3-phenylpropanoate (469) and 
(S)-methyl 2-((R)-2-hydroxy-3-phenylpropanamido)-3-phenylpropanoate (481) 
 
Following the procedure for compound 469 above, a mixture of two diastereoisomers 469 
and 481 were synthesised and separated via flash column chromatography on silica gel 
(eluent: dichloromethane / ethyl acetate (10%). Compound 469 was isolated as a 
colourless oil (278 mg, 0.85 mmol, 36% yield) whose physicochemical properties 
matched those reported above. Compound 481 was isolated as a colourless oil (332 mg, 
1.01 mmol, 43% yield). 
316: Rf = 0.43; 
1
H-NMR (500 MHz, CDCl3) δ 7.35 – 7.19 (m, 8H, Ar-H), 7.12 – 7.07 (m, 
2H, Ar-H), 6.89 (d, J = 7.7 Hz, 1H, -NH-), 4.88 (dt, J = 8.2, 6.1 Hz, 1H, -NHCH-), 4.27 
(dd, J = 9.0, 4.0 Hz, 1H, -CHOH), 3.71 (s, 3H, -OCH3), 3.21 (dd, J = 14.0, 4.0 Hz, 1H, -
CH2Ph), 3.12 (qd, J = 13.9, 6.1 Hz, 2H, -CH2Ph), 2.84 (dd, J = 14.0, 9.0 Hz, 1H, -
CH2Ph); 
13
C-NMR (126 MHz, CDCl3) δ 172.3 (-C=O), 171.8 (-C=O), 136.8, 135.9, 
129.6, 129.4, 129.0, 128.8, 127.3, 127.3, 73.0 (-CHOH), 53.0 (-NHCH-), 52.5 (-OCH3), 
40.9 (-CH2Ph), 38.1 (-CH2Ph); FT-IR (thin film): υ (cm
-1
) = 3390 (N-H), 3066, 3028, 
2952, 2924, 1741 (ester C=O), 1655 (amide C=O), 1521, 1497, 1455, 1438, 1362, 1217, 
1086; [α]D
20
 +86.4 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 350.2 [M+Na]
+
; HRMS 
(HNESP) exact mass calculated for C19H22NO4 requires m/z 328.1543, found m/z 
328.1543 [M+H]
+
. 
(S)-Methyl 2-((R)-2-hydroxy-3-phenylpropanamido)-4-methylpentanoate (480) 
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Compound 480 was prepared according to the procedure for compound 469. Purification 
via flash column chromatography on silica (dichloromethane / ethyl acetate 10%; Rf = 
0.42) afforded a white solid whose physicochemical properties were consistent with those 
of the title compound (354 mg, 1.21 mmol, 81% yield). 
M.p. 45–47 °C; 1H-NMR (500 MHz, CDCl3) δ 7.37 – 7.31 (m, 2H, Ar-H), 7.30 – 7.23 
(m, 3H, Ar-H), 6.77 (d, J = 8.3 Hz, 1H, -NH-), 4.63 (dt, J = 8.8, 5.0 Hz, 1H, -NHCH-), 
4.36 – 4.30 (m, 1H, -CHOH), 3.73 (s, 3H, -OCH3), 3.25 (dd, J = 14.0, 4.2 Hz, 1H-
CH2Ph), 2.91 (dd, J = 14.0, 8.8 Hz, 1H, -CH2Ph), 2.39 (s, 1H, -OH), 1.69 – 1.49 (m, 3H, -
CH2CH(CH3)2), 0.91 (d, J = 2.7 Hz, 3H, -CH(CH3)2), 0.90 (d, J = 2.8 Hz, 3H, -
CH(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 173.1 (-C=O), 172.9 (-C=O), 137.0, 129.6, 
128.7, 126.9, 72.9 (-CHOH), 52.4 (-NHCH-), 50.4 (-OCH3), 41.5 (-CH2CH(CH3)2), 40.8 
(-CH2Ph), 24.8 (-CH(CH3)2), 22.8 (-CH(CH3)2), 21.9 (-CH(CH3)2); FT-IR (thin film): υ 
(cm
-1
) = 3389 (N-H), 3032, 2956, 2874, 1744 (ester C=O), 1658 (amide C=O), 1531, 
1456, 1439, 1370, 1277, 1209, 1154, 1088; [α]D
19
 +48.6 (c 1.0, CHCl3); MS (MALDI-
TOF) m/z 332.4 [M+K]
+
; HRMS (HNESP) exact mass calculated for C16H24NO4 requires 
m/z 294.1700, found m/z 294.1702 [M+H]
+
. 
(S)-Methyl 2-((S)-2-hydroxy-3-phenylpropanamido)-4-methylpentanoate (480) and 
(S)-methyl 2-((R)-2-hydroxy-3-phenylpropanamido)-4-methylpentanoate (482) 
 
Following the procedure for compound 469, a mixture of two diastereoisomers 480 and 
482 were synthesised and separated via flash column chromatography on silica gel 
(eluent: dichloromethane / ethyl acetate 10 %). Compound 480 was isolated as a white 
solid (111 mg, 0.38 mmol, 41% yield) whose physicochemical properties matched those 
reported above. Compound 482 was isolated as a white solid (103 mg, 0.35 mmol, 38% 
yield). 
482: Rf = 0.20; M.p. 83–85 °C; 
1
H-NMR (500 MHz, CDCl3) δ 7.31 – 7.25 (m, 2H, Ar-H), 
7.25 – 7.19 (m, 3H, Ar-H), 6.93 (d, J = 8.5 Hz, 1H, -NH-), 4.55 (dt, J = 8.9, 5.1 Hz, 1H, -
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NHCH-), 4.33 (dt, J = 8.3, 4.4 Hz, 1H, -CHOH), 3.68 (s, 3H, -OCH3), 3.43 (brs, 1H, -
OH), 3.16 (dd, J = 14.0, 3.9 Hz, 1H, -CH2Ph), 2.91 (dd, J = 14.0, 7.6 Hz, 1H, -CH2Ph), 
1.60 – 1.52 (m, 1H, -CH(CH3)2), 1.50 – 1.34 (m, 2H, -CH2CH(CH3)2), 0.87 (d, J = 2.8 
Hz, 3H, -CH(CH3)2), 0.86 (d, J = 2.9 Hz, 3H, -CH(CH3)2); 
13
C-NMR (126 MHz, CDCl3) 
δ 173.6 (-C=O), 173.1 (-C=O), 137.0, 129.8, 128.5, 126.9, 72.8 (-CHOH), 52.4 (-NHCH-
), 50.3 (-OCH3), 41.3 (-CH2CH(CH3)2), 40.6 (-CH2Ph), 24.7 (-CH(CH3)2), 22.9 (-
CH(CH3)2), 21.8 (-CH(CH3)2); FT-IR (thin film): υ (cm
-1
) = 3372 (N-H), 3186, 2955, 
2924, 2866, 1752 (ester C=O), 1662 (amide C=O), 1541, 1448, 1421, 1366, 1269, 1235, 
1190, 1152, 1093; [α]D
20
 – 60.2 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 332.37 [M+K]
+
; 
HRMS (HNESP) exact mass calculated for C16H24NO4requires m/z 294.1700, found m/z 
294.1702 [M+H]
+
. 
(S)-Methyl 2-(2-hydroxy-3-phenylpropanamido)-2-methylpropanoate (478) 
 
Compound 478 was prepared according to the procedure for compound 469. Purification 
via flash column chromatography on silica gel (eluent: dichloromethane / ethyl acetate 
10%; Rf = 0.13) afforded a colourless oil whose physicochemical properties were 
consistent with those of the title compound (154 mg, 0.58 mmol, 84% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.36 – 7.29 (m, 2H, Ar-H), 7.29 – 7.23 (m, 3H, Ar-H), 
6.89 (s, 1H, -NH-), 4.26 (dd, J = 8.1, 4.5 Hz, 1H, -NHCH-), 3.74 (s, 3H, -OCH3), 3.17 
(dd, J = 14.0, 4.4 Hz, 1H, -CH2Ph), 2.93 (dd, J = 13.9, 8.1 Hz, 1H, -CH2Ph), 2.55 (s, 1H, -
OH), 1.52 (s, 3H, -CH3), 1.51 (s, 3H, -CH3); 
13
C-NMR (126 MHz, CDCl3) δ 174.9 (-
C=O), 172.4 (-C=O), 137.0, 129.8, 128.6, 127.0, 72.8 (-CHOH), 56.2 (-NHCH-), 52.7 (-
OCH3), 40.7 (-CH2Ph), 25.0 (-CH3), 24.7 (-CH3); FT-IR (thin film): υ (cm
-1
) = 3382 (N-
H), 3033, 2991, 2953, 1742 (ester C=O), 1654 (amide C=O), 1528, 1456, 1385, 1296, 
1162, 1090; [α]D
20– 49.1 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 304.3 [M+K]
+
; HRMS 
(HNESP) exact mass calculated for C14H20NO4 requires m/z 266.1387, found m/z 
266.1390 [M+H]
+
. 
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(S)-Methyl 2-((R)-2-hydroxy-3-phenylpropanamido)-4-(methylthio)butanoate (479) 
 
Compound 479 was prepared according to the procedure for compound 469. Purification 
via flash column chromatography on silica gel (eluent: dichloromethane / ethyl acetate 
10%; Rf = 0.10) afforded a white solid whose physicochemical properties were consistent 
with those of the title compound (166 mg, 0.53 mmol, 88% yield). 
M.p. 60–62 °C; 1H-NMR (500 MHz, CDCl3) δ 7.36 – 7.23 (m, 5H, Ar-H), 7.14 (d, J = 8.0 
Hz, 1H, -NH-), 4.69 (dt, J = 7.9, 5.2 Hz, 1H, -NHCH-), 4.39 (dd, J = 7.6, 3.9 Hz, 1H, -
CHOH), 3.74 (s, 3H, -OCH3), 3.20 (dd, J = 13.9, 4.0 Hz, 1H, -CH2Ph), 2.97 (dd, J = 13.9, 
7.6 Hz, 2H, -CH2Ph), 2.38 – 2.26 (m, 2H, -CH2S-), 2.13 – 2.07 (m, 1H, -CH2CH2S-), 2.06 
(s, 3H, -SCH3), 1.96 – 1.86 (m, 1H, -CH2CH2S-); 
13
C-NMR (126 MHz, CDCl3) δ 173.0 (-
C=O), 172.3 (-C=O), 136.6, 129.8, 128.7, 127.1, 72.7 (-CHOH), 52.7 (-NHCH-), 51.1 (-
OCH3), 40.7 (-CH2Ph), 31.6 (-CH2CH2S-), 29.8 (-CH2S-), 15.5 (-SCH3); FT-IR (thin 
film): υ (cm-1) = 3377 (N-H), 3255, 2957, 2913, 1752 (ester C=O), 1660 (amide C=O), 
1542, 1447, 1352, 1274, 1223, 1196, 1189, 1169, 1125, 1088; [α]D
20 – 29.5 (c 1.0, 
CHCl3); MS (MALDI-TOF) m/z 334.3 [M+Na]
+
, 350.3 [M+K]
+
; HRMS (HNESP) exact 
mass calculated for C15H21NO4S requires m/z 312.1264, found m/z 312.1267 [M+H]
+
. 
(S)-Methyl 2-((S)-2-hydroxy-3-phenylpropanamido)-4-(methylthio)butanoate (479) 
and (S)-Methyl 2-((R)-2-hydroxy-3-phenylpropanamido)-4-(methylthio)butanoate 
(483) 
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Using the procedure for compound 469, a 1:1 mixture of diastereoisomers 479 and 483 
were made and separated via flash column chromatography on silica gel (eluent: 
dichloromethane / ethyl acetate 20%). Compound 479 was isolated as a white solid (87 
mg, 0.28 mmol, 33% yield) whose physicochemical properties matched those reported 
above. Compound 483 was isolated as a white solid (74 mg, 0.24 mmol, 28% yield). 
319: Rf = 0.28; 
1
H-NMR (500 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H, Ar-H), 7.23 – 7.16 (m, 
3H, Ar-H), 6.98 (d, J = 8.1 Hz, 1H, -NH-), 4.65 (dt, J = 7.8, 5.3 Hz, 1H, -NHCH-), 4.27 
(dd, J = 8.8, 4.1 Hz, 1H, -CHOH), 3.68 (s, 3H, -OCH3), 3.18 (dd, J = 14.0, 4.1 Hz, 1H, -
CH2Ph), 2.83 (dd, J = 14.0, 8.8 Hz, 1H, -CH2Ph), 2.40 (t, J = 7.4 Hz, 2H, -CH2S-), 2.14 – 
2.04 (m, 1H, -CH2CH2S-), 2.02 (s, 3H, -SCH3), 1.97 – 1.86 (m, 1H, -CH2CH2S-); 
13
C-
NMR (126 MHz, CDCl3) δ 172.8 (-C=O), 172.1 (-C=O), 136.9, 129.6, 128.9, 127.1, 73.0 
(-CHOH), 52.7 (-NHCH-), 51.3 (-OCH3), 40.9 (-CH2Ph), 31.7 (-CH2CH2S-), 30.0 (-
CH2S-), 15.5 (-SCH3); FT-IR (thin film): υ (cm
-1
) = 3382 (N-H), 3059, 3028, 2953, 2919, 
2850, 1741 (ester C=O), 1658 (amide C=O), 1524, 1435, 1360, 1277, 1226, 1171, 1088, 
1030; [α]D
22 
+33.1 (c 1.0, CHCl3); MS (MALDI-TOF) m/z 349.7 [M+K]
+
; HRMS 
(HNESP) exact mass calculated for C15H22NO4S requires m/z 312.1264, found m/z 
312.1265 [M+H]
+
. 
(S)-Methyl 2-((R)-2-((S)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-3-
phenylpropanamido)-3-phenylpropanoate (466) 
 
A Biotage Endeavor glass hydrogenation vial was charged with a solution of (S)-methyl 
2-((2R,3R)-1-((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-3-phenylaziridine-2-
carboxamido)-3-phenylpropanoate 427 (100 mg, 0.21 mmol, 1 equiv.) in ethanol (4 mL). 
Palladium on carbon (10 wt%) (22 mg, 0.021 mmol, 10 mol%) was added, and the 
mixture stirred under 50 psi of hydrogen at room temperature for 12 hours. The mixture 
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was filtered through a short plug of celite and the solvent removed in vacuo. Purification 
via flash column chromatography on silica gel (eluent: dichloromethane / ethyl acetate 
10%; Rf = 0.44) afforded a colourless oil whose physicochemical properties were 
consistent with those of the title compound (96 mg, 0.20 mmol, 96% yield).  
1
H-NMR (500 MHz, CDCl3) δ 7.71 (s, 1H, -NH-), 7.25 – 7.14 (m, 9H, Ar-H), 7.10 (d, J = 
6.6 Hz, 2H, Ar-H), 7.04 – 6.99 (m, 2H, Ar-H), 6.81 (d, J = 5.9 Hz, 2H, Ar-H), 4.85 (dt, J 
= 8.3, 6.5 Hz, 1H, -NHCH-), 3.70 (s, 3H, -OCH3), 3.56 (s, 3H, -OCH3), 3.34 (dd, J = 9.1, 
4.3 Hz, 1H, -NHCH-), 3.29 (t, J = 6.5 Hz, 1H, -NHCH-), 3.18 – 3.03 (m, 3H, -CH2Ph), 
2.76 – 2.63 (m, 3H, -CH2Ph); 
13
C NMR (126 MHz, CDCl3) δ 173.3 (-C=O), 173.2 (-
C=O), 172.0 (-C=O), 137.2, 136.4, 136.3, 129.4, 129.3, 129.2, 129.0, 128.8, 128.7, 127.1, 
127.0(2), 126.9(6), 62.6 (-NHCH-), 61.6 (-NHCH-), 53.2 (-NHCH-), 52.3 (-OCH3), 52.0 
(-OCH3), 39.1 (-CH2Ph), 38.1 (-CH2Ph), 38.0 (-CH2Ph); FT-IR (thin film): υ (cm
-1
) = 
3339, 2920, 2858, 1746, 1672, 1500, 1457, 1203, 1027; [α]D
20
 +11.9 (c 1.0, CHCl3); MS 
(MALDI-TOF) m/z 489.6 [M+Na]
+
; HRMS (HNESP) exact mass calculated for 
C29H33N2O5 requires m/z 489.2384, found m/z 489.2378 [M+H]
+
. 
(S)-Methyl 2-((R)-2-((S)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-3-
phenylpropanamido)-3-phenylpropanoate (466) 
 
A flame-dried 5 mL microwave vial containing a magnetic stirrer bar was charged with a 
solution of trifluoromethanesulfonic anhydride (51 µL, 0.31 mmol, 1 equiv.) in dry 
dichloromethane (1 mL) and cooled to 0 °C under a nitrogen atmosphere using an ice 
bath. A solution of (S)-methyl 2-((S)-2-hydroxy-3-phenylpropanamido)-3-
phenylpropanoate 469 (100 mg, 0.31 mmol, 1 equiv.) and pyridine (25 µL, 0.31 mmol, 1 
equiv.) in dry dichloromethane (2 mL) was added dropwise via syringe over 1 hour. The 
reaction was allowed to warm slowly to room temperature, and the solvent removed in 
vacuo. Pentane (5 mL) was added and the resulting white precipitate was removed by 
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filtration. The filtrate was concentrated in vacuo before being redissolved in dry 
dichloromethane (2 mL) and added dropwise to a solution of L-phenylalanine methyl 
ester 426 (109 mg, 0.61 mmol, 2 equiv.) in dichloromethane (2 mL) at -70 °C in a 5 mL 
microwave vial under a nitrogen atmosphere. The reaction was stirred at -70 °C for one 
hour before being allowed to warm to room temperature and stirred for a further 16 hours. 
The white solid precipitate was removed by filtration and the filtrate concentrated in 
vacuo. Purification via flash column chromatography on silica gel (eluent: 
dichloromethane / ethyl acetate 10%; Rf = 0.44) afforded a colourless oil (28 mg, 0.058 
mmol, 19% yield) whose physicochemical properties were consistent with those of the 
title compound and matched those obtained by hydrogenation of the corresponding 
aziridine 427 described above. 
(S)-Methyl 2-((S)-2-((S)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-3-
phenylpropanamido)-3-phenylpropanoate (489) 
 
Compound 489 was prepared according to the procedure for compound 466. Purification 
via flash column chromatography on silica (dichloromethane / ethyl acetate 10%; Rf = 
0.32) afforded a colourless oil whose physicochemical properties were consistent with 
those of the title compound (36 mg, 0.073 mmol, 24% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.32 – 7.20 (m, 10H, Ar-H), 7.11 – 7.05 (m, 4H, Ar-H), 
6.96 (d, J = 7.2 Hz, 2H, Ar-H), 4.71 (td, J = 8.3, 5.3 Hz, 1H, -NHCH-), 3.73 (s, 3H, -
OCH3), 3.48 (s, 3H, -OCH3 + -NHCH-), 3.25 (dd, J = 8.8, 3.9 Hz, 1H, -NHCH-), 2.99 
(dd, J = 13.9, 5.3 Hz, 1H, -CH2Ph), 2.94 (dd, J = 13.9, 4.1 Hz, 1H, -CH2Ph), 2.83 – 2.63 
(m, 3H, -CH2Ph), 2.46 – 2.39 (m, 1H, -CH2Ph); 
13
C-NMR (126 MHz, CDCl3) δ 173.3 (-
C=O), 172.9 (-C=O), 171.8 (-C=O), 137.0, 136.7, 136.4, 129.7, 129.5, 129.3, 128.7(1), 
128.6(7), 128.5, 127.2, 127.1, 127.0, 62.2 (-NHCH-), 61.1 (-NHCH-), 52.4 (-NHCH- + -
OCH3), 51.9 (-OCH3), 40.0 (-CH2Ph), 39.6 (-CH2Ph), 37.4 (-CH2Ph); FT-IR (thin film): υ 
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(cm
-1
) = 3351 (N-H), 2924, 2854, 1743 (ester C=O), 1680 (amide C=O), 1504, 1453, 
1203; [α]D
20
 -7.2 (c 0.6, CHCl3); MS (MALDI-TOF) m/z 511.37 [M+Na]
+
; HRMS 
(HNESP) exact mass calculated for C29H33N2O5 requires m/z 489.2384, found m/z 
489.2375 [M+H]
+
.  
(S)-tert-Butyl 1-(allylamino)-4-methyl-1-oxopentan-2-ylcarbamate (494)
253
 
 
A 150 mL round-bottom flask was charged with a solution of (S)-2-((tert-
butoxycarbonyl)amino)-4-methylpentanoic acid 493 (1.0 g, 4.32 mmol, 1 equiv.) in dry 
tetrahydrofuran (20 mL) and cooled to -25 °C under a nitrogen atmosphere. 4-
Methylmorpholine (0.48 mL, 4.32 mmol, 1 equiv.), ethyl chloroformate (0.41 mL, 4.32 
mmol, 1 equiv.) and allylamine (0.36 mL, 4.75 mmol, 1.1 equiv.) were added sequentially 
via syringe (3 x 1 mL) and with vigorous stirring of the reaction mixture. The resulting 
suspension was allowed to warm to room temperature and stirred for 18 hours. The 
solvent was removed in vacuo and the residue diluted with distilled water (15 mL) and 
adjusted to pH 1 with 1 M aqueous potassium hydrogen sulfate. The resulting mixture 
was extracted with ethyl acetate (3 x 30 mL) and the combined organic layers washed 
with distilled water (100 mL), then saturated aqueous sodium bicarbonate (100 mL) and 
finally brine (100 mL). The separated organic solution was dried over magnesium sulfate, 
filtered, and the solvent removed in vacuo. Purification via flash column chromatography 
on silica gel (eluent: petroleum ether / diethyl ether 1:1; Rf = 0.24) afforded a white solid 
whose physicochemical properties matched those previously reported (527 mg, 1.95 
mmol, 45% yield). 
M.p. 78–80 °C; 1H-NMR (500 MHz, CDCl3) δ = 6.19 (br s, 1H, -NH-), 5.87 – 5.78 (m, 
1H, -CH=CH2), 5.19 (dd, J = 17.2, 1.4 Hz, 1H, -CH=CH2), 5.13 (dd, J = 10.3, 1.3 Hz, 1H, 
-CH=CH2), 4.85 (br s, 1H, BocNH-), 4.08 (br s, 1H, BocNHCH-), 3.88 (br s, 2H, -
NHCH2-), 1.73 – 1.63 (m, 2H, -CH2CH(CH3)2), 1.52 – 1.40 (m, 1H, -CH(CH3)2), 1.44 (s, 
9H, -C(CH3)3), 0.95 (d, J = 4.8 Hz, 3H, -CH(CH3)2), 0.93 (d, J = 4.8 Hz, 3H, -CH(CH3)2); 
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13
C-NMR (126 MHz, CDCl3) δ 172.7 (amide –C=O), 156.0 (carbamate -C=O), 134.1 (-
CH=CH2), 116.3 (-CH=CH2), 80.2 (-C(CH3)3), 53.2 (-NHCH-), 41.8, 41.4, 28.4 (-
C(CH3)3), 24.9 (-CH(CH3)2), 23.1 (-CH(CH3)2), 22.1 (-CH(CH3)2); MS (MALDI-TOF): 
m/z 309.2 [M+K]
+
. 
(S)-N-allyl-2-amino-4-methylpentanamide (495) 
 
To a 150 mL round-bottom flask containing a solution of (S)-tert-butyl 1-(allylamino)-4-
methyl-1-oxopentan-2-ylcarbamate 494 (400 mg, 1.48 mmol, 1 equiv.) in dry 
dichloromethane under a nitrogen atmosphere was added trifluoroacetic acid (0.68 mL, 
8.88 mmol, 8 equiv.) dropwise via a 2 mL syringe. The resulting solution was stirred at 
room temperature for 6 hours. When the starting material was no longer observed by thin 
layer chromatography (eluent: petroleum ether / diethyl ether 1:1), the reaction mixture 
was cooled to 0 °C and quenched by the dropwise addition of triethylamine (1.5 mL, 11.1 
mmol, 10 equiv.) via a 2.5 mL syringe. After stirring for a further one hour at room 
temperature, the solvents were removed in vacuo to afford a colourless oil that was used 
without further purification (146 mg, 0.86 mmol, 58% yield); the physicochemical 
properties were consistent with those of the title compound.  
1
H-NMR (500 MHz, CDCl3) δ = 7.38 (br s, 1H, -NH-), 5.84 (ddt, J = 17.2, 10.2, 5.6 Hz, 
1H, -CH=CH2), 5.17 (dd, J = 17.2, 1.5 Hz, 1H, -CH=CH2), 5.12 (dd, J = 10.2, 1.5 Hz, 1H, 
-CH=CH2), 3.88 (t, J = 5.6 Hz, 2H, -NH2CH-), 3.40 (dd, J = 9.8, 3.3 Hz, 1H, -NHCH2-), 
1.76 – 1.68 (m, 2H, -CH2CH(CH3)2), 1.48 (br s, 2H, -NH2), 1.37 – 1.32 (m, 1H, -
CH(CH3)2), 0.96 (d, J = 6.1 Hz, 3H, -CH(CH3)2), 0.93 (d, J = 6.1 Hz, 3H, -CH(CH3)2); 
13
C-NMR (126 MHz, CDCl3) δ 175.5 (-C=O), 134.6 (-CH=CH2), 116.1 (-CH=CH2), 53.7 
(-CHNH2), 44.3 (-NHCH2-), 41.5 (-CH2CH(CH3)2), 25.0 (-CH2CH(CH3)2), 23.6 (-
CH(CH3)2), 21.4 (-CH(CH3)2); FT-IR (thin film, cm
-1
) υ = 3290 (N-H), 3074 (C-H), 2952 
(C-H), 2935 (C-H), 2876 (C-H), 1654 (C=O), 1540, 1472, 1371, 1261, 1147, 990, 918; 
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[α]D
17
 –20.6 (c 1.0, CHCl3); MS (MALDI-TOF): m/z = 209.1 [M+K]
+
; HRMS (HNESP) 
exact mass calculated for C9H19N2O requires m/z 171.1492, found m/z 171.1491 [M+H]
+
. 
 (S)-3-(1-((Benzyloxy)carbonyl)-1H-indol-3-yl)-1-methoxy-1-oxopropan-2-aminium 
trifluoroacetate (497) 
 
To a 500 mL two-necked round-bottom flask under a nitrogen atmosphere was added (S)-
benzyl 3-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-indole-1-
carboxylate 329 (9.33 g, 20.6 mmol, 1 equiv.) and a magnetic stirrer bar. The white solid 
was dissolved in dichloromethane (60 mL) and trifluoroacetic acid (12.6 mL, 165 mmol, 
8 equiv.) was added via a 20 mL syringe. The solution was stirred at room temperature 
for 16 hours, by which time complete disappearance of the starting material was observed 
by thin layer chromatography (eluent: petroleum ether / diethyl ether 1:1). The solvent 
was removed in vacuo to afford a colourless oil, and a white solid precipitate was formed 
on the addition of diethyl ether. The solid was filtered, washed with diethyl ether and 
dried in vacuo. The physicochemical properties were consistent with those of the title 
compound (6.71 g, 20.2 mmol, 98% yield). 
M.p. 138–140 °C; 1H-NMR (500 MHz, MeOD) δ 8.18 (d, J = 8.1 Hz, 1H, Ar-H), 7.66 (s, 
1H, ind. C-2 H), 7.60 – 7.56 (m, 1H, Ar-H), 7.55 – 7.51 (m, 2H, Ar-H), 7.46 – 7.33 (m, 
4H, Ar-H), 7.30 (t, J = 7.5 Hz, 1H, Ar-H), 5.48 (s, 2H, -CH2Ph), 4.39 (br s, 1H, -CHNH2), 
3.78 (s, 3H, -OCH3), 3.42 (dd, J = 15.2, 5.1 Hz, 1H, -CH2-ind), 3.34 – 3.25 (m, 1H, -CH2-
ind); 
13
C-NMR (126 MHz, MeOD) δ 170.5 (-C=O), 162.2 (-C=O), 151.8 (-C=O), 137.0, 
136.6, 130.9, 129.8, 129.7, 129.6, 126.1, 126.1, 124.2, 119.7, 116.3, 114.9, 69.9 (-
CH2Ph), 53.7 (-OCH3), 27.0 (-CH2-ind); FT-IR (thin film): υ (cm
-1
) = 3441 (N-H), 3038 
(C-H), 2959 (C-H), 2921 (C-H), 2855 (C-H), 1741 (ester C=O), 1679 (carbamate C=O), 
1610, 1521, 1462, 1403, 1362, 1345, 1303, 1255, 1203, 1135, 1093, 1024, 945; [α]D
19
 
+4.8 (c 1.0, MeOH); MS (MALDI-TOF) m/z 352.5 [M]
+
 (free amine); HRMS (HNESP) 
exact mass calculated for C20H21N2O4 requires m/z 353.1496, found m/z 353.1494 [M+H]
+
 
(free amine). 
  
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
220 
 
Bibliography 
 
1. M. H. McCormick, W. M. Stark, G. E. Pittenger, R. C. Pittenger and G. M. 
McGuire, Antibiot. Annu., 1955–56, 606; D. P. Levine, Clin. Infect. Dis., 2006, 
42, S5. 
2. C.Watanakunakorn, J. Antimicrob. Chemother., 1984, 14 (Suppl. D), 7. 
3. R. C. Moellering, Clin. Infect. Dis., 2006, 42, S3.  
4. N. H. Cynamon and P. A. Granato, Antimicrob. Agents Chemother., 1982, 21, 
504; C. H. Wallas and J. L. Strominger, J. Biol. Chem., 1963, 238, 2264. 
5. F. M. Aarestrup, A. M. Seyfarth, H.-D. Emborg, K. Pedersen, R. S. Hendriksen 
and F. Bager, Antimicrob. Agents Chemother., 2001, 45, 2054. 
6. K. Hiramatsu, Drug Resist. Updates, 1998, 1, 135. 
7. Review of the ‘‘Chemistry, biology and medicine of the glycopeptide 
antibiotics’’, K. C. Nicolaou, C. N. C. Boddy, S. Braïse and N. Winssinger, 
Angew. Chem., Int. Ed., 1999, 38, 2096. 
8. D. H. Williams and J. R. Kalman, J. Am. Chem. Soc., 1977, 99, 2768. 
9. G. M. Sheldrick, P. G. Jones, O. Kennard, D. H. Williams and G. A. Smith, 
Nature, 1978, 271, 223. 
10. C. M. Harris and T. M. Harris, J. Am. Chem. Soc., 1982, 104, 4295. 
11. D. H. Williams, U. Gerhard, J. P. Mackay and R. A. Maplestone, J. Am. Chem. 
Soc., 1993, 115, 232. 
12. M. Shäfer, T. R. Schneider and G. M. Sheldrick, Structure, 1996, 4, 1510. 
13. D. L. Boger, S. Miyazaki, S. Heon Kim, J. H. Wu, S. L. Castle, O. Loiseleur and 
Q. Jin, J. Am. Chem. Soc., 1999, 121, 10004. 
14. J. P. Mackay, U. Gerhard, R. A. Maplestone and D. H. Williams, J. Am. Chem. 
Soc., 1994, 116, 4573. 
15. J. P. Mackay, U. Gerhard, D. A. Beauregard, D. H. Williams, M. S. Westwell and 
M. S. Searle, J. Am. Chem. Soc., 1994, 116, 4581. 
16. B. M. Crowley and D. L. Boger, J. Am. Chem. Soc., 2006, 128, 2885. 
17. D. Kahne, C. Leimkuhler, W. Lu and C. Walsh, Chem. Rev., 2005, 105, 425. 
18. Y. Nitanai, T. Kikuchi, K. Kakoi, S. Hanamaki, I. Fujisawa and K. Aoki, J. Mol. 
Biol., 2009, 385, 1422. 
19. R. Nagarajan, J. Antibiot., 1993, 46, 1181. 
221 
 
20. A. Leighton, A. B. Gottlieb, M.-B. Dorr, D. Jabes, G. Mosconi, C. Van Saders, E. 
J. Mroszczak, K. C. M. Campbell and E. Kelly, Antimicrob. Agents Chemother., 
2004, 48, 940. 
21. R. A. Blouin, L. A. Bauer, D. D. Miller, K. E. Record and W. O. Griffen Jr., 
Antimicrob. Agents Chemother., 1982, 21, 575. 
22. A. Belley, G. A. McKay, F. F. Arhin, I. Sarmiento, S. Beaulieu, I. Fadhil, T. R. 
Parr Jr. and G. Moeck, Antimicrob. Agents Chemother., 2010, 12, 5369. 
23. E. Bouza and A. Burillo, Int. J. Antimicrob. Agents, 2010, 6, 401. 
24. M. R. Leadbetter, S. M. Adams, B. Bazzini, P. R. Fatheree, D. E. Karr, K. M. 
Krause, B. M. T. Lam, M. S. Linsell, M. B. Nodwell, J. L. Pace, K. Quast, J.-P. 
Shaw, E. Soriano, S. G. Trapp, J. D. Villena, T. X. Wu, B. G. Christensen and J. 
K. Judice, J. Antibiot., 2004, 5, 326. 
25. J. L. Pace and G. Yang, Biochem. Pharmacol., 2006, 71, 968. 
26. D. L. Boger, R. T. Beresis, O. Loiseleur, J. H. Wu and S. L. Castle, Bioorg. Med. 
Chem. Lett., 1998, 8, 721. 
27. J. Jeffrey McAfee, S. L. Castle, Q. Jin and D. L. Boger, Bioorg. Med. Chem. Lett., 
2002, 12, 1319. 
28. C. C. McComas, B. M. Crowley, I. Hwang and D. L. Boger, Bioorg. Med. Chem. 
Lett., 2003, 13, 2933. 
29. C. M. Crane and D. L. Boger, J. Med. Chem., 2009, 52, 1471. 
30. S. Weist, B. Bister, O. Puk, D. Bischoff, S. Pelzer, G. J Nicholson, W. Wohlleben, 
G. Jung and R. D. Süssmuth, Angew. Chem., Int. Ed., 2002, 41, 3383. 
31. B. Bister, D. Bischoff, G. J Nicholson, S. Stockert, J. Wink, C. Brumati, S. 
Donadio, S. Pelzer, W. Wohlleben and R. D. Süssmuth, ChemBioChem, 2003, 4, 
649. 
32. O. Yoshida, T. Yasukata, Y. Sumino, T. Munekage, Y. Narukawa and Y. 
Nishitani, Bioorg. Med. Chem. Lett., 2002, 12, 3031. 
33. T. Yasukata, H. Shindo, O. Yoshida, Y. Sumino, T. Munekage, Y. Narukawa and 
Y. Nishitani, Bioorg. Med. Chem. Lett., 2002, 12, 3033. 
34. (a) T. I. Nicas, D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, R. E. 
Stratford and R. D. G. Cooper, Antimicrob. Agents Chemother., 1995, 39, 2585; 
(b) N. E. Allen, D. L. Le Tourneau and J. N. Hobbs Jr., Antimicrob. Agents 
Chemother., 1997, 41, 66; (c) T. I. Nicas, D. L. Mullen, J. E. Flokowitsch, D. A. 
222 
 
Preston, N. J. Snyder, M. J. Zweifel, M. J. Rodriguez, R. C. Thompson and R. D. 
G. Cooper, Antimicrob. Agents Chemother., 1996, 40, 2194. 
35. O. Yoshida, T. Yasukata, Y. Sumino, T. Munekage, Y. Narukawa and Y. 
Nishitani, Bioorg. Med. Chem. Lett., 2002, 12, 3027. 
36. A. Y. Pavlov, M. N. Preobrazhenskaya, A. Malabarba, R. Ciabatti and L. 
Colombo, J. Antibiot., 1998, 51, 73. 
37. A. Y. Pavlov, E. I. Lazhko and M. N. Preobrazhenskaya, J. Antibiot., 1997, 50, 
509. 
38. X. Fu, C. Albermann, C. Zhang and J. S. Thorson, Org. Lett., 2005, 7, 1513. 
39. G. Pinter, G. Batta, S. Keki, A. Mandi, I. Komaromi, K. Takacs-Novak, F. 
Sztaricskai, E. Roth, E. Ostorhazi, F. Rozgonyi, L. Naesens and P. Herczegh, J. 
Med. Chem., 2009, 59, 564. 
40. G. Pinter, I. Bereczki, G. Batta, R. Otvos, F. Sztaricskai, E. Roth, E. Ostorhazi, F. 
Rozgonyi, L. Naesens, M. Szarvas, Z. Boda and P. Herczegh, Bioorg. Med. Chem. 
Lett., 2010, 20, 2713. 
41. L. Naesens, E. Vanderlinden, E. Roth, J. Jeko, G. Andrei, R. Snoeck, C. 
Pannecouque, E. Illyes, G. Batta, P. Herczegh and F. Sztaricskai, Antiviral Res., 
2009, 82, 89. 
42. S. S. Printsevskaya, A. Y. Pavlov, E. N. Olsufyeva, E. P. Mirchink, E. B. Isakova, 
M. I. Reznikova, R. C. Goldman, A. A. Branstrom, E. R. Baizman, C. B. Longley, 
F. Sztaricskai, G. Batta and M. N. Preobrazhenskaya, J. Med. Chem., 2002, 45, 
1340. 
43. K. R. Maples, C. Wheeler, E. Ip, J. J. Plattner, D. Chu, Y.-K. Zhang, M. N. 
Preobrazhenskaya, S. S. Printsevskaya, S. E. Solovieva, E. N. Olsufyeva, H. 
Heine, J. Lovchik and C. R. Lyons, J. Med. Chem., 2007, 50, 3681. 
44. Y. Nakama, O. Yoshida, M. Yoda, K. Araki, Y. Sawada, J. Nakamura, S. Xu, K. 
Miura, H. Maki and H. Arimoto, J. Med. Chem., 2010, 53, 2528. 
45. K. W. Anderson and S. L. Buchwald, Angew. Chem., Int. Ed., 2005, 44, 6173. 
46. D. H. Williams and M. A. Cooper, Chem. Biol., 1999, 6, 892. 
47. K. C. Nicolaou, R. Hughes, S. Young Cho, N. Winssinger, C. Smethurst, H. 
Labischinski and R. Endermann, Angew. Chem. Int. Ed., 2000, 39, 3823. 
48. R. K. Jain, J. Trias and J. A. Ellman, J. Am. Chem. Soc., 2003, 125, 8740. 
49. M. Mammen, S.-K. Choi and G. M. Whitesides, Angew. Chem., Int. Ed., 1998, 37, 
2754. 
223 
 
50. J. Lu, O. Yoshida, S. Hayashic and H. Arimoto, Chem. Commun., 2007, 251. 
51. B. Xing, C.-W. Yu, K.-H. Chow, P.-L. Ho, D. Fu and B. Xu, J. Am. Chem. Soc., 
2002, 124, 14846. 
52. B. Xing, C.-W. Yu, P.-L. Ho, K.-H. Chow, T. Cheung, H. Gu, Z. Cai and B. Xu, 
J. Med. Chem., 2003, 46, 4904. 
53. B. Xing, T. Jiang, W. Bi, Y. Yang, L. Li, M. Ma, C.-K. Chang, B. Xu and E. Kok 
Lee Yeow, Chem. Commun., 2011, 47, 1601. 
54. A notable exception: O. A. Mirgorodskaya, E. N. Olsufyeva, D. E. Kolume, T. J. 
D. Joergensen, P. Roepstorff, A. Yu. Pavlov, O. V. Miroshnikova and M. N. 
Preobrazhenskaya, Russ. J. Bioorg. Chem., 2000, 26, 566. 
55. J. H. Griffin, M. S. Linsell, M. B. Nodwell, Q. Chen, J. L. Pace, K. L. Quast, K. 
M. Krause, L. Farrington, T. X. Wu, D. L. Higgins, T. E. Jenkins, B. G. 
Christensen and J. K. Judice, J. Am. Chem. Soc., 2003, 125, 6517. 
56. O. Yoshida, J. Nakamura, H. Yamashiro, K. Miura, S. Hayashi, K. Umetsu, S. Xu, 
H. Maki and Hirokazu Arimoto, Med. Chem. Commun., 2011, 2, 278. 
57. I. Kaneko, D. T. Fearon and K. F. Austen, J. Immunol., 1980, 124, 1194. 
58. H. Seto, K. Fujioka, K. Furihata, I. Kaneko and S. Takashashi, Tetrahedron Lett., 
1989, 42, 236. 
59. (a) K. Matsuzaki, H. Ikeda, T. Ogino, A. Matsumoto, H. B. Woodruff, H. Tanaka 
and S. Omura, J. Antibiot., 1994, 47, 1173; (b) H. Gouda, K. Matsuzaki, H. 
Tanaka, S. Hirono, S. Omura, J. A. McCauley, P. A. Sprengeler, G. T. Furst and 
A. B. Smith III, J. Am. Chem. Soc., 1996, 118, 13087. 
60. T. Shinohara, H. Deng, M. L. Snapper and A. H. Hoveyda, J. Am. Chem. Soc., 
2005, 127, 7334. 
61. H. Jayasuriya, G. M. Salituro, S. K. Smith, J. V. Heck, S. J. Gould, S. B. Singh, C. 
F. Homnick, M. K. Holloway, S. M. Pitzenberger and M. A. Patane, Tetrahedron 
Lett., 1998, 39, 2247. 
62. For a review of the anti-HIV behaviour of the compounds discussed in this paper: 
M. N. Preobrazhenskaya and E. N. Olsufyeva, Antiviral Res., 2006, 71, 227. 
63. S. B. Singh, H. Jayasuriya, G. M. Salituro, D. L. Zink, A. Shafiee, B. Heimbuch, 
K. C. Silverman, R. B. Lingham, O. Genilloud, A. Teran, D. Vilella, P. Felock and 
D. Hazuda, J. Nat. Prod., 2001, 64, 874. 
64. G. Roussi, E. G. Zamora, A.-C. Carbonnelle and R. Beugelmans, Tetrahedron 
Lett., 1997, 38, 4401. 
224 
 
65. M. K. Gurjar and N. K. Tripathy, Tetrahedron Lett., 1997, 38, 2163. 
66. A. M. Elder and D. H. Rich, Org. Lett., 1999, 1, 1443. 
67. H. Deng, J.-K. Jung, T. Liu, K. W. Kuntz, M. L. Snapper and A. H. Hoveyda, J. 
Am. Chem. Soc., 2003, 125, 9032. 
68. A. F. Littke, L. Schwarz and G. C. Fu, J. Am. Chem. Soc., 2002, 124, 6343. 
69. Z. Wang, M. Bois-Choussy, Y. Jia and J. Zhu, Angew. Chem. Int. Ed., 2010, 49, 
2018. 
70. H. Shimamura, S. P. Breazzano, J. Garfunkle, F. S. Kimball, J. D. Trzupek and D. 
L. Boger, J. Am. Chem. Soc., 2010, 132, 7776. 
71. R. C. Larock and E. K. Yum, J. Am. Chem. Soc., 1991, 113, 6689. 
72. R. C. Larock, E. K. Yum and M. D. Refvik, J. Org. Chem., 1998, 63, 7652. 
73. B. M. Crowley, Y. Mori, C. C. McComas, D. Tang and D. L. Boger, J. Am. Chem. 
Soc., 2004, 126, 4310. 
74. C. A. Lewis, K. E. Longcore, S. J. Miller and P. A. Wender., J. Nat. Prod., 2009, 
72, 1864. 
75. S. J. Miller and T. P. Pathak, J. Am. Chem. Soc., 2012, 134, 6120. 
76. R. H. Mitchell, Y.-H. Lai and R. V. Williams, J. Org. Chem., 1979, 44, 4733. 
77. S. J. Miller and Tejas P. Pathak, J. Am. Chem. Soc., 2013, 135, 8415. 
78. A. Sipos, G. Máté, E. Rőth, A. Borbás, G. Batta, I. Bereczki, S. Kéki, I. Jóna, E. 
Ostorházi, F. Rozgonyi, E. Vanderlinden, L. Naesens and P. Herczegh, Eur. J. 
Med. Chem., 2012, 58, 361; A. Sipos, Z. Török, E. Rőth, A. Kiss-Szikszai, G. 
Batta, I. Bereczki, Z. Fejes, A. Borbás, E. Ostorházi, F. Rozgonyi, L. Naesens, P. 
Herczegh, Bioorg. Med. Chem. Lett., 2012, 22, 7092. 
79. Michael Zasloff, Nature, 2002, 415, 389.  
80. V. Yarlagadda, P. Akkapeddi, G. B. Manjunath and J. Haldar, J. Med. Chem., 
2013, 57, 4558. 
81. T. Warne, M. J. Serrano-Vega, J. G. Baker, R. Moukhametzianov, P. C. Edwards, 
R. Henderson, A. G. W. Leslie, C. G. Tate and G. F. X. Schertler, Nature, 2008, 
454, 486. 
82. J. Clayden and N. Vassiliou, Org. Biomol. Chem., 2006, 4, 2667; J. Clayden, 
L. Vallverdú and M. Helliwell, Chem. Commun., 2007, 2357; J. Clayden, M. 
Pickworth and L. H. Jones, Chem. Commun., 2009, 547; J. Clayden, A. 
Castellanos, J. Solà and G. A. Morris, Angew. Chemie Int. Ed., 2009, 8, 5962; 
J. Solà, S. P. Fletcher, A. Castellanos and J. Clayden, Angew. Chemie Int. Ed., 
225 
 
2010, 49, 6836; J. Solà, M. Helliwell and J. Clayden, J. Am. Chem. Soc., 
2010, 132, 4548; T. Boddaert, J. Solà, M. Helliwell and J. Clayden, 
Chem. Commun., 2012, 48, 3397; R. A. Brown, V. Diemer, S. J. Webb and J. 
Clayden, Nature Chem., 2013, 5, 853; L. Byrne, J. Solà, T. Boddaert, T. Marcelli, 
R. W. Adams, G. A. Morris and J. Clayden, Angew. Chemie Int. Ed., 2014, 53, 
151. 
83. S. Dutt, C. Wilch and T. Schrader, Chem. Commun., 2011, 47, 5376; T. R. 
Simmons, G. Berggren, M. Bacchi, M. Fontecave and V. Artero, Coordination 
Chem. Rev., 2014, 270, 127. 
84. For a comprehensive review see D. Parmar, E. Sugiono, S. Raja and M. Rueping, 
Chem. Rev., 2014, 114, 9047. 
85. Y. Zhang, Z. Lu, W. D. Wulff, Synlett, 2009, 17, 2715. 
86. J. Bao, W. D. Wulff, J. B. Dominy, M. J. Fumo, E. B. Grant, A. C. Rob, M. C. 
Whitcomb, S.-M. Yeung, R. L. Ostrander and A. L. Rheingold, J. Am. Chem. Soc., 
1996, 118, 3392. 
87. E. J. Corey and H. E. Ensley, J. Am. Chem. Soc., 1975, 97, 6908; D. A. Evans, K. 
T. Chapman, and J. Bisaha, J. Am. Chem. Soc., 1988, 110, 1238. 
88. M. M. Heravi and V. Zadsirjan, Tetrahedron: Asymmetry, 2013, 24, 1149. 
89. B. Huang, L. Wang, L. Gong and E. Meggers, Chem. Asian J., 2013, 8, 2274. 
90. M. M. Heravi and V. Zadsirjan, Tetrahedron: Asymmetry, 2014, 25, 1061. 
91. S. G. Davies, H. J. Sanganee and P. Szolcsanyi, Tetrahedron, 1999, 55, 3337. 
92. A. B. Smith and A. S. Thompson, J. Org. Chem., 1984, 49, 1469. 
93. J. K. Whitesell, Chem. Rev., 1992, 92, 953; H.-U. Blaser, Chem. Rev., 1992, 92, 
935. 
94. A. H. Hoveyda, D. A. Evans and G. C. Fu, Chem. Rev., 1993, 93, 1307. 
95. J. Clayden, Chem. Soc. Rev., 2009, 38, 817. 
96. A. J. Frontiera and C. Collison, Tetrahedron, 2005, 61, 7577. 
97. L. N. Pridgen, K. Huang, S. Shilcrat, A. Tickner-Eldridge, C. DeBrosse and R. 
Curtis Haltiwanger, Synlett, 1999, 10, 1612. 
98. R. Hayashi, M. C. Walton, R. P. Hsung, J. H. Schwab and X. Yu, Org. Lett., 2010, 
12, 5768. 
99. S. V. Ley, L. R. Cox, G. Meek, K.-H. Metten, C. Piqué and J. M. Worrall, J. 
Chem. Soc., Perkin Trans. 1, 1997, 3299. 
100. C. J. Hollowood, S. V. Ley and E. A. Wright, Org. Biomol. Chem., 2003, 1, 3208. 
226 
 
101. C. J. Hollowood and S. V. Ley, Chem. Commun., 2002, 2130. 
102. G. A. Molander and K. L. Bobbitt, J. Am. Chem. Soc., 1993, 115, 7517. 
103. C. Aurisicchio, E. Baciocchi, M. F. Gerini and O. Lanzalunga, Org. Lett., 2007, 9, 
1939. 
104. F. M. Hauser and S. R. Ellenberger, J. Am. Chem. Soc., 1984, 106, 2458. 
105. G. Solladié, F. Colobert and F. Somny, Tetrahedron Lett., 1999, 40, 1227; Y. 
Arai, A. Suzuki, T. Masuda, Y. Masaki and M. Shiro, Chem. Pharm. Bull., 1996, 
44, 1765; C. Iwata, Y. Moritani, K. Sugiyama, M. Fujita and T. Imanishi, 
Tetrahedron Lett., 1987, 28, 2255. 
106. P. C. B. Page, M. J. McKenzie, S. M. Allin, E. W. Collington and R. A. E. Carr, 
Tetrahedron, 1995, 51, 1285. 
107. N. Maezaki, T. Shogaki, T. Imamura, K. Tokuno, K. Ohkubo,T. Tanaka and C. 
Iwata, Chem. Pharm. Bull., 1998, 46, 837. 
108. J. L. G. Ruano, M. Á. Fernández-Ibánez and M. C. Maestro, Tetrahedron, 2006, 
62, 12297. 
109. J. L. García Ruano, J. Alemán, M. Teresa Aranda, M. A. Fernández-Ibánez, M. 
Mercedes Rodríguez-Fernández and M. C. Maestro, Tetrahedron, 2004, 60, 
10067. 
110. Y. Arai, T. Masuda and Y. Masaki, J. Chem. Soc., Perkin Trans. 1, 1999, 2165. 
111. K. Mikami, M. Shimizu, H.-C. Zhang and B. E. Maryanoff, Tetrahedron, 2001, 
57, 2917. 
112. W. Xuan, C. Zhu, Y. Liu and Y. Cui, Chem. Soc. Rev., 2012, 41, 1677. 
113. H. Otsuka and S. Shinkai, Supramol. Sci., 1996, 3, 189. 
114. U. Boas, J. B. Christensen and P. M. H. Heegaard, J. Mater. Chem., 2006, 16, 
3785. 
115. H. C. Kolb, M. G. Finn, and K. B. Sharpless, Angew. Chem. Int. Ed., 2001, 40, 
2004. 
116. S. E. Bode, M. Wolberg and M. Müller, Synthesis, 2006, 4, 557. 
117. A. Lorente, K. Makowski and F. Albericio and M. Álvarez, Ann. Mar. Biol. Res., 
2014, 1, 1003. 
118. L. C. Dias and A. M. Aguilar, Chem. Soc. Rev., 2008, 37, 451. 
119. Y. Zhang, C. C. Arpin, A. J. Cullen, M. J. Mitton-Fry and T. Sammakia, J. Org. 
Chem., 2011, 76, 7641; F. Wu, M. E. Green and P. E. Floreancig, Angew. Chem. 
Int. Ed., 2011, 50, 1131. 
227 
 
120. D. A. Evans, J. L. Duffy and M. J. Dart, Tetrahedron Lett. 1994, 35, 8537; D. A. 
Evans, M. J. Dart, J. L. Duffy and M. G. Yang, J. Am. Chem. Soc., 1996, 118, 
4322. 
121. D. A. Evans, P. J. Coleman and B. Côté, J. Org. Chem., 1997, 62, 788. 
122. J. M. Goodman and R. S. Paton, Chem. Commun., 2007, 2124. 
123. D. A. Evans, B. Côté, P. J. Coleman and B. T. Connell, J. Am. Chem. Soc., 2003, 
125, 10895. 
124. I. Paterson, O. Delgado, G. J. Florence, I. Lyothier, J. P. Scott and N. Sereinig, 
Org. Lett., 2003, 5, 35. 
125. L. C. Dias, P. K. Kuroishi, E. C. Polo and E. C. de Lucca Jr, Tetrahedron Lett., 
2013, 54, 980. 
126. M. Akakura, M. B. Boxer and H. Yamamoto, ARKIVOC, 2007, 10, 337. 
127. Y. Yamaoka and H. Yamamoto, J. Am. Chem. Soc., 2010, 132, 5354. 
128. S. E. Denmark and J. Fu, Chem. Rev., 2003, 103, 2763. 
129. E. J. Thomas, Chem Rec., 2007, 7, 115. 
130. A. H. MacNeill and E. J. Thomas, Synthesis, 1994, 322; J. C. Carey and E. J. 
Thomas, Tetrahedron Lett., 1993, 34, 3935; J. C. Carey and E. J. Thomas, J. 
Chem. Soc. Chem. Commun., 1994, 283. 
131. E. K. Hoegenauer and E. J. Thomas, Org. Biomol. Chem., 2012, 10, 6995. 
132. M. Hoch, Appl. Geochem., 2001, 16, 719. 
133. E. J. Thomas and A. P. Weston, Tetrahedron Lett., 2007, 48, 341. 
134. Y. Tamai, T. Hattori, M. Date, H. Takayama, Y Kamikubo, Y. Minato and S. 
Miyano, J. Chem. Soc. Perkin Trans. 1, 1999, 1141. 
135. H. Takahashi, K. Tanahashi, K. Higashiyama and H. Onishi, Chem. Pharm. Bull., 
1986, 34, 479. 
136. H. Takahashi, K. Hattori, K. Higashiyama and Y. Ueno, Chem. Pharm. Bull., 
1990, 38, 1062. 
137. A. W. Frank, Crit. Rev. Biochem., 1984, 16, 51. 
138. G. Castelot-Deliencourt, E. Roger, X. Pannecoucke and J.-C. Quirion, Eur. J. Org. 
Chem., 2001, 3031. 
139. P. Linnane, N. Magnus and P. Magnus, Nature, 1997, 385, 799. 
140. N. Magnus and P. Magnus, Tetrahedron Lett., 1997, 38, 3491. 
141. J. Clayden, M. Darbyshire, J. H. Pink, N. Westlund and F. X. Wilson, 
Tetrahedron Lett., 1997, 38, 8587. 
228 
 
142. J. Clayden, J. H. Pink and S. A. Yasin, Tetrahedron Lett., 1998, 39, 105. 
143. S. D. Bull, S. G. Davies, S. W. Epstein and J. V. A. Ouzman, Chem. Commun., 
1998, 659. 
144. J. Clayden, A. Lund, L. Vallverdú and M. Helliwell, Nature, 2004, 431, 966. 
145. L. Byrne, J. Solà, T. Boddaert, T. Marcelli, R. W. Adams, G. A. Morris and J. 
Clayden, Angew. Chem. Int. Ed., 2014, 53, 151. 
146. R. Crabtree, Acc. Chem. Res., 1979, 12, 331. 
147.  P. Li, E. M. Forbeck, C. D. Evans and M. M. Joullié, Org. Lett., 2006, 8, 5106. 
148. A. Alam, Y.Takaguchi, S. Tsuboi, H. Ito and T. Yoshida, Tetrahedron, 2005, 61, 
       1909. 
149. Y. Yilmaz and R.T. Toledo, J. Agric. Food Chem., 2004, 52, 255. 
150.     F. Ullmann and P. Sponagel, Chem. Ber., 1905, 38, 2212. 
151
.
     A. A. Moroz and M. S. Shvartsberg, Russ. Chem. Rev., 1974, 43, 679. 
152.     S. Verma, N. Kumar and S. L. Jain, Tetrahedron Lett., 2012, 35, 4665. 
153.     D. A. Evans, J. L. Katz and T. R. West, Tetrahedron Lett., 1998, 39, 2937. 
154. C. H. Burgos, T. E. Barder, X. Huang and S. L. Buchwald, Angew. Chem. Int. Ed., 
2006, 45, 4321. 
155.    D. L. Boger, R. M. Borzilleri, S. Nukui and R. T. Beresis, J. Org. Chem., 1997, 62, 
4721. 
156. M. J. Mann, N. Pant and A. D. Hamilton, J. Chem. Soc., Chem. Commun., 1986, 
158. 
157.     K. C. Nicolaou, C. N. C. Boddy, S. Natarajan, T.-Y.Yue, H. Li, S. Bräse and J. M. 
Ramanjulu, J. Am. Chem. Soc., 1997, 119, 3421. 
158.     K. C. Nicolaou, N. F. Jain, S. Natarajan, R. Hughes, M. E. Solomon, H. Li, J. M.  
         Ramanjulu, M. Takayanagi, A. E. Koumbis and T. Bando, Angew. Chem. Int. Ed.,   
         1998, 37, 2714. 
159.   T. P. Petersen, A. F. Larsen, A. Ritzén and T. Ulven, J. Org. Chem., 2013, 78, 
4190. 
160. CRC Handbook of Chemistry and Physics, 66
th
 Ed., R. C. Weast, Ed.; CRC Press: 
Boca Raton, FL, 1985; F-165. 
161. J. A. Cella and S. W. Bacon, J. Org. Chem., 1984, 49, 1122. 
162. Theoretical pKa values were calculated in Marvinsketch 15.1.19 using the 
protonation plugin. 
163. T. Okazoe, Proc. Jpn. Acad., Ser. B, 2009, 85, 276. 
229 
 
164. F. H. Allen, O. Kennard, D. G. Watson, L. Brammer, A. G. Orpen and R. Taylor, 
J. Chem. Soc., Perkin Trans. 2, 1987, S1. 
165. S. J. Blanksby and G. B. Ellison, Acc. Chem. Res., 2003, 36, 255. 
166. A. L. Allred, J. Inorg. Nucl. Chem., 1961, 17, 215.  
167. P. J. Loll, A. E. Bevivino, B. D. Korty and P. H. Axelsen, J. Am. Chem. Soc., 
1997, 119, 1516. 
168. R. J. Abraham and M. Mobli, Modelling 
1
H NMR Spectra of Organic 
Compounds: Theory, Applications and NMR Prediction Software, 1
st
 ed.; John 
Wiley & Sons, Ltd, Chichester, 2008, p. 56. 
169. Brian C. Smith, Infrared Spectral Interpretation: A Systematic Approach, 1
st
 ed.; 
CRC Press: Boca Raton, FL, 1999, p 93. 
170. J. Wegner, S. Ceylan and A. Kirschning, Adv. Synth. Catal., 2012, 354, 17. 
171. C. Wiles and P. Watts, Green Chem., 2012, 14, 38. 
172. C. F. Carter, H. Lange, S. V. Ley, I. R. Baxendale, B. Wittkamp, J. G. Goode and 
N. L. Gaunt, Org. Process Res. Dev., 2010, 14, 393. 
173.  J. Bart, A. J. Kolkman, A. J. Oosthoek-de Vries, K. Koch, P. J. Nieuwland, H. J. 
W. G. Janssen, J. P. J. M. van Bentum, K. A. M. Ampt, F. P. J. T. Rutjes, S. S. 
Wijmenga, H. J. G. E. Gardeniers and A. P. M. Kentgens, J. Am. Chem. 
Soc., 2009, 131, 5014. 
174. For examples, see J. Hartwig, J. B. Metternich, N. Nikbin, A. Kirschninga and S. 
V. Ley, Org. Biomol. Chem., 2014, 12, 3611; J.-I Yoshida, Y. Takahashi and A. 
Nagaki, Chem. Commun., 2013, 49, 9896. 
175. J. Yoshida, Flash Chemistry: Fast Organic Synthesis in Microsystems, 1
st
 ed.; 
John Wiley & Sons, Ltd, Chichester, 2008. 
176. C. Wiles and P. Watts, Beilstein J. Org. Chem. 2011, 7, 1372. 
177. J. A. Marafie and J. D. Moseley, Org. Biomol. Chem., 2010, 8, 2219. 
178. For examples see: D. L. Boger, R. M. Borzilleri, S. Nukui and R. T. Beresis, J. 
Org. Chem., 1997, 62, 4721; A. J. Pearson and D. V. Ciurea, J. Org. Chem. 2008, 
73, 760. 
179. M. Schelhaas and H. Waldmann, Angew. Chem. Int. Ed., 1996, 35, 2056. 
180.  A. Alam, Y. Takaguchi, H. Ito, T. Yoshida and S. Tsuboi, Tetrahedron, 2005, 61, 
1909. 
181. K.-F. Chan, Y. Zhao, L. M. C. Chow and T. H. Chan, Tetrahedron, 2005, 61, 
4149. 
230 
 
182. R. Johansson and B. Samuelsson, J. Chem. Soc. Perkin Trans. 1, 1984, 2371. 
183. M. Kodama, Y. Shiobara, H. Sumitomo, K. Matsumura, M. Tsukamoto and C. 
Harada, J. Org. Chem., 1988, 53, 72. 
184. Nagase and Company, Ltd., 2007, EU Patent EP1870403 A1 
185. P. K. Mandal and J. S. McMurray, J. Org. Chem., 2007, 72, 6599. 
186. Y. Nishihama, Y. Ishikawa and S. Nishiyama, Tetrahedron Lett., 2009, 50, 2801. 
187. A. M. DiLauro, W. Seo and S. T. Phillips, J. Org. Chem., 2011, 76, 7352. 
188. C.-E. Yeom, H. W. Kim, S. Y. Lee and B. M. Kim, Synlett, 2007, 146. 
189. R. S. Porto, M. L. A. A. Vasconcellos, E. Ventura and F. Coelho, Synthesis, 2005, 
14, 2297. 
190. A. Bartoszewicz, M. Kalek, J. Nilsson, R. Hiresova and J. Stawinski, Synlett, 
2008, 1, 37. 
191. T. J. Barton, R. Rogido and J. C. Clardy, Tetrahedron, 2011, 11, 2081. 
192. F. Huet, A. Lechevallier, M. Pellet and J. M. Conia, Synthesis, 1978, 1, 63. 
193. P. G. M. Wuts and T. W. Greene, Greene's Protective Groups in Organic 
Synthesis, 4th Ed., John Wiley & Sons, Ltd, Chichester, 2007, p. 448. 
194. H. M. H. G. Albers, L. J. D. Hendrickx, R. J. P. van Tol, J. Hausmann, A. Perrakis 
and H. Ovaa, J. Med. Chem., 2011, 54, 4619. 
195. Z. Yongpeng and X. Jiaxi, Prog. Chem., 2014, 26, 1471. 
196. V. Percec, H.-J. Sun, P. Leowanawat, M. Peterca, R. Graf, H. W. Spiess, 
X. Zeng, G. Ungar and P. A. Heiney, J. Am. Chem. Soc., 2013, 135, 4129. 
197. P. Garner and J. M. Park, J. Org. Chem., 1987, 52, 2361. 
198. D. S. Seferos, D. A. Banach, N. A. Alcantar, J. N. Israelachvili and G. C. Bazan, 
J. Org. Chem., 2004, 69, 1110; V. Leandri, R. Ruffo, V. Trifiletti and A. Abbotto, 
Eur. J. Org. Chem. 2013, 30, 6793; J. McNulty, C. Zepeda-Velázquez and D. 
McLeod, Green Chem., 2013, 15, 3146. 
199. Y. Seeleib, G. Nemecek, D. Pfaff, B. D. Sueveges, J. Podlech, Synth. Comm., 
2014, 44, 2966. 
200. D. S. Seferos, D. A. Banach, N. A. Alcantar, J. N. Israelachvili and G. C. Bazan, 
J. Org. Chem., 2004, 69, 1110. 
201. M. Firstenberg, K. Nanjunda Shivananda, I. Cohen, O. Solomeshch, V. 
Medvedev, N. Tessler and Y. Eichen, Adv. Funct. Mater. 2011, 21, 634. 
202.  S. P. Bew, R. Carrington, D. L. Hughes, J. Liddle and Paolo Pesce, Adv. Synth. 
Catal., 2009, 351, 2579. 
231 
 
203. R. K. Bansal, Heterocyclic Chemistry, 3
rd
 Ed.; New Age International (P) Ltd., 
New Delhi, 1999, p 11. 
204. Graph based on the equation 
3
JHH’ = A + B cos ϕ + C cos 2 ϕ where A = 4.22, B = 
-0.5 and C = 4.5 Hz from M. Karplus, J. Am. Chem. Soc., 1963, 85, 2870. 
205. J. Crugeiras, A. Rios, E. Riveiros and J. P. Richard, J. Am. Chem. Soc., 2009, 131, 
15815. 
206. L. Chmurzynski, J. Heterocyclic Chem., 2000, 37, 71. 
207. M. Regitz, Diazo Compounds: Properties and Synthesis, 1
st
 Ed., Academic Press 
Inc., Orlando, FL, 1986, p 13. 
208. D. L. Wright and M. C. McMills, Org. Lett., 1999, 1, 667. 
209. P. Pesce, Organocatalytic methods towards the synthesis of chiral racemic and 
chiral non-racemic C2,3-functionalised N-alkyl and N-arylaziridines, Ph.D. Thesis, 
University of East Anglia, UK, 2010.  
210. T. Curtius, Chem. Ber., 1883, 16, 2230. 
211. L. Giraldi, C. Monti-Bragadin, and R. Della-Loggia, Experientia, 1974, 30, 496. 
212. L. Baldini and G. Brambilla, Cancer Res., 1966, 26, 1754. 
213. T. Curtius and A. Darapsky, Chem. Ber., 1906, 39, 1378. 
214. V. K. Antonov, Russ. Chem. Bull. (Int. Ed.), 1963, 1030; M. Mokotoff, J. F. 
Bagaglio and B. S. Parikh, J. Med. Chem., 1975, 18, 354; A. Ouihia, L. René and 
B. Badet, Tetrahedron Lett., 1992, 33, 5509. 
215. T. Toma, J. Shimokawa and T. Fukuyama, Org. Lett., 2007, 9, 3195. 
216. U. Ragnarsson and L. Grehn, Tetrahedron Lett., 2012, 53, 1045. 
217. A. Trabocchi, G. Menchi, N. Cini, F. Bianchini, S. Raspanti, A. Bottoncetti, A. 
Pupi, L. Calorini and A. Guarna, J. Med. Chem., 2010, 19, 7119; S. P. Bew, P. 
Ashford and D. U. Bachera, Synthesis, 2013, 45, 903 
218. E. Vaz, M. Fernandez-Suarez and L. Munoz, Tetrahedron: Asymmetry., 2003, 13, 
1935. 
219. V. Haridas, S. Sadanandan, Y. Sharma, S. Chinthalapalli and A. Shandilya, 
Tetrahedron Lett., 2012, 6, 623. 
220. M. Ordonez, E. Hernandez-Fernandez, M. Montiel-Perez, R. Bautista, P. Bustos, 
H. Rojas-Cabrera, M. Fernandez-Zertuche and O. Garcia-Barradas, Tetrahedron: 
Asymmetry, 2007, 20, 2427. 
221. R. A. Franich, G. Lowe and J. Parker, J. Chem. Soc., Perkin Trans. 1, 1972, 2034. 
232 
 
222. A. Ouihia, L. Rene, J. Guilhem, C. Pascard and B. Badet, J. Org. Chem, 1993, 58, 
1641. 
223. S. P. Bew, S. A. Fairhurst, D. L. Hughes, L. Legentil, J. Liddle, P. Pesce, S. 
Nigudkar and M. A. Wilson, Org. Lett., 2009, 20, 4552. 
224. A. Mazumdar, Z. Xue, M. F. Mayer, Synlett, 2007, 13, 2025. 
225. N. G. Anderson, Practical Process Research & Development, 2
nd
 Ed., Academic 
Press Inc., Oxford, 2012, p. 329.  
226. A. A. Desai and W. D. Wulff, J. Am. Chem. Soc., 2010, 132, 13100. 
227. T. Hashimoto, N. Uchiyama and K. Maruoka, J. Am. Chem. Soc., 2008, 130, 
14380. 
228. T. Schirmeister, J. Med. Chem., 1999, 42, 560; T. Schirmeister and M. Peric, 
Bioorg. Med. Chem., 2000, 6, 1281. 
229. N. Yoichi, F. Masaki, W. Kaoru, M. Shigeki and F. Nobuhiro, J. Am. Chem. Soc., 
2000, 122, 10462. 
230. B. K. W. Chung, J. L. Hickey, C. C. G. Scully, S. Zaretsky, A. Yudin, Med. 
Chem. Commun., 2013, 4, 1124; C. J. White, J. L. Hickey, C. C. G. Scully and 
A. K. Yudin, J. Am. Chem. Soc., 2014, 136, 3728. 
231. N. D. Ide, D. P. Galonić, W. A. van der Donk and D. Y. Gin, Synlett., 2005, 13, 
2011; F. B. Dyer, C.-M. Park, R. Joseph and P. Garner, J. Am. Chem. Soc., 2011, 
133, 20033. 
232. C. Büchold, Y. Hemberger, C. Heindl, A. Welker, B. Degel, T. Pfeuffer, P. Staib, 
S. Schneider, P. J. Rosenthal, J. Gut, J. Morschhäuser, G. Bringmann and T. 
Schirmeister, ChemMedChem, 2011, 6, 141. 
233. G. L. Thomas, R. J. Spandl, F. G. Glansdorp, M. Welch, A. Bender, J. Cockfield, 
J. A. Lindsay, C. Bryant, D. F. J. Brown, O. Loiseleur, H. Rudyk, M. Ladlow and 
D. R. Spring, Angew. Chem. Int. Ed., 2008, 15, 2808. 
234. A. N. Tkachenko, P. K. Mykhailiuk, S. Afonin, D. S. Radchenko, V. S. 
Kubyshkin, A. S. Ulrich and I. V. Komarov, Angew. Chem. Int. Ed., 2013, 52, 
1486. 
235. K. J. Schafer-Hales, K. D. Belfield, S. Yao, P. K. Frederiksen, J. M. Hales, P. E. 
Kolattukudy, J. Biomed. Opt., 2005, 5, 051402. 
236. E. Hillard, A. Vessières, L. Thouin, G. Jaouen and C. Amatore, Angew. Chem. Int. 
Ed., 2006, 45, 285; F. Dubar, T. J. Egan, B. Pradines, D. Kuter, K. K. Ncokazi, D. 
Forge, J.-F. Paul, C. Pierrot, H. Kalamou, J. Khalife, E. Buisine, C. Rogier, H. 
233 
 
Vezin, I. Forfar, C. Slomianny, X. Trivelli, S. Kapishnikov, L. Leiserowitz, D. 
Dive and C. Biot, ACS Chem. Biol., 2011, 6, 275. 
237. K. Kerman and H.-B. Kraatz, Analyst, 2009, 134, 2400. 
238. R. S. Herrick, C. J. Ziegler, M. Precopio, K. Crandall, J. Shaw and R. M. Jarret, J. 
Organomet. Chem., 2008, 693, 619. 
239. T. D. Turbitt and W. E. Watts, J. Chem. Soc., Perkin Trans. 2, 1974, 185. 
240. C. Imrie, C. Loubser, P. Engelbrecht and C. W. McCleland, J. Chem. Soc., Perkin 
Trans. 1, 1999, 2513. 
241.  For a review of the use of α-methylbenzylamine in asymmetric synthesis, see: E. 
Juaristi, J. L. León-Romo, A. Reyes and J. Escalante, Tetrahedron: Asymmetry, 
1999, 10, 2441. 
242. M. Ziółkowski, Z. Czarnocki, A. Leniewski and J. K. Maurin, Tetrahedron: 
Asymmetry, 1999, 10, 3371. 
243. G. Knupp and A. W. Frahm, Chem. Ber., 1984, 6, 2076. 
244. S. H. Lee, I. W. Song, Bull. Korean Chem. Soc., 2005, 26, 223. 
245. L. Huang, Y. Zhang, R. J. Staples, R. H. Huang and W. D. Wulff, Chem. Eur. J., 
2012, 18, 5302. 
246. L. Byrne, J. Sol, T. Boddaert, T. Marcelli, R. W. Adams, G. A. Morris and J. 
Clayden, Angew. Chem. (Int. Ed.), 2014, 1, 151. 
247. M. Poterala and J. Plenkiewicz, Tetrahedron: Asymmetry, 2011, 3, 294. 
248. D. Yang, B. Li, F.-F. Ng, Y.-L. Yan, J. Qu and Y. D. Wu, J. Org. Chem., 2001,  
22, 7303. 
249. C. Abalain and M. Langlois, Eur. J. Med. Chem., 1998, 33, 155. 
250. K. Sivasubramanian, L. S. Kaanumalle, S. Uppili and V. Ramamurthy, Org. 
Biomol. Chem., 2007, 5, 1569. 
251. D. Crich, K. Sana and S. Guo, Org. Lett., 2007, 9, 4423. 
252. P. Zajdel, G. Nomezine, N. Masurier, M. Amblard, M. Pawłowski, J. Martinez 
and G. Subra, Chem. Eur. J., 2010, 16, 7547. 
253. V. Balraju, R. Vasu Dev, D. Srinivasa Reddy and J. Iqbal, Tetrahedron Lett., 
2006, 47, 3569. 
254. D. Savage, J. F. Gallagher, Y. Ida and P. T.M. Kenny, Inorg. Chem. Comm., 2002, 
12, 1034. 
 
 
  
 
 
 
 
 
 
 
APPENDIX 
 
X-ray crystallographic data 
 
APPENDIX X-ray crystallographic data 
235 
 
Appendix 1: X-ray crystal structure and crystallographic data for methyl 3,5-bis(4-
formylphenoxy)-4-hydroxybenzoate 305i 
 
Figure 1 • An Ortep representation of the crystal structure of 305. Thermal ellipsoids are drawn at 
50% probability level. 
 
Crystal data and structure refinement details: 
Identification code  2011src0044 (PA298)   
Empirical formula  C22H16O7 
Formula weight  392.35 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n  
Unit cell dimensions a = 11.2899(5) Å  = 90° 
 b = 8.8623(4) Å  = 99.367(2)° 
 c = 17.9619(9) Å   = 90° 
Volume 1773.20(14) Å3 
Z 4 
Density (calculated) 1.470 Mg / m3 
Absorption coefficient 0.111 mm1 
F(000) 816 
Crystal Fragment; Pale Brown 
Crystal size 0.20  0.18  0.07 mm3 
                                                          
i All x-ray crystallographic data collection and structure analysis carried out by Dr Mateusz B. 
Pitak, UK National Crystallography Service, Southampton. 
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 range for data collection 2.94  24.99° 
Index ranges 13  h  13, 10  k  10, 21  l  21 
Reflections collected 13357 
Independent reflections 3079 [Rint = 0.0355] 
Completeness to  = 24.99° 98.7 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 0.9923 and 0.9782 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3079 / 0 / 264 
Goodness-of-fit on F2 1.101 
Final R indices [F2 > 2(F2)] R1 = 0.0456, wR2 = 0.1014 
R indices (all data) R1 = 0.0574, wR2 = 0.1108 
Largest diff. peak and hole 0.351 and 0.276 e Å3 
 
Table 1 • Atomic coordinates [ 104], equivalent isotropic displacement parameters [Å2  103] 
and site occupancy factors. Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
Atom  x y z Ueq S.o.f. 
 
C1 8061(2) 3839(3) 8764(1) 31(1) 1 
C2 8627(2) 3187(2) 8164(1) 26(1) 1 
C3 9391(2) 1959(2) 8318(1) 28(1) 1 
C4 9919(2) 1303(2) 7757(1) 26(1) 1 
C5 9699(2) 1909(2) 7036(1) 23(1) 1 
C6 8956(2) 3156(2) 6872(1) 24(1) 1 
C7 8413(2) 3785(2) 7434(1) 26(1) 1 
C8 10364(2) 1974(2) 5843(1) 23(1) 1 
C9 11390(2) 2828(2) 5852(1) 24(1) 1 
C10 11568(2) 3597(2) 5205(1) 23(1) 1 
C11 10707(2) 3496(2) 4553(1) 24(1) 1 
C12 9698(2) 2626(2) 4551(1) 24(1) 1 
C13 9503(2) 1839(2) 5199(1) 23(1) 1 
C14 12657(2) 4552(2) 5240(1) 24(1) 1 
C15 13613(2) 6438(3) 4613(1) 33(1) 1 
C16 8929(2) 3063(2) 3245(1) 26(1) 1 
C17 9795(2) 2454(2) 2868(1) 28(1) 1 
C18 9836(2) 2925(2) 2140(1) 29(1) 1 
C19 9022(2) 3995(2) 1793(1) 27(1) 1 
C20 8179(2) 4602(2) 2188(1) 31(1) 1 
C21 8125(2) 4131(3) 2915(1) 31(1) 1 
C22 8997(2) 4421(3) 998(1) 36(1) 1 
O1 7287(1) 4813(2) 8660(1) 38(1) 1 
O2 10212(1) 1165(2) 6490(1) 25(1) 1 
O3 13455(1) 4629(2) 5775(1) 30(1) 1 
O4 12649(1) 5351(2) 4604(1) 30(1) 1 
O5 8488(1) 1022(2) 5156(1) 30(1) 1 
O6 8765(1) 2525(2) 3951(1) 33(1) 1 
O7 9629(2) 3859(2) 588(1) 52(1) 1 
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Table 2 • Bond lengths [Å] and angles [°]. 
  
C1O1 1.221(3) 
C1C2 1.460(3) 
C1H1 0.9500 
C2C3 1.388(3) 
C2C7 1.398(3) 
C3C4 1.380(3) 
C3H3 0.9500 
C4C5 1.387(3) 
C4H4 0.9500 
C5O2 1.384(2) 
C5C6 1.389(3) 
C6C7 1.381(3) 
C6H6 0.9500 
C7H7 0.9500 
C8C9 1.381(3) 
C8C13 1.389(3) 
C8O2 1.401(2) 
C9C10 1.390(3) 
C9H9 0.9500 
C10C11 1.397(3) 
C10C14 1.485(3) 
C11C12 1.374(3) 
C11H11 0.9500 
C12O6 1.382(2) 
C12C13 1.406(3) 
C13O5 1.347(2) 
C14O3 1.208(2) 
C14O4 1.343(2) 
C15O4 1.451(2) 
C15H15A 0.9800 
C15H15B 0.9800 
C15H15C 0.9800 
C16C21 1.378(3) 
C16C17 1.386(3) 
C16O6 1.394(2) 
C17C18 1.381(3) 
C17H17 0.9500 
C18C19 1.395(3) 
C18H18 0.9500 
C19C20 1.384(3) 
C19C22 1.473(3) 
C20C21 1.382(3) 
C20H20 0.9500 
C21H21 0.9500 
C22O7 1.212(3) 
C22H22 0.9500 
O5H5 0.8400 
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O1C1C2 123.7(2) 
O1C1H1 118.1 
C2C1H1 118.1 
C3C2C7 119.46(19) 
C3C2C1 119.63(19) 
C7C2C1 120.91(19) 
C4C3C2 120.81(19) 
C4C3H3 119.6 
C2C3H3 119.6 
C3C4C5 119.04(19) 
C3C4H4 120.5 
C5C4H4 120.5 
O2C5C4 116.41(18) 
O2C5C6 122.39(17) 
C4C5C6 121.13(18) 
C7C6C5 119.34(18) 
C7C6H6 120.3 
C5C6H6 120.3 
C6C7C2 120.19(19) 
C6C7H7 119.9 
C2C7H7 119.9 
C9C8C13 121.99(18) 
C9C8O2 119.09(17) 
C13C8O2 118.85(17) 
C8C9C10 119.59(18) 
C8C9H9 120.2 
C10C9H9 120.2 
C9C10C11 119.53(18) 
C9C10C14 118.39(18) 
C11C10C14 122.05(18) 
C12C11C10 120.13(18) 
C12C11H11 119.9 
C10C11H11 119.9 
C11C12O6 124.38(18) 
C11C12C13 121.17(18) 
O6C12C13 114.31(17) 
O5C13C8 124.70(18) 
O5C13C12 117.71(17) 
C8C13C12 117.58(18) 
O3C14O4 123.19(19) 
O3C14C10 124.86(18) 
O4C14C10 111.94(16) 
O4C15H15A 109.5 
O4C15H15B 109.5 
H15AC15H15B 109.5 
O4C15H15C 109.5 
H15AC15H15C 109.5 
H15BC15H15C 109.5 
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C21C16C17 121.66(19) 
C21C16O6 116.80(19) 
C17C16O6 121.30(19) 
C18C17C16 118.67(19) 
C18C17H17 120.7 
C16C17H17 120.7 
C17C18C19 120.5(2) 
C17C18H18 119.7 
C19C18H18 119.7 
C20C19C18 119.52(19) 
C20C19C22 119.4(2) 
C18C19C22 121.0(2) 
C21C20C19 120.4(2) 
C21C20H20 119.8 
C19C20H20 119.8 
C16C21C20 119.2(2) 
C16C21H21 120.4 
C20C21H21 120.4 
O7C22C19 124.3(2) 
O7C22H22 117.9 
C19C22H22 117.9 
C5O2C8 117.81(15) 
C14O4C15 116.10(16) 
C13O5H5 109.5 
C12O6C16 119.33(15) 
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Table 3 • Anisotropic displacement parameters [Å2 103]. The anisotropic displacement 
factor exponent takes the form: 2 2[h2a*2U11 + ... + 2 h k a* b* U12 ]. 
 
Atom U11 U22 U33 U23 U13 U12 
 
C1 29(1)  40(1) 24(1)  3(1) 6(1)  0(1) 
C2 23(1)  30(1) 24(1)  2(1) 4(1)  0(1) 
C3 28(1)  34(1) 21(1)  2(1) 2(1)  1(1) 
C4 25(1)  27(1) 26(1)  4(1) 2(1)  4(1) 
C5 22(1)  26(1) 22(1)  2(1) 6(1)  2(1) 
C6 26(1)  27(1) 21(1)  2(1) 3(1)  0(1) 
C7 25(1)  28(1) 25(1)  0(1) 2(1)  4(1) 
C8 28(1)  24(1) 20(1)  2(1) 8(1)  3(1) 
C9 24(1)  25(1) 22(1)  0(1) 3(1)  5(1) 
C10 22(1)  25(1) 24(1)  0(1) 6(1)  2(1) 
C11 24(1)  28(1) 20(1)  1(1) 7(1)  0(1) 
C12 22(1)  31(1) 19(1)  4(1) 3(1)  1(1) 
C13 22(1)  26(1) 23(1)  2(1) 8(1)  0(1) 
C14 23(1)  29(1) 23(1)  2(1) 6(1)  4(1) 
C15 25(1)  36(1) 38(1)  6(1) 6(1)  6(1) 
C16 26(1)  32(1) 20(1)  1(1) 1(1)  11(1) 
C17 29(1)  29(1) 25(1)  2(1) 1(1)  3(1) 
C18 30(1)  34(1) 23(1)  1(1) 5(1)  2(1) 
C19 27(1)  29(1) 23(1)  0(1) 1(1)  3(1) 
C20 30(1)  30(1) 31(1)  2(1) 0(1)  2(1) 
C21 24(1)  40(1) 28(1)  7(1) 3(1)  0(1) 
C22 37(1)  41(1) 28(1)  4(1) 2(1)  2(1) 
O1 37(1)  48(1) 31(1)  6(1) 7(1)  10(1) 
O2 31(1)  26(1) 21(1)  4(1) 9(1)  4(1) 
O3 24(1)  41(1) 24(1)  2(1) 1(1)  4(1) 
O4 24(1)  39(1) 27(1)  8(1) 1(1)  7(1) 
O5 28(1)  36(1) 26(1)  2(1) 8(1)  8(1) 
O6 28(1)  53(1) 19(1)  4(1) 0(1)  13(1) 
O7 59(1)  67(1) 33(1)  11(1) 13(1)  6(1) 
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Table 4 • Hydrogen coordinates [ 104] and isotropic displacement parameters [Å2  103]. 
 
Atom  x y z Ueq S.o.f.
 
 
H1 8309 3485 9265 37 1 
H3 9552 1566 8817 33 1 
H4 10426 447 7864 31 1 
H6 8823 3571 6378 29 1 
H7 7892 4626 7324 32 1 
H9 11970 2888 6298 28 1 
H11 10819 4028 4111 29 1 
H15A 13675 7059 5069 49 1 
H15B 13442 7087 4166 49 1 
H15C 14371 5903 4609 49 1 
H17 10349 1726 3106 34 1 
H18 10423 2518 1874 35 1 
H20 7635 5347 1957 37 1 
H21 7540 4538 3183 37 1 
H22 8449 5185 792 43 1 
H5 8436 666 5582 45 1 
  
 
Table 5 • Hydrogen bonds [Å and °]. 
 
 DH···A d(DH) d(H···A) d(D···A) (DHA) 
 
 O5H5...O1i 0.84 1.86 2.654(2) 157.8 
 
Possible intramolecular H-bond 
 O5H5...O2 0.84 2.41 2.834(2) 112.0  
 Symmetry transformations used to generate equivalent atoms:  
(i) x+3/2,y1/2,z+3/2   
  
Diffractometer: Nonius KappaCCD area detector ( scans and  scans to fill asymmetric unit 
sphere).  
Cell determination: DirAx (Duisenberg, A.J.M.(1992). J. Appl. Cryst. 25, 92-96.)  
Data collection: Collect (Collect: Data collection software, R. Hooft, Nonius B.V., 1998).  
Data reduction and cell refinement: Denzo (Z. Otwinowski & W. Minor, Methods in 
Enzymology (1997) Vol. 276: Macromolecular Crystallography, part A, pp. 307326; C. W. 
Carter, Jr. & R. M. Sweet, Eds., Academic Press).  
Absorption correction: SADABS (Sheldrick, G. M. (2007). SADABS. Version 2007/2. Bruker 
AXS Inc., Madison, Wisconsin, USA.).  
Structure solution: SHELXS97 (Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122.).  
Structure refinement: SHELXL97 (G Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122.). 
Graphics: OLEX2 (Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & 
Puschmann, H. (2009). J. Appl. Cryst. 42, 339-341.) 
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Appendix 2: X-ray crystal structure and crystallographic data for cis-(S)-methyl 2-
(1-(4-methoxyphenyl)-3-phenylaziridine-2-carboxamido)-3-phenylpropanoate 406a 
 
Figure 1 • Molecular structure of rac,cis-406a. Displacement ellipsoids – 50% probability. 
 
Crystal data and structure refinement details: 
 
Identification code  2012ncs0332 (PA531) 
Empirical formula  C26H26N2O4 
Formula weight  430.49 
Temperature  120(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P1  
Unit cell dimensions a = 9.6355(2) Å  = 98.751(7)° 
 b = 9.9156(2) Å  = 97.164(7)° 
 c = 12.9883(9) Å   = 113.516(8)° 
Volume 1100.83(8) Å3 
Z 2 
Density (calculated) 1.299 Mg / m3 
APPENDIX X-ray crystallographic data 
243 
 
Absorption coefficient 0.088 mm1 
F(000) 456 
Crystal Prism; colourless 
Crystal size 0.60  0.37  0.17 mm3 
 range for data collection 2.99  27.45° 
Index ranges 12  h  12, 12  k  12, 16  l  14 
Reflections collected 19839 
Independent reflections 5019 [Rint = 0.0140] 
Completeness to  = 27.45° 99.7 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 0.9852 and 0.9491 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5019 / 0 / 295 
Goodness-of-fit on F2 1.045 
Final R indices [F2 > 2(F2)] R1 = 0.0348, wR2 = 0.0926 
R indices (all data) R1 = 0.0377, wR2 = 0.0948 
Largest diff. peak and hole 0.325 and 0.198 e Å3 
 
 
Special details:  
The crystal structure of 2012ncs0332 (PA531) crystallises in centrosymmetric spacegroup 
triclinic P-1. This means, that the crystal structure is a 50/50 racemic mixture of two enantiomers. 
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Table 1 • Atomic coordinates [ 104], equivalent isotropic displacement parameters [Å2  103] 
and site occupancy factors. Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
Atom  x y z Ueq S.o.f. 
 
C1 8253(1) 260(1) 7885(1) 30(1) 1 
C2 9479(1) 80(2) 7373(1) 35(1) 1 
C3 9319(1) 46(1) 6303(1) 30(1) 1 
C4 7925(1) 186(1) 5740(1) 26(1) 1 
C5 6708(1) 340(1) 6262(1) 24(1) 1 
C6 6851(1) 376(1) 7339(1) 22(1) 1 
C7 5546(1) 473(1) 7904(1) 23(1) 1 
C8 5753(1) 1088(1) 8512(1) 18(1) 1 
C9 7150(1) 1779(1) 9425(1) 18(1) 1 
C10 8185(1) 1492(1) 11077(1) 29(1) 1 
C11 4723(1) 2108(1) 7163(1) 19(1) 1 
C12 5120(1) 3240(1) 6474(1) 20(1) 1 
C13 5796(1) 4927(1) 6906(1) 20(1) 1 
C14 6133(1) 5642(1) 8062(1) 19(1) 1 
C15 7570(1) 6070(1) 8713(1) 24(1) 1 
C16 7866(1) 6776(1) 9781(1) 27(1) 1 
C17 6723(1) 7041(1) 10208(1) 27(1) 1 
C18 5281(1) 6593(1) 9565(1) 28(1) 1 
C19 4988(1) 5912(1) 8496(1) 24(1) 1 
C21 7298(1) 4414(1) 5578(1) 19(1) 1 
C22 7773(1) 5783(1) 5271(1) 23(1) 1 
C23 8367(1) 5952(1) 4343(1) 24(1) 1 
C24 8490(1) 4742(1) 3731(1) 22(1) 1 
C25 8036(1) 3371(1) 4050(1) 23(1) 1 
C26 7442(1) 3210(1) 4963(1) 22(1) 1 
C27 9606(1) 6166(1) 2475(1) 32(1) 1 
N1 5929(1) 2150(1) 7829(1) 19(1) 1 
N2 6765(1) 4214(1) 6550(1) 19(1) 1 
O1 6916(1) 959(1) 10170(1) 23(1) 1 
O2 8307(1) 2895(1) 9473(1) 26(1) 1 
O3 3370(1) 1207(1) 7093(1) 27(1) 1 
O4 9032(1) 4765(1) 2801(1) 29(1) 1 
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Table 2 • Bond lengths [Å] and angles [°]. 
  
C1C2 1.3911(16) 
C1C6 1.3982(15) 
C1H1 0.9500 
C2C3 1.3857(16) 
C2H2 0.9500 
C3C4 1.3904(15) 
C3H3 0.9500 
C4C5 1.3940(14) 
C4H4 0.9500 
C5C6 1.3962(14) 
C5H5 0.9500 
C6C7 1.5114(13) 
C7C8 1.5497(13) 
C7H7A 0.9900 
C7H7B 0.9900 
C8N1 1.4510(11) 
C8C9 1.5181(13) 
C8H8 1.0000 
C9O2 1.2038(12) 
C9O1 1.3395(11) 
C10O1 1.4482(12) 
C10H10A 0.9800 
C10H10B 0.9800 
C10H10C 0.9800 
C11O3 1.2330(12) 
C11N1 1.3412(12) 
C11C12 1.5025(13) 
C12N2 1.4715(12) 
C12C13 1.5136(13) 
C12H12 1.0000 
C13N2 1.4565(12) 
C13C14 1.4943(13) 
C13H13 1.0000 
C14C15 1.3936(13) 
C14C19 1.3966(13) 
C15C16 1.3943(15) 
C15H15 0.9500 
C16C17 1.3891(15) 
C16H16 0.9500 
C17C18 1.3889(16) 
C17H17 0.9500 
C18C19 1.3892(15) 
C18H18 0.9500 
C19H19 0.9500 
C21C22 1.3876(13) 
C21C26 1.3974(14) 
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C21N2 1.4326(11) 
C22C23 1.4010(14) 
C22H22 0.9500 
C23C24 1.3899(15) 
C23H23 0.9500 
C24O4 1.3747(12) 
C24C25 1.3971(14) 
C25C26 1.3838(13) 
C25H25 0.9500 
C26H26 0.9500 
C27O4 1.4276(13) 
C27H27A 0.9800 
C27H27B 0.9800 
C27H27C 0.9800 
N1H1N 0.855(14) 
 
C2C1C6 120.71(10) 
C2C1H1 119.6 
C6C1H1 119.6 
C3C2C1 120.47(10) 
C3C2H2 119.8 
C1C2H2 119.8 
C2C3C4 119.73(10) 
C2C3H3 120.1 
C4C3H3 120.1 
C3C4C5 119.61(10) 
C3C4H4 120.2 
C5C4H4 120.2 
C4C5C6 121.37(10) 
C4C5H5 119.3 
C6C5H5 119.3 
C5C6C1 118.09(9) 
C5C6C7 120.66(9) 
C1C6C7 121.20(9) 
C6C7C8 112.83(8) 
C6C7H7A 109.0 
C8C7H7A 109.0 
C6C7H7B 109.0 
C8C7H7B 109.0 
H7AC7H7B 107.8 
N1C8C9 108.21(7) 
N1C8C7 112.53(8) 
C9C8C7 111.36(8) 
N1C8H8 108.2 
C9C8H8 108.2 
C7C8H8 108.2 
O2C9O1 124.67(9) 
O2C9C8 125.14(8) 
O1C9C8 110.19(8) 
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O1C10H10A 109.5 
O1C10H10B 109.5 
H10AC10H10B 109.5 
O1C10H10C 109.5 
H10AC10H10C 109.5 
H10BC10H10C 109.5 
O3C11N1 123.93(9) 
O3C11C12 120.75(8) 
N1C11C12 115.32(8) 
N2C12C11 117.86(8) 
N2C12C13 58.39(6) 
C11C12C13 123.55(8) 
N2C12H12 115.0 
C11C12H12 115.0 
C13C12H12 115.0 
N2C13C14 117.63(8) 
N2C13C12 59.36(6) 
C14C13C12 123.57(8) 
N2C13H13 114.9 
C14C13H13 114.9 
C12C13H13 114.9 
C15C14C19 119.21(9) 
C15C14C13 121.60(9) 
C19C14C13 119.17(9) 
C14C15C16 120.34(9) 
C14C15H15 119.8 
C16C15H15 119.8 
C17C16C15 120.15(10) 
C17C16H16 119.9 
C15C16H16 119.9 
C18C17C16 119.63(10) 
C18C17H17 120.2 
C16C17H17 120.2 
C17C18C19 120.44(10) 
C17C18H18 119.8 
C19C18H18 119.8 
C18C19C14 120.21(9) 
C18C19H19 119.9 
C14C19H19 119.9 
C22C21C26 119.34(9) 
C22C21N2 122.37(9) 
C26C21N2 118.12(8) 
C21C22C23 120.50(9) 
C21C22H22 119.7 
C23C22H22 119.7 
C24C23C22 119.66(9) 
C24C23H23 120.2 
C22C23H23 120.2 
O4C24C23 124.97(9) 
APPENDIX X-ray crystallographic data 
248 
 
O4C24C25 115.14(9) 
C23C24C25 119.89(9) 
C26C25C24 120.09(9) 
C26C25H25 120.0 
C24C25H25 120.0 
C25C26C21 120.49(9) 
C25C26H26 119.8 
C21C26H26 119.8 
O4C27H27A 109.5 
O4C27H27B 109.5 
H27AC27H27B 109.5 
O4C27H27C 109.5 
H27AC27H27C 109.5 
H27BC27H27C 109.5 
C11N1C8 122.31(8) 
C11N1H1N 117.6(9) 
C8N1H1N 120.0(9) 
C21N2C13 120.15(8) 
C21N2C12 117.80(7) 
C13N2C12 62.25(6) 
C9O1C10 115.43(8) 
C24O4C27 117.50(8) 
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Table 3 • Anisotropic displacement parameters [Å2 103]. The anisotropic displacement factor 
exponent takes the form: 2 2[h2a*2U11 + ... + 2 h k a* b* U12 ]. 
 
Atom U11 U22 U33 U23 U13 U12 
 
C1 44(1)  35(1) 23(1)  11(1) 9(1)  27(1) 
C2 39(1)  45(1) 33(1)  11(1) 7(1)  31(1) 
C3 35(1)  31(1) 32(1)  7(1) 14(1)  20(1) 
C4 34(1)  25(1) 20(1)  3(1) 8(1)  12(1) 
C5 25(1)  23(1) 20(1)  2(1) 3(1)  8(1) 
C6 30(1)  16(1) 22(1)  4(1) 7(1)  10(1) 
C7 28(1)  17(1) 21(1)  4(1) 8(1)  5(1) 
C8 19(1)  19(1) 17(1)  7(1) 7(1)  6(1) 
C9 21(1)  19(1) 18(1)  6(1) 8(1)  10(1) 
C10 25(1)  37(1) 23(1)  13(1) 2(1)  9(1) 
C11 20(1)  21(1) 15(1)  3(1) 6(1)  7(1) 
C12 18(1)  23(1) 16(1)  6(1) 3(1)  7(1) 
C13 20(1)  22(1) 19(1)  8(1) 5(1)  9(1) 
C14 23(1)  16(1) 20(1)  7(1) 6(1)  7(1) 
C15 22(1)  27(1) 22(1)  6(1) 6(1)  9(1) 
C16 26(1)  28(1) 22(1)  5(1) 2(1)  7(1) 
C17 37(1)  22(1) 21(1)  4(1) 8(1)  11(1) 
C18 33(1)  25(1) 31(1)  4(1) 13(1)  16(1) 
C19 24(1)  21(1) 27(1)  5(1) 5(1)  12(1) 
C21 17(1)  24(1) 16(1)  7(1) 3(1)  7(1) 
C22 24(1)  22(1) 22(1)  7(1) 6(1)  9(1) 
C23 25(1)  24(1) 23(1)  12(1) 7(1)  7(1) 
C24 18(1)  28(1) 16(1)  7(1) 4(1)  5(1) 
C25 22(1)  24(1) 19(1)  4(1) 4(1)  7(1) 
C26 23(1)  21(1) 21(1)  8(1) 5(1)  7(1) 
C27 31(1)  38(1) 26(1)  17(1) 12(1)  7(1) 
N1 17(1)  19(1) 20(1)  8(1) 5(1)  5(1) 
N2 19(1)  21(1) 17(1)  7(1) 5(1)  7(1) 
O1 22(1)  25(1) 20(1)  10(1) 4(1)  7(1) 
O2 21(1)  26(1) 26(1)  10(1) 5(1)  4(1) 
O3 18(1)  32(1) 25(1)  10(1) 4(1)  3(1) 
O4 33(1)  32(1) 20(1)  9(1) 12(1)  8(1) 
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Table 4 • Hydrogen coordinates [ 104] and isotropic displacement parameters [Å2  103]. 
 
Atom  x y z Ueq S.o.f.
 
 
H1 8370 305 8615 36 1 
H2 10433 21 7758 41 1 
H3 10158 72 5955 36 1 
H4 7803 175 5004 32 1 
H5 5762 423 5876 29 1 
H7A 5481 1134 8413 28 1 
H7B 4558 942 7374 28 1 
H8 4812 944 8815 22 1 
H10A 9080 1402 10845 43 1 
H10B 7872 884 11606 43 1 
H10C 8462 2551 11393 43 1 
H12 4471 2876 5739 24 1 
H13 5520 5504 6411 24 1 
H15 8352 5881 8427 28 1 
H16 8852 7075 10219 33 1 
H17 6925 7526 10935 33 1 
H18 4490 6753 9859 34 1 
H19 4006 5629 8058 28 1 
H22 7695 6611 5692 27 1 
H23 8684 6890 4134 29 1 
H25 8135 2548 3638 27 1 
H26 7131 2274 5174 26 1 
H27A 8792 6520 2394 48 1 
H27B 9923 6024 1793 48 1 
H27C 10497 6914 3013 48 1 
H1N 6830(16) 2804(15) 7818(10) 27(3) 1 
 
 
 
 
Diffractometer: Rigaku R-Axis Spider including curved Fujifilm image plate and a graphite 
monochromated sealed tube Mo generator.   
Cell determination and data collection: CrystalClear-SM Expert 2.0 r11 (Rigaku, 2011).  
Data reduction, cell refinement and absorption correction: CrystalClear-SM Expert 2.0 r13 
(Rigaku, 2011).  
Structure solution: SHELXS97 (Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122).  
Structure refinement: SHELXL97 (Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122).  
Graphics: OLEX2 (Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & 
Puschmann, H. (2009). J. Appl. Cryst. 42, 339-341). 
 
